10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2020

or

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number: 001-38196

DUPONT DE NEMOURS, INC.

(Exact name of registrant as specified in its charter)

Delaware	81-1224539
State or other jurisdiction of incorporation or organization	(I.R.S. Employer Identification No.)

974 Centre Road	Building 730	Wilmington	Delaware	19805
(Address of Principal Executive Offices)				(Zip Code)

(302) 774-3034

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.01 per share	DD	New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

                                                ☑ Yes ¨ No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

                                 ☑ Yes ¨ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer	☑	Accelerated filer	¨
Non-accelerated filer	¨	Smaller reporting company	☐
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). ☐ Yes ☑ No

The registrant had 733,849,605 shares of common stock, $0.01 par value, outstanding at October 28, 2020.

DuPont de Nemours, Inc.

QUARTERLY REPORT ON FORM 10-Q

For the quarterly period ended September 30, 2020

TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION		PAGE
Item 1.	Consolidated Financial Statements (Unaudited)
	Consolidated Statements of Operations	6
	Consolidated Statements of Comprehensive Income	7
	Condensed Consolidated Balance Sheets	8
	Consolidated Statements of Cash Flows	9
	Consolidated Statements of Equity	10
	Notes to the Consolidated Financial Statements (Unaudited)	12
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	48
	Recent Developments	49
	Selected Financial Data	50
	Results of Operations	50
	Changes in Financial Condition	61
	Contractual Obligations	64
	Other Matters	65
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	66
Item 4.	Controls and Procedures	66
PART II - OTHER INFORMATION
Item 1.	Legal Proceedings	67
Item 1A.	Risk Factors	68
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	68
Item 4.	Mine Safety Disclosures	68
Item 5.	Other Information	69
Item 6.	Exhibits	70
SIGNATURES		71

3

DuPont de Nemours, Inc.

Throughout this Quarterly Report on Form 10-Q, except as otherwise noted by the context, the terms "DuPont" or "Company" used herein mean DuPont de Nemours, Inc. and its consolidated subsidiaries. On June 1, 2019, DowDuPont Inc. changed its registered name to DuPont de Nemours, Inc. (“DuPont”) (for certain events prior to June 1, 2019, the Company may be referred to as DowDuPont). Beginning on June 3, 2019, the Company's common stock is traded on the New York Stock Exchange under the ticker symbol "DD."

On April 1, 2019, the Company completed the separation of its materials science business into a separate and independent public company by way of a distribution of Dow Inc. (“Dow”) through a pro rata dividend in-kind of all of the then-issued and outstanding shares of Dow’s common stock (the “Dow Distribution”). On June 1, 2019, the Company completed the separation of its agriculture business into a separate and independent public company by way of a distribution of Corteva, Inc. (“Corteva”) through a pro rata dividend in-kind of all of the then-issued and outstanding shares of Corteva’s common stock (the “Corteva Distribution”).

Following the Corteva Distribution, DuPont holds the specialty products business as continuing operations. The results of operations of DuPont for the 2019 interim periods presented reflect the historical financial results of Dow and Corteva as discontinued operations, as applicable. The cash flows and comprehensive income related to Dow and Corteva have not been segregated and are included in the interim Consolidated Statements of Cash Flows and interim Consolidated Statements of Comprehensive Income, respectively, for the applicable period. Unless otherwise indicated, the information in the notes to the interim Consolidated Financial Statements refer only to DuPont's continuing operations and do not include discussion of balances or activity of Dow or Corteva.

On December 15, 2019, DuPont and International Flavors & Fragrances Inc. ("IFF") announced entry into definitive agreements to combine DuPont’s Nutrition & Biosciences business (the "N&B Business") with IFF in a transaction that would result in IFF issuing shares to DuPont shareholders. The transaction is expected to close in the first quarter of 2021, subject to customary closing conditions, including receipt of regulatory approvals and receipt by DuPont of an opinion of tax counsel.

DuPontTM and all products, unless otherwise noted, denoted with TM, SM or ® are trademarks, service marks or registered trademarks of affiliates of DuPont de Nemours, Inc.

FORWARD-LOOKING STATEMENTS

This communication contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as "expect," "anticipate," "intend," "plan," "believe," "seek," "see," "will," "would," "target," and similar expressions and variations or negatives of these words.

Forward-looking statements address matters that are, to varying degrees, uncertain and subject to risks, uncertainties and assumptions, many of which that are beyond DuPont's control, that could cause actual results to differ materially from those expressed in any forward-looking statements. Forward-looking statements are not guarantees of future results. Some of the important factors that could cause DuPont's actual results to differ materially from those projected in any such forward-looking statements include, but are not limited to: (i) the parties’ ability to meet expectations regarding the timing, completion and accounting and tax treatments of the intended transaction with IFF; changes in relevant tax and other laws, (ii) failure to obtain necessary regulatory approvals, anticipated tax treatment or any required financing or to satisfy any of the other conditions to the intended transaction with IFF, (iii) the possibility that unforeseen liabilities, future capital expenditures, revenues, expenses, earnings, synergies, economic performance, indebtedness, financial condition, losses, future prospects, business and management strategies that could impact the value, timing or pursuit of the intended transaction with IFF, (iv) risks and costs and pursuit and/or implementation of the separation of the N&B Business, including timing anticipated to complete the separation, any changes to the configuration of businesses included in the separation if implemented, (v) risks and costs related to the Dow Distribution and the Corteva Distribution (together, the “DWDP Distributions”) including (a) with respect to achieving all expected benefits from the DWDP Distributions; (b) the incurrence of significant costs in connection with the DWDP Distributions, including costs to service debt incurred by the Company to establish the relative credit profiles of Corteva, Dow and DuPont and increased costs related to supply, service and other arrangements that, prior to the Dow Distribution, were between entities under the common control of DuPont; (c) indemnification of certain legacy liabilities of E. I. du Pont de Nemours and Company ("Historical EID") in connection with the Corteva Distribution; and (d) potential liability arising from fraudulent conveyance and similar laws in connection with the DWDP Distributions; (vi) failure to effectively manage acquisitions, divestitures, alliances, joint ventures and other portfolio changes, including meeting conditions under the Letter Agreement entered in connection with the Corteva Distribution, related to the transfer of certain levels of assets and

4

businesses; (vii) uncertainty as to the long-term value of DuPont common stock; (viii) potential inability or reduced access to the capital markets or increased cost of borrowings, including as a result of a credit rating downgrade (ix) risks and uncertainties related to the novel coronavirus (COVID-19) and the responses thereto (such as voluntary and in some cases, mandatory quarantines as well as shut downs and other restrictions on travel and commercial, social and other activities) on DuPont’s business, results of operations, access to sources of liquidity and financial condition which depend on highly uncertain and unpredictable future developments, including, but not limited to, the duration and spread of the COVID-19 outbreak, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions resume and (x) other risks to DuPont's business, operations and results of operations including from: failure to develop and market new products and optimally manage product life cycles; ability, cost and impact on business operations, including the supply chain, of responding to changes in market acceptance, rules, regulations and policies and failure to respond to such changes; outcome of significant litigation, environmental matters and other commitments and contingencies; failure to appropriately manage process safety and product stewardship issues; global economic and capital market conditions, including the continued availability of capital and financing, as well as inflation, interest and currency exchange rates; changes in political conditions, including tariffs, trade disputes and retaliatory actions; impairment of goodwill or intangible assets; the availability of and fluctuations in the cost of energy and raw materials; business or supply disruption, including in connection with the DWDP Distributions; ability to effectively manage costs as the company’s portfolio evolves; security threats, such as acts of sabotage, terrorism or war, global health concerns and pandemics, natural disasters and weather events and patterns which could or could continue to result in a significant operational event for DuPont, adversely impact demand or production; ability to discover, develop and protect new technologies and to protect and enforce DuPont's intellectual property rights; unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism or outbreak of war or hostilities, as well as management's response to any of the aforementioned factors. These risks are and will be more fully discussed in DuPont's current, quarterly and annual reports and other filings made with the U.S. Securities and Exchange Commission, in each case, as may be amended from time to time in future filings with the SEC. While the list of factors presented here is considered representative, no such list should be considered a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on DuPont’s consolidated financial condition, results of operations, credit rating or liquidity. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. DuPont assumes no obligation to publicly provide revisions or updates to any forward-looking statements whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. A detailed discussion of some of the significant risks and uncertainties which may cause results and events to differ materially from such forward-looking statements is included in the section titled “Risk Factors” in (Part I, Item 1A) of DuPont’s 2019 Annual Report on Form 10-K and in (Part II, Item 1A) of this Form 10-Q.

5

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

DuPont de Nemours, Inc.

Consolidated Statements of Operations

	Three Months Ended September 30,				Nine Months Ended September 30,
In millions, except per share amounts (Unaudited)	2020		2019		2020		2019
Net sales	$	5,096	$	5,426	$	15,145	$	16,308
Cost of sales	3,392		3,531		10,001		10,648
Research and development expenses	199		225		644		724
Selling, general and administrative expenses	524		645		1,698		2,013
Amortization of intangibles	530		247		1,591		755
Restructuring and asset related charges - net	384		82		807		290
Goodwill impairment charges	183		—		3,214		1,175
Integration and separation costs	127		191		469		1,149
Equity in earnings of nonconsolidated affiliates	30		43		172		132
Sundry income (expense) - net	430		79		627		144
Interest expense	197		177		573		493
Income (loss) from continuing operations before income taxes	20		450		(3,053)		(663)
Provision for income taxes on continuing operations	92		78		100		142
(Loss) income from continuing operations, net of tax	(72)		372		(3,153)		(805)
Income from discontinued operations, net of tax	—		5		—		1,217
Net (loss) income	(72)		377		(3,153)		412
Net income attributable to noncontrolling interests	7		5		20		90
Net (loss) income available for DuPont common stockholders	$	(79)	$	372	$	(3,173)	$	322
Per common share data:
(Loss) earnings per common share from continuing operations - basic	$	(0.11)	$	0.49	$	(4.31)	$	(1.10)
Earnings per common share from discontinued operations - basic	—		0.01		—		1.53
(Loss) earnings per common share - basic	$	(0.11)	$	0.50	$	(4.31)	$	0.43
(Loss) earnings per common share from continuing operations - diluted	$	(0.11)	$	0.49	$	(4.31)	$	(1.10)
Earnings per common share from discontinued operations - diluted	—		0.01		—		1.53
(Loss) earnings per common share - diluted	$	(0.11)	$	0.50	$	(4.31)	$	0.43
Weighted-average common shares outstanding - basic	734.4		745.5		735.8		748.2
Weighted-average common shares outstanding - diluted	734.4		747.7		735.8		748.2

See Notes to the Consolidated Financial Statements.

6

DuPont de Nemours, Inc.

Consolidated Statements of Comprehensive Income

	Three Months Ended September 30,				Nine Months Ended September 30,
In millions (Unaudited)	2020		2019		2020		2019
Net (loss) income	$	(72)	$	377	$	(3,153)	$	412
Other comprehensive income (loss), net of tax
Unrealized gains on investments	—		—		—		67
Cumulative translation adjustments	606		(694)		547		(829)
Pension and other post-employment benefit plans	4		(4)		9		187
Derivative instruments	—		—		—		(58)
Total other comprehensive income (loss)	610		(698)		556		(633)
Comprehensive income (loss)	538		(321)		(2,597)		(221)
Comprehensive income attributable to noncontrolling interests, net of tax	11		4		19		102
Comprehensive income (loss) attributable to DuPont	$	527	$	(325)	$	(2,616)	$	(323)

See Notes to the Consolidated Financial Statements.

7

DuPont de Nemours, Inc.

Condensed Consolidated Balance Sheets

In millions, except share amounts (Unaudited)	September 30, 2020		December 31, 2019
Assets
Current Assets
Cash and cash equivalents	$	4,008	$	1,540
Accounts and notes receivable - net	3,623		3,802
Inventories	3,902		4,319
Other current assets	238		338
Assets held for sale	835		—
Total current assets	12,606		9,999
Investments
Investments in nonconsolidated affiliates	951		1,204
Other investments	24		24
Noncurrent receivables	147		32
Total investments	1,122		1,260
Property, plant and equipment - net of accumulated depreciation (September 30, 2020 - $5,757; December 31, 2019 - $4,969)	9,686		10,143
Other Assets
Goodwill	29,690		33,151
Other intangible assets	11,528		13,593
Restricted cash	6,206		—
Deferred income tax assets	237		189
Deferred charges and other assets	1,066		1,014
Total other assets	48,727		47,947
Total Assets	$	72,141	$	69,349
Liabilities and Equity
Current Liabilities
Short-term borrowings and finance lease obligations	$	2,394	$	3,830
Accounts payable	2,685		2,934
Income taxes payable	414		240
Accrued and other current liabilities	1,364		1,342
Liabilities related to assets held for sale	127		—
Total current liabilities	6,984		8,346
Long-Term Debt	21,802		13,617
Other Noncurrent Liabilities
Deferred income tax liabilities	3,011		3,467
Pension and other post-employment benefits - noncurrent	1,193		1,172
Other noncurrent obligations	1,033		1,191
Total other noncurrent liabilities	5,237		5,830
Total Liabilities	34,023		27,793
Commitments and contingent liabilities
Stockholders' Equity
Common stock (authorized 1,666,666,667 shares of $0.01 par value each; issued 2020: 733,845,391 shares; 2019: 738,564,728 shares)	7		7
Additional paid-in capital	50,219		50,796
(Accumulated deficit) Retained earnings	(11,808)		(8,400)
Accumulated other comprehensive loss	(859)		(1,416)
Total DuPont stockholders' equity	37,559		40,987
Noncontrolling interests	559		569
Total equity	38,118		41,556
Total Liabilities and Equity	$	72,141	$	69,349

See Notes to the Consolidated Financial Statements.

8

DuPont de Nemours, Inc.

Consolidated Statements of Cash Flows

	Nine Months Ended September 30,
In millions (Unaudited)	2020		2019
Operating Activities
Net (loss) income	$	(3,153)	$	412
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization	2,326		2,662
Credit for deferred income tax and other tax related items	(481)		(658)
Earnings of nonconsolidated affiliates (in excess of) less than dividends received	(120)		700
Net periodic pension benefit cost (credit)	30		(58)
Pension contributions	(77)		(485)
Net gain on sales of assets, businesses and investments	(612)		(119)
Restructuring and asset related charges - net	807		564
Goodwill impairment charges	3,214		1,175
Amortization of merger-related inventory step-up	—		253
Other net loss	127		326
Changes in assets and liabilities, net of effects of acquired and divested companies:
Accounts and notes receivable	133		(2,418)
Inventories	312		339
Accounts payable	43		(805)
Other assets and liabilities, net	245		(1,057)
Cash provided by operating activities	2,794		831
Investing Activities
Capital expenditures	(922)		(2,091)
Investment in gas field developments	—		(25)
Proceeds from sales of property, businesses, and ownership interests in nonconsolidated affiliates, net of cash divested	1,008		259
Acquisitions of property and businesses, net of cash acquired	(73)		(9)
Purchases of investments	(1)		(195)
Proceeds from sales and maturities of investments	1		233
Other investing activities, net	22		21
Cash provided by (used for) investing activities	35		(1,807)
Financing Activities
Changes in short-term notes payable	(1,439)		2,876
Proceeds from issuance of long-term debt	8,275		4,005
Payments on long-term debt	(29)		(6,899)
Purchases of common stock	(232)		(2,040)
Proceeds from issuance of Company stock	34		76
Employee taxes paid for share-based payment arrangements	(14)		(83)
Distributions to noncontrolling interests	(48)		(18)
Dividends paid to stockholders	(662)		(1,389)
Cash held by Dow and Corteva at the respective DWDP Distributions	—		(7,315)
Debt extinguishment costs	—		(104)
Other financing activities, net	(55)		(6)
Cash provided by (used for) financing activities	5,830		(10,897)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	4		(2)
Increase (Decrease) in cash, cash equivalents and restricted cash	8,663		(11,875)
Cash, cash equivalents and restricted cash from continuing operations, beginning of period	1,577		8,591
Cash, cash equivalents and restricted cash from discontinued operations, beginning of period	—		5,431
Cash, cash equivalents and restricted cash at beginning of period	1,577		14,022
Cash, cash equivalents and restricted cash from continuing operations, end of period	10,240		2,147
Cash, cash equivalents and restricted cash from discontinued operations, end of period	—		—
Cash, cash equivalents and restricted cash at end of period	$	10,240	$	2,147

See Notes to the Consolidated Financial Statements.

9

DuPont de Nemours, Inc.

Consolidated Statements of Equity

For the nine months ended September 30, 2020 and 2019

In millions (Unaudited)	Common Stock		Additional Paid-in Capital		Retained Earnings (Accumulated Deficit)		Accumulated Other Comp Loss		Unearned ESOP		Treasury Stock		Non-controlling Interests		Total Equity
Balance at December 31, 2018	$	8	$	81,976	$	30,257	$	(12,394)	$	(134)	$	(5,421)	$	1,608	$	95,900
Adoption of accounting standards	—		—		(111)		—		—		—		—		(111)
Net income	—		—		322		—		—		—		90		412
Other comprehensive (loss) income	—		—		—		(633)		—		—		12		(621)
Dividends ($1.86 per common share)	—		(224)		(1,165)		—		—		—		—		(1,389)
Common stock issued/sold	—		76		—		—		—		—		—		76
Stock-based compensation and allocation of ESOP shares	—		173		(1)		—		29		—		—		201
Distributions to non-controlling interests	—		—		—		—		—		—		(18)		(18)
Purchases of treasury stock	—		—		—		—		—		(2,040)		—		(2,040)
Retirement of treasury stock	—		—		(7,461)		—		—		7,461		—		—
Spin-off of Dow and Corteva	—		(30,843)		(30,123)		11,498		105		—		(1,124)		(50,487)
Other	(1)		(3)		(7)		—		—		—		—		(11)
Balance at September 30, 2019	$	7	$	51,155	$	(8,289)	$	(1,529)	$	—	$	—	$	568	$	41,912
Balance at December 31, 2019	$	7	$	50,796	$	(8,400)	$	(1,416)	$	—	$	—	$	569	$	41,556
Adoption of accounting standards	—		—		(3)		—		—		—		—		(3)
Net (loss) income	—		—		(3,173)		—		—		—		20		(3,153)
Other comprehensive income (loss)	—		—		—		557		—		—		(1)		556
Dividends ($.90 per common share)	—		(662)		—		—		—		—		—		(662)
Common stock issued/sold	—		34		—		—		—		—		—		34
Stock-based compensation	—		81		—		—		—		—		—		81
Distributions to non-controlling interests	—		—		—		—		—		—		(48)		(48)
Purchases of treasury stock	—		—		—		—		—		(232)		—		(232)
Retirement of treasury stock	—		—		(232)		—		—		232		—		—
Other	—		(30)		—		—		—		—		19		(11)
Balance at September 30, 2020	$	7	$	50,219	$	(11,808)	$	(859)	$	—	$	—	$	559	$	38,118

See Notes to the Consolidated Financial Statements.

10

DuPont de Nemours, Inc.

Consolidated Statements of Equity

For the three months ended September 30, 2020 and 2019

In millions (Unaudited)	Common Stock		Additional Paid-in Capital		Retained Earnings (Accumulated Deficit)		Accumulated Other Comp Loss		Treasury Stock		Non-controlling Interests		Total Equity
Balance at June 30, 2019	$	7	$	51,129	$	(8,299)	$	(831)	$	—	$	570	$	42,576
Net income	—		—		372		—		—		5		377
Other comprehensive loss	—		—		—		(698)		—		(1)		(699)
Common stock issued/sold	—		9		—		—		—		—		9
Stock-based compensation and allocation of ESOP shares	—		20		(1)		—		—		—		19
Distributions to non-controlling interests	—		—		—		—		—		(6)		(6)
Purchases of treasury stock	—		—		—		—		(359)		—		(359)
Retirement of treasury stock	—		—		(359)		—		359		—		—
Other	—		(3)		(2)		—		—		—		(5)
Balance at September 30, 2019	$	7	$	51,155	$	(8,289)	$	(1,529)	$	—	$	568	$	41,912
Balance at June 30, 2020	$	7	$	50,191	$	(11,728)	$	(1,465)	$	—	$	572	$	37,577
Net (loss) income	—		—		(79)		—		—		7		(72)
Other comprehensive income	—		—		—		606		—		4		610
Common stock issued/sold	—		—		—		—		—		—		—
Stock-based compensation	—		24		—		—		—		—		24
Distributions to non-controlling interests	—		—		—		—		—		(38)		(38)
Other	—		4		(1)		—		—		14		17
Balance at September 30, 2020	$	7	$	50,219	$	(11,808)	$	(859)	$	—	$	559	$	38,118

See Notes to the Consolidated Financial Statements.

11

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Table of Contents

Note		Page
1	Summary of Significant Accounting Policies	13
2	Recent Accounting Guidance	14
3	Divestitures	15
4	Revenue	19
5	Restructuring and Asset Related Charges - Net	20
6	Supplementary Information	24
7	Income Taxes	25
8	Earnings Per Share Calculations	26
9	Inventories	27
10	Nonconsolidated Affiliates	27
11	Goodwill and Other Intangible Assets	28
12	Short-Term Borrowings, Long-Term Debt and Available Credit Facilities	30
13	Commitments and Contingent Liabilities	32
14	Operating Leases	37
15	Stockholders' Equity	37
16	Noncontrolling Interests	38
17	Pension Plans and Other Post-Employment Benefits	39
18	Stock-Based Compensation	40
19	Financial Instruments	41
20	Fair Value Measurements	43
21	Segments and Geographic Regions	44

12

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Interim Financial Statements

The accompanying unaudited interim Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP") for interim financial information and the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. In the opinion of management, the interim statements reflect all adjustments (including normal recurring accruals) which are considered necessary for the fair statement of the results for the periods presented. Results from interim periods should not be considered indicative of results for the full year. These interim Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, collectively referred to as the “2019 Annual Report.” The interim Consolidated Financial Statements include the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained.

Impact of the Novel Coronavirus (“COVID-19”) Pandemic

The COVID-19 pandemic has resulted in significant economic disruption and continues to adversely impact the broader global economy. The extent of the impact on the Company's operational and financial performance will depend on future developments, including, but not limited to, the duration and spread of the outbreak and its impact on the Company's customers and suppliers. As of the date of issuance of these interim Consolidated Financial Statements, the full extent to which the COVID-19 pandemic may materially impact the Company's financial condition, liquidity, or results of operations remains uncertain.

Basis of Presentation

Effective August 31, 2017, pursuant to the merger of equals transaction contemplated by the Agreement and Plan of Merger, dated as of December 11, 2015, as amended on March 31, 2017 ("DWDP Merger Agreement"), The Dow Chemical Company ("Historical Dow") and E. I. du Pont de Nemours and Company ("Historical EID") each merged with subsidiaries of DowDuPont Inc. ("DowDuPont") and, as a result, Historical Dow and Historical EID became subsidiaries of DowDuPont (the "DWDP Merger"). Prior to the DWDP Merger, DowDuPont did not conduct any business activities other than those required for its formation and matters contemplated by the DWDP Merger Agreement. Historical Dow was determined to be the accounting acquirer in the DWDP Merger.

Except as otherwise indicated by the context, the term "Historical Dow" includes Historical Dow and its consolidated subsidiaries, "Historical EID" includes Historical EID and its consolidated subsidiaries, and "Dow Silicones" means Dow Silicones Corporation, a wholly owned subsidiary of Historical Dow.

Distributions

Effective as of 5:00 p.m. on April 1, 2019, the Company completed the separation of its materials science business into a separate and independent public company by way of a distribution of Dow Inc. (“Dow”) through a pro rata dividend in-kind of all of the then-issued and outstanding shares of Dow’s common stock (the “Dow Common Stock”), to holders of the Company’s common stock (the “DowDuPont common stock”), as of the close of business on March 21, 2019 (the “Dow Distribution”).

Effective as of 12:01 a.m. on June 1, 2019, the Company completed the separation of its agriculture business into a separate and independent public company by way of a distribution of Corteva, Inc. (“Corteva”) through a pro rata dividend in-kind of all of the then-issued and outstanding shares of Corteva’s common stock (the “Corteva Common Stock”), to holders of the Company’s common stock as of the close of business on May 24, 2019 (the “Corteva Distribution” and, together with the Dow Distribution, the “DWDP Distributions”).

Following the Corteva Distribution, DuPont holds the specialty products business. On June 1, 2019, DowDuPont changed its registered name from "DowDuPont Inc." to "DuPont de Nemours, Inc." doing business as "DuPont." Beginning on June 3, 2019, the Company's common stock is traded on the NYSE under the ticker symbol "DD."

The results of operations of DuPont for the 2019 interim periods presented reflect the historical financial results of Dow and Corteva as discontinued operations, as applicable. The cash flows and comprehensive income related to Dow and Corteva have not been segregated and are included in the interim Consolidated Statements of Cash Flows and interim Consolidated Statements of Comprehensive Income, respectively, for the applicable period. Unless otherwise indicated, the information in the notes to the interim Consolidated Financial Statements refer only to DuPont's continuing operations and do not include discussion of balances or activity of Dow or Corteva.

13

On December 15, 2019, the Company entered into definitive agreements to separate and combine the Nutrition & Biosciences business segment (the "N&B Business") with International Flavors & Fragrances Inc. ("IFF") in a tax-efficient Reverse Morris Trust transaction, (the "Intended N&B Transaction"). The transaction is expected to close in the first quarter of 2021, subject to approval by IFF shareholders and other customary closing conditions, including regulatory approvals and receipt by DuPont of an opinion of tax counsel. The financial results of the N&B Business are included in continuing operations for the periods presented.

NOTE 2 - RECENT ACCOUNTING GUIDANCE

Recently Adopted Accounting Guidance

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, and associated ASUs related to Topic 326. The new guidance introduces the current expected credit loss (“CECL”) model, which requires organizations to record an allowance for credit losses for certain financial instruments and financial assets, including trade receivables, based on expected losses rather than incurred losses. Under this update, on initial recognition and at each reporting period, an entity will be required to recognize an allowance that reflects the entity’s current estimate of credit losses expected to be incurred over the life of the financial instrument. This update became effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019.

The Company adopted the new standard in the first quarter of 2020, which required a modified retrospective transition approach, applying the new standard's cumulative-effect adjustment at the date of initial adoption. This cumulative-effect has been reflected as of January 1, 2020 and prior periods have not been restated. The impact of initial adoption was not material to the Company’s interim Condensed Consolidated Balance Sheet, interim Consolidated Statements of Operations, and interim Consolidated Statement of Cash Flows.

14

NOTE 3 - DIVESTITURES

Separation Agreements

In connection with the Dow Distribution and the Corteva Distribution, the Company entered into certain agreements that, among other things, effected the separations, provides for the allocation of assets, employees, liabilities and obligations (including its investments, property and employee benefits and tax-related assets and liabilities) among DuPont, Dow, and Corteva (together, the “Parties” and each a “Party”), and provides a framework for DuPont’s relationship with Dow and Corteva following the DWDP Distributions. Effective April 1, 2019, the Parties entered into the following agreements referred herein as: the DWDP Separation and Distribution Agreement; the DWDP Tax Matters Agreement; the DWDP Employee Matters Agreement; and the Intellectual Property Cross-License Agreement (the “DuPont-Dow IP Cross-License Agreement”). In addition to the agreements above, DuPont has entered into certain various supply agreements with Dow. These agreements provide for different pricing than the historical intercompany and intracompany practices prior to the DWDP Distributions.

Effective June 1, 2019, in connection with the Corteva Distribution, DuPont and Corteva entered into the following agreements: the Intellectual Property Cross-License Agreement (the “DuPont-Corteva IP Cross-License Agreement”); the Letter Agreement; and the Amended and Restated DWDP Tax Matters Agreement.

In connection with the DWDP Distributions, Dow and Corteva indemnify the Company against, and DuPont indemnifies Dow and Corteva against certain litigation, environmental, income taxes, and other liabilities that arose prior to the DWDP Distributions, as applicable. The term of this indemnification is generally indefinite and includes defense costs and expenses, as well as monetary and non-monetary settlements and judgments. Refer to Note 13 for additional information regarding treatment of litigation and environmental related matters under the DWDP Separation and Distribution Agreement and the Letter Agreement.

Materials Science Division

On April 1, 2019, DowDuPont completed the separation of its Materials Science businesses, including the businesses and operations that comprised the Company's former Performance Materials & Coating, Industrial Intermediates & Infrastructure and the Packaging & Specialty Plastics segments, (the "Materials Science Division") through the consummation of the Dow Distribution.

On April 1, 2019, prior to the Dow Distribution, the Company contributed $2,024 million in cash to Dow.

The results of operations of the Materials Science Division are presented as discontinued operations as summarized below:

	Nine Months Ended September 30, 2019
In millions
Net sales	$	10,867
Cost of sales	8,917
Research and development expenses	163
Selling, general and administrative expenses	329
Amortization of intangibles	116
Restructuring and asset related charges - net	157
Integration and separation costs	44
Equity in earnings of nonconsolidated affiliates	(13)
Sundry income (expense) - net 1	17
Interest expense	240
Income from discontinued operations before income taxes	905
Provision for income taxes on discontinued operations 1	176
Income from discontinued operations, net of tax	729
Income from discontinued operations attributable to noncontrolling interests, net of tax	37
Income from discontinued operations attributable to DuPont stockholders, net of tax	$	692

1.The three and nine months ended September 30, 2019 includes $82 million of expense in "Sundry income (expense) - net" and a benefit of $85 million in "Provision for income taxes on discontinued operations" related to certain unrecognized tax benefits for positions taken on items from prior years.

15

The following table presents depreciation, amortization, and capital expenditures of the discontinued operations related to the Materials Science Division:

	Nine Months Ended September 30, 2019
In millions
Depreciation and amortization	$	744
Capital expenditures	$	597

Agriculture Division

On June 1, 2019, the Company completed the separation of its Agriculture business, including the businesses and operations that comprised the Company's former Agriculture segment (the "Agriculture Division"), through the consummation of the Corteva Distribution.

In 2019, prior to the distribution of Corteva, the Company contributed $7,139 million in cash to Corteva, a portion of which was used to retire indebtedness of Historical EID.

The results of operations of the Agriculture Division are presented as discontinued operations as summarized below:

	Nine Months Ended September 30, 2019
In millions
Net sales	$	7,144
Cost of sales	4,218
Research and development expenses	470
Selling, general and administrative expenses	1,294
Amortization of intangibles	176
Restructuring and asset related charges - net	117
Integration and separation costs	430
Equity in earnings of nonconsolidated affiliates	(4)
Sundry income (expense) - net 1	52
Interest expense	91
Income from discontinued operations before income taxes	396
Provision for income taxes on discontinued operations 1	74
Income from discontinued operations, net of tax	322
Income from discontinued operations attributable to noncontrolling interests, net of tax	35
Income from discontinued operations attributable to DuPont stockholders, net of tax	$	287

1.The three and nine months ended September 30, 2019 includes $6 million of expense in "Sundry income (expense) - net" and a benefit of $8 million in "Provision for income taxes on discontinued operations" related to certain unrecognized tax benefits for positions taken on items from prior years.

The following table presents depreciation, amortization, and capital expenditures of the discontinued operations related to the Agriculture Division:

	Nine Months Ended September 30, 2019
In millions
Depreciation and amortization	$	385
Capital expenditures	$	383

Assets Held for Sale

In October 2020, the Company entered into a definitive agreement to sell its biomaterials business unit, which includes the Company's equity method investment in DuPont Tate & Lyle Bio Products, for $240 million. The sale is subject to customary closing conditions and is expected to close in the first half of 2021. The Company determined that the assets and liabilities associated with the biomaterials business unit, which are reported in Non-Core, met the held for sale criteria as of September 30, 2020.

In addition, certain other assets and liabilities within Non-Core are expected to be disposed of within one year and met the held for sale criteria during the third quarter of 2020. The following table summarizes the carrying value of the major assets and liabilities of the biomaterials business unit, as well as these certain other assets and liabilities within Non-Core classified as held for sale as of September 30, 2020 (collectively, the “Non-Core Held for Sale Disposal Groups”):

16

In millions	September 30, 2020
Assets
Accounts and notes receivable - net	$	61
Inventories	96
Other current assets	40
Investments in nonconsolidated affiliates	166
Property, plant and equipment - net	32
Goodwill	267
Other intangible assets	169
Deferred charges and other assets	4
Assets held for sale	$	835
Liabilities
Accounts payable	$	29
Income taxes payable	1
Accrued and other current liabilities	48
Deferred income tax liabilities	30
Pension and other post-employment benefits - noncurrent	1
Other noncurrent obligations	18
Liabilities related to assets held for sale	$	127

In connection with the held for sale classification, the Non-Core Held for Sale Disposal Groups were measured at fair value less estimated cost to sell. As a result, the Company recorded a $25 million pre-tax goodwill impairment charge during the third quarter of 2020 which is reflected in “Goodwill impairment charges” in the Company’s interim Consolidated Statements of Operations for the three and nine months ended September 30, 2020.

Sale of TCS/HSC Disposal Group

In the third quarter of 2020, the Company completed the sale of its trichlorosilane business (“TCS Business”) along with its equity ownership interest in DC HSC Holdings LLC and Hemlock Semiconductor L.L.C. (the "HSC Group,” and together with the TCS Business, the “TCS/HSC Disposal Group” and the sale of the TCS/HSC Disposal Group, the “TCS/HSC Disposal”) to the HSC Group, both of which were part of the Non-Core segment. In connection with the TCS/HSC Disposal, the Company received $550 million in cash at closing, subject to certain claw-back provisions, and will receive an additional $175 million in equal installments over the course of the next three years associated with the settlement of an existing supply agreement dispute with the HSC Group. The TCS/HSC Disposal resulted in a net pre-tax benefit of $393 million ($232 million net of tax), including the settlement of the supply agreement dispute and after allocation of goodwill to the TCS Business. The net pre-tax benefit is recorded in “Sundry income (expense) – net” in the Company’s interim Consolidated Statements of Operations for the three and nine months ended September 30, 2020.

Sale of Compound Semiconductor Solutions

In the first quarter of 2020, the Company completed the sale of its Compound Semiconductor Solutions business unit, a part of the Electronics & Imaging segment, to SK Siltron. The proceeds received in the first quarter of 2020 related to the sale of the business were approximately $420 million. The sale resulted in a pre-tax gain of $197 million ($102 million net of tax) recorded in "Sundry income (expense) - net" in the Company's interim Consolidated Statements of Operations for the nine months ended September 30, 2020.

Sale of DuPont Sustainable Solutions

In the third quarter of 2019, the Company completed the sale of its Sustainable Solutions business unit, a part of the Non-Core segment, to Gyrus Capital. The sale resulted in a pre-tax gain of $28 million ($22 million net of tax). The gain was recorded in "Sundry income (expense) - net" in the Company's interim Consolidated Statements of Operations for the three and nine months ended September 30, 2019.

Other Discontinued Operations Activity

For the nine months ended September 30, 2019, the Company recorded "Income from discontinued operations, net of tax" of $86 million related to the adjustment of certain unrecognized tax benefits for positions taken on items from prior years from previously divested businesses and $80 million related to changes in accruals for certain prior year tax positions related to the divested crop protection business and research and development assets of Historical EID.

17

Integration and Separation Costs

Integration and separation costs for continuing operations through September 30, 2020, primarily have consisted of financial advisory, information technology, legal, accounting, consulting, and other professional advisory fees associated with the preparation and execution of activities related to the intended separation of the Nutrition & Biosciences business beginning in the fourth quarter of 2019, the DWDP Merger, post-DWDP Merger integration, and the DWDP Distributions.

These costs are recorded within "Integration and separation costs" within the interim Consolidated Statements of Operations.

	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2020		2019		2020		2019
Integration and separation costs	$	127	$	191	$	469	$	1,149

18

NOTE 4 - REVENUE

Revenue Recognition

Products

Substantially all of DuPont's revenue is derived from product sales. Product sales consist of sales of DuPont's products to manufacturers and distributors. DuPont considers purchase orders, which in some cases are governed by master supply agreements, to be a contract with a customer. Contracts with customers are considered to be short-term when the time between order confirmation and satisfaction of the performance obligations is equal to or less than one year.

Disaggregation of Revenue

The Company disaggregates its revenue from contracts with customers by segment and business or major product line and geographic region, as the Company believes it best depicts the nature, amount, timing and uncertainty of its revenue and cash flows.

During the second quarter of 2020, Electronics & Imaging realigned a component within the Semiconductor Technologies product line to the Image Solutions product line. The reporting changes have been retrospectively reflected for all periods presented.

Net Trade Revenue by Segment and Business or Major Product Line	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2020		2019		2020		2019
Image Solutions	$	172	$	167	$	491	$	507
Interconnect Solutions	370		339		910		859
Semiconductor Technologies	462		428		1,392		1,251
Electronics & Imaging	$	1,004	$	934	$	2,793	$	2,617
Food & Beverage	$	686	$	736	$	2,163	$	2,237
Health & Biosciences	570		582		1,754		1,756
Pharma Solutions	211		207		640		625
Nutrition & Biosciences	$	1,467	$	1,525	$	4,557	$	4,618
Healthcare & Specialty	$	352	$	376	$	1,002	$	1,148
Industrial & Consumer	233		274		680		875
Mobility Solutions	460		559		1,339		1,772
Transportation & Industrial	$	1,045	$	1,209	$	3,021	$	3,795
Safety Solutions	$	534	$	630	$	1,746	$	1,952
Shelter Solutions	387		411		1,051		1,166
Water Solutions	328		286		972		833
Safety & Construction	$	1,249	$	1,327	$	3,769	$	3,951
Biomaterials	$	37	$	54	$	98	$	166
Clean Technologies	48		78		175		219
DuPont Teijin Films	47		48		124		127
Photovoltaic & Advanced Materials 1	199		223		608		707
Sustainable Solutions 2	—		28		—		108
Non-Core	$	331	$	431	$	1,005	$	1,327
Total	$	5,096	$	5,426	$	15,145	$	16,308

1. The TCS Business within Photovoltaic & Advanced Materials was divested in the third quarter of 2020.

2. The Sustainable Solutions business was divested in the third quarter of 2019.

Net Trade Revenue by Geographic Region	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2020		2019		2020		2019
U.S. & Canada	$	1,620	$	1,822	$	4,875	$	5,424
EMEA 1	1,069		1,227		3,405		3,898
Asia Pacific	2,120		2,057		6,045		6,036
Latin America	287		320		820		950
Total	$	5,096	$	5,426	$	15,145	$	16,308

1.Europe, Middle East and Africa.

19

Contract Balances

From time to time, the Company enters into arrangements in which it receives payments from customers based upon contractual billing schedules. The Company records accounts receivable when the right to consideration becomes unconditional. Contract assets include amounts related to the Company’s contractual right to consideration for completed performance obligations not yet invoiced. Contract liabilities primarily reflect deferred revenue from advance payment for product that the Company has received from customers. The Company classifies deferred revenue as current or noncurrent based on the timing of when the Company expects to recognize revenue.

Revenue recognized in the first nine months of 2020 from amounts included in contract liabilities at the beginning of the period was approximately $25 million (approximately $28 million in the first nine months of 2019). The amount of contract assets reclassified to receivables as a result of the right to the transaction consideration becoming unconditional was insignificant. The Company did not recognize any asset impairment charges related to contract assets during the period.

Contract Balances	September 30, 2020		December 31, 2019
In millions
Accounts and notes receivable - trade 1	$	2,938	$	3,007
Contract assets - current 2	$	—	$	35
Deferred revenue - current 3	$	18	$	20
Deferred revenue - noncurrent 4	$	25	$	24

1.Included in "Accounts and notes receivable - net" in the interim Condensed Consolidated Balance Sheets.

2.Included in "Other current assets" in the interim Condensed Consolidated Balance Sheets.

3.Included in "Accrued and other current liabilities" in the interim Condensed Consolidated Balance Sheets.

4.Included in "Other noncurrent obligations" in the interim Condensed Consolidated Balance Sheets.

NOTE 5 - RESTRUCTURING AND ASSET RELATED CHARGES - NET

Charges for restructuring programs and asset related charges, which include asset impairments, were $384 million and $807 million for the three and nine months ended September 30, 2020 ($82 million and $290 million for the three and nine months ended September 30, 2019). These charges were recorded in "Restructuring and asset related charges - net" in the interim Consolidated Statements of Operations. The total liability related to restructuring programs was $127 million at September 30, 2020 ($162 million at December 31, 2019). Restructuring activity consists of the following:

2020 Restructuring Program

In the first quarter of 2020, the Company approved restructuring actions designed to capture near-term cost reductions and to further simplify certain organizational structures in anticipation of the expected closure of the Intended N&B Transaction (the "2020 Restructuring Program").

The following tables summarize the charges related to the 2020 Restructuring Program for the three and nine months ended September 30, 2020:

	Three Months Ended September 30, 2020		Nine Months Ended September 30, 2020
In millions
Severance and related benefit costs	$	10	$	112
Asset related charges	4		28
Total restructuring and asset related charges - net	$	14	$	140

2020 Restructuring Program Charges by Segment	Three Months Ended September 30, 2020		Nine Months Ended September 30, 2020
In millions
Electronics & Imaging	$	1	$	5
Nutrition & Biosciences	5		12
Transportation & Industrial	—		21
Safety & Construction	2		24
Non-Core	1		1
Corporate	5		77
Total	$	14	$	140

20

The following table summarizes the activities related to the 2020 Restructuring Program:

2020 Restructuring Program	Severance and Related Benefit Costs		Asset Related Charges		Total
In millions
Year-to-date restructuring charges	$	112	$	28	$	140
Charges against the reserve	—		(28)		(28)
Cash payments	(42)		—		(42)
Reserve balance at September 30, 2020	$	70	$	—	$	70

At September 30, 2020, total liabilities related to the 2020 Restructuring Program were $70 million, recognized in "Accrued and other current liabilities" in the interim Condensed Consolidated Balance Sheets. The Company expects actions related to this program to be substantially complete by the end of 2020.

2019 Restructuring Program

During the second quarter of 2019 and in connection with the ongoing integration activities, DuPont approved restructuring actions to simplify and optimize certain organizational structures following the completion of the DWDP Distributions (the "2019 Restructuring Program"). The Company has recorded pre-tax restructuring charges of $140 million inception-to-date, consisting of severance and related benefit costs of $106 million and asset related charges of $34 million.

There were no charges incurred related to the 2019 Restructuring Program for the three months ended September 30, 2020. The following table summarizes the charges incurred for the three months ended September 30, 2019 and the nine months ended September 30, 2020 and September 30, 2019:

	Three Months Ended September 30,		Nine Months Ended September 30,
In millions	2019		2020		2019
Severance and related benefit costs	$	48	$	2	$	98
Asset related charges	21		—		24
Total restructuring and asset related charges - net	$	69	$	2	$	122

2019 Restructuring Program Charges (Credits) by Segment	Three Months Ended September 30,		Nine Months Ended September 30,
In millions	2019		2020		2019
Electronics & Imaging	$	35	$	(3)	$	42
Nutrition & Biosciences	4		(3)		18
Transportation & Industrial	6		(7)		18
Safety & Construction	3		(14)		20
Non-Core	3		—		3
Corporate	18		29		21
Total	$	69	$	2	$	122

The following table summarizes the activities related to the 2019 Restructuring Program:

2019 Restructuring Program	Severance and Related Benefit Costs
In millions
Reserve balance at December 31, 2019	$	86
Year-to-date restructuring charges	2
Non-cash compensation	(6)
Cash payments	(55)
Reserve balance at September 30, 2020	$	27

At September 30, 2020, total liabilities related to the 2019 Restructuring Program were $27 million, recognized in "Accrued and other current liabilities" ($86 million at December 31, 2019) in the interim Condensed Consolidated Balance Sheets. The 2019 Restructuring Program was considered substantially complete at June 30, 2020.

21

DowDuPont Cost Synergy Program

In September and November 2017, the Company approved post-merger restructuring actions under the DowDuPont Cost Synergy Program, which was designed to integrate and optimize the organization following the DWDP Merger and in preparation for the DWDP Distributions. The portions of the charges, costs and expenses attributable to integration and optimization within the Agriculture and Materials Science Divisions are reflected in discontinued operations. The Company has recorded pre-tax restructuring charges attributable to the continuing operations of DuPont of $489 million inception-to-date, consisting of severance and related benefit costs of $213 million, asset related charges of $209 million and contract termination and other charges of $67 million.

There were no charges incurred related to the DowDuPont Cost Synergy Program for the three months ended September 30, 2020. The following table summarizes the charges incurred for the three months ended September 30, 2019 and the nine months ended September 30, 2020 and September 30, 2019:

	Three Months Ended September 30,		Nine Months Ended September 30,
In millions	2019		2020		2019
Severance and related benefit costs (credits)	$	—	$	(2)	$	49
Contract termination and other charges	—		6		16
Asset related charges	14		—		43
Total restructuring and asset related charges - net 1	$	14	$	4	$	108

1. The charge for the three and nine months ended September 30, 2019 includes $13 million and $105 million which was recognized in "Restructuring and asset related charges - net" and $1 million and $3 million which was recognized in "Equity in earnings of nonconsolidated affiliates" in the interim Consolidated Statements of Operations.

DowDuPont Cost Synergy Program Charges (Credits) by Segment	Three Months Ended September 30,		Nine Months Ended September 30,
In millions	2019		2020		2019
Electronics & Imaging	$	—	$	—	$	—
Nutrition & Biosciences	3		—		38
Transportation & Industrial	—		1		—
Safety & Construction	2		5		7
Non-Core	(1)		—		(1)
Corporate	10		(2)		64
Total	$	14	$	4	$	108

The following table summarizes the activities related to the DowDuPont Cost Synergy Program:

DowDuPont Cost Synergy Program	Severance and Related Benefit Costs		Contract Termination Charges		Total
In millions
Reserve balance at December 31, 2019	$	74	$	2	$	76
Year-to-date restructuring (credits) charges	(2)		6		4
Charges against the reserve	—		(1)		(1)
Cash payments	(47)		(2)		(49)
Reserve balance at September 30, 2020	$	25	$	5	$	30

At September 30, 2020, total liabilities related to the DowDuPont Cost Synergy Program were $30 million, recognized in "Accrued and other current liabilities" ($76 million at December 31, 2019) in the interim Condensed Consolidated Balance Sheets. The DowDuPont Cost Synergy Program was considered substantially complete at June 30, 2020.

Asset Impairments

In the third quarter of 2020, the TCS/HSC Disposal within the Non-Core segment, as well as further softening conditions in the aerospace markets, gave rise to fair value indicators and, thus, served as triggering events requiring the Company to perform a recoverability assessment related to asset groups within its Photovoltaic and Advanced Materials (“PVAM”) business unit. The Company first performed a long-lived asset impairment test and determined that, based on undiscounted cash flows, the carrying amount of certain long-lived assets was not recoverable. Accordingly, the Company estimated the fair value of these assets using both an income approach and a market approach utilizing Level 3 unobservable inputs. As a result, the Company recognized a pre-tax impairment charge of $318 million ($242 million net of tax) recorded within “Restructuring and asset

22

related charges - net” in the interim Consolidated Statements of Operations for the three and nine months ended September 30, 2020 with the charge impacting definite-lived intangible assets and property, plant, and equipment. See Note 11 for further discussion of goodwill impairment charges recorded during the third quarter of 2020 resulting from the above triggering events.

Additionally, the Company recorded a pre-tax asset impairment charge of $52 million ($39 million net of tax) in the third quarter of 2020 related to indefinite-lived intangible assets within the Non-Core segment which were deemed no longer recoverable as a result of the Non-Core Held for Sale Disposal Groups classification (refer to Note 3 for additional information). The charge was recorded within “Restructuring and asset related charges – net” in the interim Consolidated Statements of Operations for the three and nine months ended September 30, 2020.

In the second quarter of 2020, the Company recorded a pre-tax impairment charge of $21 million ($16 million net of tax) related to indefinite-lived intangible assets within the Transportation & Industrial segment. This charge was recorded within “Restructuring and asset related charges - net” in the interim Consolidated Statements of Operations for the nine months ended September 30, 2020. See Note 11 for further discussion.

In the first quarter of 2020, expectations of proceeds related to certain potential divestitures within the Non-Core segment gave rise to fair value indicators and, thus, triggering events requiring the Company to perform a recoverability assessment related to its biomaterials business unit. The Company performed a long-lived asset impairment test and determined that, based on undiscounted cash flows, the carrying amount of certain long-lived assets was not recoverable. Accordingly, the Company estimated the fair value of these assets using a market approach utilizing Level 3 unobservable inputs. As a result, the Company recognized a pre-tax impairment charge of $270 million ($206 million net of tax) recorded within “Restructuring and asset related charges - net” in the interim Consolidated Statements of Operations for the nine months ended September 30, 2020 with the charge impacting definite-lived intangible assets and property, plant, and equipment.

Equity Method Investment Impairment Related Charges

In preparation for the Corteva Distribution, Historical EID completed the separation of the assets and liabilities related to its specialty products businesses into separate legal entities (the “SP Legal Entities”) and on May 1, 2019, Historical EID distributed the SP Legal Entities to DowDuPont (the “Internal SP Distribution”). The Internal SP Distribution served as a triggering event requiring the Company to perform an impairment analysis related to equity method investments held by the Company as of May 1, 2019. The Company applied the net asset value method under the cost approach to determine the fair value of the equity method investments in the Nutrition & Biosciences segment. Based on updated projections, the Company determined the fair value of the equity method investment was below the carrying value and had no expectation the fair value would recover in the short-term due to the current economic environment. As a result, management concluded the impairment was other-than-temporary and recorded a pre-tax impairment charge of $63 million ($47 million net of tax) in “Restructuring and asset related charges - net” in the interim Consolidated Statements of Operations related to the Nutrition & Biosciences segment for the nine months ended September 30, 2019.

23

NOTE 6 - SUPPLEMENTARY INFORMATION

Sundry Income (Expense) - Net	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2020		2019		2020		2019
Non-operating pension and other post-employment benefit (OPEB) credits	$	5	$	21	$	24	$	60
Interest income	3		1		7		50
Net gain on divestiture and sales of other assets and investments 1,2,3	419		64		612		127
Foreign exchange losses, net	(10)		(23)		(41)		(101)
Miscellaneous income (expenses) - net 4	13		16		25		8
Sundry income (expense) - net	$	430	$	79	$	627	$	144

1.The three and nine months ended September 30, 2020 includes a net benefit of $393 million related to the TCS/HSC Disposal, including the settlement of a supply agreement dispute, within the Non-Core segment. Refer to Note 3 for further information.

2. The nine months ended September 30, 2020 includes income of $197 million related to the gain on sale of the Compound Semiconductor Solutions business unit within the Electronics & Imaging segment.

3. The three and nine months ended September 30, 2020 includes income of $30 million related to a prior year sale of assets within the Electronics & Imaging segment. The three and nine months ended September 30, 2019 includes income of $34 million and $85 million, respectively, related to a sale of assets within the Electronics & Imaging segment, as well as a gain of $28 million related to the sale of the Sustainable Solutions business unit within the Non-Core segment.

4. Miscellaneous income (expenses) - net for the nine months ended September 30, 2019 includes a $48 million charge reflecting a reduction in gross proceeds from lower withholding taxes related to a prior year settlement. The nine months ended September 30, 2019 also includes $26 million related to licensing income within the Safety & Construction segment.

Cash, Cash Equivalents and Restricted Cash

On September 16, 2020, Nutrition & Biosciences, Inc. (presently a wholly owned subsidiary of DuPont) (“N&B Inc.”) completed an offering of $6.25 billion of senior unsecured notes (the “N&B Notes Offering”). The net proceeds of approximately $6.2 billion from the N&B Notes Offering were deposited into an escrow account. In connection with the intended merger of DuPont's Nutrition & Biosciences business with IFF (the "Intended Merger"), N&B Inc. will make a special cash payment of $7.3 billion, (the “Special Cash Payment”), subject to adjustment, to DuPont, which N&B Inc. will fund with the net proceeds from the N&B Notes Offering together with borrowings under N&B Inc.’s existing Term Loan facilities. The availability of the net proceeds to fund part of the Special Cash Payment and to pay the related financing fees and expenses is subject to certain conditions, including among others, satisfaction of substantially all the conditions to the consummation of the intended transaction with IFF. However, if the closing of the Intended Merger has not occurred on or prior to September 15, 2021, or, if prior to such date, the Merger Agreement is validly terminated, (each a “Special Mandatory Redemption Event”), N&B Inc. must redeem all of the Notes on or before the 15th business day following the Special Mandatory Redemption Event (such date of redemption, the “Special Mandatory Redemption Date”) at a redemption price equal to 101% of the aggregate principal amount of the applicable series of Notes, plus accrued and unpaid interest to, but not including, the Special Mandatory Redemption Date.

At September 30, 2020, the Company had approximately $6.2 billion in net proceeds from the N&B Notes Offering recorded within non-current “Restricted cash” in the interim Condensed Consolidated Balance Sheets. See Note 12 for further discussion of the N&B Notes Offering.

From time to time, the Company is required to set aside funds for various activities that arise in the normal course of business. These funds typically have legal restrictions associated with them and are deposited in an escrow account or held in a separately identifiable account by the Company. Historical EID entered into a trust agreement in 2013 (as amended and restated in 2017), establishing and requiring Historical EID to fund a trust (the "Trust") for cash obligations under certain non-qualified benefit and deferred compensation plans upon a change in control event as defined in the Trust agreement. Under the Trust agreement, the consummation of the DWDP Merger was a change in control event. After the distribution of Corteva, the Trust assets related to Corteva employees were transferred to a new trust for Corteva (the "Corteva Trust"). As a result, the Trust currently held by DuPont relates to funding obligations to DuPont employees. At September 30, 2020, the Company had restricted cash attributed to the Trust of $26 million ($37 million at December 31, 2019) included in "Other current assets" in the interim Condensed Consolidated Balance Sheets.

Accrued and Other Current Liabilities

"Accrued and other current liabilities" in the interim Condensed Consolidated Balance Sheets were $1,364 million at September 30, 2020 and $1,342 million at December 31, 2019. Accrued payroll, which is a component of "Accrued and other current liabilities," was $431 million at September 30, 2020 and $479 million at December 31, 2019. No other component of "Accrued and other current liabilities" was more than 5 percent of total current liabilities.

24

NOTE 7 - INCOME TAXES

For periods between the DWDP Merger and the DWDP Distributions, DuPont's consolidated federal income tax group and consolidated tax return included the Dow and Corteva entities. Generally, the consolidated tax liability of the DuPont U.S. tax group for each year was apportioned among the members of the consolidated group in accordance with the terms of the Amended and Restated DWDP Tax Matters Agreement. DuPont, Corteva and Dow intend that to the extent Federal and/or State corporate income tax liabilities are reduced through the utilization of tax attributes of the other, settlement of any receivable and payable generated from the use of the other party’s sub-group attributes will be in accordance with the Amended and Restated DWDP Tax Matters Agreement.

The Company's effective tax rate fluctuates based on, among other factors, where income is earned and the level of income relative to tax attributes. The effective tax rate on continuing operations for the third quarter of 2020 was 460.0 percent, compared with an effective tax rate of 17.3 percent for the third quarter of 2019. The effective tax rate for the third quarter of 2020 was principally the result of a non-tax-deductible goodwill impairment charge and a non-tax-deductible goodwill allocation in connection with the TCS/HSC Disposal impacting the Non-Core segment. The effective tax rate for the third quarter of 2019 was favorably impacted by, among other items, tax benefits related to the adjustment of certain unrecognized benefits for positions taken on items from a prior year.

For the first nine months of 2020, the effective tax rate on continuing operations was (3.3) percent, compared with (21.4) percent for the first nine months of 2019. The effective tax rate for the first nine months of 2020 was principally the result of a non-tax-deductible goodwill impairment charge impacting the Non-Core segment in the first and third quarter and a non-tax-deductible goodwill impairment charge impacting the Transportation and Industrial segment in the second quarter, coupled with an allocation of non-tax-deductible goodwill related to the TCS/HSC Disposal. The tax rate in the first nine months of 2019 was principally the result of the non-tax-deductible goodwill impairment charges impacting the Nutrition & Biosciences and Non-Core segments. See Note 11 for more information regarding the goodwill impairment charges.

Each year the Company files hundreds of tax returns in the various national, state and local income taxing jurisdictions in which it operates. These tax returns are subject to examination and possible challenge by the tax authorities. Positions challenged by the tax authorities may be settled or appealed by the Company. As a result, there is an uncertainty in income taxes recognized in the Company’s financial statements in accordance with accounting for income taxes and accounting for uncertainty in income taxes. The ultimate resolution of such uncertainties is not expected to have a material impact on the Company's results of operations.

25

NOTE 8 - EARNINGS PER SHARE CALCULATIONS

The following tables provide earnings per share calculations for the three and nine months ended September 30, 2020 and 2019:

Net Income for Earnings Per Share Calculations - Basic & Diluted	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2020		2019		2020		2019
(Loss) income from continuing operations, net of tax	$	(72)	$	372	$	(3,153)	$	(805)
Net income from continuing operations attributable to noncontrolling interests	7		5		20		18
Net income from continuing operations attributable to participating securities 1	—		—		—		1
(Loss) income from continuing operations attributable to common stockholders	$	(79)	$	367	$	(3,173)	$	(824)
Income from discontinued operations, net of tax	—		5		—		1,217
Net income from discontinued operations attributable to noncontrolling interests	—		—		—		72
Income from discontinued operations attributable to common stockholders	—		5		—		1,145
Net (loss) income attributable to common stockholders	$	(79)	$	372	$	(3,173)	$	321

Earnings Per Share Calculations - Basic	Three Months Ended September 30,				Nine Months Ended September 30,
Dollars per share	2020		2019		2020		2019
(Loss) earnings from continuing operations attributable to common stockholders	$	(0.11)	$	0.49	$	(4.31)	$	(1.10)
Income from discontinued operations, net of tax	—		0.01		—		1.53
Net (loss) earnings attributable to common stockholders	$	(0.11)	$	0.50	$	(4.31)	$	0.43

Earnings Per Share Calculations - Diluted	Three Months Ended September 30,				Nine Months Ended September 30,
Dollars per share	2020		2019		2020		2019
(Loss) earnings from continuing operations attributable to common stockholders	$	(0.11)	$	0.49	$	(4.31)	$	(1.10)
Income from discontinued operations, net of tax	—		0.01		—		1.53
Net (loss) earnings attributable to common stockholders	$	(0.11)	$	0.50	$	(4.31)	$	0.43

Share Count Information	Three Months Ended September 30,		Nine Months Ended September 30,
Shares in millions	2020	2019	2020	2019
Weighted-average common shares - basic	734.4	745.5	735.8	748.2
Plus dilutive effect of equity compensation plans	—	2.2	—	—
Weighted-average common shares - diluted	734.4	747.7	735.8	748.2
Stock options and restricted stock units excluded from EPS calculations 2	5.5	3.8	6.3	2.8

1.Historical Dow restricted stock units are considered participating securities due to Historical Dow's practice of paying dividend equivalents on unvested shares.

2. These outstanding options to purchase shares of common stock and restricted stock units were excluded from the calculation of diluted earnings per share because the effect of including them would have been antidilutive.

26

NOTE 9 - INVENTORIES

Inventories	September 30, 2020		December 31, 2019
In millions
Finished goods	$	2,407	$	2,621
Work in process	803		855
Raw materials	465		599
Supplies	227		244
Total inventories	$	3,902	$	4,319

NOTE 10 - NONCONSOLIDATED AFFILIATES

The Company's investments in companies accounted for using the equity method ("nonconsolidated affiliates"), by classification in the interim Condensed Consolidated Balance Sheets, are shown in the following table:

Investments in Nonconsolidated Affiliates	September 30, 2020		December 31, 2019
In millions
Investments in nonconsolidated affiliates	$	951	$	1,204
Accrued and other current liabilities	(74)		(85)
Other noncurrent obligations	—		(358)
Net investment in nonconsolidated affiliates	$	877	$	761

At September 30, 2020, the Company had an ownership interest in 18 nonconsolidated affiliates.

HSC Group

In the third quarter of 2020, the Company sold its equity interest in the HSC group. See Note 3 for further discussion. The following table reflects the carrying value of the HSC Group investments at December 31, 2019:

Investment in the HSC Group		Investment
In millions	Balance Sheet Classification	Dec 31, 2019
Hemlock Semiconductor L.L.C.	Other noncurrent obligations	$	(358)
DC HSC Holdings LLC	Investments in nonconsolidated affiliates	$	87

Sales to nonconsolidated affiliates represented less than 2 percent of total net sales for the three and nine months ended September 30, 2020 and less than 3 percent of total net sales for the three and nine months ended September 30, 2019. Sales to nonconsolidated affiliates are primarily related to the sale of trichlorosilane, a raw material used in the production of polycrystalline silicon, to the HSC Group, prior to the TCS/Hemlock Disposal. Sales of this raw material to the HSC Group are reflected in Non-Core. Purchases from nonconsolidated affiliates represented less than 2 percent of “Cost of sales” for the three and nine months ended September 30, 2020 and 2019.

27

NOTE 11 - GOODWILL AND OTHER INTANGIBLE ASSETS

The changes in the carrying amounts of goodwill during the nine months ended September 30, 2020 were as follows:

	Elect. & Imaging		Nutrition & Biosciences		Transp. & Industrial		Safety & Const.		Non-Core		Total
In millions
Balance at December 31, 2019	$	7,092	$	11,012	$	6,931	$	6,711	$	1,405	$	33,151
Acquisitions	—		—		—		53		—		53
Divestitures 1	(199)		—		—		—		(514)		(713)
Impairments	—		—		(2,498)		—		(716)		(3,214)
Currency Translation Adjustment	41		206		67		84		—		398
Measurement Period Adjustments	—		—		—		15		—		15
Balance at September 30, 2020	$	6,934	$	11,218	$	4,500	$	6,863	$	175	$	29,690

1. Includes $267 million of goodwill related to the Non-Core segment reclassified as held for sale in connection with the Non-Core Held for Sale Disposal Groups. Refer to Note 3 for further information.

The Company tests goodwill and indefinite-lived intangible assets for impairment annually during the fourth quarter as of October 1, or more frequently when events or changes in circumstances indicate that fair value is below carrying value. As a result of the related acquisition method of accounting in connection with the DWDP Merger, Historical EID’s assets and liabilities were measured at fair value resulting in increases to the Company’s goodwill and other intangible assets. The fair value valuation increased the risk that declines in financial projections, including changes to key assumptions, could have a material, negative impact on the fair value of the Company’s reporting units and assets, and therefore could result in an impairment.

In the third quarter of 2020, the TCS/HSC Disposal within the Non-Core segment, as well as further softening conditions in aerospace markets, served as triggering events requiring the Company to perform recoverability assessments related to asset groups within its PVAM business unit. These assessments resulted in the Company recording asset impairment charges related to certain long-lived assets whose carrying values were deemed not recoverable (refer to Note 5 for additional information). The Company then performed a series of impairment analyses related to goodwill associated with the PVAM business unit. The goodwill impairment analyses included an assessment of the preceding PVAM reporting unit as well as assessments of re-defined reporting units within the PVAM business unit resulting from the TCS/HSC Disposal along with recent progress in the sales processes for other Non-Core business units, including reallocation of goodwill on a relative fair value basis. As a result of these analyses, the Company determined that the fair value of certain reporting units was below carrying value resulting in impairment charges of goodwill. In connection with the foregoing and as a result of the Non-Core Held For Sale Disposal Groups classification (see Note 3 for additional information), the Company recorded aggregate, pre-tax, non-cash impairment charges of $183 million in the third quarter of 2020 impacting the Non-Core segment and reflected in "Goodwill impairment charges" in the Consolidated Statements of Operations. As a result of the above impairment charges and previous impairment charges recorded impacting Non-Core as discussed below, the carrying value of the reporting units within Non-Core are indicative of fair value. As a result, future changes in fair value could impact the carrying value of these business units which have been and continue to be at risk for impairment charges in future periods.

The Company’s analyses above use a combination of the discounted cash flow models (a form of the income approach) utilizing Level 3 unobservable inputs and the market approach. The Company’s significant assumptions in these analyses include, but are not limited to, future cash flow projections, the weighted average cost of capital, the terminal growth rate, and the tax rate. The Company’s estimates of future cash flows are based on current regulatory and economic climates, recent operating results, and planned business strategies. These estimates could be negatively affected by changes in federal, state, or local regulations or economic downturns. Future cash flow estimates are, by their nature, subjective and actual results may differ materially from the Company’s estimates. If the Company’s ongoing estimates of future cash flows are not met, the Company may have to record additional impairment charges in future periods. As referenced, the Company also uses a form of the market approach (utilizes Level 3 unobservable inputs), which is derived from metrics of publicly traded companies or historically completed transactions of comparable businesses. The selection of comparable businesses is based on the markets in which the reporting units operate giving consideration to risk profiles, size, geography, and diversity of products and services. As such, the Company believes the current assumptions and estimates utilized are both reasonable and appropriate.

In the second quarter of 2020, continued near-term demand weakness in global automotive production resulting from the COVID-19 pandemic, along with revised views of recovery based on third party market information, served as a triggering event requiring the Company to perform an impairment analysis of the goodwill associated with its Transportation & Industrial reporting unit as of June 30, 2020. The carrying value of the Transportation & Industrial reporting unit is comprised substantially of Historical EID’s assets and liabilities which were measured at fair value in connection with the DWDP Merger, and thus inherently considered at risk for impairment. The Company performed quantitative testing on its Transportation &

28

Industrial reporting unit as of June 30, 2020, using a combination of the discounted cash flow model (a form of the income approach) utilizing Level 3 unobservable inputs and the Guideline Public Company Method (a form of the market approach). Based on the analysis performed, during the second quarter of 2020, the Company concluded that the carrying amount of the reporting unit exceeded its fair value resulting in a pre-tax, non-cash goodwill impairment charge of $2,498 million, reflected in "Goodwill impairment charges" in the Consolidated Statements of Operations for the nine months ended September 30, 2020.

In the first quarter of 2020, expectations of proceeds related to certain potential divestitures within the Non-Core segment gave rise to fair value indicators and, thus, served as triggering events requiring the Company to perform impairment analyses related to goodwill as of March 31, 2020. As part of the analysis, the Company determined that the fair value of its PVAM reporting unit was below its carrying value resulting in an impairment charge to goodwill. Valuations of the PVAM reporting unit under a combination of the market approach and income approach reflected softening conditions in photovoltaics markets as compared to prior estimates. In connection with this analysis, the Company recorded a pre-tax, non-cash goodwill impairment charge of $533 million in the first quarter of 2020 impacting the Non-Core segment. This charge is reflected in "Goodwill impairment charges" in the Consolidated Statements of Operations for the nine months ended September 30, 2020.

In the second quarter of 2019, the Company recorded pre-tax, non-cash goodwill impairment charges of $1,175 million impacting the Nutrition & Biosciences and Non-Core segments which are reflected in "Goodwill impairment charges" in the interim Consolidated Statements of Operations for the nine months ended September 30, 2019.

COVID-19 continues to adversely impact the broader global economy and has caused significant volatility in financial markets. If there is a of lack of recovery, the time period to recovery is longer than expected or further global softening is experienced in certain markets, such as automotive, aerospace, commercial construction, oil & gas and select industrial end-markets, or a sustained decline in the value of the Company's common stock, the Company may be required to perform additional impairment assessments for its goodwill, other intangibles, and long-lived assets, the results of which could result in material impairment charges.

Other Intangible Assets

The gross carrying amounts and accumulated amortization of other intangible assets by major class are as follows:

	September 30, 2020						December 31, 2019
In millions	Gross Carrying Amount		Accum Amort		Net		Gross Carrying Amount		Accum Amort		Net
Intangible assets with finite lives:
Developed technology	$	4,229	$	(1,705)	$	2,524	$	4,343	$	(1,361)	$	2,982
Trademarks/tradenames	2,395		(1,378)		1,017		2,433		(455)		1,978
Customer-related	8,942		(2,644)		6,298		8,986		(2,229)		6,757
Other	175		(85)		90		303		(98)		205
Total other intangible assets with finite lives	$	15,741	$	(5,812)	$	9,929	$	16,065	$	(4,143)	$	11,922
Intangible assets with indefinite lives:
Trademarks/tradenames	1,599		—		1,599		1,671		—		1,671
Total other intangible assets	1,599		—		1,599		1,671		—		1,671
Total	$	17,340	$	(5,812)	$	11,528	$	17,736	$	(4,143)	$	13,593

In the third quarter of 2020, the Company recorded a pre-tax asset impairment charge of $52 million ($39 million net of tax) related to indefinite-lived intangible assets within the Non-Core segment which were deemed no longer recoverable as a result of the Non-Core Held For Sale Disposal Groups classification (see Note 3 for additional information). The charge was recorded within “Restructuring and asset related charges – net” in the interim Consolidated Statements of Operations for the three and nine months ended September 30, 2020.

In the first quarter and third quarter of 2020, the Company recorded non-cash impairment charges related to definite-lived intangible assets impacting the Non-Core segment reflected within “Restructuring and asset related charges - net” in the interim Consolidated Statements of Operations for the nine months ended September 30, 2020. See Note 5 for further discussion.

In the second quarter of 2020, the Company performed quantitative testing on indefinite-lived intangible assets attributable to the Transportation & Industrial segment, for which the Company determined that the fair value of certain tradenames had declined related to the factors described above. The Company performed an analysis of the fair value using the relief from royalty method (a form of the income approach) using Level 3 inputs within the fair value hierarchy. The key assumptions used in the calculation included projected revenue, royalty rates and discount rates. These key assumptions involve management

29

judgment and estimates relating to future operating performance and economic conditions that may differ from actual cash flows. As a result of the testing, the Company recorded a pre-tax, non-cash indefinite-lived intangible asset impairment charge of $21 million ($16 million net of tax), which is reflected in "Restructuring and asset related charges - net," in the Consolidated Statements of Operations for the nine months ended September 30, 2020. The remaining net book value of the tradenames attributable to the Transportation & Industrial segment at September 30, 2020 was approximately $289 million, which represents fair value.

The following table provides the net carrying value of other intangible assets by segment:

Net Intangibles by Segment	September 30, 2020		December 31, 2019
In millions
Electronics & Imaging	$	1,686	$	1,833
Nutrition & Biosciences	3,360		4,377
Transportation & Industrial	3,429		3,590
Safety & Construction	2,956		3,082
Non-Core	97		711
Total	$	11,528	$	13,593

NOTE 12 - SHORT-TERM BORROWINGS, LONG-TERM DEBT AND AVAILABLE CREDIT FACILITIES

Nutrition & Biosciences Financing

In connection with the Intended N&B Transaction, N&B Inc. entered into a Bridge Commitment Letter (the “Bridge Letter”) in an aggregate principal amount of $7.5 billion (the “Bridge Loans”) to secure committed financing for the "Special Cash Payment" and related financing fees. The aggregate commitment under the Bridge Letter is reduced by, among other things, (1) the amount of net cash proceeds received by N&B Inc. from any issuance of senior unsecured notes pursuant to a Rule 144A offering or other private placement and (2) certain qualifying term loan commitments under senior unsecured term loan facilities.

In January 2020, N&B Inc. entered into a senior unsecured term loan agreement in the amount of $1.25 billion split evenly between three- and five-year facilities (the “N&B Term Loan Facilities”). As a result of entry into the term loan agreement, the commitments under the Bridge Commitment Letter were reduced to $6.25 billion.

On September 16, 2020 (the "Offering Date"), N&B Inc. completed an offering in the aggregate principal amount of $6.25 billion of senior unsecured notes in six series, comprised of the following (collectively, the “N&B Notes Offering” and together with the N&B Term Loan Facilities, the “Permanent Financing”): $300 million aggregate principal amount of 0.697% Senior Notes due 2022; $1.0 billion aggregate principal amount of 1.230% Senior Notes due 2025; $1.2 billion aggregate principal amount of 1.832% Senior Notes due 2027; $1.5 billion aggregate principal amount of 2.300% Senior Notes due 2030; $750 million aggregate principal amount of 3.268% Senior Notes due 2040; and $1.5 billion aggregate principal amount of 3.468% Senior Notes due 2050. As a result of the N&B Notes Offering, the commitments under the Bridge Commitment Letter were further reduced to zero and were terminated on and as of the Offering Date.

The net proceeds of approximately $6.2 billion from the N&B Notes Offering were deposited into an escrow account. The release of the net proceeds from the N&B Notes Offering and the availability of funding under the term loan agreement are subject to customary closing conditions including among others, the satisfaction of substantially all the conditions to the consummation of the intended transaction with IFF. The proceeds from the Permanent Financing will be used to make the Special Cash Payment and to pay the related financing fees and expenses. The obligations and liabilities associated with the Permanent Financing will be separated from the Company upon consummation of the Intended N&B Transaction. However, if the closing of the Intended Merger has not occurred on or prior to September 15, 2021, or, if prior to such date, the Merger Agreement is validly terminated, (each a “Special Mandatory Redemption Event”), N&B Inc. must redeem all of the Notes on or before the 15th business day following the Special Mandatory Redemption Event (such date of redemption, the “Special Mandatory Redemption Date”) at a redemption price equal to 101% of the aggregate principal amount of the applicable series of Notes, plus accrued and unpaid interest to, but not including, the Special Mandatory Redemption Date.

Pursuant to the Merger Agreement, the fees and expenses associated with the financing will be borne (A) entirely by N&B Inc. if the transaction closes; and (B) equally by DuPont and IFF if the Merger Agreement terminates. However, if the Merger Agreement is terminated by IFF, in accordance with its terms, for breach by DuPont, such fees and expenses will be borne entirely by DuPont; and if terminated by DuPont in accordance with its terms for breach by IFF, such fees and expenses will be borne entirely by IFF.

30

May Debt Offering

On May 1, 2020, the Company completed an underwritten public offering of senior unsecured notes (the “Notes”) in the aggregate principal amount of $2 billion of 2.169 percent fixed rate Notes due May 1, 2023 (the “May Debt Offering”). The proceeds from the May Debt Offering are expected to be used by the Company to repay or redeem the Company’s $0.5 billion in floating rate notes due November 2020 and $1.5 billion of 3.77 percent fixed-rate notes due November 2020 (collectively, the “2020 Notes”). Upon consummation of the Intended N&B Transaction, the Company will be required to mail a notice of redemption to holders of the Notes, with a copy to the Trustee, setting forth the date of redemption of all of the Notes on the date (“Special Mandatory Redemption Date”) that is the later of (i) three (3) Business Days after the consummation of the Intended N&B Transaction and (ii) May 1, 2021. On the Special Mandatory Redemption Date, the Company will be required to redeem all of the Notes at a redemption price equal to 100% of the aggregate principal amount of the Notes plus accrued and unpaid interest, if any, up to but excluding the Special Mandatory Redemption Date. The Indenture also contains certain limitations on the Company’s ability to incur liens and enter into sale lease-back transactions, as well as customary events of default.

Revolving Credit Facility

In June 2019, the Company entered into a $750 million, 364-day revolving credit facility (the "Old 364-Day Revolving Credit Facility"). On and effective as of April 16, 2020, the Company entered into a new $1.0 billion 364-day revolving credit facility (the “$1B Revolving Credit Facility"). As of the effectiveness of the $1B Revolving Credit Facility, the Old 364-Day Revolving Credit Facility was terminated.

31

NOTE 13 - COMMITMENTS AND CONTINGENT LIABILITIES

Litigation and Environmental Matters

As of September 30, 2020, the Company had recorded liabilities of $23 million associated with litigation matters and $79 million associated with environmental matters. These recorded liabilities include the Company’s indemnification obligations to each of Dow and Corteva.

Under the DWDP Separation and Distribution Agreement, liabilities, including cost and expenses, associated with litigation and environmental matters that primarily related to the materials science business, the agriculture business or the specialty products business were generally allocated to or retained by Dow, Corteva or the Company, respectively, through retention, assumption or indemnification. Related to the foregoing, at September 30, 2020, DuPont has recorded (i) a liability of $37 million (although it is reasonably possible that the ultimate cost could range up to $108 million above the amount accrued) for retained or assumed environmental liabilities, (ii) a liability of $2 million for retained or assumed litigation liabilities, and (iii) an indemnification liability related to legal and environmental matters of $58 million. Liabilities associated with discontinued and/or divested operations and businesses of Historical Dow generally were allocated to or retained by Dow. The allocation of liabilities associated with the discontinued and/or divested operations and businesses of Historical EID is discussed below.

Discontinued and/or Divested Operations and Businesses ("DDOB") Liabilities of Historical EID

Under the DWDP Separation and Distribution Agreement and the Letter Agreement between Corteva and DuPont, DDOB liabilities of Historical EID primarily related to Historical EID’s agriculture business were allocated to or retained by Corteva and those primarily related to Historical EID’s specialty products business were allocated to or retained by the Company. Historical EID DDOB liabilities not primarily related to Historical EID’s agriculture business or specialty products business (“Stray Liabilities”), are allocated as follows:

•Generally, indemnifiable losses as defined in the DWDP Separation and Distribution Agreement, (“Indemnifiable Losses”) for Stray Liabilities, to the extent they do not arise out of actions related to or resulting from the development, testing, manufacture or sale of PFAS, defined below, (“Non-PFAS Stray Liabilities”) that are known as of April 1, 2019 are borne by Corteva up to a specified amount set forth in the schedules to the DWDP Separation and Distribution Agreement and/or Letter Agreement. Non-PFAS Stray Liabilities in excess of such specified amounts and any Non-PFAS Stray Liabilities not listed in the schedules to the DWDP Separation and Distribution Agreement or Letter Agreement are borne by Corteva and/or DuPont up to separate, aggregate thresholds of $200 million each to the extent Corteva or DuPont, as applicable, incurs an Indemnifiable Loss. Once Corteva’s or DuPont’s $200 million threshold is met, the other would generally bear all Non-PFAS Stray Liabilities until meeting its $200 million threshold. After the respective $200 million thresholds are met, DuPont will bear 71 percent of such losses and Corteva will bear 29 percent of such losses.

•Generally, Corteva and the Company will each bear 50 percent of the first $300 million (up to $150 million each) for Indemnifiable Losses arising out of actions to the extent related to or resulting from the development, testing, manufacture or sale of per- or polyfluoroalkyl substances, which include collectively perfluorooctanoic acids and its salts (“PFOA”), perfluorooctanesulfonic acid (“PFOS”) and perfluorinated chemicals and compounds (“PFCs”) (all such substances, “PFAS” and such Stray Liabilities referred to as “PFAS Stray Liabilities”). Indemnifiable Losses to the extent related to PFAS Stray Liabilities in excess of $300 million generally will be borne 71 percent by the Company and 29 percent by Corteva, unless either Corteva or DuPont has met its $200 million threshold. In that event, the other company would bear all PFAS Stray Liabilities until that company meets its $200 million threshold, at which point DuPont will bear 71 percent of such losses and Corteva will bear 29 percent of such losses.

•Indemnifiable Losses incurred by the companies in relation to PFAS Stray Liabilities up to $300 million (e.g., up to $150 million each) will be applied to each company’s respective $200 million threshold.

Indemnifiable Losses, as defined in the DWDP Separation and Distribution Agreement, include, among other things, attorneys’, accountants’, consultants’ and other professionals’ fees and expenses incurred in the investigation or defense of Stray Liabilities.

DuPont expects to continue to incur directly and as Indemnifiable Losses, costs and expenses related to litigation defense, such as attorneys’ fees and expenses and court costs, in connection with the Stray Liabilities described below. In accordance with its accounting policy for litigation matters, the Company will expense such litigation defense costs as incurred which could be significant to the Company’s financial condition and/or cash flows in the period.

32

Even when the Company believes the probability of loss or of an adverse unappealable final judgment is remote, the Company may consider settlement of these matters, and may enter into settlement agreements, if it believes settlement is in the best interest of the Company, including avoidance of future distraction and litigation defense cost, and its shareholders.

Stray Liabilities

Non-PFAS Stray Liabilities

While DuPont believes it is probable that it will incur a liability related to Non-PFAS Stray Liabilities, such liability is not reasonably estimable at September 30, 2020. Therefore, at September 30, 2020, DuPont has not recorded an accrual related to Non-PFAS Liabilities.

PFAS Stray Liabilities

Chemours Suit

On July 1, 2015, Historical EID completed the separation of Historical EID’s Performance Chemicals segment through the spin-off of all the issued and outstanding stock of The Chemours Company (“Chemours”) to holders of Historical EID common stock. In connection with the spin, Historical EID and Chemours entered into a Separation Agreement (as amended, the "Chemours Separation Agreement"). Pursuant to the Chemours Separation Agreement, Chemours is obligated to indemnify Historical EID, including its current or former affiliates, against certain litigation, environmental and other liabilities that arose prior to the Chemours Separation. The term of this indemnification is generally indefinite and includes defense costs and expenses, as well as monetary and non-monetary settlements and judgments.

In 2017, Historical EID and Chemours amended the Chemours Separation Agreement to provide for a limited sharing of potential future PFOA liabilities for a five-year period that began on July 6, 2017. The amended agreement provides that during that five-year period, Chemours will annually pay the first $25 million of future PFOA liabilities and, if that amount is exceeded, Historical EID will pay any excess amount up to the next $25 million, with Chemours annually bearing any excess liabilities above that amount. If Historical EID were required to pay PFOA liabilities pursuant to the amended agreement, fifty percent of such obligation would be borne by the Company in accordance with the Letter Agreement. In connection with the foregoing, the Company has not recorded or paid a PFOA liability. At the end of the five-year period, this limited sharing agreement will expire, and Chemours’ indemnification obligations under the Chemours Separation Agreement will continue unchanged.

On May 13, 2019, Chemours filed suit in the Delaware Court of Chancery against Historical EID, Corteva and the Company in an attempt to limit its responsibility for the litigation and environmental liabilities allocated to and assumed by Chemours under the Chemours Separation Agreement. Chemours is asking the court to rewrite the Chemours Separation Agreement by either limiting Chemours’ liabilities or, alternatively, ordering the return to Chemours of all or a portion of a $3.91 billion dividend that Chemours paid to Historical EID, Chemours’ then-sole-shareholder, just prior to the spin of Chemours. DuPont and Corteva, acting jointly, filed a motion to dismiss the lawsuit for lack of subject matter jurisdiction and initiated an arbitration of the dispute as required under the Chemours Separation Agreement. In December 2019, following argument, the Delaware Court of Chancery stayed arbitration pending resolution of the motion to dismiss. On March 30, 2020, the Court of Chancery granted the motion to dismiss and rejected Chemours’ arguments in their entirety. Chemours filed a notice of appeal on April 17, 2020 with the Delaware Supreme Court. The Delaware Supreme Court will hear oral argument on the appeal en banc on December 2, 2020. Meanwhile, the confidential arbitration process is proceeding.

Indemnifiable Losses related to the Chemours suit are PFAS Stray Liabilities subject to the sharing arrangement between DuPont and Corteva, described above. The Company believes the probability of a final unappealable judgment of liability with respect to the Chemours suit to be remote; the defendants continue to vigorously defend full indemnity rights as set forth in the Chemours Separation Agreement. 

PFAS Matters

Historical EID is a party to legal proceedings relating to the use of PFOA and PFCs by its former Performance Chemicals segment. Indemnifiable Losses related to PFAS liabilities allocated to and assumed by Chemours under the Chemours Separation Agreement generally are PFAS Stray Liabilities subject to the sharing arrangement between DuPont and Corteva, described above.

Generally, Chemours, with reservations, including as to alleged fraudulent conveyance and voidable transactions, is defending and indemnifying Historical EID in the PFAS Matters discussed below. Although Chemours has refused the tender of the Company’s defense in the actions in which the Company has been named, DuPont believes it is remote that it will ultimately incur a liability in connection with these PFAS Matters.

33

Ohio MDL Personal Injury Cases

DuPont, which was formed after the spin-off of Chemours, is not named in the personal injury and other PFAS actions discussed below.

In 2004, Historical EID settled a West Virginia state court class action, Leach v. DuPont, which alleged that PFOA from Historical EID’s former Washington Works facility had contaminated area drinking water supplies and affected the health of area residents. Historical EID has residual liabilities under the Leach settlement related to providing PFOA water treatment to six area water districts and private well users and to fund, through an escrow account, up to $235 million for a medical monitoring program for eligible class members.

Members of the Leach class have standing to pursue personal injury claims for just six health conditions that an expert panel appointed under the Leach settlement reported in 2012 had a “probable link” (as defined in the settlement) with PFOA: pregnancy-induced hypertension, including preeclampsia; kidney cancer; testicular cancer; thyroid disease; ulcerative colitis; and diagnosed high cholesterol. In 2017, Chemours and Historical EID each paid $335 million to settle the multi-district litigation in the U.S. District Court for the Southern District of Ohio (“Ohio MDL”), thereby resolving claims of about 3,550 plaintiffs alleging injury from exposure to PFOA in drinking water. The 2017 settlement did not resolve claims of Leach class members who did not have claims in the Ohio MDL or whose claims are based on diseases first diagnosed after February 11, 2017. About 80 claims alleging personal injury, including kidney and testicular cancer claims, have been filed since the 2017 settlement. These claims are currently pending in the Ohio MDL. The first two cases, one captioned “Abbott v E. I. du Pont de Nemours and Company” and the other “Swartz v. E. I. du Pont de Nemours and Company”, involving a testicular cancer and a kidney cancer claim, respectively, proceeded to trial in January 2020. In the Abbott case, the jury returned a verdict in March 2020 against Historical EID, awarding $50 million in compensatory damages to the plaintiff and his wife, who claimed that exposure to PFOA in drinking water caused him to develop testicular cancer. Historical EID will appeal the verdict. The plaintiffs also sought but were not awarded punitive damages. In the Swartz matter, the jury could not reach a verdict. Therefore, the court declared a mistrial and the matter will be retried at a later date. The trials in the cases originally scheduled for June 2020 have been further postponed from October 2020 to late November due to the COVID-19 pandemic.

Natural Resource Damage Claims and Other Claims for Environmental Damages

In addition to the actions described above, there several cases alleging damages to natural resources, the environment, water, and/or property as well as various other allegations. DuPont and Corteva are named or have been added as defendants in most of the actions discussed below. Such actions include additional claims based on allegations that the transfer by Historical EID of certain PFAS liabilities to Chemours prior to separating Chemours resulted in a fraudulent conveyance or voidable transaction.

Natural Resource Damage Matters

Since May 2017, a number of state attorneys general have filed lawsuits against DuPont, Corteva, Historical EID, Chemours, and others, claiming environmental contamination by certain PFAS compounds. Such actions are currently pending in Michigan, New Jersey, New Hampshire, New York, North Carolina, Ohio and Vermont. Generally, the states raise common law tort claims and seek economic impact damages for alleged harm to natural resources, punitive damages, present and future costs to cleanup contamination from certain PFAS compounds, and to abate the alleged nuisance. The North Carolina action includes fraudulent transfer claims related to the Chemours separation, the DowDuPont separations, and questions potential loss of assets caused by future divestitures.

Other PFAS Environmental Matters

Several lawsuits have been filed by residents, local water districts, and private water companies against Historical EID and Chemours in New York. Additionally, a water district in West Virginia, filed suit in state court against Historical EID, Chemours, Corteva, DuPont, and others alleging contamination as a result of PFOA and PFOS and seeking compensatory, consequential and punitive damages, and attorneys’ fees. The complaint includes a fraudulent transfer allegation associated with the Chemours separation. In September 2020, a complaint was filed in the Central District of California on behalf of Golden State Water Company against DuPont, Corteva, Historical EID, Chemours, and others, alleging contamination of water systems from PFOS and PFOA. The complaint includes fraudulent transfer claims related to the Chemours separation, the DowDuPont separations, and questions potential loss of assets caused by future divestitures.

North Carolina PFAS Actions

There are several actions pending in federal court against Historical EID and Chemours, relating to discharges of PFCs, including GenX, into the Cape Fear River. GenX is a polymerization processing aid and a replacement for PFOA introduced by Historical EID which Chemours continues to manufacture at its Fayetteville Works facility in Bladen County, North Carolina. One of these actions is a consolidated putative class action that asserts claims for damages and other relief on behalf of putative classes of property owners and residents in areas near or who draw drinking water from the Cape Fear River. Another action is

34

a consolidated action brought by various North Carolina water authorities, including the Cape Fear Public Utility Authority and Brunswick County, that seek actual and punitive damages as well as injunctive relief. In addition, an action is pending in North Carolina state court on behalf of about 100 plaintiffs who own wells and property near the Fayetteville Works facility. The plaintiffs seek damages for nuisance allegedly caused by releases of certain PFCs from the site.

In the third quarter 2020, 3 lawsuits were filed in North Carolina state court against Chemours, Historical EID, Corteva and DuPont. The lawsuits seek damages for alleged personal injuries to more than 100 individuals due to alleged exposure to PFOA and GenX originating from the Fayetteville Works plant. These lawsuits also include fraudulent transfer allegations related to the Chemours separation.

Aqueous Film Forming Foam

Beginning in April 2019, several dozen lawsuits involving water contamination arising from the use of PFAS-containing aqueous firefighting foams (“AFFF”) were filed against Historical EID, Chemours, 3M and other AFFF manufacturers and in different parts of the country. Most were consolidated in multi-district litigation docket in federal district court in South Carolina (the “SC MDL”). Many of those cases also name DuPont as a defendant. Those actions largely seek remediation of the alleged PFAS contamination in and around military bases and airports as well as medical monitoring of affected residents. In September 2020, a complaint was filed in Missouri state court on behalf of a deceased firefighter against 3M, DuPont, Corteva, Historical EID, Chemours and others. The suit seeks damages for injuries and wrongful death of the plaintiff allegedly from his exposure to PFAS contained in firefighting foam. This case has not been removed to the SC MDL.

As of the end of September 2020, approximately 750 personal injury cases have been filed directly in the SC MDL and assert claims on behalf of individual firefighters and others who allege that exposure to PFAS in firefighting foam caused them to develop cancer, including kidney and testicular cancer. DuPont has been named as a defendant in most of these personal injury AFFF cases. DuPont is seeking the dismissal of DowDuPont and DuPont from these actions. Historical EID and the Company have never made or sold aqueous film forming foam, PFOS or PFOS containing products.

Additionally, a case filed by a former firefighter is pending in the Southern District of Ohio seeking certification of a nationwide class of individuals who have detectable levels of PFAS in their blood serum. The suit was filed against 3M and several other defendants in addition to Chemours and Historical EID. The complaint specifically seeks, among other things, the creation of a “PFAS Science Panel” to study the effects of PFAS, but expressly states that the class does not seek compensatory damages for personal injuries. In February 2020, the court denied the defendants' motion to transfer this case to the SC MDL.

Other Litigation Matters

In addition to the specific matters described above, the Company is party to other claims and lawsuits arising out of the normal course of business with respect to product liability, patent infringement, governmental regulation, contract and commercial litigation, and other actions. Certain of these actions may purport to be class actions and seek damages in very large amounts. It is the opinion of the Company’s management that the possibility is remote that the aggregate of all such other claims and lawsuits will have a material adverse impact on the results of operations, financial condition and cash flows of the Company.

Environmental Matters

Accruals for environmental matters are recorded when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on current law and existing technologies. At September 30, 2020, the Company had accrued obligations of $79 million for probable environmental remediation and restoration costs, inclusive of $37 million retained and assumed following the DWDP Distributions and $42 million of indemnified liabilities. These obligations are included in "Accrued and other current liabilities" and "Other noncurrent obligations" in the interim Condensed Consolidated Balance Sheets. This is management’s best estimate of the costs for remediation and restoration with respect to environmental matters for which the Company has accrued liabilities, although it is reasonably possible that the ultimate cost with respect to these particular matters could range up to $172 million above the amount accrued at September 30, 2020. Consequently, it is reasonably possible that environmental remediation and restoration costs in excess of amounts accrued could have a material impact on the Company’s results of operations, financial condition and cash flows. Inherent uncertainties exist in these estimates primarily due to unknown conditions, changing governmental regulations and legal standards regarding liability, and emerging remediation technologies for handling site remediation and restoration. At December 31, 2019, the Company had accrued obligations of $77 million for probable environmental remediation and restoration costs.

Pursuant to the DWDP Separation and Distribution Agreement, the Company is required to indemnify certain clean-up responsibilities and associated remediation costs. The accrued environmental obligations of $79 million as of September 30, 2020 includes amount for which the Company indemnifies Dow and Corteva. At September 30, 2020, the Company has indemnified Dow and Corteva $8 million and $34 million, respectively.

35

Indemnifications

In connection with the ongoing divestitures and transactions, the Company has indemnified and has been indemnified by respective parties against certain liabilities that may arise in connection with these transactions and business activities prior to the completion of the respective transactions. The term of these indemnifications, which typically pertain to environmental, tax and product liabilities, is generally indefinite. At September 30, 2020, indemnified assets were $88 million within "Accounts and notes receivable, net" and $117 million within "Deferred charges and other assets" and indemnified liabilities were $60 million within "Accrued and other current liabilities" and $94 million within "Other noncurrent obligations."

Guarantees

Obligations for Equity Affiliates & Others

The Company has directly guaranteed various debt obligations under agreements with third parties related to equity affiliates and customers. At September 30, 2020 and December 31, 2019, the Company had directly guaranteed $177 million and $187 million, respectively, of such obligations. These amounts represent the maximum potential amount of future (undiscounted) payments that the Company could be required to make under the guarantees. The Company would be required to perform on these guarantees in the event of default by the guaranteed party.

The Company assesses the payment/performance risk by assigning default rates based on the duration of the guarantees. These default rates are assigned based on the external credit rating of the counterparty or through internal credit analysis and historical default history for counterparties that do not have published credit ratings. For counterparties without an external rating or available credit history, a cumulative average default rate is used.

In certain cases, the Company has recourse to assets held as collateral, as well as personal guarantees from customers. Assuming liquidation, these assets are estimated to cover less than 1 percent of the $17 million of guaranteed obligations of customers. The following table provides a summary of the final expiration year and maximum future payments for each type of guarantee:

Guarantees at September 30, 2020	Final Expiration Year	Maximum Future Payments
In millions
Obligations for customers 1:
Bank borrowings	2021	$	17
Obligations for non-consolidated affiliates 2:
Bank borrowings	2020	160
Total guarantees		$	177

1. Existing guarantees for select customers, as part of contractual agreements. The terms of the guarantees are equivalent to the terms of the customer loans that are primarily made to finance customer invoices. At September 30, 2020 all maximum future payments had terms less than a year.

2. Existing guarantees for non-consolidated affiliates' liquidity needs in normal operations.

36

NOTE 14 - OPERATING LEASES

The components of lease cost for operating leases were as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2020		2019		2020		2019
Operating lease costs	$	49	$	51	$	135	$	141

Operating cash flows from operating leases were $136 million and $150 million for the nine months ended September 30, 2020 and 2019, respectively.

Operating lease right-of-use assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. New operating lease assets and liabilities entered into during the nine months ended September 30, 2020 and 2019 were $168 million and $111 million, respectively. Supplemental balance sheet information related to leases was as follows:

In millions	September 30, 2020		December 31, 2019
Operating Leases
Operating lease right-of-use assets 1	$	621	$	556
Current operating lease liabilities 2	159		138
Noncurrent operating lease liabilities 3	465		416
Total operating lease liabilities	$	624	$	554

1.Included in "Deferred charges and other assets" in the interim Condensed Consolidated Balance Sheet.

2.Included in "Accrued and other current liabilities" in the interim Condensed Consolidated Balance Sheet.

3.Included in "Other noncurrent obligations" in the interim Condensed Consolidated Balance Sheet.

NOTE 15 - STOCKHOLDERS' EQUITY

Share Repurchase Program

On June 1, 2019, the Company's Board of Directors approved a $2 billion share buyback program, which expires on June 1, 2021. During the third quarter of 2020, the Company did not repurchase any shares. As of September 30, 2020, the Company had repurchased and retired 16.9 million shares under this program since inception at a total cost of $982 million.

Accumulated Other Comprehensive Loss

The following table summarizes the activity related to each component of accumulated other comprehensive loss ("AOCL") for the nine months ended September 30, 2020 and 2019:

Accumulated Other Comprehensive Loss	Unrealized Gains (Losses) on Investments		Cumulative Translation Adj		Pension and OPEB		Derivative Instruments		Total
In millions
2019
Balance at January 1, 2019	$	(51)	$	(3,785)	$	(8,476)	$	(82)	$	(12,394)
Other comprehensive income (loss) before reclassifications	68		(811)		47		(43)		(739)
Amounts reclassified from accumulated other comprehensive income (loss)	(1)		(18)		140		(15)		106
Net other comprehensive income (loss)	$	67	$	(829)	$	187	$	(58)	$	(633)
Spin-offs of Dow and Corteva	$	(16)	$	3,179	$	8,196	$	139	$	11,498
Balance at September 30, 2019	$	—	$	(1,435)	$	(93)	$	(1)	$	(1,529)
2020
Balance at January 1, 2020	$	—	$	(1,070)	$	(345)	$	(1)	$	(1,416)
Other comprehensive income (loss) before reclassifications	—		548		(9)		—		539
Amounts reclassified from accumulated other comprehensive income	—		—		18		—		18
Net other comprehensive income	$	—	$	548	$	9	$	—	$	557
Balance at September 30, 2020	$	—	$	(522)	$	(336)	$	(1)	$	(859)

37

The tax effects on the net activity related to each component of other comprehensive income (loss) for the three and nine months ended September 30, 2020 and 2019 were as follows:

Tax Benefit (Expense)	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2020		2019		2020		2019
Unrealized gains (losses) on investments	$	—	$	—	$	—	$	(18)
Cumulative translation adjustments	—		—		—		(1)
Pension and other post-employment benefit plans	1		(6)		3		(41)
Derivative instruments	—		—		—		16
Tax expense from income taxes related to other comprehensive income items	$	1	$	(6)	$	3	$	(44)

A summary of the reclassifications out of AOCL for the three and nine months ended September 30, 2020 and 2019 is provided as follows:

Reclassifications Out of Accumulated Other Comprehensive Loss	Three Months Ended September 30,				Nine Months Ended September 30,				Income Classification
In millions	2020		2019		2020		2019
Unrealized gains on investments	$	—	$	—	$	—	$	(1)	See (1) below
Tax expense (benefit)	—		—		—		—		See (2) below
After tax	$	—	$	—	$	—	$	(1)
Cumulative translation adjustments	$	—	$	—	$	—	$	(18)	See (3) below
Pension and other post-employment benefit plans	$	7	$	4	$	15	$	171	See (4) below
Tax expense (benefit)	2		(6)		3		(31)		See (2) below
After tax	$	9	$	(2)	$	18	$	140
Derivative Instruments	$	—	$	—	$	—	$	(18)	See (5) below
Tax expense	—		—		—		3		See (2) below
After tax	$	—	$	—	$	—	$	(15)
Total reclassifications for the period, after tax	$	9	$	(2)	$	18	$	106

1. "Net sales" and "Sundry income (expense) - net."

2. "Provision for income taxes on continuing operations."

3. "Sundry income (expense) - net."

4. These AOCL components are included in the computation of net periodic benefit cost of the Company's defined benefit pension and other post-employment benefit plans. See Note 17 for additional information.

5. "Cost of sales," "Sundry income (expense) - net" and "Interest expense."

NOTE 16 - NONCONTROLLING INTERESTS

Ownership interests in the Company's subsidiaries held by parties other than the Company are presented separately from the Company's equity in the interim Condensed Consolidated Balance Sheets as "Noncontrolling interests." The amounts of consolidated net income attributable to the Company and the noncontrolling interests are both presented on the face of the interim Consolidated Statements of Operations.

The following table summarizes the activity for equity attributable to noncontrolling interests for the three and nine months ended September 30, 2020 and 2019:

Noncontrolling Interests	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2020		2019		2020		2019
Balance at beginning of period	$	572	$	570	$	569	$	1,608
Net income attributable to noncontrolling interests	7		5		20		90
Distributions to noncontrolling interests	(38)		(6)		(48)		(18)
Cumulative translation adjustments	4		(2)		(1)		14
Spin-off of Dow and Corteva	—		—		—		(1,124)
Other	14		1		19		(2)
Balance at end of period	$	559	$	568	$	559	$	568

38

NOTE 17 - PENSION PLANS AND OTHER POST-EMPLOYMENT BENEFITS

A summary of the Company's pension plans and other post-employment benefits can be found in Note 20 to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019. Historical Dow and Historical EID did not merge their defined benefit pension and other post-employment benefit plans as a result of the DWDP Merger.

The following sets forth the components of the Company's net periodic benefit (credit) cost for defined benefit pension plans and other post-employment benefits:

Net Periodic Benefit (Credit) Cost for All Plans	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2020		2019		2020		2019
Defined Benefit Pension Plans:
Service cost 1	$	20	$	17	$	55	$	166
Interest cost 2	14		19		42		610
Expected return on plan assets 3	(28)		(35)		(82)		(954)
Amortization of prior service credit 4	(1)		(1)		(4)		(8)
Amortization of net loss (gain) 5	3		(6)		11		129
Curtailment/settlement 6	6		1		8		(1)
Net periodic benefit cost (credit) - total	$	14	$	(5)	$	30	$	(58)
Less: Net periodic benefit credit - discontinued operations	—		—		—		(45)
Net periodic benefit cost (credit) - continuing operations	$	14	$	(5)	$	30	$	(13)
Other Post-Employment Benefits:
Service cost 1	$	—	$	—	$	—	$	5
Interest cost 2	1		—		1		52
Amortization of net gain 5	—		—		—		(6)
Net periodic benefit cost - total	$	1	$	—	$	1	$	51
Less: Net periodic benefit cost - discontinued operations	—		—		—		50
Net periodic benefit cost - continuing operations	$	1	$	—	$	1	$	1

1. The service cost from continuing operations was $17 million and $47 million for the three and nine months ended September 30, 2019, respectively. The activity from OPEBs was immaterial.

2. The interest cost from continuing operations was $19 million and $60 million for the three and nine months ended September 30, 2019, respectively. The activity from OPEBs was immaterial.

3. The expected return on plan assets from continuing operations was $35 million and $114 million for the three and nine months ended September 30, 2019, respectively. The activity from OPEBs was immaterial.

4. The amortization of prior service credit from continuing operations was $1 million and $2 million for the three and nine months ended September 30, 2019, respectively. The activity from OPEBs was immaterial.

5. The amortization of unrecognized net gain from continuing operations was $6 million and $3 million for the three and nine months ended September 30, 2019, respectively. The activity from OPEBs was immaterial.

6. Curtailments and settlements from continuing operations resulted in a loss of $1 million for the three months ended September 30, 2019 and a gain of $1 million for the nine months ended September 30, 2019. The activity from OPEBs was immaterial.

The continuing operations portion of the net periodic benefit (credit) cost, other than the service cost component, is included in "Sundry income (expense) - net" in the interim Consolidated Statements of Operations.

DuPont expects to make additional contributions in the aggregate of approximately $30 million by year-end 2020.

39

NOTE 18 - STOCK-BASED COMPENSATION

A summary of the Historical Dow and Historical DuPont stock-based compensation plans can be found in Note 21 to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019. Historical Dow and Historical EID did not merge their equity incentive plans as a result of the DWDP Merger. The Historical Dow and Historical EID stock-based compensation plans were assumed by the Company and remained in place with the ability to grant and issue DowDuPont common stock until the DWDP Distributions.

Immediately following the Corteva Distribution, DuPont adopted the DuPont Omnibus Incentive Plan ("DuPont OIP") which provides for equity-based and cash incentive awards to certain employees, directors, independent contractors and consultants in the form of stock options, restricted stock units ("RSUs") and performance-based restricted stock units ("PSUs"). Upon adoption of the DuPont OIP, the Historical Dow and Historical EID plans were maintained and rolled into the DuPont OIP as separate subplans. The equity awards under these subplans have the same terms and conditions that were applicable to the awards under the Historical Dow and Historical EID plans immediately prior to the DWDP Distributions. Under the DuPont OIP, a maximum of 10 million shares of common stock are available for award as of September 30, 2020.

During the second quarter of 2020, the stockholders of DuPont approved the DuPont 2020 Equity and Incentive Plan (the "2020 Plan"). The 2020 Plan limits the number of shares that may be subject to awards payable in shares of DuPont common stock to 19 million. The 2020 Plan authorizes the Company to grant options, share appreciation rights, restricted shares, RSUs, share bonuses, other share-based awards, cash awards, each as defined in the 2020 Plan, or any combination of the foregoing. The approval of the 2020 Plan had no effect on the Company’s ability to make future grants under the DuPont OIP in accordance with its terms, and awards that are outstanding under the DuPont OIP remain outstanding in accordance with their terms. There has been no activity under the 2020 Plan to date.

DuPont recognized share-based compensation expense in continuing operations of $25 million and $30 million for the three months ended September 30, 2020 and 2019, respectively, and $94 million and $85 million during the nine months ended September 30, 2020 and 2019, respectively. The income tax benefits related to stock-based compensation arrangements were $5 million and $6 million for the three months ended September 30, 2020 and 2019, respectively, and $19 million and $18 million for the nine months ended September 30, 2020 and 2019, respectively.

In the first quarter of 2020, the Company granted 1.0 million RSUs, 0.8 million stock options and 0.3 million PSUs. The weighted-average fair values per share associated with the grants were $53.49 per RSU, $8.84 per stock option and $50.23 per PSU. The stock options had a weighted-average exercise price per share of $53.50. There was minimal activity in the second and third quarter of 2020.

40

NOTE 19 - FINANCIAL INSTRUMENTS

The following table summarizes the fair value of financial instruments at September 30, 2020 and December 31, 2019:

Fair Value of Financial Instruments	September 30, 2020								December 31, 2019
In millions	Cost		Gain		Loss		Fair Value		Cost		Gain		Loss		Fair Value
Cash equivalents	$	2,534	$	—	$	—	$	2,534	$	417	$	—	$	—	$	417
Restricted cash equivalents 1	$	6,232	$	—	$	—	$	6,232	$	37	$	—	$	—	$	37
Total cash and restricted cash equivalents	$	8,766	$	—	$	—	$	8,766	$	454	$	—	$	—	$	454
Long-term debt including debt due within one year	$	(23,806)	$	2	$	(2,375)	$	(26,179)	$	(15,618)	$	—	$	(1,633)	$	(17,251)
Derivatives relating to:
Foreign currency 2	—		4		(6)		(2)		—		6		(7)		(1)
Total derivatives	$	—	$	4	$	(6)	$	(2)	$	—	$	6	$	(7)	$	(1)

1.Includes $26 million of restricted cash classified as "Other current assets" and $6.2 billion classified as "Restricted cash" in the interim Condensed Consolidated Balance Sheets. Refer to Note 6 for further information.

2.Presented net of cash collateral where master netting arrangements allow.

Derivative Instruments

Objectives and Strategies for Holding Derivative Instruments

In the ordinary course of business, the Company enters into contractual arrangements (derivatives) to reduce its exposure to foreign currency, interest rate and commodity price risks. The Company has established a variety of derivative programs to be utilized for financial risk management. These programs reflect varying levels of exposure coverage and time horizons based on an assessment of risk.

Derivative programs have procedures and controls and are approved by the Corporate Financial Risk Management Committee, consistent with the Company's financial risk management policies and guidelines. Derivative instruments used are forwards, options, futures and swaps. As of the third quarter of 2020, the Company has not designated any derivatives or non-derivatives as hedging instruments.

The Company's financial risk management procedures also address counterparty credit approval, limits and routine exposure monitoring and reporting. The counterparties to these contractual arrangements are major financial institutions and major commodity exchanges. The Company is exposed to credit loss in the event of nonperformance by these counterparties. The Company utilizes collateral support annex agreements with certain counterparties to limit its exposure to credit losses. The Company anticipates performance by counterparties to these contracts and therefore no material loss is expected. Market and counterparty credit risks associated with these instruments are regularly reported to management.

The notional amounts of the Company's derivative instruments were as follows:

Notional Amounts	September 30, 2020		December 31, 2019
In millions
Derivatives not designated as hedging instruments:
Foreign currency contracts 1	$	(299)	$	26
Commodity contracts	$	8	$	11

1.Presented net of contracts bought and sold.

Derivatives not Designated in Hedging Relationships

Foreign Currency Contracts

The Company routinely uses forward exchange contracts to reduce its net exposure, by currency, related to foreign currency-denominated monetary assets and liabilities of its operations so that exchange gains and losses resulting from exchange rate changes are minimized. The netting of such exposures precludes the use of hedge accounting; however, the required revaluation of the forward contracts and the associated foreign currency-denominated monetary assets and liabilities intends to achieve a minimal earnings impact, after taxes. The Company may use foreign currency exchange contracts to offset a portion of the Company's exposure to certain foreign currency-denominated revenues so that gains and losses on the contracts offset changes in the USD value of the related foreign currency-denominated revenues.

41

Commodity Contracts

The Company utilizes options, futures and swaps that are not designated as hedging instruments to reduce exposure to commodity price fluctuations on purchases of inventory such as soybeans, soybean oil and soybean meal.

Fair Value of Derivative Instruments

Asset and liability derivatives subject to an enforceable master netting arrangement with the same counterparty are presented on a net basis in the interim Condensed Consolidated Balance Sheets. The presentation of the Company's derivative assets and liabilities is as follows:

		September 30, 2020
In millions	Balance Sheet Classification	Gross		Counterparty and Cash Collateral Netting 1		Net Amounts Included in the Consolidated Balance Sheet
Asset derivatives:
Derivatives not designated as hedging instruments:
Foreign currency contracts	Other current assets	$	20	$	(16)	$	4
Total asset derivatives		$	20	$	(16)	$	4
Liability derivatives:
Derivatives not designated as hedging instruments:
Foreign currency contracts	Accrued and other current liabilities	$	22	$	(16)	$	6
Total liability derivatives		$	22	$	(16)	$	6

		December 31, 2019
In millions	Balance Sheet Classification	Gross		Counterparty and Cash Collateral Netting 1		Net Amounts Included in the Consolidated Balance Sheet
Asset derivatives:
Derivatives not designated as hedging instruments:
Foreign currency contracts	Other current assets	$	16	$	(10)	$	6
Total asset derivatives		$	16	$	(10)	$	6
Liability derivatives:
Derivatives not designated as hedging instruments:
Foreign currency contracts	Accrued and other current liabilities	$	17	$	(10)	$	7
Total liability derivatives		$	17	$	(10)	$	7

1.Counterparty and cash collateral amounts represent the estimated net settlement amount when applying netting and set-off rights included in master netting arrangements between the Company and its counterparties and the payable or receivable for cash collateral held or placed with the same counterparty.

Effect of Derivative Instruments

Foreign currency derivatives not designated as hedges are used to offset foreign exchange gains or losses resulting from the underlying exposures of foreign currency-denominated assets and liabilities. The amount charged on a pre-tax basis related to foreign currency derivatives not designated as a hedge, which was included in “Sundry income (expense) - net” in the interim Consolidated Statements of Operations, was a loss of $3 million for the three months ended September 30, 2020 and 2019, and a gain of $1 million for the nine months ended September 30, 2020 ($63 million loss for the nine months ended September 30, 2019). The income statement effects of other derivatives were immaterial.

Reclassification from AOCL

The Company does not expect to reclassify gains or losses related to foreign currency contracts from AOCL to income within the next 12 months and there are currently no such amounts included within AOCL.

42

NOTE 20 - FAIR VALUE MEASUREMENTS

Fair Value Measurements on a Recurring Basis

The following tables summarize the basis used to measure certain assets and liabilities at fair value on a recurring basis:

Basis of Fair Value Measurements on a Recurring Basis at September 30, 2020	Significant Other Observable Inputs (Level 2)
In millions
Assets at fair value:
Cash equivalents and restricted cash equivalents 1	$	8,766
Derivatives relating to: 2
Foreign currency contracts	20
Total assets at fair value	$	8,786
Liabilities at fair value:
Long-term debt including debt due within one year 3	$	26,179
Derivatives relating to: 2
Foreign currency contracts	22
Total liabilities at fair value	$	26,201

1.Treasury bills, time deposits, and money market funds included in "Cash and cash equivalents" and money market funds included in "Other current assets" and "Restricted cash" in the interim Condensed Consolidated Balance Sheets and held at amortized cost, which approximates fair value.

2. See Note 19 for the classification of derivatives in the interim Condensed Consolidated Balance Sheets.

3. Fair value is based on quoted market prices for the same or similar issues, or on current rates offered to the company for debt of the same remaining maturities and terms.

Basis of Fair Value Measurements on a Recurring Basis at December 31, 2019	Significant Other Observable Inputs (Level 2)
In millions
Assets at fair value:
Cash equivalents and restricted cash equivalents 1	$	454
Derivatives relating to: 2
Foreign currency contracts	16
Total assets at fair value	$	470
Liabilities at fair value:
Long-term debt including debt due within one year 3	$	17,251
Derivatives relating to: 2
Foreign currency contracts	17
Total liabilities at fair value	$	17,268

1. Treasury bills, time deposits, and money market funds included in "Cash and cash equivalents" and money market funds included in "Other current assets" in the interim Condensed Consolidated Balance Sheets and held at amortized cost, which approximates fair value.

2. See Note 19 for the classification of derivatives in the interim Condensed Consolidated Balance Sheets.

3. Fair value is based on quoted market prices for the same or similar issues, or on current rates offered to the company for debt of the same remaining maturities and terms.

Fair Value Measurements on a Nonrecurring Basis

During the third quarter of 2020, the Company recorded impairment charges related to goodwill, indefinite-lived intangible assets, and long-lived assets within the Non-Core segment. These impairment analyses were performed using Level 3 inputs within the fair value hierarchy. See Notes 3, 5, and 11 for further discussion.

During the second quarter of 2020, the Company recorded impairment charges related to goodwill and indefinite-lived intangible assets within the Transportation & Industrial segment. See Notes 5 and 11 for further discussion of these fair value measurements.

During the first quarter of 2020, the Company recorded impairment charges related to goodwill and long-lived assets within the Non-Core segment. See Notes 5 and 11 for further discussion of these fair value measurements.

During the second quarter of 2019, the Company recorded goodwill impairment charges related to the Nutrition & Biosciences and Non-Core segments. The Company also recorded an other-than-temporary impairment, classified as Level 3 measurements, on an equity method investment. See Notes 5 and 11 for further discussion of these fair value measurements.

43

NOTE 21 - SEGMENTS AND GEOGRAPHIC REGIONS

In the first quarter of 2020, in preparation for the Intended N&B Transaction, DuPont changed its management and reporting structure to realign costs associated with its polysaccharides pre-commercial activities from the Non-Core segment to the N&B segment. The reporting changes have been retrospectively reflected in the segment results for all periods presented.

Prior to April 1, 2019, the Company's measure of profit / loss for segment reporting purposes is pro forma Operating EBITDA as this is the manner in which the Company's chief operating decision maker ("CODM") assessed performance and allocates resources. The Company defines pro forma Operating EBITDA as pro forma earnings (i.e. pro forma "Income (loss) from continuing operations before income taxes") before interest, depreciation, amortization, non-operating pension / other post-employment benefits (“OPEB”) / charges, and foreign exchange gains/losses, excluding the impact of costs historically allocated to the materials science and agriculture businesses that did not meet the criteria to be recorded as discontinued operations and adjusted for significant items. Effective April 1, 2019, the Company's measure of profit/loss for segment reporting purposes is Operating EBITDA as this is the manner in which the Company's chief operating decision maker ("CODM") assesses performance and allocates resources. The Company defines Operating EBITDA as earnings (i.e., “Income from continuing operations before income taxes") before interest, depreciation, amortization, non-operating pension / OPEB benefits / charges, and foreign exchange gains / losses, adjusted for significant items. Reconciliations of these measures are provided on the following pages.

Pro forma adjustments were determined in accordance with Article 11 of Regulation S-X. Pro forma financial information is based on the Consolidated Financial Statements of DuPont, adjusted to give effect to the impact of certain items directly attributable to the DWDP Distributions, and the Term Loan Facilities, the 2018 Senior Notes and the Funding CP Issuance (together, the "Financings"), including the use of proceeds from such Financings (collectively the "Transactions"). The historical consolidated financial information has been adjusted to give effect to pro forma events that are (1) directly attributable to the Transactions, (2) factually supportable and (3) with respect to the statements of operations, expected to have a continuing impact on the results. Events that are not expected to have a continuing impact on the combined results are excluded from the pro forma adjustments. Those pro forma adjustments include the impact of various supply agreements entered into in connection with the Dow Distribution ("supply agreements") and are adjustments to "Cost of sales." Pro forma Operating EBITDA for the nine months ended September 30, 2019 has been adjusted to reflect the supply agreements if they had been effective January 1, 2018 as they are included in the measure of profit/loss reviewed by the CODM in order to show meaningful comparability among periods while assessing performance and making resource allocation decisions. There were no pro forma adjustments for the three or nine months ended September 30, 2020 and the three months ended September 30, 2019.

Segment Information	Elect. & Imaging		Nutrition & Biosciences		Transp. & Industrial		Safety & Const.		Non-Core		Corp.		Total
In millions
Three months ended September 30, 2020
Net sales	$	1,004	$	1,467	$	1,045	$	1,249	$	331	$	—	$	5,096
Operating EBITDA 1	$	357	$	379	$	242	$	324	$	14	$	(16)	$	1,300
Equity in earnings of nonconsolidated affiliates	$	8	$	1	$	1	$	7	$	13	$	—	$	30
Three months ended September 30, 2019
Net sales	$	934	$	1,525	$	1,209	$	1,327	$	431	$	—	$	5,426
Operating EBITDA 1	$	320	$	354	$	306	$	352	$	94	$	(25)	$	1,401
Equity in earnings of nonconsolidated affiliates 2	$	10	$	—	$	1	$	7	$	26	$	—	$	44
Nine months ended September 30, 2020
Net sales	$	2,793	$	4,557	$	3,021	$	3,769	$	1,005	$	—	$	15,145
Operating EBITDA 1	$	887	$	1,182	$	599	$	1,041	$	149	$	(102)	$	3,756
Equity in earnings of nonconsolidated affiliates	$	27	$	2	$	3	$	19	$	121	$	—	$	172
Nine months ended September 30, 2019
Net sales	$	2,617	$	4,618	$	3,795	$	3,951	$	1,327	$	—	$	16,308
Pro forma operating EBITDA 1	$	854	$	1,089	$	1,036	$	1,108	$	296	$	(130)	$	4,253
Equity in earnings of nonconsolidated affiliates 2	$	18	$	—	$	3	$	22	$	92	$	—	$	135

1.A reconciliation of "Income (loss) from continuing operations, net of tax" to Operating EBITDA and pro forma Operating EBITDA, as applicable, is provided below.

2.Represents equity in earnings (losses) of nonconsolidated affiliates included in pro forma Operating EBITDA, the Company's measure of profit/loss for segment reporting purposes, which excludes significant items. Accordingly, the Non-Core segment presented above excludes restructuring charges of $1 million and $3 million for the three and nine months ended September 30, 2019, respectively, which is presented in "Equity in earnings of nonconsolidated affiliates" in the Company's interim Consolidated Statements of Operations.

44

Reconciliation of "Income (loss) from continuing operations, net of tax" to Operating EBITDA for the Three Months Ended September 30, 2020 and 2019	Three Months Ended September 30,
In millions	2020		2019
Loss (income) from continuing operations, net of tax	$	(72)	$	372
+ Provision for income taxes on continuing operations	92		78
Income from continuing operations before income taxes	$	20	$	450
+ Depreciation and amortization	780		499
- Interest income 1	3		1
+ Interest expense 2	165		177
- Non-operating pension/OPEB benefit 1	5		21
- Foreign exchange losses, net 1	(10)		(23)
- Significant items 3	(333)		(274)
Operating EBITDA	$	1,300	$	1,401

1. Included in "Sundry income (expense) - net."

2. The three months ended September 30, 2020 excludes N&B financing activity. Refer to details of significant items below.

3. The significant items for the three months ended September 30, 2020 and 2019 are presented on an as reported basis.

Reconciliation of "Income (loss) from continuing operations, net of tax" to Operating EBITDA for the Nine Months Ended September 30, 2020 and 2019	Nine Months Ended September 30,
In millions	2020		2019
Loss from continuing operations, net of tax	$	(3,153)	$	(805)
+ Provision for income taxes on continuing operations	100		142
Loss from continuing operations before income taxes	$	(3,053)	$	(663)
+ Pro forma adjustments 1	—		122
+ Depreciation and amortization	2,326		1,533
- Interest income 2	7		50
+ Interest expense 3	519		522
- Non-operating pension/OPEB benefit 2	24		60
- Foreign exchange losses, net 2	(41)		(101)
+ Costs historically allocated to the materials science and agriculture businesses 4	—		256
- Significant items 5	(3,954)		(2,492)
Operating EBITDA 1	$	3,756	$	4,253

1. For the nine months ended September 30, 2019, operating EBITDA is on a pro forma basis. The pro forma adjustment reflects the net pro forma impact of items directly attributable to the Transactions, as applicable.

2. Included in "Sundry income (expense) - net."

3. The nine months ended September 30, 2020 excludes N&B financing activity. Refer to details of significant items below.

4. Costs previously allocated to the materials science and agriculture businesses that did not meet the definition of expenses related to discontinued operations in accordance with ASC 205.

5. The significant items for the nine months ended September 30, 2020 are presented on an as reported basis. The significant items for the nine months ended September 30, 2019 are presented on a pro forma basis.

45

The significant items for the three months ended September 30, 2020 and 2019 and the nine months ended September 30, 2020 are presented on an as reported basis. The significant items for the nine months ended September 30, 2019 are presented on a pro forma basis. The following tables summarize the pre-tax impact of significant items by segment that are excluded from Operating EBITDA and pro forma Operating EBITDA above:

Significant Items by Segment for the Three Months Ended September 30, 2020	Elect. & Imaging		Nutrition & Biosciences		Transp. & Industrial		Safety & Construction		Non-Core		Corporate		Total
In millions
Integration and separation costs 1	$	—	$	—	$	—	$	—	$	—	$	(127)	$	(127)
Restructuring and asset related credits (charges) - net 2	(1)		(5)		—		(2)		(1)		(5)		(14)
Goodwill impairment charges 3	—		—		—		—		(183)		—		(183)
Asset impairment charges 3, 4	—		—		—		—		(370)		—		(370)
Gain on divestitures 5	—		—		—		—		393		—		393
N&B financing activity - net 6	—		—		—		—		—		(32)		(32)
Total	$	(1)	$	(5)	$	—	$	(2)	$	(161)	$	(164)	$	(333)

1. Integration and separation costs related to the post-DWDP Merger integration and the intended separation of the N&B Business.

2. Includes Board approved restructuring plans and asset related charges. See Note 5 for additional information.

3. Refer to Note 11 for additional information.

4. Refer to Note 5 for additional information.

5. Refer to Note 3 for additional information.

6. Represents interest expense, net related to the N&B Notes as well as the financing fee amortization related to the intended separation of the N&B Business.

Significant Items by Segment for the Three Months Ended September 30, 2019	Elect. & Imaging		Nutrition & Biosciences		Transp. & Industrial		Safety & Construction		Non-Core		Corporate		Total
In millions
Integration and separation costs 1	$	—	$	—	$	—	$	—	$	—	$	(191)	$	(191)
Restructuring and asset related charges - net 2	(35)		(7)		(6)		(5)		(2)		(28)		(83)
Total	$	(35)	$	(7)	$	(6)	$	(5)	$	(2)	$	(219)	$	(274)

1.Integration and separation costs related to post-DWDP Merger integration and business separation activities.

2. Includes Board approved restructuring plans and asset related charges. See Note 5 for additional information.

46

Significant Items by Segment for the Nine Months Ended September 30, 2020	Elect. & Imaging		Nutrition & Biosciences		Transp. & Industrial		Safety & Construction		Non-Core		Corporate		Total
In millions
Integration and separation costs 1	$	—	$	—	$	—	$	—	$	—	$	(469)	$	(469)
Restructuring and asset related charges - net 2	(2)		(9)		(15)		(15)		(1)		(104)		(146)
Goodwill impairment charges 3	—		—		(2,498)		—		(716)		—		(3,214)
Asset impairment charges 3, 4	—		—		(21)		—		(640)		—		(661)
Gain on divestitures 5	197		—		—		—		393		—		590
N&B financing activity - net 6	—		—		—		—		—		(54)		(54)
Total	$	195	$	(9)	$	(2,534)	$	(15)	$	(964)	$	(627)	$	(3,954)

1. Integration and separation costs related to the post-DWDP Merger integration and the intended separation of the N&B Business.

2. Includes Board approved restructuring plans and asset related charges. See Note 5 for additional information.

3. Refer to Note 11 for additional information.

4. Refer to Note 5 for additional information.

5. Refer to Note 3 for additional information.

6. Represents interest expense, net related to the N&B Notes as well as the financing fee amortization related to the intended separation of the N&B Business.

Significant Items by Segment for the Nine Months Ended September 30, 2019 (Pro Forma)	Elect. & Imaging		Nutrition & Biosciences		Transp. & Industrial		Safety & Construction		Non-Core		Corporate		Total
In millions
Integration and separation costs 1	$	—	$	—	$	—	$	—	$	—	$	(976)	$	(976)
Restructuring and asset related charges - net 2	(42)		(56)		(18)		(27)		(2)		(85)		(230)
Goodwill impairment charges 3	—		(933)		—		—		(242)		—		(1,175)
Asset impairment charges 4	—		(63)		—		—		—		—		(63)
Income tax relates item 5	—		—		—		(48)		—		—		(48)
Total	$	(42)	$	(1,052)	$	(18)	$	(75)	$	(244)	$	(1,061)	$	(2,492)

1.Integration and separation costs related to the DWDP Merger, post-DWDP Merger integration and business separation activities.

2. Includes Board approved restructuring plans and asset related charges. See Note 5 for additional information.

3. Refer to Note 11 for additional information.

4. Refer to Note 5 for additional information.

5. Charge included in "Sundry income (expense) - net" which reflects a reduction in gross proceeds from lower withholding taxes related to a prior year legal settlement.

47

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Effective August 31, 2017, pursuant to the merger of equals transactions contemplated by the Agreement and Plan of Merger, dated as of December 11, 2015, as amended on March 31, 2017 ("DWDP Merger Agreement"), The Dow Chemical Company ("Historical Dow") and E. I. du Pont de Nemours and Company ("Historical EID") each merged with subsidiaries of DowDuPont Inc. ("DowDuPont") and, as a result, Historical Dow and Historical EID became subsidiaries of DowDuPont (the "DWDP Merger"). Prior to the DWDP Merger, DowDuPont did not conduct any business activities other than those required for its formation and matters contemplated by the DWDP Merger Agreement. Historical Dow was determined to be the accounting acquirer in the DWDP Merger.

DowDuPont completed a series of internal reorganizations and realignment steps in order to separate into three, independent, publicly traded companies - one for each of its agriculture, materials science and specialty products businesses. DowDuPont formed two wholly owned subsidiaries: Dow Inc. ("Dow", formerly known as Dow Holdings Inc.), to serve as a holding company for its materials science business, and Corteva, Inc. ("Corteva"), to serve as a holding company for its agriculture business.

Effective as of 5:00 p.m. on April 1, 2019, DowDuPont completed the separation of its materials science business into a separate and independent public company by way of a distribution of Dow through a pro rata dividend in-kind of all of the then-issued and outstanding shares of Dow’s common stock, par value $0.01 per share (the “Dow Common Stock”), to holders of the Company’s common stock, par value $0.01 per share (the “DowDuPont common stock”), as of the close of business on March 21, 2019 (the “Dow Distribution”).

Effective as of 12:01 a.m. on June 1, 2019, DuPont de Nemours, Inc. (formerly known as DowDuPont Inc.), completed the separation of its agriculture business into a separate and independent public company by way of a distribution of Corteva through a pro rata dividend in-kind of all of the then-issued and outstanding shares of Corteva’s common stock, par value $0.01 per share (the “Corteva Common Stock”), to holders of the Company’s common stock, par value $0.01 per share, as of the close of business on May 24, 2019 (the “Corteva Distribution” and, together with the Dow Distribution, the “DWDP Distributions”).

Following the Corteva Distribution, the Company holds the specialty products business. On June 1, 2019, DowDuPont changed its registered name from "DowDuPont Inc." to "DuPont de Nemours, Inc." doing business as "DuPont" (the "Company"). Beginning on June 3, 2019, the Company's common stock is traded on the NYSE under the ticker symbol "DD."

The results of operations of DuPont for the 2019 interim periods presented reflect the historical financial results of Dow and Corteva as discontinued operations, as applicable. The cash flows and comprehensive income related to Dow and Corteva have not been segregated and are included in the interim Consolidated Statements of Cash Flows and interim Consolidated Statements of Comprehensive Income, respectively, for the applicable period. Unless otherwise indicated, the information in the notes to the interim Consolidated Financial Statements refer only to DuPont's continuing operations and do not include discussion of balances or activity of Dow or Corteva.

The statements of operations and pro forma statements of operations included in this report and as discussed below include costs previously allocated to the materials science and agriculture businesses that did not meet the definition of expenses related to discontinued operations in accordance with Financial Accounting Standards Codification 205, "Presentation of Financial Statements" ("ASC 205") and thus are reflected in the Company's results of continuing operations. A significant portion of these costs relate to Historical Dow and consist of leveraged services provided through service centers, as well as other corporate overhead costs related to information technology, finance, manufacturing, research & development, sales & marketing, supply chain, human resources, sourcing & logistics, legal and communications, public affairs & government affairs functions. These costs are no longer incurred by the Company following the DWDP Distributions.

On December 15, 2019, the Company entered into definitive agreements to separate and combine the Nutrition & Biosciences business segment (the "N&B Business") with International Flavors & Fragrances Inc. ("IFF") in a tax-efficient Reverse Morris Trust transaction, (the "Intended N&B Transaction"). The transaction is expected to close in the first quarter of 2021, subject to approval by IFF shareholders and other customary closing conditions, including regulatory approvals and receipt by DuPont of an opinion of tax counsel. The financial results of the N&B Business are included in continuing operations for the periods presented.

48

RECENT DEVELOPMENTS

COVID-19

The novel coronavirus (“COVID-19”) pandemic has resulted in significant economic disruption and continues to adversely impact the broader global economy, including certain of the Company’s customers and suppliers. Given the dynamic nature of this situation, the Company cannot reasonably estimate the impacts of COVID-19 on its financial condition, results of operations or cash flows into the foreseeable future. The ultimate extent of the effects of the COVID-19 pandemic on the Company is highly uncertain and will depend on future developments, and such effects could exist for an extended period of time even after the pandemic subsides.

During the third quarter of 2020, the Company benefited from strong demand in certain key end-markets, principally electronics, water filtration, health & wellness and personal protection. In addition, third quarter 2020 results reflect notable improvements in automotive markets, along with residential construction, compared to second quarter of 2020. Although management currently expects continued improvement from certain markets in the fourth quarter of 2020, the COVID-19 pandemic is expected to continue to adversely impact demand in aerospace, commercial construction, oil & gas, and select industrial end-markets. In response to this uncertainty, the Company has delayed certain capital investments in select sectors.

Sale of TCS/HSC Disposal Group

In the third quarter of 2020, the Company completed the sale of its trichlorosilane business (“TCS Business”) along with its equity ownership interest in DC HSC Holdings LLC and Hemlock Semiconductor L.L.C. (the "HSC Group,” and together with the TCS Business, the “TCS/HSC Disposal Group” and the sale of the TCS/HSC Disposal Group, the “TCS/HSC Disposal”) to the HSC Group, both of which were part of the Non-Core segment. In connection with the TCS/HSC Disposal, the Company received $550 million in cash at closing, subject to certain claw-back provisions, and will receive an additional $175 million in equal installments over the course of the next three years associated with the settlement of an existing supply agreement dispute with the HSC Group. The TCS/HSC Disposal resulted in a net pre-tax benefit of $393 million ($232 million net of tax), including the settlement of the supply agreement dispute and after allocation of goodwill to the TCS Business. The net pre-tax benefit is recorded in “Sundry income (expense) – net” in the Company’s interim Consolidated Statements of Operations. Refer to Note 3 of the interim Consolidated Financial Statements.

Non-Core Impairments

Multiple triggering events occurred in the third quarter of 2020 requiring the Company to perform impairment analyses associated with its Non-Core segment. As a result of the analyses performed, the Company recognized aggregate pre-tax, non-cash goodwill impairment charges of $183 million recorded within "Goodwill impairment charges" and aggregate pre-tax, non-cash asset impairment charges of $370 million recorded within “Restructuring and asset related charges - net” in the interim Consolidated Statements of Operations. Refer to Notes 3, 5, and 11 of the interim Consolidated Financial Statements.

Nutrition & Biosciences Notes Offering

On September 16, 2020, Nutrition & Biosciences, Inc. (presently a wholly owned subsidiary of DuPont) (“N&B Inc.”) completed an offering of $6.25 billion of senior unsecured notes (the “N&B Notes Offering”). The net proceeds of approximately $6.2 billion from the N&B Notes Offering were deposited into an escrow account. Prior to the intended merger of DuPont's Nutrition & Biosciences business with IFF, N&B Inc. will make a special cash payment of $7.3 billion, (the “Special Cash Payment”), subject to adjustment, to DuPont, which N&B Inc. will fund with the net proceeds from the N&B Notes Offering together with borrowings under N&B Inc.’s existing Term Loan facilities. Refer to Notes 6 and 12 of the interim Consolidated Financial Statements.

Dividends

On June 25, 2020, the Company announced that its Board of Directors declared a third quarter dividend of $0.30 per share paid on September 15, 2020, to shareholders of record on July 31, 2020.

On October 14, 2020, the Company announced that its Board of Directors declared a fourth quarter dividend of $0.30 per share payable on December 15, 2020, to shareholders of record on November 30, 2020.

49

SELECTED FINANCIAL DATA

	Three Months Ended September 30,		Nine Months Ended September 30,
In millions, except per share amounts	2020	2019	2020	2019
Net sales	$5,096	$5,426	$15,145	$16,308
Cost of sales	$3,392	$3,531	$10,001	$10,648
Percent of net sales	66.6%	65.1%	66.0%	65.3%
Research and development expenses	$199	$225	$644	$724
Percent of net sales	3.9%	4.1%	4.3%	4.4%
Selling, general and administrative expenses	$524	$645	$1,698	$2,013
Percent of net sales	10.3%	11.9%	11.2%	12.3%
Effective tax rate - continuing operations	460.0%	17.3%	(3.3)%	(21.4)%
Net (loss) earnings available for DuPont common stockholders	$(79)	$372	$(3,173)	$322
(Loss) earnings per common share – basic	$(0.11)	$0.50	$(4.31)	$0.43
(Loss) earnings per common share – diluted	$(0.11)	$0.50	$(4.31)	$0.43

RESULTS OF OPERATIONS

Summary of Sales Results	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2020		2019		2020		2019
Net sales	$	5,096	$	5,426	$	15,145	$	16,308

The following table summarizes sales variances by segment and geographic region from the prior year:

Sales Variances by Segment and Geographic Region
	Three Months Ended September 30, 2020										Nine Months Ended September 30, 2020
Percentage change from prior year	Local Price & Product Mix		Currency		Volume		Portfolio & Other		Total		Local Price & Product Mix		Currency		Volume		Portfolio & Other		Total
Electronics & Imaging	(1)	%	—	%	9	%	(1)	%	7	%	(1)	%	—	%	8	%	—	%	7	%
Nutrition & Biosciences	—		—		(4)		—		(4)		1		(1)		(1)		—		(1)
Transportation & Industrial	(5)		—		(9)		—		(14)		(5)		—		(15)		—		(20)
Safety & Construction	1		—		(10)		3		(6)		2		(1)		(8)		2		(5)
Non-Core	5		—		(18)		(10)		(23)		3		(1)		(17)		(9)		(24)
Total	—	%	—	%	(6)	%	—	%	(6)	%	—	%	(1)	%	(6)	%	—	%	(7)	%
U.S. & Canada	(1)	%	—	%	(9)	%	(1)	%	(11)	%	(1)	%	—	%	(9)	%	—	%	(10)	%
EMEA 1	(1)		2		(14)		—		(13)		—		(1)		(12)		—		(13)
Asia Pacific	(1)		—		4		—		3		(1)		(1)		2		—		—
Latin America	5		(6)		(8)		(1)		(10)		3		(5)		(11)		(1)		(14)
Total	—	%	—	%	(6)	%	—	%	(6)	%	—	%	(1)	%	(6)	%	—	%	(7)	%

1.Europe, Middle East and Africa.

50

The Company reported net sales for the three months ended September 30, 2020 of $5.1 billion, down 6 percent from $5.4 billion for the three months ended September 30, 2019, due to a 6 percent decrease in volume. Local price and product mix, currency, and portfolio remained flat. Volume declined across all geographic regions with the exception of Asia Pacific where it increased 4 percent. Volume declined across all segments with the exception of Electronics & Imaging (up 9 percent). The most notable volume decreases were in Non-Core (down 18 percent), Safety & Construction (down 10 percent) and Transportation & Industrial (down 9 percent). Currency was flat compared with the same period last year in all segments. Portfolio and other changes were flat overall while Non-Core saw a decrease of 10 percent. Local price was flat compared with the same period last year. Local price increased in Latin America (up 5 percent) and in Non-Core (up 5 percent) and Safety & Construction (up 1 percent).

Net sales for the nine months ended September 30, 2020 were $15.1 billion, down 7 percent from $16.3 billion for the nine months ended September 30, 2019, due to a 6 percent decrease in volume and a 1 percent unfavorable currency impact. Local price and product mix and portfolio actions remained flat. Volume declined across all geographic regions with the exception of Asia Pacific where it increased 2 percent. Volume declined across all segments with the exception of Electronics & Imaging (up 8 percent). The most notable volume decreases were in Non-Core (down 17 percent), Transportation & Industrial (down 15 percent) and Safety-Construction (down 8 percent). Currency was down 1 percent compared with the same period last year, driven primarily by Latin American currencies (down 5 percent) and EMEA and Asia Pacific currencies (down 1 percent each). Portfolio and other changes were flat overall while Non-Core saw a negative impact on sales from portfolio changes (down 9 percent). Local price and product mix was flat compared with the same period last year. Local price increased in Latin America (up 3 percent) and in all segments except Transportation & Industrial (down 5 percent) and Electronics & Imaging (down 1 percent).

Cost of Sales

Cost of sales was $3.4 billion for the three months ended September 30, 2020, down from $3.5 billion for the three months ended September 30, 2019 primarily due to lower sales volume and cost synergies offset by approximately $60 million of charges associated with temporarily idling several manufacturing plants to align supply with demand, mainly in the Transportation & Industrial and Safety & Construction segments.

Cost of sales as a percentage of net sales for the three months ended September 30, 2020 was 67 percent compared with 65 percent for the three months ended September 30, 2019, driven mainly by the charges associated with temporary idling several manufacturing plans referenced above.

For the nine months ended September 30, 2020, cost of sales was $10.0 billion, down from $10.6 billion for the nine months ended September 30, 2019. Cost of sales decreased for the nine months ended September 30, 2020 primarily due to lower sales volume, cost synergies, currency impacts, and lower costs previously allocated to the materials science and agriculture businesses that did not meet the definition of expenses related to discontinued operations in accordance with ASC 205 and therefore remained as costs of continuing operations for periods prior to the DWDP Distributions, offset by approximately $220 million of charges associated with temporarily idling several manufacturing plants to align supply with demand due to COVID-19, driven primarily by the Transportation & Industrial segment.

Cost of sales as a percentage of net sales for the nine months ended September 30, 2020 was 66 percent compared with 65 percent for the nine months ended September 30, 2019.

Research and Development Expenses ("R&D")

R&D expenses totaled $199 million in the third quarter of 2020, down from $225 million in the third quarter of 2019. R&D as a percentage of net sales was 4 percent for the three months ended September 30, 2020 and 2019.

For the first nine months of 2020, R&D expenses totaled $644 million, down from $724 million in the first nine months of 2019. R&D as a percentage of net sales was 4 percent for the nine months ended September 30, 2020 and 2019.

Selling, General and Administrative Expenses ("SG&A")

SG&A expenses were $524 million in the third quarter of 2020, down from $645 million in the third quarter of 2019 primarily due to productivity actions and reduced spending. SG&A as a percentage of net sales was 10 percent and 12 percent for the three months ended September 30, 2020 and 2019, respectively.

For the first nine months of 2020, SG&A expenses totaled $1,698 million, down from $2,013 million in the first nine months of 2019. SG&A as a percentage of net sales was 11 percent and 12 percent for the nine months ended September 30, 2020 and 2019, respectively.

51

The decrease for the nine months ended September 30, 2020 compared with the same period of the prior year was primarily due to productivity actions, reduced spending and the absence of SG&A costs previously allocated to the materials science and agriculture businesses that did not meet the definition of expenses related to discontinued operations in accordance with ASC 205 and therefore remained as costs of continuing operations for periods prior to the DWDP Distributions.

Amortization of Intangibles

Amortization of intangibles was $530 million in the third quarter of 2020, up from $247 million in the third quarter of 2019. In the first nine months of 2020, amortization of intangibles was $1,591 million, up from $755 million in the same period last year. The increase was primarily due to the amortization of the Nutrition and Biosciences tradenames that were reclassified to definite-lived intangibles in the fourth quarter of 2019 in connection with the Intended N&B Transaction.

Restructuring and Asset Related Charges - Net

Restructuring and asset related charges - net were $384 million in the third quarter of 2020, up from $82 million in the third quarter of 2019. The activity in the third quarter of 2020 included asset impairment charges in the Non-Core segment of $318 million related to long-lived assets and $52 million related to indefinite-lived intangible assets, and a $14 million charge related to the 2020 Restructuring Program. The charges in the third quarter of 2019 included a $69 million charge related to the 2019 Restructuring Program and a $13 million charge related to the DowDuPont Cost Synergy Program.

In the first nine months of 2020, restructuring and asset related charges - net were $807 million, up from $290 million in the same period last year. The activity for the nine months of 2020 included asset impairment charges in the Non-Core segment of $588 million related to long-lived assets and $52 million related to indefinite-lived intangible assets, a $21 million impairment charge related to indefinite-lived intangible assets in the Transportation & Industrial segment, a $140 million charge related to the 2020 Restructuring Program, a $2 million charge related to the 2019 Restructuring Program and a $4 million charge related to the DowDuPont Cost Synergy Program. The charges in the same period of 2019 included a charge of $122 million related to the 2019 Restructuring Program, a $105 million charge related to the DowDuPont Cost Synergy Program, and $63 million impairment charge related to an equity method investment.

See Note 5 to the interim Consolidated Financial Statements for additional information.

Goodwill Impairment Charges

Goodwill impairment charges were $183 million in the third quarter of 2020. There were no goodwill related impairments in the third quarter of 2019. Goodwill impairment charges were $3,214 million in the nine months ended September 30, 2020, up from $1,175 million in the same period last year. The third quarter of 2020 goodwill impairment charges relate to the Non-Core segment. In the first nine months of 2020, goodwill impairment charges relate to the Transportation & Industrial and Non-Core segments. Goodwill impairment charges for the first nine months of 2019 relate to the Nutrition & Biosciences and Non-Core segments. See Note 11 to the interim Consolidated Financial Statements for additional information.

Integration and Separation Costs

Integration and separation costs, which primarily reflect costs related to the Intended N&B Transaction beginning in the fourth quarter of 2019, the post-DWDP Merger integration, and activities related to the DWDP Distributions, were $127 million in the third quarter of 2020, down from $191 million in the third quarter of 2019. In the first nine months of 2020, integration and separation costs were $469 million, down from $1,149 million in the same period last year. The decline was primarily related to the timing of the DWDP Distributions.

Equity in Earnings of Nonconsolidated Affiliates

The Company's share of the earnings of nonconsolidated affiliates was $30 million in the third quarter of 2020, down from $43 million in the third quarter of 2019 primarily due to lower HSC Group equity earnings coupled with the sale of the Company's equity interest in the HSC Group in the third quarter of 2020. In the first nine months of 2020, the Company's share of the earnings of nonconsolidated affiliates was $172 million, up from $132 million in the first nine months of 2019. The increase is primarily due to higher HSC Group equity earnings in the first half of 2020, mainly driven by customer settlements in the second quarter of 2020.

Sundry Income (Expense) - Net

Sundry income (expense) - net includes a variety of income and expense items such as foreign currency exchange gains or losses, interest income, dividends from investments, gains and losses on sales of investments and assets, non-operating pension and other post-employment benefit plan credits or costs, and certain litigation matters. Sundry income (expense) - net in the third quarter of 2020 was income of $430 million compared with income of $79 million in the third quarter of 2019.

52

The third quarter of 2020 included a net pre-tax benefit of $393 million related to the TCS/HSC Disposal in the Non-Core segment, which includes the settlement of a supply agreement dispute. The third quarter of 2019 included benefits related to sales of assets of $64 million and income related to non-operating pension and other post-employment benefit credits of $21 million, partially offset by foreign currency exchange losses of $23 million.

In the first nine months of 2020, sundry income (expense) - net was income of $627 million compared with income of $144 million in the first nine months of 2019. The first nine months of 2020 included a net pre-tax net benefit of $393 million associated with the TCS/HSC Disposal as discussed above, a gain of $197 million related to the sale of the Compound Semiconductor Solutions business unit in the Electronics & Imaging segment, and income related to non-operating pension and other post-employment benefit credits of $24 million, partially offset by foreign currency exchange losses of $41 million. The first nine months of 2019 included benefits related to sales of assets of $127 million, income related to non-operating pension and other post-employment benefit plans of $60 million and interest income of $50 million, partially offset by foreign currency exchange losses of $101 million and a $48 million charge reflecting a reduction in gross proceeds from lower withholding taxes related to a prior year legal settlement.

Interest Expense

Interest expense was $197 million in the third quarter of 2020, up from $177 million in the third quarter of 2019. The increase primarily relates to financing costs associated with the Intended N&B transaction.

In the first nine months of 2020, interest expense was $573 million, up from $493 million in the same period last year. The increase primarily relates to financing costs associated with the Intended N&B Transaction and the May Debt Offering.

Provision for Income Taxes on Continuing Operations

The Company's effective tax rate fluctuates based on, among other factors, where income is earned and the level of income relative to tax attribute. The effective tax rate on continuing operations for the third quarter of 2020 was 460.0 percent, compared with an effective tax rate of 17.3 percent for the third quarter of 2019. The effective tax rate for the third quarter of 2020 was principally the result of a non-tax-deductible goodwill impairment charge and a non-tax-deductible goodwill allocation in connection with the TCS/HSC Disposal impacting the Non-Core segment in the third quarter. The effective tax rate for the third quarter of 2019 was favorably impacted by, among other items, tax benefits related to the adjustment of certain unrecognized benefits for positions taken on items from a prior year.

For the first nine months of 2020, the effective tax rate on continuing operations was (3.3) percent, compared with (21.4) percent for the first nine months of 2019. The effective tax rate for the first nine months of 2020 was principally the result of a non-tax-deductible goodwill impairment charge impacting the Non-Core segment in the first and third quarter and a non-tax-deductible goodwill impairment charge impacting the Transportation and Industrial segment in the second quarter, coupled with an allocation of non-tax-deductible goodwill related to the TCS/HSC Disposal. The tax rate for the first nine months of 2019 was principally the result of non-tax-deductible goodwill impairment charges impacting the Nutrition & Biosciences and Non-Core segments. See Note 11 to the interim Consolidated Financial Statements for additional information on the goodwill impairment charges.

Income from Discontinued Operations, Net of Tax

In the third quarter of 2020 and for the first nine months of 2020, the Company did not have activity from discontinued operations. In the third quarter of 2019 and for the nine months of 2019, income from discontinued operation, net of tax was $5 million and $1,217 million, respectively. The decrease period over period is attributable to the timing of the DWDP Distributions. Refer to Note 3 to the interim Consolidated Financial Statements for additional information.

Net Income Attributable to Noncontrolling Interests

Net income attributable to noncontrolling interests was $7 million in the third quarter of 2020, up from $5 million in the third quarter of 2019. For the first nine months of 2020, net income attributable to noncontrolling interests was $20 million, down from $90 million for the same period last year due to the timing of the DWDP Distributions.

53

SUPPLEMENTAL UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION

The following supplemental unaudited pro forma financial information (the “unaudited pro forma financial statements”) is derived from DuPont’s Consolidated Financial Statements, adjusted to give effect to certain events directly attributable to the DWDP Distributions. In contemplation of the DWDP Distributions and to achieve the respective credit profiles of each of the current companies, in the fourth quarter of 2018, DowDuPont borrowed $12.7 billion under the 2018 Senior Notes and entered the Term Loan Facilities with an aggregate principal amount of $3.0 billion. Additionally, DuPont issued approximately $1.4 billion in commercial paper in May 2019 in anticipation of the Corteva Distribution (the “Funding CP Issuance” together with the 2018 Senior Notes and the Term Loan Facilities, the "Financings"). The unaudited pro forma financial statements for the nine months ended September 30, 2019 were prepared in accordance with Article 11 of Regulation S-X. The historical consolidated financial information has been adjusted to give effect to pro forma events that are (1) directly attributable to the DWDP Distributions and the Financings (collectively the "Transactions"), (2) factually supportable and (3) with respect to the statements of operations, expected to have a continuing impact on the results. The unaudited pro forma statements of operations for the nine months ended September 30, 2019 give effect to the pro forma events as if they had been consummated on January 1, 2018. There were no pro forma adjustments for the three and nine months ended September 30, 2020 and for the three months ended September 30, 2019.

Restructuring or integration activities or other costs following the DWDP Distributions that may be incurred to achieve cost or growth synergies of DuPont are not reflected. The unaudited pro forma income statement provides shareholders with summary financial information and historical data that is on a basis consistent with how DuPont reports current financial information.

The unaudited pro forma financial statements are presented for informational purposes only, and do not purport to represent what DuPont's results of operations or financial position would have been had the Transactions occurred on the dates indicated, nor do they purport to project the results of operations or financial position for any future period or as of any future date.

Unaudited Pro Forma Combined Statements of Operations	Nine Months Ended September 30,
	2019
In millions, except per share amounts	DuPont 1		Pro Forma Adjustments2		Pro Forma
Net sales	$	16,308	$	—	$	16,308
Cost of sales	10,648		22		10,670
Research and development expenses	724		—		724
Selling, general and administrative expenses	2,013		—		2,013
Amortization of intangibles	755		—		755
Restructuring and asset related charges - net	290		—		290
Goodwill impairment charges	1,175		—		1,175
Integration and separation costs	1,149		(173)		976
Equity in earnings of nonconsolidated affiliates	132		—		132
Sundry income (expense) - net	144		—		144
Interest expense	493		29		522
Loss from continuing operations before income taxes	(663)		122		(541)
Provision for income taxes on continuing operations	142		30		172
Loss from continuing operations, net of tax	(805)		92		(713)
Net income attributable to noncontrolling interests of continuing operations	18		—		18
Net loss from continuing operations attributable to DuPont	$	(823)	$	92	$	(731)
Per common share data:
Loss per common share from continuing operations - basic	$	(1.10)			$	(0.98)
Loss per common share from continuing operations - diluted	$	(1.10)			$	(0.98)
Weighted-average common shares outstanding - basic	748.2				748.2
Weighted-average common shares outstanding - diluted	748.2				748.2

1.See the historical U.S. GAAP Consolidated Statements of Operations.

2. Certain pro forma adjustments were made to illustrate the estimated effects of the Transactions, assuming that the Transactions had occurred on January 1, 2018. The adjustments include the impact to "Cost of sales" of different pricing than historical intercompany and intracompany practices related to various supply agreements entered into with the Dow Distribution, adjustments to "Integration and separation costs" to eliminate one-time transaction costs directly attributable to the DWDP Distributions, and adjustments to "Interest expense" to reflect the impact of the Financings.

54

SEGMENT RESULTS

In the first quarter of 2020, in preparation for the Intended N&B Transaction, DuPont changed its management and reporting structure to realign costs associated with its polysaccharides pre-commercial activities from the Non-Core segment to the N&B segment. The reporting changes have been retrospectively reflected in the following discussion of segment results for all periods presented. Refer to Note 21 to the interim Consolidated Financial Statements for additional information.

Prior to April 1, 2019, the Company's measure of profit/loss for segment reporting purposes is pro forma Operating EBITDA as this is the manner in which the Company's chief operating decision maker ("CODM") assessed performance and allocated resources. The Company defines pro forma Operating EBITDA as pro forma earnings (i.e., pro forma “Income from continuing operations before income taxes") before interest, depreciation, amortization, non-operating pension / other post-employment benefits (“OPEB”) / charges, and foreign exchange gains / losses, excluding the impact of costs historically allocated to the materials science and agriculture businesses that did not meet the criteria to be recorded as discontinued operations and adjusted for significant items. Effective April 1, 2019, the Company's measure of profit/loss for segment reporting purposes is Operating EBITDA as this is the manner in which the Company's CODM assesses performance and allocates resources. The Company defines Operating EBITDA as earnings (i.e., “Income from continuing operations before income taxes") before interest, depreciation, amortization, non-operating pension / OPEB benefits / charges, and foreign exchange gains / losses, adjusted for significant items. Reconciliations of these measures can be found in Note 21 to the interim Consolidated Financial Statements. Prior year data has been updated to conform with the current year presentation.

Pro forma adjustments used in the calculation of pro forma Operating EBITDA were determined in accordance with Article 11 of Regulation S-X and were derived from DuPont's historical Consolidated Financial Statements and accompanying notes, adjusted to give effect to the DWDP Distributions as if they had been consummated on January 1, 2018. The pro forma adjustments impacting pro forma Operating EBITDA reflect the impact of various supply agreements ("supply agreements") entered into in connection with the Dow Distribution and are outlined in the preceding section, Supplemental Unaudited Pro Forma Combined Financial Information, as adjustments to "Cost of sales." The impact of these supply agreements is reflected in pro forma Operating EBITDA for the periods noted above as it is included in the measure of profit/loss reviewed by the CODM in order to show meaningful comparability among periods while assessing performance and making resource allocation decisions. There were no pro forma adjustments for the three and nine months ended September 30, 2020 and for the three months ended September 30, 2019.

55

ELECTRONICS & IMAGING

The Electronics & Imaging segment is a leading global supplier of differentiated materials and systems for a broad range of consumer electronics including mobile devices, television monitors, personal computers and electronics used in a variety of industries. The segment is a leading provider of materials and solutions for the fabrication of semiconductors and integrated circuits, and provides innovative metallization processes for metal finishing, decorative, and industrial applications as well as films and laminate materials for a broad range of uses in printed circuit board and other electronic industry applications. Electronics & Imaging is a leading provider of platemaking systems and photopolymer plates for the packaging graphics industry and digital printing inks for a variety of applications in the textile, commercial printing, and home-office markets. In addition, the segment provides cutting-edge materials for the manufacturing of rigid and flexible displays for organic light emitting diode ("OLED"), and other display applications.

Electronics & Imaging	Three Months Ended				Nine Months Ended
In millions	September 30, 2020		September 30, 2019		September 30, 2020		September 30, 2019
Net sales	$	1,004	$	934	$	2,793	$	2,617
Operating EBITDA 1	$	357	$	320	$	887	$	854
Equity earnings	$	8	$	10	$	27	$	18

1.For the nine months ended September 30, 2019, operating EBITDA is on a pro forma basis.

Electronics & Imaging	Three Months Ended		Nine Months Ended
Percentage change from prior year	September 30, 2020		September 30, 2020
Change in Net Sales from Prior Period due to:
Local price & product mix	(1)	%	(1)	%
Currency	—		—
Volume	9		8
Portfolio & other	(1)		—
Total	7	%	7	%

Electronics & Imaging net sales were $1,004 million for the three months ended September 30, 2020, up 7 percent from $934 million for the three months ended September 30, 2019. Net sales increased due to a 9 percent increase in volume partially offset by a 1 percent local price decline and a 1 percent decrease from prior portfolio actions. Volume growth was driven by Semiconductor Technologies with continued strength in the logic and foundry segment. Volume growth within Interconnect Solutions was driven by increased material content in next-generation smartphones. Within Image Solutions, volume growth in OLED materials for displays offset weakness in flexographic plates and textile inks.

Operating EBITDA was $357 million for the three months ended September 30, 2020, up 12 percent compared with $320 million for the three months ended September 30, 2019 due to volume gains and cost productivity actions. The three months ended September 30, 2020 and 2019 include income of $30 million and $34 million, respectively, related to an asset sale from 2019.

Electronics & Imaging net sales were $2,793 million for the nine months ended September 30, 2020, up 7 percent from $2,617 million for the nine months ended September 30, 2019. Net sales increased due to an 8 percent volume growth offset by a 1 percent decline in local price. Volume growth was driven by demand in Semiconductor Technologies in the logic and foundry segment, higher material content in smartphones and increased demand for OLED materials.

Operating EBITDA was $887 million for the nine months ended September 30, 2020, down 4 percent compared with pro forma Operating EBITDA of $854 million for the nine months ended September 30, 2019. Favorable impacts from volume gains and cost productivity actions were offset by higher logistics costs and $55 million decrease in income compared to prior year related to a 2019 asset sale.

56

NUTRITION & BIOSCIENCES

The Nutrition & Biosciences segment is an innovation-driven and customer-focused segment that provides solutions for the global food and beverage, dietary supplements, home and personal care, energy, animal nutrition and pharma markets. The segment is one of the world's largest producers of specialty ingredients, developing and manufacturing solutions for the global food and beverage, dietary supplements, enzymes and pharmaceutical excipient markets. Additionally, the segment is an industry pioneer and innovator that works with customers to improve the performance, productivity and sustainability of their products and processes, through differentiated technology in ingredients applications, fermentation, biotechnology, chemistry and manufacturing process excellence.

Nutrition & Biosciences	Three Months Ended				Nine Months Ended
In millions	September 30, 2020		September 30, 2019		September 30, 2020		September 30, 2019
Net sales	$	1,467	$	1,525	$	4,557	$	4,618
Operating EBITDA 1	$	379	$	354	$	1,182	$	1,089
Equity earnings	$	1	$	—	$	2	$	—

1. For the nine months ended September 30, 2019, operating EBITDA is on a pro forma basis.

Nutrition & Biosciences	Three Months Ended		Nine Months Ended
Percentage change from prior year	September 30, 2020		September 30, 2020
Change in Net Sales from Prior Period due to:
Local price & product mix	—	%	1	%
Currency	—		(1)
Volume	(4)		(1)
Portfolio & other	—		—
Total	(4)	%	(1)	%

Nutrition & Biosciences net sales were $1,467 million for the three months ended September 30, 2020, down 4 percent from $1,525 million for the three months ended September 30, 2019 due to a 4 percent decrease in volume. Food & Beverage volumes declined due to continued weak demand in food service and in sweeteners. Health & Biosciences volume gains in probiotics and strong demand in home & personal care were more than offset by declined demand in biorefinery and microbial control. Pharma Solutions sales were relatively flat compared to the prior period.

Operating EBITDA was $379 million for the three months ended September 30, 2020, up 7 percent compared with $354 million for the three months ended September 30, 2019 due to cost productivity actions and favorable product mix more than offsetting the lower volumes.

Nutrition & Biosciences net sales were $4,557 million for the nine months ended September 30, 2020, down 1 percent compared with $4,618 million for the nine months ended September 30, 2019. A 1 percent increase in local price was offset by a 1 percent decrease in volume and a 1 percent unfavorable currency impact. Food & Beverage volume declined due to decreased demand in food service and sweeteners applications, partially offset by higher demand for plant-based meat. Health & Biosciences volume gains were driven by probiotics along with strong demand in home & personal care and animal nutrition, offset by declined demand in biorefinery and microbial control. Pharma Solutions volume gains were driven by increased demand in key products.

Operating EBITDA was $1,182 million for the nine months ended September 30, 2020, up 9 percent compared with pro forma Operating EBITDA of $1,089 million for the nine months ended September 30, 2019 due to a cost productivity actions, favorable product mix led by Health & Biosciences, and pricing gains.

57

TRANSPORTATION & INDUSTRIAL

The Transportation & Industrial segment provides high-performance engineering resins, adhesives, silicones, lubricants and parts to engineers and designers in the transportation, electronics, healthcare, industrial and consumer end-markets to enable systems solutions for demanding applications and environments. The segment delivers a broad range of polymer-based high-performance materials in its product portfolio, including elastomers and thermoplastic and thermoset engineering polymers which are used by customers to fabricate components for mechanical, chemical and electrical systems. In addition, the segment produces innovative engineering polymer solutions, high performance parts, specialty silicones and differentiated adhesive technologies to meet customer specifications in automotive, aerospace, electronics, industrial, healthcare and consumer markets. Transportation & Industrial is a global leader of advanced materials that provides technologies that differentiate customers’ products with improved performance characteristics enabling the transition to hybrid-electric-connected vehicles, high speed high frequency connectivity and smart healthcare.

Transportation & Industrial	Three Months Ended				Nine Months Ended
In millions	September 30, 2020		September 30, 2019		September 30, 2020		September 30, 2019
Net sales	$	1,045	$	1,209	$	3,021	$	3,795
Operating EBITDA 1	$	242	$	306	$	599	$	1,036
Equity earnings	$	1	$	1	$	3	$	3

1. For the nine months ended September 30, 2019, operating EBITDA is on a pro forma basis.

Transportation & Industrial	Three Months Ended		Nine Months Ended
Percentage change from prior year	September 30, 2020		September 30, 2020
Change in Net Sales from Prior Period due to:
Local price & product mix	(5)	%	(5)	%
Currency	—		—
Volume	(9)		(15)
Portfolio & other	—		—
Total	(14)	%	(20)	%

Transportation & Industrial net sales were $1,045 million for the three months ended September 30, 2020, down from $1,209 million for the three months ended September 30, 2019. The change in net sales was due to a 9 percent decrease in volume and a 5 percent decrease in local price. While volume improved notably from second quarter of 2020, volume declines compared to prior year due to the impact of the COVID-19 pandemic on the automotive industry and the other key industrial end markets more than offset strong demand for KALREZ® within Healthcare & Specialty in the semiconductor market.

Operating EBITDA was $242 million for the three months ended September 30, 2020, down 21 percent compared with $306 million for the three months ended September 30, 2019. Cost productivity actions were more than offset by volume declines and the impact of temporarily idling manufacturing plants to align supply with demand due to the COVID-19 pandemic, along with lower price.

Transportation & Industrial net sales were $3,021 million for the nine months ended September 30, 2020, down from $3,795 million for the nine months ended September 30, 2019 due to a 15 percent decrease in volume and a 5 percent decrease in local price. Volume declines were primarily due to impact of the COVID-19 pandemic on the automotive industry and the other key industrial markets.

Operating EBITDA was $599 million for the nine months ended September 30, 2020, down 42 percent compared with pro forma Operating EBITDA of $1,036 million for the nine months ended September 30, 2019 driven primarily by volume declines due to the COVID-19 pandemic, price declines, and approximately $160 million in charges associated with temporarily idling several manufacturing plants to align supply with demand.

58

SAFETY & CONSTRUCTION

The Safety & Construction segment is a leading provider of engineered products and integrated systems for a number of industries including worker safety, water purification and separation, aerospace, energy, medical packaging and building materials. The segment satisfies the growing global needs of businesses, governments, and consumers for solutions that make life safer, healthier, and better. By uniting market-driven science with the strength of highly regarded brands, the segment strives to bring new products and solutions to solve customers' needs faster, better and more cost effectively.

Safety & Construction	Three Months Ended				Nine Months Ended
In millions	September 30, 2020		September 30, 2019		September 30, 2020		September 30, 2019
Net sales	$	1,249	$	1,327	$	3,769	$	3,951
Operating EBITDA 1	$	324	$	352	$	1,041	$	1,108
Equity earnings	$	7	$	7	$	19	$	22

1. For the nine months ended September 30, 2019, operating EBITDA is on a pro forma basis.

Safety & Construction	Three Months Ended		Nine Months Ended
Percentage change from prior year	September 30, 2020		September 30, 2020
Change in Net Sales from Prior Period due to:
Local price & product mix	1	%	2	%
Currency	—		(1)
Volume	(10)		(8)
Portfolio & other	3		2
Total	(6)	%	(5)	%

Safety & Construction net sales were $1,249 million for the three months ended September 30, 2020, down from $1,327 million for the three months ended September 30, 2019 as a 3 percent increase in portfolio and a 1 percent increase in local price were more than offset by a 10 percent decline in volume. The portfolio impact reflects the recent acquisitions in the Water Solutions business. Local price increased led by Safety Solutions. Volume gains in Water Solutions and demand for TYVEK® protective garments were more than offset by volume declines in Safety and Shelter Solutions due to weakened demand across end markets and declined commercial construction activity as a result of the COVID-19 pandemic.

Operating EBITDA was $324 million for the three months ended September 30, 2020, down 8 percent compared with $352 million for the three months ended September 30, 2019 due to lower volumes and costs associated with capacity reductions to align supply with demand more than offsetting productivity actions and lower raw material costs.

Safety & Construction net sales were $3,769 million for the nine months ended September 30, 2020, down from $3,951 million for the nine months ended September 30, 2019 as a 2 percent increase in local price and 2 percent increase in portfolio were more than offset by a 8 percent volume decline and a 1 percent unfavorable impact from currency. The portfolio impact reflects the recent acquisitions in the Water Solutions business. Volume growth in the segment was led by gains in Water Solutions and TYVEK® protective garment sales within Safety Solutions which were more than offset by weakened demand in end markets for NOMEX® and KEVLAR®. Shelter Solutions volume declined due to the COVID-19 pandemic and the resulting impact on commercial construction activity.

Operating EBITDA was $1,041 million for the nine months ended September 30, 2020, down 6 percent compared with pro forma Operating EBITDA of $1,108 million for the nine months ended September 30, 2019 due to lower volumes, the absence of licensing income, and costs associated with capacity reductions more than offsetting pricing gains, improved product mix, and productivity actions.

59

NON-CORE

The Non-Core segment is a leading global supplier of key materials for the manufacturing of photovoltaic cells and panels, including innovative metallization pastes, backsheet materials and silicone encapsulants and adhesives. The segment also includes the Company's share of the results of the HSC Group, a U.S.-based group of companies that manufacture and sell polycrystalline silicon products for the photovoltaic and semiconductor industries. Additionally, the segment provides materials used in components and films for consumer electronics, automotive, and aerospace markets. The segment also provides sustainable materials and services for sulfuric acid production and regeneration technologies, alkylation technology for production of clean, high-octane gasoline, and a comprehensive suite of aftermarket service and solutions offerings, including safety consulting and services, to improve the safety, productivity, and sustainability of organizations across a range of industries. The Non-Core segment is also a leading producer of specialty biotechnology materials for carpet and apparel markets as well as polyester films for the healthcare, photovoltaics, electronics, packaging and labels, and electrical insulation industries.

Non-Core	Three Months Ended				Nine Months Ended
In millions	September 30, 2020		September 30, 2019		September 30, 2020		September 30, 2019
Net sales	$	331	$	431	$	1,005	$	1,327
Operating EBITDA 1	$	14	$	94	$	149	$	296
Equity earnings 2	$	13	$	26	$	121	$	92

1. For the nine months ended September 30, 2019, operating EBITDA is on a pro forma basis.

2. Represents equity in earnings (losses) of nonconsolidated affiliates included in pro forma Operating EBITDA, the Company's measure of profit/loss for segment reporting purposes, which excludes significant items. Accordingly, the Non-Core segment presented above excludes a restructuring charge of $1 million and $3 million for the three and nine months ended September 30, 2019 which is presented in "Equity in earnings of nonconsolidated affiliates" in the Company's interim Consolidated Statements of Operations.

Non-Core	Three Months Ended		Nine Months Ended
Percentage change from prior year	September 30, 2020		September 30, 2020
Change in Net Sales from Prior Period due to:
Local price & product mix	5	%	3	%
Currency	—		(1)
Volume	(18)		(17)
Portfolio & other	(10)		(9)
Total	(23)	%	(24)	%

Non-Core net sales were $331 million for the three months ended September 30, 2020, down from $431 million for the three months ended September 30, 2019 due to 5 percent pricing gains more than offset by a 18 percent volume decline and a 10 percent portfolio decline. The portfolio decline was driven by the third quarter 2020 sale of the trichlorosilane ("TCS") business within Photovoltaic & Advanced Materials and the third quarter 2019 sale of the Sustainable Solutions business. Price gains were driven by increased metal prices. Volume gains for photovoltaic materials were more than offset by declines in demand for trichlorosilane, lower volumes in Clean Technologies, and declines in demand for biomaterials as a result of weakened demand in carpet and apparel markets.

Operating EBITDA was $14 million for the three months ended September 30, 2020, down 85 percent compared with $94 million for the three months ended September 30, 2019 due to volume declines, the absence of the gain on the sale of the Sustainable Solutions business, and the absence of earnings from the Sustainable Solutions, TCS, and HSC businesses.

Non-Core net sales were $1,005 million for the nine months ended September 30, 2020, down from $1,327 million for the nine months ended September 30, 2019. Net sales declined due to a 17 percent decline in volume, a 9 percent portfolio decline due to the sale of the Sustainable Solutions and TCS businesses and a 1 percent unfavorable impact from currency, which more than offset a 3 percent increase in local price. Volume declines were driven by declines in demand for trichlorosilane, TEDLAR® aircraft films, biomaterials due to weakened demand in carpet and apparel markets, and lower volumes in Clean Technologies.

Operating EBITDA was $149 million for the nine months ended September 30, 2020, down 50 percent compared with pro forma Operating EBITDA of $296 million for the nine months ended September 30, 2019 as a customer settlement gain of $64 million was more than offset by volume declines, the absence of the gain on the sale of the Sustainable Solutions business, and the absence of earnings from the Sustainable Solutions, TCS, and HSC businesses.

60

CHANGES IN FINANCIAL CONDITION

Liquidity & Capital Resources

Information related to the Company's liquidity and capital resources can be found in the Company's 2019 Annual Report, Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations, Liquidity and Capital Resources. Discussion below provides the updates to this information for the nine months ended September 30, 2020.

The Company continually reviews its sources of liquidity and debt portfolio and may make adjustments to one or both to ensure adequate liquidity and increase the Company’s optionality and financing efficiency as it relates to financing cost and balancing terms/maturities. The Company’s primary source of incremental liquidity is cash flows from operating activities. COVID-19 continues to adversely impact the broader global economy, including negatively impacting economic growth and creating disruption and volatility in the global financial and capital markets, which could result in increases in the cost of capital and/or adversely impact the availability of and access to capital, which could negatively affect DuPont’s liquidity. Management expects the generation of cash from operations and the ability to access the debt capital markets and other sources of liquidity will continue to provide sufficient liquidity and financial flexibility to meet the Company’s and its subsidiaries obligations as they come due; however, DuPont is unable to predict the extent of COVID-19 related impacts which depends on highly uncertain and unpredictable future developments, including the duration and spread of the COVID-19 outbreak, and the speed and extent of the resumption of normal economic and operating conditions. In light of this uncertainty, the Company has taken steps to further ensure liquidity and capital resources, as discussed below.

In millions	September 30, 2020		December 31, 2019
Cash and cash equivalents 1	$	4,008	$	1,540
Total debt	$	24,196	$	17,447

1.The net proceeds of approximately $6.2 billion from the N&B Notes Offering were recorded within non-current “Restricted cash” in the interim Condensed Consolidated Balance Sheets at September 30, 2020 and thus are not included in "Cash and cash equivalents" as presented in the table above.

The Company's cash and cash equivalents at September 30, 2020 and December 31, 2019 were $4.0 billion and $1.5 billion, respectively, of which $1.7 billion at September 30, 2020 and $1.4 billion at December 31, 2019 were held by subsidiaries in foreign countries, including United States territories. For each of its foreign subsidiaries, the Company makes an assertion regarding the amount of earnings intended for permanent reinvestment, with the balance available to be repatriated to the United States. The increase in cash and cash equivalents was primarily due to receipt of proceeds from the May Debt Offering, discussed further below.

Total debt at September 30, 2020 and December 31, 2019 was $24.2 billion and $17.4 billion, respectively. The increase was primarily due to the N&B Notes Offering and the May Debt Offering, partially offset by a decline in commercial paper.

Term Loan and Revolving Credit Facilities

In November 2018, the Company entered into a term loan agreement that establishes two term loan facilities in the aggregate principal amount of $3 billion, (the “Term Loan Facilities”) as well as a five-year $3 billion revolving credit facility (the “Five-Year Revolving Credit Facility”). Effective May 2, 2019, the Company fully drew the two Term Loan Facilities in the aggregate principal amount of $3 billion and the Five-Year Revolving Credit Facility became effective and available. The Five-Year Revolving Credit Facility is generally expected to remain undrawn, and serve as a backstop to the Company’s commercial paper and letter of credit issuance. In June 2019, the Company entered into a 364-day $750 million revolving credit facility (the “Old 364-Day Revolving Credit Facility”).

In April 2020, the Company entered into a $1.0 billion 364-day revolving credit facility (the “$1B Revolving Credit Facility"). The $1B Revolving Credit Facility replaced the Old 364-Day Revolving Credit Facility, improving the Company’s liquidity position in response to near term uncertainties. As of the effectiveness of the $1B Revolving Credit Facility, the Old 364-Day Revolving Credit Facility was terminated. The $1B Revolving Credit facility may be used for general corporate purposes.

May Debt Offering

On May 1, 2020, the Company completed an underwritten public offering of senior unsecured notes (the “Notes”) in the aggregate principal amount of $2 billion of 2.169 percent fixed rate Notes due May 1, 2023 (the “May Debt Offering”). The proceeds from the May Debt Offering are expected to be used by the Company to repay or redeem the Company’s $0.5 billion in floating rate notes due November 2020 and $1.5 billion of 3.77 percent fixed-rate notes due November 2020 (collectively, the “2020 Notes”). Upon consummation of the Intended N&B Transaction, the Company will be required to mail a notice of redemption to holders of the Notes, with a copy to the Trustee, setting forth the date of redemption of all of the Notes on the date (“Special Mandatory Redemption Date”) that is the later of (i) three (3) Business Days after the consummation of the Intended N&B Transaction and (ii) May 1, 2021. On the Special Mandatory Redemption Date, the Company will be required to redeem all of the Notes at a redemption price equal to 100% of the aggregate principal amount of the Notes plus accrued and

61

unpaid interest, if any, up to but excluding the Special Mandatory Redemption Date. In the event a special mandatory redemption is triggered, the Company expects to fund the redemption with proceeds from the Special Cash Payment.

Commercial Paper

In April 2019, DuPont authorized a $3 billion commercial paper program (the “DuPont Commercial Paper Program”). At September 30, 2020, the Company had issued $390 million of commercial paper ($1.8 billion at December 31, 2019).

Nutrition & Biosciences Financing    

In connection with the Intended N&B Transaction, N&B Inc. entered into a Bridge Commitment Letter (the "Bridge Letter") in an aggregate principal amount of $7.5 billion, (the “Bridge Loans”) to secure committed financing for the Special Cash Payment and related financing fees and expenses. The aggregate commitment under the Bridge Letter is reduced by, among other things, (1) the amount of net cash proceeds received by N&B Inc. from any issuance of senior unsecured notes pursuant to a Rule 144A offering or other private placement and (2) certain qualifying term loan commitments under senior unsecured term loan facilities.

In January 2020, N&B Inc. entered into a senior unsecured term loan agreement in the amount of $1.25 billion split evenly between three- and five-year facilities (the "N&B Term Loan Facilities"). As a result of entry into the term loan agreement, the commitments under the Bridge Commitment Letter were reduced to $6.25 billion.

On September 16, 2020 (the “Offering Date”), N&B Inc. completed an offering in the aggregate principal amount of $6.25 billion of senior unsecured notes in six series, comprised of the following (collectively, the “N&B Notes Offering" and together with the N&B Term Loan Facilities, the “Permanent Financing”): $300 million aggregate principal amount of 0.697% Senior Notes due 2022; $1.0 billion aggregate principal amount of 1.230% Senior Notes due 2025; $1.2 billion aggregate principal amount of 1.832% Senior Notes due 2027; $1.5 billion aggregate principal amount of 2.300% Senior Notes due 2030; $750 million aggregate principal amount of 3.268% Senior Notes due 2040; and $1.5 billion aggregate principal amount of 3.468% Senior Notes due 2050. As a result of the N&B Notes Offering, the commitments under the Bridge Commitment Letter were further reduced to zero and terminated on and as of the Offering Date.

The net proceeds of approximately $6.2 billion from the N&B Notes Offering were deposited into an escrow account. The release of the net proceeds from the N&B Notes Offering and the availability of funding under the term loan agreement are subject to customary closing conditions including among others, the satisfaction of substantially all the conditions to the consummation of the intended transaction with IFF. The proceeds from the Permanent Financing will be used to make the Special Cash Payment and to pay the related financing fees and expenses. The obligations and liabilities associated with the Permanent Financing will be separated from the Company upon consummation of the Intended N&B Transaction. However, if the closing of the Intended Merger has not occurred on or prior to September 15, 2021, or, if prior to such date, the Merger Agreement is validly terminated, (each a “Special Mandatory Redemption Event”), N&B Inc. must redeem all of the Notes on or before the 15th business day following the Special Mandatory Redemption Event (such date of redemption, the “Special Mandatory Redemption Date”) at a redemption price equal to 101% of the aggregate principal amount of the applicable series of Notes, plus accrued and unpaid interest to, but not including, the Special Mandatory Redemption Date. Borrowing under the term loan agreement would occur immediately prior to the closing of the Intended N&B Transaction.

Pursuant to the Merger Agreement, the fees and expenses associated with the financing will be borne (A) entirely by N&B Inc. if the transaction closes; and (B) equally by DuPont and IFF if the Merger Agreement terminates. However, if the Merger Agreement is terminated by IFF, in accordance with its terms, for breach by DuPont, such fees and expenses will be borne entirely by DuPont; and if terminated by DuPont in accordance with its terms for breach by IFF, such fees and expenses will be borne entirely by IFF.

Credit Ratings

The Company's credit ratings impact its access to the debt capital markets and cost of capital. The Company remains committed to a strong financial position and strong investment-grade rating. At October 28, 2020, DuPont's credit ratings were as follows:

Credit Ratings	Long-Term Rating	Short-Term Rating	Outlook
Standard & Poor’s	BBB+	A-2	Negative Watch
Moody’s Investors Service	Baa1	P-2	Stable
Fitch Ratings	BBB+	F-2	Stable

The Company's indenture covenants related to its 2018 Senior Notes and May Debt Offering contains certain limitations on the Company’s ability to incur liens and enter into sale lease-back transactions, mergers and consolidations as well as customary events of default. The Term Loan Facilities, the Five-Year Revolving Credit Facility and the $1B Revolving Credit Facility

62

contain a financial covenant, typical for companies with similar credit ratings, requiring that the ratio of Total Indebtedness to Total Capitalization for the Company and its consolidated subsidiaries not exceed 0.60. At September 30, 2020, the Company was in compliance with this financial covenant.

Summary of Cash Flows

The Company’s cash flows from operating, investing and financing activities, as reflected in the interim Consolidated Statements of Cash Flows, are summarized in the following table. The cash flows related to the Materials Science and Agriculture businesses have not been segregated and are included in the interim Consolidated Statements of Cash Flows for the nine months ended September 30, 2019.

Cash Flow Summary	Nine Months Ended September 30,
In millions	2020		2019
Cash provided by (used for):
Operating activities	$	2,794	$	831
Investing activities	$	35	$	(1,807)
Financing activities	$	5,830	$	(10,897)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	$	4	$	(2)

Cash Flows from Operating Activities

In the first nine months of 2020, cash provided by operating activities was $2,794 million, compared with $831 million in the same period last year. The increase in cash provided by operating activities was primarily due to a decrease in cash used for working capital, offset by the impact of the DWDP Distributions to period earnings.

Net Working Capital	Sept 30, 2020		Dec 31, 2019
In millions (except ratio)
Current assets	$	12,606	$	9,999
Current liabilities	6,984		8,346
Net working capital	$	5,622	$	1,653
Current ratio	1.80:1		1.20:1

Cash Flows from Investing Activities

In the first nine months of 2020, cash provided by investing activities was $35 million, compared with cash used for investing activities of $1,807 million in the first nine months of 2019. Cash provided by investing activities was driven by proceeds from sales of property and businesses in 2020 and lower capital expenditures compared to the same period of prior year. The first nine months of 2019 also contains activity related to the Materials Science and Agriculture businesses prior to the DWDP Distributions.

Cash Flows from Financing Activities

In the first nine months of 2020, cash provided by financing activities was $5,830 million compared with cash used for financing activities of $10,897 million in the same period last year. The primary driver of the increase in cash provided was an increase in proceeds from issuances of long-term debt as well as a decrease in cash used for payments related to the DWDP Distributions of the Materials Science and Agriculture businesses, a reduction in payments on long-term debt, and a reduction in share repurchase of common stock, partially offset by decreased issuances of short-term notes payable. The first nine months of 2019 also contains activity related to the Materials Science and Agriculture businesses prior to the DWDP Distributions.

Dividends

On February 12, 2020, the Board of Directors declared a first quarter dividend of $0.30 per share, paid on March 16, 2020, to shareholders of record on February 28, 2020.

On April 29, 2020, the Company announced that its Board declared a second quarter dividend of $0.30 per share, paid on June 15, 2020, to shareholders of record on May 29, 2020.

On June 25, 2020, the Company announced that its Board declared a third quarter dividend of $0.30 per share paid on September 15, 2020, to shareholders of record on July 31, 2020.

On October 14, 2020, the Company announced that its Board of Directors declared a fourth quarter dividend of $0.30 per share payable on December 15, 2020, to shareholders of record on November 30, 2020.

63

Share Buyback Programs

On June 1, 2019, the Company's Board of Directors authorized a new $2 billion share buyback program, which expires on June 1, 2021. During the third quarter of 2020, the Company did not repurchase any shares. As of September 30, 2020, the Company repurchased 16.9 million shares under this program since inception at a total cost of $982 million. See Part II, Item 2. Unregistered Sales of Equity Securities and Use of Proceeds, for additional information.

Pension and Other Post-Employment Plans

DuPont expects to make additional contributions in the aggregate of approximately $30 million by year-end 2020 to certain non-US pension and other post-employment benefit plans. Any such contribution could be funded by existing cash balances and/or cash from other available sources of liquidity.

Restructuring

In March 2020, the Company approved restructuring actions designed to capture near-term cost reductions following the expected closure of the Intended N&B Transaction (the "2020 Restructuring Program"). As a result of these actions, the Company recorded pre-tax restructuring charges of $140 million inception-to-date, consisting of severance and related benefit costs of $112 million and asset related charges of $28 million. The Company expects actions related to this program to be substantially complete by the end of 2020. Future cash payments related to the 2020 Restructuring Program are anticipated to be $70 million primarily related to the payment of severance and related benefits.

In June 2019, DuPont approved restructuring actions to simplify and optimize certain organizational structures following the completion of the DWDP Distributions (the "2019 Restructuring Program"). As a result of these actions, the Company has recorded pre-tax restructuring charges of $140 million inception-to-date, consisting of severance and related benefit costs of $106 million and asset related charges of $34 million. Actions associated with the 2019 Restructuring Program are considered substantially complete. Future cash payments related to the 2019 Restructuring Program are anticipated to be $27 million, primarily related to the payment of severance and related benefits.

In September and November 2017, the Company approved post-merger restructuring actions under the DowDuPont Cost Synergy Program, adopted by the DowDuPont Board of Directors. The DowDuPont Cost Synergy Program was designed to integrate and optimize the organization following the DWDP Merger and in preparation for the DWDP Distributions whereby the Company has recorded pre-tax restructuring charges attributable to the continuing operations of DuPont of $489 million inception-to-date, consisting of severance and related benefit costs of $213 million, asset related charges of $209 million and contract termination charges of $67 million. The activities related to the DowDuPont Cost Synergy Program are expected to result in additional cash expenditures of $30 million consisting of severance and related benefit costs and contract terminations. Actions associated with the DowDuPont Cost Synergy Program, including employee separations, are considered substantially complete (see Note 5 to the interim Consolidated Financial Statements).

Off-balance Sheet Arrangements

Guarantees arise in the ordinary course of business from relationships with customers and nonconsolidated affiliates when the Company undertakes an obligation to guarantee the performance of others if specific triggering events occur. At September 30, 2020 and December 31, 2019, the Company had directly guaranteed $177 million and $187 million, respectively, of such obligations. Additional information related to the guarantees of the Subsidiaries can be found in the “Guarantees” section of Note 13 to the interim Consolidated Financial Statements.

Contractual Obligations

Information related to the Company's contractual obligations at December 31, 2019 can be found in the Company's 2019 Annual Report, Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations, Contractual Obligations. There were no material changes to the Company's contractual obligations during the first nine months of 2020, outside of the items shown below.

			Payments Due In
In millions	Total at September 30, 2020		Remainder of 2020		2021-2022		2023-2024		2025 and beyond
Long-term debt obligations 1	$	23,959	$	2,001	$	3,307	$	4,801	$	13,850
Expected cash requirements for interest 1	9,546		311		1,463		1,209		6,563
Total contractual obligations	$	33,505	$	2,312	$	4,770	$	6,010	$	20,413

1.A portion of these obligations relate to the N&B Notes Offering. The obligations associated with the N&B Notes Offering will be separated from the Company upon consummation of the Intended N&B Transaction. Refer to the Liquidity and Capital Resources section for more information.

64

OTHER MATTERS

Recent Accounting Guidance

See Note 2 to the interim Consolidated Financial Statements for a description of recent accounting guidance.

Critical Accounting Estimates

The preparation of financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make judgments, assumptions and estimates that affect the amounts reported in the interim Consolidated Financial Statements and accompanying notes. Note 1 to the Consolidated Financial Statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 (“2019 Annual Report”) describes the significant accounting policies and methods used in the preparation of the Consolidated Financial Statements. DuPont’s accounting policies that are impacted by judgments, assumptions and estimates are described in Management’s Discussion and Analysis of Financial Condition and Results of Operations in the Company’s 2019 Annual Report. Since December 31, 2019, there have been no material changes in the Company’s accounting policies that are impacted by judgments, assumptions and estimates. See the discussion in this section for information regarding the valuation of assets and impairment considerations.

Valuation of Assets and Impairment Considerations

The Company tests goodwill and indefinite-lived intangible assets for impairment annually during the fourth quarter as of October 1, or more frequently when events or changes in circumstances indicate that the fair value is below its carrying value. Goodwill is evaluated for impairment using qualitative and/or quantitative testing procedures. The Company performs goodwill impairment testing at the reporting unit level which is defined as the operating segment or one level below the operating segment. One level below the operating segment, or component, is a business in which discrete financial information is available and regularly reviewed by segment management. The Company aggregates certain components into reporting units based on economic similarities.

As a result of the related acquisition method of accounting in connection with the DWDP Merger, Historical EID’s assets and liabilities were measured at fair value resulting in increases to the Company’s goodwill and other intangible assets. The fair value valuation increased the risk that declines in financial projections, including changes to key assumptions, could have a material, negative impact on the fair value of the Company’s reporting units and assets, and therefore could result in an impairment.

COVID-19 continues to adversely impact the broader global economy and has caused significant volatility in financial markets. If there is a of lack of recovery, the time period to recovery is longer than expected or further global softening is experienced in certain markets, such as automotive, aerospace, commercial construction, oil & gas and select industrial end-markets, or a sustained decline in the value of the Company's common stock, the Company may be required to perform additional impairment assessments for its goodwill, other intangibles, and long-lived assets, the results of which could result in material impairment charges.

65

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

See Note 19 to the interim Consolidated Financial Statements. See also Part II, Item 7A. Quantitative and Qualitative Disclosures About Market Risk, of the Company's 2019 Annual Report on Form 10-K for information on the Company's utilization of financial instruments and an analysis of the sensitivity of these instruments.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

The Company maintains a system of disclosure controls and procedures to give reasonable assurance that information required to be disclosed in the Company's reports filed or submitted under the Securities Exchange Act of 1934 (Exchange Act) is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. These controls and procedures also give reasonable assurance that information required to be disclosed in such reports is accumulated and communicated to management to allow timely decisions regarding required disclosures.

As of September 30, 2020, the Company's Chief Executive Officer (CEO) and Chief Financial Officer (CFO), together with management, conducted an evaluation of the effectiveness of the Company's disclosure controls and procedures pursuant to Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Based on that evaluation, the CEO and CFO concluded that these disclosure controls and procedures are effective.

Changes in Internal Control Over Financial Reporting

There were no changes in the Company's internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Exchange Act Rules 13a-15 and 15d-15 that was conducted during the three months ended September 30, 2020 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

In connection with the Intended N&B Transaction, there are several processes, policies, operations, technologies and information systems that are expected to be transferred or separated. During the quarter ended September 30, 2020, the Company continues to take steps to ensure that adequate controls are designed and maintained throughout this transition period.

66

DuPont de Nemours Inc.
PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

The Company and its subsidiaries are subject to various litigation matters, including, but not limited to, product liability, patent infringement, antitrust claims, and claims for third party property damage or personal injury stemming from alleged environmental torts. Information regarding certain of these matters is set forth below and in Note 13 to the interim Consolidated Financial Statements.

Litigation

See Note 13 to the interim Consolidated Financial Statements.

Environmental Proceedings

The Company believes it is remote that the following matters will have a material impact on its financial position, liquidity or results of operations. The description is included per Regulation S-K, Item 103(5)(c) of the Securities Exchange Act of 1934.

Divested Neoprene Facility, La Place, Louisiana - EPA Compliance Inspection

In 2016, the EPA conducted a focused compliance investigation at the Denka Performance Elastomer LLC (“Denka”) neoprene manufacturing facility in La Place, Louisiana. Historical EID sold the neoprene business, including this manufacturing facility, to Denka in the fourth quarter of 2015. Subsequent to this inspection, the U.S. Environmental Protection Agency (“EPA”), the U.S. Department of Justice (“DOJ”), the Louisiana Department of Environmental Quality (“DEQ”), the Company (originally through Historical EID), and Denka began discussions in the spring of 2017 relating to the inspection conclusions and allegations of noncompliance arising under the Clean Air Act, including leak detection and repair. DuPont, Denka, EPA, DOJ and DEQ are continuing these discussions, which include potential settlement options.

New Jersey Directive PFAS

On March 25, 2019, the New Jersey Department of Environmental Protection (“NJDEP”) issued a Directive and Notice to Insurers to a number of companies, including Chemours, DowDuPont, Historical EID, and certain DuPont subsidiaries. NJDEP’s allegations relate to former operations of Historical EID involving poly- and perfluoroalkyl substances, (“PFAS”), including PFOA and PFOA- replacement products. The NJDEP seeks past and future costs of investigating, monitoring, testing, treating, and remediating New Jersey’s drinking water and waste systems, private drinking water wells and natural resources including groundwater, surface water, soil, sediments and biota. The Directive seeks certain information as to future costs and information related to the historic uses of PFAS and replacement chemicals including “information ranging from use and discharge of the chemicals through wastewater treatment plants, air emissions, and sales of products containing the chemicals to current development, manufacture, use and release of newer chemicals in the state.”

67

ITEM 1A. RISK FACTORS

Other than the risk factor set forth below, there have been no material changes in the Company's risk factors discussed in Part I, Item 1A, Risk Factors, in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.

The extent to which the novel coronavirus (COVID-19) and measures taken in response to it, impact DuPont’s business, results of operations, access to sources of liquidity and financial condition depends on future developments, which are highly uncertain and cannot be predicted.

DuPont is actively monitoring the global impacts of COVID-19, including the impacts from responsive measures, and remains focused on its top priorities - the safety and health of its employees and the needs of its customers. The Company’s business and financial condition, and the business and financial condition of the company’s customers and suppliers, have been impacted by the significantly increased economic and demand uncertainties created by the COVID-19 outbreak. In addition, public and private sector responsive measures, such as the imposition of travel restrictions, quarantines, adoption of remote working, and suspension of non-essential business and government services, have impacted the company’s business and financial condition. Many of DuPont’s facilities and employees are based in areas impacted by the virus. While most DuPont manufacturing sites remain in operation, DuPont has reduced or furloughed certain operations in response to government measures, employee welfare concerns and the impact of COVID-19 on the global demand and supply chain. DuPont’s manufacturing operations may be further adversely affected by impacts from COVID-19 including, among other things, additional government actions and other responsive measures, more and /or deeper supply chain disruptions, quarantines and health and availability of essential onsite personnel. Furthermore, COVID-19 continues to adversely impact the broader global economy, including negatively impacting economic growth and creating disruption and volatility in the global financial and capital markets, which could result in increases in the cost of capital and/or adversely impact the availability of and access to capital, which could negatively affect DuPont’s liquidity. DuPont is unable to predict the extent of COVID-19 related impacts on its business, results of operations, access to sources of liquidity and financial condition which depends on highly uncertain and unpredictable future developments, including, but not limited to, the duration and spread of the COVID-19 outbreak, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions resume. DuPont’s financial results may be materially and adversely impacted by a variety of factors that have not yet been determined, including potential impairments of goodwill and other assets. DuPont is taking actions, including reducing costs, restructuring actions, and delaying certain capital expenditures and non-essential spend. In addition, the Company may consider further reductions in or furloughing additional operations in response to further and/or deeper declines in demand and/or or supply chain disruptions. There can be no guaranty that such actions will significantly mitigate the impact of COVID-19 on the company’s business, results of operations, access to sources of liquidity or financial condition. After the COVID-19 outbreak has subsided, DuPont may experience materially adverse impacts to its business, results of operations and financial condition as a result of related global economic impacts, including any recession that has occurred or may occur in the future.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Issuer Purchases of Equity Securities

On June 1, 2019, the Company announced a $2 billion share buyback program, which expires on June 1, 2021. For the three months ended September 30, 2020, there were no purchases of the Company’s common stock under this share repurchase program. At September 30, 2020, $1,018 million is the approximate dollar value of shares that may yet be purchased by the Company under this program.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

68

ITEM 5. OTHER INFORMATION

In anticipation of and to facilitate the intended transaction with IFF, DuPont is planning for the internal separation of the N&B Business, both domestically and internationally, through a series of transactions that are intended to be tax-efficient from both a United States and foreign perspective (collectively, the "N&B Internal Separations"). See Part I, Item 1 and Part II, Item 1A of this report for more information regarding the intended transaction. The N&B Internal Separations are currently expected to consist of internal transactions undertaken by DuPont and its subsidiaries to separate ownership of the N&B Business from ownership of their other businesses, including a number of distributions intended to qualify as tax-free spinoffs for United States tax purposes under Section 355 of the Internal Revenue Code. The N&B Internal Separations are expected to occur in the United States and in (or involving entities domiciled in) various jurisdictions, including (but not limited to) the Netherlands. Following the completion of the N&B Internal Separations, DuPont expects that DuPont will effectuate the separation, pending DuPont Board approval, in a distribution intended to qualify as a tax-free spinoff for United States tax purposes under Section 355 of the Internal Revenue Code. The DuPont subsidiaries, or their successors, that are included in the current plans for the N&B Internal Separations as distributing corporations in the N&B Internal Separations (each in one or more tax-free spinoffs for United States tax purposes under Section 355 of the Internal Revenue Code) are the following: Specialty Electronic Materials Netherlands B.V.; DDP Specialty Electronic Materials US, LLC; DDP Specialty Electronic Materials US 4, LLC; DDP Specialty Electronic Materials US 5, LLC; DDP Specialty Electronic Materials US 8, LLC; DuPont Services Company B.V.; Performance Specialty Products NA, LLC; DuPont Polymers, Inc.; Danisco Holding USA Inc.; DuPont US Holding, LLC; Rohm and Haas Electronic Materials CMP, LLC.; Specialty Products US, LLC; and Specialty Products US 4, LLC.

69

ITEM 6. EXHIBITS

EXHIBIT NO.	DESCRIPTION
31.1*	Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*	Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*	Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2*	Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS	XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH	XBRL Taxonomy Extension Schema Document.
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB	XBRL Taxonomy Extension Label Linkbase Document.
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document.
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

*Filed herewith

70

DuPont de Nemours, Inc.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

DUPONT DE NEMOURS, INC.

Registrant

Date: October 30, 2020

By:	/s/ MICHAEL G. GOSS
Name:	Michael G. Goss
Title:	Vice President and Controller
City:	Wilmington
State:	Delaware

71

EX-31.1

DuPont de Nemours, Inc. EXHIBIT 31.1

Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Edward D. Breen, certify that:

1.    I have reviewed this quarterly report on Form 10-Q of DuPont de Nemours, Inc.;

2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.    The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.    The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

a)     all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)    any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: October 30, 2020

/s/ Edward D. Breen

Edward D. Breen

Chief Executive Officer

72

EX-31.2

DuPont de Nemours, Inc. EXHIBIT 31.2

Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Lori Koch, certify that:

1.I have reviewed this quarterly report on Form 10-Q of DuPont de Nemours, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: October 30, 2020

/s/ Lori Koch

Lori Koch

Chief Financial Officer

73

EX-32.1

DuPont de Nemours, Inc. EXHIBIT 32.1

Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

I, Edward D. Breen, Chief Executive Officer of DuPont de Nemours, Inc. (the “Company”), certify that:

1.the Quarterly Report on Form 10-Q of the Company for the quarter ended September 30, 2020 as filed with the Securities and Exchange Commission (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Edward D. Breen

Edward D. Breen

Chief Executive Officer

October 30, 2020

74

EX-32.2

DuPont de Nemours, Inc. EXHIBIT 32.2

Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

I, Lori Koch, Chief Financial Officer of DuPont de Nemours, Inc. (the “Company”), certify that:

1.the Quarterly Report on Form 10-Q of the Company for the quarter ended September 30, 2020 as filed with the Securities and Exchange Commission (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Lori Koch

Lori Koch

Chief Financial Officer

October 30, 2020

75

XML

Document and Entity Information - $ / shares	9 Months Ended
	Sep. 30, 2020	Oct. 28, 2020
Entity Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2020
Entity Registrant Name	DUPONT DE NEMOURS, INC.
Entity File Number	001-38196
Amendment Flag	false
Document Transition Report	false
City Area Code	302
Local Phone Number	774-3034
Entity Central Index Key	0001666700
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	81-1224539
Entity Address, Address Line One	974 Centre Road
Entity Address, Address Line Two	Building 730
Entity Address, City or Town	Wilmington
Entity Address, State or Province	DE
Entity Address, Postal Zip Code	19805
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	DD
Security Exchange Name	NYSE
Entity Common Stock, Share Outstanding		733,849,605
Par Value	$ 0.01	$ 0.01

XML

Consolidated Statements of Income - USD ($) shares in Millions, $ in Millions	3 Months Ended			9 Months Ended
	Sep. 30, 2020		Sep. 30, 2019	Sep. 30, 2020		Sep. 30, 2019
Net sales	$ 5,096		$ 5,426	$ 15,145		$ 16,308
Cost of sales	3,392		3,531	10,001		10,648
Research and development expenses	199		225	644		724
Selling, general and administrative expenses	524		645	1,698		2,013
Amortization of intangibles	530		247	1,591		755
Restructuring and asset related charges - net	384		82	807		290
Goodwill impairment charges	183	[1]	0	3,214	[2]	1,175
Integration and separation costs	127		191	469		1,149
Equity in earnings of nonconsolidated affiliates	30		43	172		132
Sundry income (expense) - net	430		79	627		144
Interest expense	197		177	573		493
Income (loss) from continuing operations before income taxes	20		450	(3,053)		(663)
Provision for income taxes on continuing operations	92		78	100		142
(Loss) income from continuing operations, net of tax	(72)		372	(3,153)		(805)
Income from discontinued operations, net of tax	0		5	0		1,217
Net (loss) income	(72)		377	(3,153)		412
Net income attributable to noncontrolling interests	7		5	20		90
Net (loss) income available for DuPont common stockholders	$ (79)		$ 372	$ (3,173)		$ 322
Per common share data:
(Loss) earnings per common share from continuing operations - basic	$ (0.11)		$ 0.49	$ (4.31)		$ (1.10)
Earnings per common share from discontinued operations - basic	0		0.01	0		1.53
(Loss) earnings per common share - basic	(0.11)		0.50	(4.31)		0.43
(Loss) earnings per common share from continuing operations - diluted	(0.11)		0.49	(4.31)		(1.10)
Earnings per common share from discontinued operations - diluted	0		0.01	0		1.53
(Loss) earnings per common share - diluted	$ (0.11)		$ 0.50	$ (4.31)		$ 0.43
Weighted-average common shares outstanding - basic	734.4		745.5	735.8		748.2
Weighted-average common shares outstanding - diluted	734.4		747.7	735.8		748.2

[1] Refer to Note 11 for additional information.

[2] Refer to Note 11 for additional information.

XML

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Net (loss) income	$ (72)	$ 377	$ (3,153)	$ 412
Other comprehensive income (loss), net of tax
Unrealized gains on investments	0	0	0	67
Cumulative translation adjustments	606	(694)	547	(829)
Pension and other post-employment benefit plans	4	(4)	9	187
Derivative instruments	0	0	0	(58)
Total other comprehensive income (loss)	610	(699)	556	(621)
Comprehensive income (loss)	538	(321)	(2,597)	(221)
Comprehensive income attributable to noncontrolling interests, net of tax	11	4	19	102
Comprehensive income (loss) attributable to DuPont	527	(325)	(2,616)	(323)
Total
Other comprehensive income (loss), net of tax
Total other comprehensive income (loss)	$ 606	$ (698)	$ 557	$ (633)

XML

Consolidated Balance Sheets - USD ($) $ in Millions	Sep. 30, 2020	Dec. 31, 2019
Current Assets
Cash and cash equivalents	$ 4,008	$ 1,540
Accounts and notes receivable - net	3,623	3,802
Inventories	3,902	4,319
Other current assets	238	338
Assets held for sale	835	0
Total current assets	12,606	9,999
Investments
Investments in nonconsolidated affiliates	951	1,204
Other investments	24	24
Noncurrent receivables	147	32
Total investments	1,122	1,260
Property, plant and equipment - net of accumulated depreciation (September 30, 2020 - $5,757; December 31, 2019 - $4,969)	9,686	10,143
Other Assets
Goodwill	29,690	33,151
Other intangible assets	11,528	13,593
Restricted cash	6,206	0
Deferred income tax assets	237	189
Deferred charges and other assets	1,066	1,014
Total other assets	48,727	47,947
Total Assets	72,141	69,349
Current Liabilities
Short-term borrowings and finance lease obligations	2,394	3,830
Accounts payable	2,685	2,934
Income taxes payable	414	240
Accrued and other current liabilities	1,364	1,342
Liabilities related to assets held for sale	127	0
Total current liabilities	6,984	8,346
Long-Term Debt	21,802	13,617
Other Noncurrent Liabilities
Deferred income tax liabilities	3,011	3,467
Pension and other post-employment benefits - noncurrent	1,193	1,172
Other noncurrent obligations	1,033	1,191
Total other noncurrent liabilities	5,237	5,830
Total Liabilities	34,023	27,793
Stockholders' Equity
Common stock (authorized 1,666,666,667 shares of $0.01 par value each; issued 2020: 733,845,391 shares; 2019: 738,564,728 shares)	7	7
Additional paid-in capital	50,219	50,796
(Accumulated deficit) Retained earnings	(11,808)	(8,400)
Accumulated other comprehensive loss	(859)	(1,416)
Total DuPont stockholders' equity	37,559	40,987
Noncontrolling interests	559	569
Total equity	38,118	41,556
Total Liabilities and Equity	$ 72,141	$ 69,349

XML

Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Millions	Sep. 30, 2020	Dec. 31, 2019
Accumulated depreciation	$ 5,757	$ 4,969
Common stock authorized	1,666,666,667	1,666,666,667
Common stock par value	$ 0.01	$ 0.01
Common stock issued	733,845,391	738,564,728

XML

Consolidated Statements of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2020		Sep. 30, 2019
Operating Activities
Net (loss) income	$ (3,153)		$ 412
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization	2,326
Goodwill impairment charges	3,214	[1]	1,175
Financing Activities
Cash, cash equivalents and restricted cash at beginning of period	1,577		14,022
Cash, cash equivalents and restricted cash at end of period	10,240		2,147
Continuing Operations [Member]
Financing Activities
Cash, cash equivalents and restricted cash at beginning of period	1,577		8,591
Cash, cash equivalents and restricted cash at end of period	10,240		2,147
Discontinued Operations, Disposed of by Means Other than Sale, Spinoff [Member]
Financing Activities
Cash, cash equivalents and restricted cash at beginning of period	0		5,431
Cash, cash equivalents and restricted cash at end of period	0		0
Total Company [Domain]
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization	2,326		2,662
Credit for deferred income tax and other tax related items	(481)		(658)
Earnings of nonconsolidated affiliates (in excess of) less than dividends received	(120)		700
Net periodic pension benefit cost (credit)	30		(58)
Pension contributions	(77)		(485)
Net gain on sales of assets, businesses and investments	(612)		(119)
Restructuring and asset related charges - net	807		564
Goodwill impairment charges	3,214		1,175
Amortization of merger-related inventory step-up	0		253
Other net loss	127		326
Accounts and notes receivable	133		(2,418)
Inventories	312		339
Accounts payable	43		(805)
Other assets and liabilities, net	245		(1,057)
Cash provided by operating activities	2,794		831
Investing Activities
Capital expenditures	(922)		(2,091)
Investment in gas field developments	0		(25)
Proceeds from sales of property, businesses, and ownership interests in nonconsolidated affiliates, net of cash divested	1,008		259
Acquisitions of property and businesses, net of cash acquired	(73)		(9)
Purchases of investments	(1)		(195)
Proceeds from sales and maturities of investments	1		233
Other investing activities, net	22		21
Cash provided by (used for) investing activities	35		(1,807)
Financing Activities
Changes in short-term notes payable	(1,439)		2,876
Proceeds from issuance of long-term debt	8,275		4,005
Payments on long-term debt	(29)		(6,899)
Purchases of common stock	(232)		(2,040)
Proceeds from issuance of Company stock	34		76
Employee taxes paid for share-based payment arrangements	(14)		(83)
Distributions to noncontrolling interests	(48)		(18)
Dividends paid to stockholders	(662)		(1,389)
Cash held by Dow and Corteva at the respective DWDP Distributions	0		(7,315)
Debt extinguishment costs	0		(104)
Other financing activities, net	(55)		(6)
Cash provided by (used for) financing activities	5,830		(10,897)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	4		(2)
Increase (Decrease) in cash, cash equivalents and restricted cash	$ 8,663		$ (11,875)

[1] Refer to Note 11 for additional information.

XML

Consolidated Statements of Equity - USD ($) $ in Millions	Total	Common Stock	Add'l Paid in Capital	Retained Earnings (Accumulated Deficit)	Accumulated Other Comp Loss	Unearned ESOP	Treasury Stock	Non-controlling Interests
Beginning balance at Dec. 31, 2018	$ 95,900	$ 8	$ 81,976	$ 30,257	$ (12,394)	$ (134)	$ (5,421)	$ 1,608
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Cumulative Effect Of New Accounting Principle	(111)			(111)
Net (loss) income	412			322				90
Other comprehensive (loss) income	(621)				(633)			12
Dividends	(1,389)		(224)	(1,165)
Common stock issued/sold	76		76
Stock-based compensation and allocation of ESOP shares	201		173	(1)		29
Distributions to non-controlling interests	(18)							(18)
Purchases of treasury stock	(2,040)						(2,040)
Retirement of treasury stock				(7,461)			7,461
Spin-off of Dow and Corteva	(50,487)		(30,843)	(30,123)	11,498	$ 105		(1,124)
Other	(11)	(1)	(3)	(7)
Ending balance at Sep. 30, 2019	41,912	7	51,155	(8,289)	(1,529)			568
Beginning balance at Jun. 30, 2019	42,576	7	51,129	(8,299)	(831)			570
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	377			372				5
Other comprehensive (loss) income	(699)				(698)			(1)
Common stock issued/sold	9		9
Stock-based compensation and allocation of ESOP shares	19		20	(1)
Distributions to non-controlling interests	(6)							(6)
Purchases of treasury stock	(359)						(359)
Retirement of treasury stock				(359)			359
Other	(5)		(3)	(2)
Ending balance at Sep. 30, 2019	41,912	7	51,155	(8,289)	(1,529)			568
Beginning balance at Dec. 31, 2019	41,556	7	50,796	(8,400)	(1,416)			569
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Cumulative Effect Of New Accounting Principle	(3)			(3)
Net (loss) income	(3,153)			(3,173)				20
Other comprehensive (loss) income	556				557			(1)
Dividends	(662)		(662)
Common stock issued/sold	34		34
Stock-based compensation and allocation of ESOP shares	81		81
Distributions to non-controlling interests	(48)							(48)
Purchases of treasury stock	(232)						(232)
Retirement of treasury stock				(232)			$ 232
Other	(11)		(30)					19
Ending balance at Sep. 30, 2020	38,118	7	50,219	(11,808)	(859)			559
Beginning balance at Jun. 30, 2020	37,577	7	50,191	(11,728)	(1,465)			572
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	(72)			(79)				7
Other comprehensive (loss) income	610				606			4
Stock-based compensation and allocation of ESOP shares	24		24
Distributions to non-controlling interests	(38)							(38)
Other	17		4	(1)				14
Ending balance at Sep. 30, 2020	$ 38,118	$ 7	$ 50,219	$ (11,808)	$ (859)			$ 559

XML

Consolidated Statements of Equity (Parentheticals) - $ / shares	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Common Stock, Dividends, Per Share, Declared	$ 0.90	$ 1.86

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Interim Financial Statements

The accompanying unaudited interim Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP") for interim financial information and the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. In the opinion of management, the interim statements reflect all adjustments (including normal recurring accruals) which are considered necessary for the fair statement of the results for the periods presented. Results from interim periods should not be considered indicative of results for the full year. These interim Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, collectively referred to as the “2019 Annual Report.” The interim Consolidated Financial Statements include the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained.

Impact of the Novel Coronavirus (“COVID-19”) Pandemic

The COVID-19 pandemic has resulted in significant economic disruption and continues to adversely impact the broader global economy. The extent of the impact on the Company's operational and financial performance will depend on future developments, including, but not limited to, the duration and spread of the outbreak and its impact on the Company's customers and suppliers. As of the date of issuance of these interim Consolidated Financial Statements, the full extent to which the COVID-19 pandemic may materially impact the Company's financial condition, liquidity, or results of operations remains uncertain.

Basis of Presentation

Effective August 31, 2017, pursuant to the merger of equals transaction contemplated by the Agreement and Plan of Merger, dated as of December 11, 2015, as amended on March 31, 2017 ("DWDP Merger Agreement"), The Dow Chemical Company ("Historical Dow") and E. I. du Pont de Nemours and Company ("Historical EID") each merged with subsidiaries of DowDuPont Inc. ("DowDuPont") and, as a result, Historical Dow and Historical EID became subsidiaries of DowDuPont (the "DWDP Merger"). Prior to the DWDP Merger, DowDuPont did not conduct any business activities other than those required for its formation and matters contemplated by the DWDP Merger Agreement. Historical Dow was determined to be the accounting acquirer in the DWDP Merger.

Except as otherwise indicated by the context, the term "Historical Dow" includes Historical Dow and its consolidated subsidiaries, "Historical EID" includes Historical EID and its consolidated subsidiaries, and "Dow Silicones" means Dow Silicones Corporation, a wholly owned subsidiary of Historical Dow.

Distributions

Effective as of 5:00 p.m. on April 1, 2019, the Company completed the separation of its materials science business into a separate and independent public company by way of a distribution of Dow Inc. (“Dow”) through a pro rata dividend in-kind of all of the then-issued and outstanding shares of Dow’s common stock (the “Dow Common Stock”), to holders of the Company’s common stock (the “DowDuPont common stock”), as of the close of business on March 21, 2019 (the “Dow Distribution”).

Effective as of 12:01 a.m. on June 1, 2019, the Company completed the separation of its agriculture business into a separate and independent public company by way of a distribution of Corteva, Inc. (“Corteva”) through a pro rata dividend in-kind of all of the then-issued and outstanding shares of Corteva’s common stock (the “Corteva Common Stock”), to holders of the Company’s common stock as of the close of business on May 24, 2019 (the “Corteva Distribution” and, together with the Dow Distribution, the “DWDP Distributions”).

Following the Corteva Distribution, DuPont holds the specialty products business. On June 1, 2019, DowDuPont changed its registered name from "DowDuPont Inc." to "DuPont de Nemours, Inc." doing business as "DuPont." Beginning on June 3, 2019, the Company's common stock is traded on the NYSE under the ticker symbol "DD."

The results of operations of DuPont for the 2019 interim periods presented reflect the historical financial results of Dow and Corteva as discontinued operations, as applicable. The cash flows and comprehensive income related to Dow and Corteva have not been segregated and are included in the interim Consolidated Statements of Cash Flows and interim Consolidated Statements of Comprehensive Income, respectively, for the applicable period. Unless otherwise indicated, the information in the notes to the interim Consolidated Financial Statements refer only to DuPont's continuing operations and do not include discussion of balances or activity of Dow or Corteva.

On December 15, 2019, the Company entered into definitive agreements to separate and combine the Nutrition & Biosciences business segment (the "N&B Business") with International Flavors & Fragrances Inc. ("IFF") in a tax-efficient Reverse Morris Trust transaction, (the "Intended N&B Transaction"). The transaction is expected to close in the first quarter of 2021, subject to approval by IFF shareholders and other customary closing conditions, including regulatory approvals and receipt by DuPont of an opinion of tax counsel. The financial results of the N&B Business are included in continuing operations for the periods presented.

XML

RECENT ACCOUNTING GUIDANCE (Notes)

9 Months Ended

Sep. 30, 2020

Recent Accounting Guidance [Abstract]

Accounting Standards Update and Change in Accounting Principle [Text Block]

RECENT ACCOUNTING GUIDANCE

Recently Adopted Accounting Guidance

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, and associated ASUs related to Topic 326. The new guidance introduces the current expected credit loss (“CECL”) model, which requires organizations to record an allowance for credit losses for certain financial instruments and financial assets, including trade receivables, based on expected losses rather than incurred losses. Under this update, on initial recognition and at each reporting period, an entity will be required to recognize an allowance that reflects the entity’s current estimate of credit losses expected to be incurred over the life of the financial instrument. This update became effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019.

The Company adopted the new standard in the first quarter of 2020, which required a modified retrospective transition approach, applying the new standard's cumulative-effect adjustment at the date of initial adoption. This cumulative-effect has been reflected as of January 1, 2020 and prior periods have not been restated. The impact of initial adoption was not material to the Company’s interim Condensed Consolidated Balance Sheet, interim Consolidated Statements of Operations, and interim Consolidated Statement of Cash Flows.

XML

DIVESTITURES (Notes)

9 Months Ended

Sep. 30, 2020

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]

DIVESTITURES

Separation Agreements

In connection with the Dow Distribution and the Corteva Distribution, the Company entered into certain agreements that, among other things, effected the separations, provides for the allocation of assets, employees, liabilities and obligations (including its investments, property and employee benefits and tax-related assets and liabilities) among DuPont, Dow, and Corteva (together, the “Parties” and each a “Party”), and provides a framework for DuPont’s relationship with Dow and Corteva following the DWDP Distributions. Effective April 1, 2019, the Parties entered into the following agreements referred herein as: the DWDP Separation and Distribution Agreement; the DWDP Tax Matters Agreement; the DWDP Employee Matters Agreement; and the Intellectual Property Cross-License Agreement (the “DuPont-Dow IP Cross-License Agreement”). In addition to the agreements above, DuPont has entered into certain various supply agreements with Dow. These agreements provide for different pricing than the historical intercompany and intracompany practices prior to the DWDP Distributions.

Effective June 1, 2019, in connection with the Corteva Distribution, DuPont and Corteva entered into the following agreements: the Intellectual Property Cross-License Agreement (the “DuPont-Corteva IP Cross-License Agreement”); the Letter Agreement; and the Amended and Restated DWDP Tax Matters Agreement.

In connection with the DWDP Distributions, Dow and Corteva indemnify the Company against, and DuPont indemnifies Dow and Corteva against certain litigation, environmental, income taxes, and other liabilities that arose prior to the DWDP Distributions, as applicable. The term of this indemnification is generally indefinite and includes defense costs and expenses, as well as monetary and non-monetary settlements and judgments. Refer to Note 13 for additional information regarding treatment of litigation and environmental related matters under the DWDP Separation and Distribution Agreement and the Letter Agreement.

Materials Science Division

On April 1, 2019, DowDuPont completed the separation of its Materials Science businesses, including the businesses and operations that comprised the Company's former Performance Materials & Coating, Industrial Intermediates & Infrastructure and the Packaging & Specialty Plastics segments, (the "Materials Science Division") through the consummation of the Dow Distribution.

On April 1, 2019, prior to the Dow Distribution, the Company contributed $2,024 million in cash to Dow.

The results of operations of the Materials Science Division are presented as discontinued operations as summarized below:

	Nine Months Ended September 30, 2019
In millions
Net sales	$	10,867
Cost of sales	8,917
Research and development expenses	163
Selling, general and administrative expenses	329
Amortization of intangibles	116
Restructuring and asset related charges - net	157
Integration and separation costs	44
Equity in earnings of nonconsolidated affiliates	(13)
Sundry income (expense) - net 1	17
Interest expense	240
Income from discontinued operations before income taxes	905
Provision for income taxes on discontinued operations 1	176
Income from discontinued operations, net of tax	729
Income from discontinued operations attributable to noncontrolling interests, net of tax	37
Income from discontinued operations attributable to DuPont stockholders, net of tax	$	692

1.The three and nine months ended September 30, 2019 includes $82 million of expense in "Sundry income (expense) - net" and a benefit of $85 million in "Provision for income taxes on discontinued operations" related to certain unrecognized tax benefits for positions taken on items from prior years.

The following table presents depreciation, amortization, and capital expenditures of the discontinued operations related to the Materials Science Division:

	Nine Months Ended September 30, 2019
In millions
Depreciation and amortization	$	744
Capital expenditures	$	597

Agriculture Division

On June 1, 2019, the Company completed the separation of its Agriculture business, including the businesses and operations that comprised the Company's former Agriculture segment (the "Agriculture Division"), through the consummation of the Corteva Distribution.

In 2019, prior to the distribution of Corteva, the Company contributed $7,139 million in cash to Corteva, a portion of which was used to retire indebtedness of Historical EID.

The results of operations of the Agriculture Division are presented as discontinued operations as summarized below:

	Nine Months Ended September 30, 2019
In millions
Net sales	$	7,144
Cost of sales	4,218
Research and development expenses	470
Selling, general and administrative expenses	1,294
Amortization of intangibles	176
Restructuring and asset related charges - net	117
Integration and separation costs	430
Equity in earnings of nonconsolidated affiliates	(4)
Sundry income (expense) - net 1	52
Interest expense	91
Income from discontinued operations before income taxes	396
Provision for income taxes on discontinued operations 1	74
Income from discontinued operations, net of tax	322
Income from discontinued operations attributable to noncontrolling interests, net of tax	35
Income from discontinued operations attributable to DuPont stockholders, net of tax	$	287

1.The three and nine months ended September 30, 2019 includes $6 million of expense in "Sundry income (expense) - net" and a benefit of $8 million in "Provision for income taxes on discontinued operations" related to certain unrecognized tax benefits for positions taken on items from prior years.

The following table presents depreciation, amortization, and capital expenditures of the discontinued operations related to the Agriculture Division:

	Nine Months Ended September 30, 2019
In millions
Depreciation and amortization	$	385
Capital expenditures	$	383

Assets Held for Sale

In October 2020, the Company entered into a definitive agreement to sell its biomaterials business unit, which includes the Company's equity method investment in DuPont Tate & Lyle Bio Products, for $240 million. The sale is subject to customary closing conditions and is expected to close in the first half of 2021. The Company determined that the assets and liabilities associated with the biomaterials business unit, which are reported in Non-Core, met the held for sale criteria as of September 30, 2020.

In addition, certain other assets and liabilities within Non-Core are expected to be disposed of within one year and met the held for sale criteria during the third quarter of 2020. The following table summarizes the carrying value of the major assets and liabilities of the biomaterials business unit, as well as these certain other assets and liabilities within Non-Core classified as held for sale as of September 30, 2020 (collectively, the “Non-Core Held for Sale Disposal Groups”):

In millions	September 30, 2020
Assets
Accounts and notes receivable - net	$	61
Inventories	96
Other current assets	40
Investments in nonconsolidated affiliates	166
Property, plant and equipment - net	32
Goodwill	267
Other intangible assets	169
Deferred charges and other assets	4
Assets held for sale	$	835
Liabilities
Accounts payable	$	29
Income taxes payable	1
Accrued and other current liabilities	48
Deferred income tax liabilities	30
Pension and other post-employment benefits - noncurrent	1
Other noncurrent obligations	18
Liabilities related to assets held for sale	$	127

In connection with the held for sale classification, the Non-Core Held for Sale Disposal Groups were measured at fair value less estimated cost to sell. As a result, the Company recorded a $25 million pre-tax goodwill impairment charge during the third quarter of 2020 which is reflected in “Goodwill impairment charges” in the Company’s interim Consolidated Statements of Operations for the three and nine months ended September 30, 2020.

Sale of TCS/HSC Disposal Group

In the third quarter of 2020, the Company completed the sale of its trichlorosilane business (“TCS Business”) along with its equity ownership interest in DC HSC Holdings LLC and Hemlock Semiconductor L.L.C. (the "HSC Group,” and together with the TCS Business, the “TCS/HSC Disposal Group” and the sale of the TCS/HSC Disposal Group, the “TCS/HSC Disposal”) to the HSC Group, both of which were part of the Non-Core segment. In connection with the TCS/HSC Disposal, the Company received $550 million in cash at closing, subject to certain claw-back provisions, and will receive an additional $175 million in equal installments over the course of the next three years associated with the settlement of an existing supply agreement dispute with the HSC Group. The TCS/HSC Disposal resulted in a net pre-tax benefit of $393 million ($232 million net of tax), including the settlement of the supply agreement dispute and after allocation of goodwill to the TCS Business. The net pre-tax benefit is recorded in “Sundry income (expense) – net” in the Company’s interim Consolidated Statements of Operations for the three and nine months ended September 30, 2020.

Sale of Compound Semiconductor Solutions

In the first quarter of 2020, the Company completed the sale of its Compound Semiconductor Solutions business unit, a part of the Electronics & Imaging segment, to SK Siltron. The proceeds received in the first quarter of 2020 related to the sale of the business were approximately $420 million. The sale resulted in a pre-tax gain of $197 million ($102 million net of tax) recorded in "Sundry income (expense) - net" in the Company's interim Consolidated Statements of Operations for the nine months ended September 30, 2020.

Sale of DuPont Sustainable Solutions

In the third quarter of 2019, the Company completed the sale of its Sustainable Solutions business unit, a part of the Non-Core segment, to Gyrus Capital. The sale resulted in a pre-tax gain of $28 million ($22 million net of tax). The gain was recorded in "Sundry income (expense) - net" in the Company's interim Consolidated Statements of Operations for the three and nine months ended September 30, 2019.

Other Discontinued Operations Activity

For the nine months ended September 30, 2019, the Company recorded "Income from discontinued operations, net of tax" of $86 million related to the adjustment of certain unrecognized tax benefits for positions taken on items from prior years from previously divested businesses and $80 million related to changes in accruals for certain prior year tax positions related to the divested crop protection business and research and development assets of Historical EID.

Integration and Separation Costs

Integration and separation costs for continuing operations through September 30, 2020, primarily have consisted of financial advisory, information technology, legal, accounting, consulting, and other professional advisory fees associated with the preparation and execution of activities related to the intended separation of the Nutrition & Biosciences business beginning in the fourth quarter of 2019, the DWDP Merger, post-DWDP Merger integration, and the DWDP Distributions.

These costs are recorded within "Integration and separation costs" within the interim Consolidated Statements of Operations.

	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2020		2019		2020		2019
Integration and separation costs	$	127	$	191	$	469	$	1,149

XML

REVENUE

9 Months Ended

Sep. 30, 2020

Revenue from Contract with Customer [Abstract]

Revenue from Contract with Customer [Text Block]

REVENUE

Revenue Recognition

Products

Substantially all of DuPont's revenue is derived from product sales. Product sales consist of sales of DuPont's products to manufacturers and distributors. DuPont considers purchase orders, which in some cases are governed by master supply agreements, to be a contract with a customer. Contracts with customers are considered to be short-term when the time between order confirmation and satisfaction of the performance obligations is equal to or less than one year.

Disaggregation of Revenue

The Company disaggregates its revenue from contracts with customers by segment and business or major product line and geographic region, as the Company believes it best depicts the nature, amount, timing and uncertainty of its revenue and cash flows.

During the second quarter of 2020, Electronics & Imaging realigned a component within the Semiconductor Technologies product line to the Image Solutions product line. The reporting changes have been retrospectively reflected for all periods presented.

Net Trade Revenue by Segment and Business or Major Product Line	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2020		2019		2020		2019
Image Solutions	$	172	$	167	$	491	$	507
Interconnect Solutions	370		339		910		859
Semiconductor Technologies	462		428		1,392		1,251
Electronics & Imaging	$	1,004	$	934	$	2,793	$	2,617
Food & Beverage	$	686	$	736	$	2,163	$	2,237
Health & Biosciences	570		582		1,754		1,756
Pharma Solutions	211		207		640		625
Nutrition & Biosciences	$	1,467	$	1,525	$	4,557	$	4,618
Healthcare & Specialty	$	352	$	376	$	1,002	$	1,148
Industrial & Consumer	233		274		680		875
Mobility Solutions	460		559		1,339		1,772
Transportation & Industrial	$	1,045	$	1,209	$	3,021	$	3,795
Safety Solutions	$	534	$	630	$	1,746	$	1,952
Shelter Solutions	387		411		1,051		1,166
Water Solutions	328		286		972		833
Safety & Construction	$	1,249	$	1,327	$	3,769	$	3,951
Biomaterials	$	37	$	54	$	98	$	166
Clean Technologies	48		78		175		219
DuPont Teijin Films	47		48		124		127
Photovoltaic & Advanced Materials 1	199		223		608		707
Sustainable Solutions 2	—		28		—		108
Non-Core	$	331	$	431	$	1,005	$	1,327
Total	$	5,096	$	5,426	$	15,145	$	16,308

1. The TCS Business within Photovoltaic & Advanced Materials was divested in the third quarter of 2020.

2. The Sustainable Solutions business was divested in the third quarter of 2019.

Net Trade Revenue by Geographic Region	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2020		2019		2020		2019
U.S. & Canada	$	1,620	$	1,822	$	4,875	$	5,424
EMEA 1	1,069		1,227		3,405		3,898
Asia Pacific	2,120		2,057		6,045		6,036
Latin America	287		320		820		950
Total	$	5,096	$	5,426	$	15,145	$	16,308

1.Europe, Middle East and Africa.

Contract Balances

From time to time, the Company enters into arrangements in which it receives payments from customers based upon contractual billing schedules. The Company records accounts receivable when the right to consideration becomes unconditional. Contract assets include amounts related to the Company’s contractual right to consideration for completed performance obligations not yet invoiced. Contract liabilities primarily reflect deferred revenue from advance payment for product that the Company has received from customers. The Company classifies deferred revenue as current or noncurrent based on the timing of when the Company expects to recognize revenue.

Revenue recognized in the first nine months of 2020 from amounts included in contract liabilities at the beginning of the period was approximately $25 million (approximately $28 million in the first nine months of 2019). The amount of contract assets reclassified to receivables as a result of the right to the transaction consideration becoming unconditional was insignificant. The Company did not recognize any asset impairment charges related to contract assets during the period.

Contract Balances	September 30, 2020		December 31, 2019
In millions
Accounts and notes receivable - trade 1	$	2,938	$	3,007
Contract assets - current 2	$	—	$	35
Deferred revenue - current 3	$	18	$	20
Deferred revenue - noncurrent 4	$	25	$	24

1.Included in "Accounts and notes receivable - net" in the interim Condensed Consolidated Balance Sheets.

2.Included in "Other current assets" in the interim Condensed Consolidated Balance Sheets.

3.Included in "Accrued and other current liabilities" in the interim Condensed Consolidated Balance Sheets.

4.Included in "Other noncurrent obligations" in the interim Condensed Consolidated Balance Sheets.

XML

RESTRUCTURING AND ASSET RELATED CHARGES - NET (Notes)

9 Months Ended

Sep. 30, 2020

Restructuring and Related Activities [Abstract]

Restructuring and Related Activities Disclosure [Text Block]

RESTRUCTURING AND ASSET RELATED CHARGES - NET

Charges for restructuring programs and asset related charges, which include asset impairments, were $384 million and $807 million for the three and nine months ended September 30, 2020 ($82 million and $290 million for the three and nine months ended September 30, 2019). These charges were recorded in "Restructuring and asset related charges - net" in the interim Consolidated Statements of Operations. The total liability related to restructuring programs was $127 million at September 30, 2020 ($162 million at December 31, 2019). Restructuring activity consists of the following:

2020 Restructuring Program

In the first quarter of 2020, the Company approved restructuring actions designed to capture near-term cost reductions and to further simplify certain organizational structures in anticipation of the expected closure of the Intended N&B Transaction (the "2020 Restructuring Program").

The following tables summarize the charges related to the 2020 Restructuring Program for the three and nine months ended September 30, 2020:

	Three Months Ended September 30, 2020		Nine Months Ended September 30, 2020
In millions
Severance and related benefit costs	$	10	$	112
Asset related charges	4		28
Total restructuring and asset related charges - net	$	14	$	140

2020 Restructuring Program Charges by Segment	Three Months Ended September 30, 2020		Nine Months Ended September 30, 2020
In millions
Electronics & Imaging	$	1	$	5
Nutrition & Biosciences	5		12
Transportation & Industrial	—		21
Safety & Construction	2		24
Non-Core	1		1
Corporate	5		77
Total	$	14	$	140

The following table summarizes the activities related to the 2020 Restructuring Program:

2020 Restructuring Program	Severance and Related Benefit Costs		Asset Related Charges		Total
In millions
Year-to-date restructuring charges	$	112	$	28	$	140
Charges against the reserve	—		(28)		(28)
Cash payments	(42)		—		(42)
Reserve balance at September 30, 2020	$	70	$	—	$	70

At September 30, 2020, total liabilities related to the 2020 Restructuring Program were $70 million, recognized in "Accrued and other current liabilities" in the interim Condensed Consolidated Balance Sheets. The Company expects actions related to this program to be substantially complete by the end of 2020.

2019 Restructuring Program

During the second quarter of 2019 and in connection with the ongoing integration activities, DuPont approved restructuring actions to simplify and optimize certain organizational structures following the completion of the DWDP Distributions (the "2019 Restructuring Program"). The Company has recorded pre-tax restructuring charges of $140 million inception-to-date, consisting of severance and related benefit costs of $106 million and asset related charges of $34 million.

There were no charges incurred related to the 2019 Restructuring Program for the three months ended September 30, 2020. The following table summarizes the charges incurred for the three months ended September 30, 2019 and the nine months ended September 30, 2020 and September 30, 2019:

	Three Months Ended September 30,		Nine Months Ended September 30,
In millions	2019		2020		2019
Severance and related benefit costs	$	48	$	2	$	98
Asset related charges	21		—		24
Total restructuring and asset related charges - net	$	69	$	2	$	122

2019 Restructuring Program Charges (Credits) by Segment	Three Months Ended September 30,		Nine Months Ended September 30,
In millions	2019		2020		2019
Electronics & Imaging	$	35	$	(3)	$	42
Nutrition & Biosciences	4		(3)		18
Transportation & Industrial	6		(7)		18
Safety & Construction	3		(14)		20
Non-Core	3		—		3
Corporate	18		29		21
Total	$	69	$	2	$	122

The following table summarizes the activities related to the 2019 Restructuring Program:

2019 Restructuring Program	Severance and Related Benefit Costs
In millions
Reserve balance at December 31, 2019	$	86
Year-to-date restructuring charges	2
Non-cash compensation	(6)
Cash payments	(55)
Reserve balance at September 30, 2020	$	27

At September 30, 2020, total liabilities related to the 2019 Restructuring Program were $27 million, recognized in "Accrued and other current liabilities" ($86 million at December 31, 2019) in the interim Condensed Consolidated Balance Sheets. The 2019 Restructuring Program was considered substantially complete at June 30, 2020.

DowDuPont Cost Synergy Program

In September and November 2017, the Company approved post-merger restructuring actions under the DowDuPont Cost Synergy Program, which was designed to integrate and optimize the organization following the DWDP Merger and in preparation for the DWDP Distributions. The portions of the charges, costs and expenses attributable to integration and optimization within the Agriculture and Materials Science Divisions are reflected in discontinued operations. The Company has recorded pre-tax restructuring charges attributable to the continuing operations of DuPont of $489 million inception-to-date, consisting of severance and related benefit costs of $213 million, asset related charges of $209 million and contract termination and other charges of $67 million.

There were no charges incurred related to the DowDuPont Cost Synergy Program for the three months ended September 30, 2020. The following table summarizes the charges incurred for the three months ended September 30, 2019 and the nine months ended September 30, 2020 and September 30, 2019:

	Three Months Ended September 30,		Nine Months Ended September 30,
In millions	2019		2020		2019
Severance and related benefit costs (credits)	$	—	$	(2)	$	49
Contract termination and other charges	—		6		16
Asset related charges	14		—		43
Total restructuring and asset related charges - net 1	$	14	$	4	$	108

1. The charge for the three and nine months ended September 30, 2019 includes $13 million and $105 million which was recognized in "Restructuring and asset related charges - net" and $1 million and $3 million which was recognized in "Equity in earnings of nonconsolidated affiliates" in the interim Consolidated Statements of Operations.

DowDuPont Cost Synergy Program Charges (Credits) by Segment	Three Months Ended September 30,		Nine Months Ended September 30,
In millions	2019		2020		2019
Electronics & Imaging	$	—	$	—	$	—
Nutrition & Biosciences	3		—		38
Transportation & Industrial	—		1		—
Safety & Construction	2		5		7
Non-Core	(1)		—		(1)
Corporate	10		(2)		64
Total	$	14	$	4	$	108

The following table summarizes the activities related to the DowDuPont Cost Synergy Program:

DowDuPont Cost Synergy Program	Severance and Related Benefit Costs		Contract Termination Charges		Total
In millions
Reserve balance at December 31, 2019	$	74	$	2	$	76
Year-to-date restructuring (credits) charges	(2)		6		4
Charges against the reserve	—		(1)		(1)
Cash payments	(47)		(2)		(49)
Reserve balance at September 30, 2020	$	25	$	5	$	30

At September 30, 2020, total liabilities related to the DowDuPont Cost Synergy Program were $30 million, recognized in "Accrued and other current liabilities" ($76 million at December 31, 2019) in the interim Condensed Consolidated Balance Sheets. The DowDuPont Cost Synergy Program was considered substantially complete at June 30, 2020.

Asset Impairments

In the third quarter of 2020, the TCS/HSC Disposal within the Non-Core segment, as well as further softening conditions in the aerospace markets, gave rise to fair value indicators and, thus, served as triggering events requiring the Company to perform a recoverability assessment related to asset groups within its Photovoltaic and Advanced Materials (“PVAM”) business unit. The Company first performed a long-lived asset impairment test and determined that, based on undiscounted cash flows, the carrying amount of certain long-lived assets was not recoverable. Accordingly, the Company estimated the fair value of these assets using both an income approach and a market approach utilizing Level 3 unobservable inputs. As a result, the Company recognized a pre-tax impairment charge of $318 million ($242 million net of tax) recorded within “Restructuring and asset

related charges - net” in the interim Consolidated Statements of Operations for the three and nine months ended September 30, 2020 with the charge impacting definite-lived intangible assets and property, plant, and equipment. See Note 11 for further discussion of goodwill impairment charges recorded during the third quarter of 2020 resulting from the above triggering events.

Additionally, the Company recorded a pre-tax asset impairment charge of $52 million ($39 million net of tax) in the third quarter of 2020 related to indefinite-lived intangible assets within the Non-Core segment which were deemed no longer recoverable as a result of the Non-Core Held for Sale Disposal Groups classification (refer to Note 3 for additional information). The charge was recorded within “Restructuring and asset related charges – net” in the interim Consolidated Statements of Operations for the three and nine months ended September 30, 2020.

In the second quarter of 2020, the Company recorded a pre-tax impairment charge of $21 million ($16 million net of tax) related to indefinite-lived intangible assets within the Transportation & Industrial segment. This charge was recorded within “Restructuring and asset related charges - net” in the interim Consolidated Statements of Operations for the nine months ended September 30, 2020. See Note 11 for further discussion.

In the first quarter of 2020, expectations of proceeds related to certain potential divestitures within the Non-Core segment gave rise to fair value indicators and, thus, triggering events requiring the Company to perform a recoverability assessment related to its biomaterials business unit. The Company performed a long-lived asset impairment test and determined that, based on undiscounted cash flows, the carrying amount of certain long-lived assets was not recoverable. Accordingly, the Company estimated the fair value of these assets using a market approach utilizing Level 3 unobservable inputs. As a result, the Company recognized a pre-tax impairment charge of $270 million ($206 million net of tax) recorded within “Restructuring and asset related charges - net” in the interim Consolidated Statements of Operations for the nine months ended September 30, 2020 with the charge impacting definite-lived intangible assets and property, plant, and equipment.

Equity Method Investment Impairment Related Charges

In preparation for the Corteva Distribution, Historical EID completed the separation of the assets and liabilities related to its specialty products businesses into separate legal entities (the “SP Legal Entities”) and on May 1, 2019, Historical EID distributed the SP Legal Entities to DowDuPont (the “Internal SP Distribution”). The Internal SP Distribution served as a triggering event requiring the Company to perform an impairment analysis related to equity method investments held by the Company as of May 1, 2019. The Company applied the net asset value method under the cost approach to determine the fair value of the equity method investments in the Nutrition & Biosciences segment. Based on updated projections, the Company determined the fair value of the equity method investment was below the carrying value and had no expectation the fair value would recover in the short-term due to the current economic environment. As a result, management concluded the impairment was other-than-temporary and recorded a pre-tax impairment charge of $63 million ($47 million net of tax) in “Restructuring and asset related charges - net” in the interim Consolidated Statements of Operations related to the Nutrition & Biosciences segment for the nine months ended September 30, 2019.

XML

INCOME TAXES

9 Months Ended

Sep. 30, 2020

Income Tax Disclosure [Abstract]

INCOME TAXES

INCOME TAXES

For periods between the DWDP Merger and the DWDP Distributions, DuPont's consolidated federal income tax group and consolidated tax return included the Dow and Corteva entities. Generally, the consolidated tax liability of the DuPont U.S. tax group for each year was apportioned among the members of the consolidated group in accordance with the terms of the Amended and Restated DWDP Tax Matters Agreement. DuPont, Corteva and Dow intend that to the extent Federal and/or State corporate income tax liabilities are reduced through the utilization of tax attributes of the other, settlement of any receivable and payable generated from the use of the other party’s sub-group attributes will be in accordance with the Amended and Restated DWDP Tax Matters Agreement.

The Company's effective tax rate fluctuates based on, among other factors, where income is earned and the level of income relative to tax attributes. The effective tax rate on continuing operations for the third quarter of 2020 was 460.0 percent, compared with an effective tax rate of 17.3 percent for the third quarter of 2019. The effective tax rate for the third quarter of 2020 was principally the result of a non-tax-deductible goodwill impairment charge and a non-tax-deductible goodwill allocation in connection with the TCS/HSC Disposal impacting the Non-Core segment. The effective tax rate for the third quarter of 2019 was favorably impacted by, among other items, tax benefits related to the adjustment of certain unrecognized benefits for positions taken on items from a prior year.

For the first nine months of 2020, the effective tax rate on continuing operations was (3.3) percent, compared with (21.4) percent for the first nine months of 2019. The effective tax rate for the first nine months of 2020 was principally the result of a non-tax-deductible goodwill impairment charge impacting the Non-Core segment in the first and third quarter and a non-tax-deductible goodwill impairment charge impacting the Transportation and Industrial segment in the second quarter, coupled with an allocation of non-tax-deductible goodwill related to the TCS/HSC Disposal. The tax rate in the first nine months of 2019 was principally the result of the non-tax-deductible goodwill impairment charges impacting the Nutrition & Biosciences and Non-Core segments. See Note 11 for more information regarding the goodwill impairment charges.

Each year the Company files hundreds of tax returns in the various national, state and local income taxing jurisdictions in which it operates. These tax returns are subject to examination and possible challenge by the tax authorities. Positions challenged by the tax authorities may be settled or appealed by the Company. As a result, there is an uncertainty in income taxes recognized in the Company’s financial statements in accordance with accounting for income taxes and accounting for uncertainty in income taxes. The ultimate resolution of such uncertainties is not expected to have a material impact on the Company's results of operations.

XML

EARNINGS PER SHARE CALCULATIONS

9 Months Ended

Sep. 30, 2020

Earnings Per Share [Abstract]

EARNINGS PER SHARE CALCULATIONS

EARNINGS PER SHARE CALCULATIONS

The following tables provide earnings per share calculations for the three and nine months ended September 30, 2020 and 2019:

Net Income for Earnings Per Share Calculations - Basic & Diluted	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2020		2019		2020		2019
(Loss) income from continuing operations, net of tax	$	(72)	$	372	$	(3,153)	$	(805)
Net income from continuing operations attributable to noncontrolling interests	7		5		20		18
Net income from continuing operations attributable to participating securities 1	—		—		—		1
(Loss) income from continuing operations attributable to common stockholders	$	(79)	$	367	$	(3,173)	$	(824)
Income from discontinued operations, net of tax	—		5		—		1,217
Net income from discontinued operations attributable to noncontrolling interests	—		—		—		72
Income from discontinued operations attributable to common stockholders	—		5		—		1,145
Net (loss) income attributable to common stockholders	$	(79)	$	372	$	(3,173)	$	321

Earnings Per Share Calculations - Basic	Three Months Ended September 30,				Nine Months Ended September 30,
Dollars per share	2020		2019		2020		2019
(Loss) earnings from continuing operations attributable to common stockholders	$	(0.11)	$	0.49	$	(4.31)	$	(1.10)
Income from discontinued operations, net of tax	—		0.01		—		1.53
Net (loss) earnings attributable to common stockholders	$	(0.11)	$	0.50	$	(4.31)	$	0.43

Earnings Per Share Calculations - Diluted	Three Months Ended September 30,				Nine Months Ended September 30,
Dollars per share	2020		2019		2020		2019
(Loss) earnings from continuing operations attributable to common stockholders	$	(0.11)	$	0.49	$	(4.31)	$	(1.10)
Income from discontinued operations, net of tax	—		0.01		—		1.53
Net (loss) earnings attributable to common stockholders	$	(0.11)	$	0.50	$	(4.31)	$	0.43

Share Count Information	Three Months Ended September 30,		Nine Months Ended September 30,
Shares in millions	2020	2019	2020	2019
Weighted-average common shares - basic	734.4	745.5	735.8	748.2
Plus dilutive effect of equity compensation plans	—	2.2	—	—
Weighted-average common shares - diluted	734.4	747.7	735.8	748.2
Stock options and restricted stock units excluded from EPS calculations 2	5.5	3.8	6.3	2.8

1.Historical Dow restricted stock units are considered participating securities due to Historical Dow's practice of paying dividend equivalents on unvested shares.

2. These outstanding options to purchase shares of common stock and restricted stock units were excluded from the calculation of diluted earnings per share because the effect of including them would have been antidilutive.

XML

INVENTORIES

9 Months Ended

Sep. 30, 2020

Inventory Disclosure [Abstract]

Inventory Disclosure

INVENTORIES

Inventories	September 30, 2020		December 31, 2019
In millions
Finished goods	$	2,407	$	2,621
Work in process	803		855
Raw materials	465		599
Supplies	227		244
Total inventories	$	3,902	$	4,319

XML

NONCONSOLIDATED AFFILIATES (Notes)

9 Months Ended

Sep. 30, 2020

Equity Method Investments and Joint Ventures [Abstract]

Equity Method Investments and Joint Ventures Disclosure [Text Block]

NONCONSOLIDATED AFFILIATES

The Company's investments in companies accounted for using the equity method ("nonconsolidated affiliates"), by classification in the interim Condensed Consolidated Balance Sheets, are shown in the following table:

Investments in Nonconsolidated Affiliates	September 30, 2020		December 31, 2019
In millions
Investments in nonconsolidated affiliates	$	951	$	1,204
Accrued and other current liabilities	(74)		(85)
Other noncurrent obligations	—		(358)
Net investment in nonconsolidated affiliates	$	877	$	761

At September 30, 2020, the Company had an ownership interest in 18 nonconsolidated affiliates.

HSC Group

In the third quarter of 2020, the Company sold its equity interest in the HSC group. See Note 3 for further discussion. The following table reflects the carrying value of the HSC Group investments at December 31, 2019:

Investment in the HSC Group		Investment
In millions	Balance Sheet Classification	Dec 31, 2019
Hemlock Semiconductor L.L.C.	Other noncurrent obligations	$	(358)
DC HSC Holdings LLC	Investments in nonconsolidated affiliates	$	87

Sales to nonconsolidated affiliates represented less than 2 percent of total net sales for the three and nine months ended September 30, 2020 and less than 3 percent of total net sales for the three and nine months ended September 30, 2019. Sales to nonconsolidated affiliates are primarily related to the sale of trichlorosilane, a raw material used in the production of polycrystalline silicon, to the HSC Group, prior to the TCS/Hemlock Disposal. Sales of this raw material to the HSC Group are reflected in Non-Core. Purchases from nonconsolidated affiliates represented less than 2 percent of “Cost of sales” for the three and nine months ended September 30, 2020 and 2019.

XML

GOODWILL AND OTHER INTANGIBLE ASSETS

9 Months Ended

Sep. 30, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

GOODWILL AND OTHER INTANGIBLE ASSETS

GOODWILL AND OTHER INTANGIBLE ASSETS

The changes in the carrying amounts of goodwill during the nine months ended September 30, 2020 were as follows:

	Elect. & Imaging		Nutrition & Biosciences		Transp. & Industrial		Safety & Const.		Non-Core		Total
In millions
Balance at December 31, 2019	$	7,092	$	11,012	$	6,931	$	6,711	$	1,405	$	33,151
Acquisitions	—		—		—		53		—		53
Divestitures 1	(199)		—		—		—		(514)		(713)
Impairments	—		—		(2,498)		—		(716)		(3,214)
Currency Translation Adjustment	41		206		67		84		—		398
Measurement Period Adjustments	—		—		—		15		—		15
Balance at September 30, 2020	$	6,934	$	11,218	$	4,500	$	6,863	$	175	$	29,690

1. Includes $267 million of goodwill related to the Non-Core segment reclassified as held for sale in connection with the Non-Core Held for Sale Disposal Groups. Refer to Note 3 for further information.

The Company tests goodwill and indefinite-lived intangible assets for impairment annually during the fourth quarter as of October 1, or more frequently when events or changes in circumstances indicate that fair value is below carrying value. As a result of the related acquisition method of accounting in connection with the DWDP Merger, Historical EID’s assets and liabilities were measured at fair value resulting in increases to the Company’s goodwill and other intangible assets. The fair value valuation increased the risk that declines in financial projections, including changes to key assumptions, could have a material, negative impact on the fair value of the Company’s reporting units and assets, and therefore could result in an impairment.

In the third quarter of 2020, the TCS/HSC Disposal within the Non-Core segment, as well as further softening conditions in aerospace markets, served as triggering events requiring the Company to perform recoverability assessments related to asset groups within its PVAM business unit. These assessments resulted in the Company recording asset impairment charges related to certain long-lived assets whose carrying values were deemed not recoverable (refer to Note 5 for additional information). The Company then performed a series of impairment analyses related to goodwill associated with the PVAM business unit. The goodwill impairment analyses included an assessment of the preceding PVAM reporting unit as well as assessments of re-defined reporting units within the PVAM business unit resulting from the TCS/HSC Disposal along with recent progress in the sales processes for other Non-Core business units, including reallocation of goodwill on a relative fair value basis. As a result of these analyses, the Company determined that the fair value of certain reporting units was below carrying value resulting in impairment charges of goodwill. In connection with the foregoing and as a result of the Non-Core Held For Sale Disposal Groups classification (see Note 3 for additional information), the Company recorded aggregate, pre-tax, non-cash impairment charges of $183 million in the third quarter of 2020 impacting the Non-Core segment and reflected in "Goodwill impairment charges" in the Consolidated Statements of Operations. As a result of the above impairment charges and previous impairment charges recorded impacting Non-Core as discussed below, the carrying value of the reporting units within Non-Core are indicative of fair value. As a result, future changes in fair value could impact the carrying value of these business units which have been and continue to be at risk for impairment charges in future periods.

The Company’s analyses above use a combination of the discounted cash flow models (a form of the income approach) utilizing Level 3 unobservable inputs and the market approach. The Company’s significant assumptions in these analyses include, but are not limited to, future cash flow projections, the weighted average cost of capital, the terminal growth rate, and the tax rate. The Company’s estimates of future cash flows are based on current regulatory and economic climates, recent operating results, and planned business strategies. These estimates could be negatively affected by changes in federal, state, or local regulations or economic downturns. Future cash flow estimates are, by their nature, subjective and actual results may differ materially from the Company’s estimates. If the Company’s ongoing estimates of future cash flows are not met, the Company may have to record additional impairment charges in future periods. As referenced, the Company also uses a form of the market approach (utilizes Level 3 unobservable inputs), which is derived from metrics of publicly traded companies or historically completed transactions of comparable businesses. The selection of comparable businesses is based on the markets in which the reporting units operate giving consideration to risk profiles, size, geography, and diversity of products and services. As such, the Company believes the current assumptions and estimates utilized are both reasonable and appropriate.

In the second quarter of 2020, continued near-term demand weakness in global automotive production resulting from the COVID-19 pandemic, along with revised views of recovery based on third party market information, served as a triggering event requiring the Company to perform an impairment analysis of the goodwill associated with its Transportation & Industrial reporting unit as of June 30, 2020. The carrying value of the Transportation & Industrial reporting unit is comprised substantially of Historical EID’s assets and liabilities which were measured at fair value in connection with the DWDP Merger, and thus inherently considered at risk for impairment. The Company performed quantitative testing on its Transportation &

Industrial reporting unit as of June 30, 2020, using a combination of the discounted cash flow model (a form of the income approach) utilizing Level 3 unobservable inputs and the Guideline Public Company Method (a form of the market approach). Based on the analysis performed, during the second quarter of 2020, the Company concluded that the carrying amount of the reporting unit exceeded its fair value resulting in a pre-tax, non-cash goodwill impairment charge of $2,498 million, reflected in "Goodwill impairment charges" in the Consolidated Statements of Operations for the nine months ended September 30, 2020.

In the first quarter of 2020, expectations of proceeds related to certain potential divestitures within the Non-Core segment gave rise to fair value indicators and, thus, served as triggering events requiring the Company to perform impairment analyses related to goodwill as of March 31, 2020. As part of the analysis, the Company determined that the fair value of its PVAM reporting unit was below its carrying value resulting in an impairment charge to goodwill. Valuations of the PVAM reporting unit under a combination of the market approach and income approach reflected softening conditions in photovoltaics markets as compared to prior estimates. In connection with this analysis, the Company recorded a pre-tax, non-cash goodwill impairment charge of $533 million in the first quarter of 2020 impacting the Non-Core segment. This charge is reflected in "Goodwill impairment charges" in the Consolidated Statements of Operations for the nine months ended September 30, 2020.

In the second quarter of 2019, the Company recorded pre-tax, non-cash goodwill impairment charges of $1,175 million impacting the Nutrition & Biosciences and Non-Core segments which are reflected in "Goodwill impairment charges" in the interim Consolidated Statements of Operations for the nine months ended September 30, 2019.

COVID-19 continues to adversely impact the broader global economy and has caused significant volatility in financial markets. If there is a of lack of recovery, the time period to recovery is longer than expected or further global softening is experienced in certain markets, such as automotive, aerospace, commercial construction, oil & gas and select industrial end-markets, or a sustained decline in the value of the Company's common stock, the Company may be required to perform additional impairment assessments for its goodwill, other intangibles, and long-lived assets, the results of which could result in material impairment charges.

Other Intangible Assets

The gross carrying amounts and accumulated amortization of other intangible assets by major class are as follows:

	September 30, 2020						December 31, 2019
In millions	Gross Carrying Amount		Accum Amort		Net		Gross Carrying Amount		Accum Amort		Net
Intangible assets with finite lives:
Developed technology	$	4,229	$	(1,705)	$	2,524	$	4,343	$	(1,361)	$	2,982
Trademarks/tradenames	2,395		(1,378)		1,017		2,433		(455)		1,978
Customer-related	8,942		(2,644)		6,298		8,986		(2,229)		6,757
Other	175		(85)		90		303		(98)		205
Total other intangible assets with finite lives	$	15,741	$	(5,812)	$	9,929	$	16,065	$	(4,143)	$	11,922
Intangible assets with indefinite lives:
Trademarks/tradenames	1,599		—		1,599		1,671		—		1,671
Total other intangible assets	1,599		—		1,599		1,671		—		1,671
Total	$	17,340	$	(5,812)	$	11,528	$	17,736	$	(4,143)	$	13,593

In the third quarter of 2020, the Company recorded a pre-tax asset impairment charge of $52 million ($39 million net of tax) related to indefinite-lived intangible assets within the Non-Core segment which were deemed no longer recoverable as a result of the Non-Core Held For Sale Disposal Groups classification (see Note 3 for additional information). The charge was recorded within “Restructuring and asset related charges – net” in the interim Consolidated Statements of Operations for the three and nine months ended September 30, 2020.

In the first quarter and third quarter of 2020, the Company recorded non-cash impairment charges related to definite-lived intangible assets impacting the Non-Core segment reflected within “Restructuring and asset related charges - net” in the interim Consolidated Statements of Operations for the nine months ended September 30, 2020. See Note 5 for further discussion.

In the second quarter of 2020, the Company performed quantitative testing on indefinite-lived intangible assets attributable to the Transportation & Industrial segment, for which the Company determined that the fair value of certain tradenames had declined related to the factors described above. The Company performed an analysis of the fair value using the relief from royalty method (a form of the income approach) using Level 3 inputs within the fair value hierarchy. The key assumptions used in the calculation included projected revenue, royalty rates and discount rates. These key assumptions involve management

judgment and estimates relating to future operating performance and economic conditions that may differ from actual cash flows. As a result of the testing, the Company recorded a pre-tax, non-cash indefinite-lived intangible asset impairment charge of $21 million ($16 million net of tax), which is reflected in "Restructuring and asset related charges - net," in the Consolidated Statements of Operations for the nine months ended September 30, 2020. The remaining net book value of the tradenames attributable to the Transportation & Industrial segment at September 30, 2020 was approximately $289 million, which represents fair value.

The following table provides the net carrying value of other intangible assets by segment:

Net Intangibles by Segment	September 30, 2020		December 31, 2019
In millions
Electronics & Imaging	$	1,686	$	1,833
Nutrition & Biosciences	3,360		4,377
Transportation & Industrial	3,429		3,590
Safety & Construction	2,956		3,082
Non-Core	97		711
Total	$	11,528	$	13,593

XML

SHORT TERM BORROWINGS, LONG-TERM DEBT AND AVAILABLE CREDIT FACILITIES

9 Months Ended

Sep. 30, 2020

Debt Disclosure [Abstract]

SHORT TERM BORROWINGS, LONG-TERM DEBT AND AVAILABLE CREDIT FACILITIES

SHORT-TERM BORROWINGS, LONG-TERM DEBT AND AVAILABLE CREDIT FACILITIES

Nutrition & Biosciences Financing

In connection with the Intended N&B Transaction, N&B Inc. entered into a Bridge Commitment Letter (the “Bridge Letter”) in an aggregate principal amount of $7.5 billion (the “Bridge Loans”) to secure committed financing for the "Special Cash Payment" and related financing fees. The aggregate commitment under the Bridge Letter is reduced by, among other things, (1) the amount of net cash proceeds received by N&B Inc. from any issuance of senior unsecured notes pursuant to a Rule 144A offering or other private placement and (2) certain qualifying term loan commitments under senior unsecured term loan facilities.

In January 2020, N&B Inc. entered into a senior unsecured term loan agreement in the amount of $1.25 billion split evenly between three- and five-year facilities (the “N&B Term Loan Facilities”). As a result of entry into the term loan agreement, the commitments under the Bridge Commitment Letter were reduced to $6.25 billion.

On September 16, 2020 (the "Offering Date"), N&B Inc. completed an offering in the aggregate principal amount of $6.25 billion of senior unsecured notes in six series, comprised of the following (collectively, the “N&B Notes Offering” and together with the N&B Term Loan Facilities, the “Permanent Financing”): $300 million aggregate principal amount of 0.697% Senior Notes due 2022; $1.0 billion aggregate principal amount of 1.230% Senior Notes due 2025; $1.2 billion aggregate principal amount of 1.832% Senior Notes due 2027; $1.5 billion aggregate principal amount of 2.300% Senior Notes due 2030; $750 million aggregate principal amount of 3.268% Senior Notes due 2040; and $1.5 billion aggregate principal amount of 3.468% Senior Notes due 2050. As a result of the N&B Notes Offering, the commitments under the Bridge Commitment Letter were further reduced to zero and were terminated on and as of the Offering Date.

The net proceeds of approximately $6.2 billion from the N&B Notes Offering were deposited into an escrow account. The release of the net proceeds from the N&B Notes Offering and the availability of funding under the term loan agreement are subject to customary closing conditions including among others, the satisfaction of substantially all the conditions to the consummation of the intended transaction with IFF. The proceeds from the Permanent Financing will be used to make the Special Cash Payment and to pay the related financing fees and expenses. The obligations and liabilities associated with the Permanent Financing will be separated from the Company upon consummation of the Intended N&B Transaction. However, if the closing of the Intended Merger has not occurred on or prior to September 15, 2021, or, if prior to such date, the Merger Agreement is validly terminated, (each a “Special Mandatory Redemption Event”), N&B Inc. must redeem all of the Notes on or before the 15th business day following the Special Mandatory Redemption Event (such date of redemption, the “Special Mandatory Redemption Date”) at a redemption price equal to 101% of the aggregate principal amount of the applicable series of Notes, plus accrued and unpaid interest to, but not including, the Special Mandatory Redemption Date.

Pursuant to the Merger Agreement, the fees and expenses associated with the financing will be borne (A) entirely by N&B Inc. if the transaction closes; and (B) equally by DuPont and IFF if the Merger Agreement terminates. However, if the Merger Agreement is terminated by IFF, in accordance with its terms, for breach by DuPont, such fees and expenses will be borne entirely by DuPont; and if terminated by DuPont in accordance with its terms for breach by IFF, such fees and expenses will be borne entirely by IFF.

May Debt Offering

On May 1, 2020, the Company completed an underwritten public offering of senior unsecured notes (the “Notes”) in the aggregate principal amount of $2 billion of 2.169 percent fixed rate Notes due May 1, 2023 (the “May Debt Offering”). The proceeds from the May Debt Offering are expected to be used by the Company to repay or redeem the Company’s $0.5 billion in floating rate notes due November 2020 and $1.5 billion of 3.77 percent fixed-rate notes due November 2020 (collectively, the “2020 Notes”). Upon consummation of the Intended N&B Transaction, the Company will be required to mail a notice of redemption to holders of the Notes, with a copy to the Trustee, setting forth the date of redemption of all of the Notes on the date (“Special Mandatory Redemption Date”) that is the later of (i) three (3) Business Days after the consummation of the Intended N&B Transaction and (ii) May 1, 2021. On the Special Mandatory Redemption Date, the Company will be required to redeem all of the Notes at a redemption price equal to 100% of the aggregate principal amount of the Notes plus accrued and unpaid interest, if any, up to but excluding the Special Mandatory Redemption Date. The Indenture also contains certain limitations on the Company’s ability to incur liens and enter into sale lease-back transactions, as well as customary events of default.

Revolving Credit Facility

In June 2019, the Company entered into a $750 million, 364-day revolving credit facility (the "Old 364-Day Revolving Credit Facility"). On and effective as of April 16, 2020, the Company entered into a new $1.0 billion 364-day revolving credit facility (the “$1B Revolving Credit Facility"). As of the effectiveness of the $1B Revolving Credit Facility, the Old 364-Day Revolving Credit Facility was terminated.

XML

COMMITMENTS AND CONTINGENT LIABILITIES

9 Months Ended

Sep. 30, 2020

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENT LIABILITIES

COMMITMENTS AND CONTINGENT LIABILITIES

Litigation and Environmental Matters

As of September 30, 2020, the Company had recorded liabilities of $23 million associated with litigation matters and $79 million associated with environmental matters. These recorded liabilities include the Company’s indemnification obligations to each of Dow and Corteva.

Under the DWDP Separation and Distribution Agreement, liabilities, including cost and expenses, associated with litigation and environmental matters that primarily related to the materials science business, the agriculture business or the specialty products business were generally allocated to or retained by Dow, Corteva or the Company, respectively, through retention, assumption or indemnification. Related to the foregoing, at September 30, 2020, DuPont has recorded (i) a liability of $37 million (although it is reasonably possible that the ultimate cost could range up to $108 million above the amount accrued) for retained or assumed environmental liabilities, (ii) a liability of $2 million for retained or assumed litigation liabilities, and (iii) an indemnification liability related to legal and environmental matters of $58 million. Liabilities associated with discontinued and/or divested operations and businesses of Historical Dow generally were allocated to or retained by Dow. The allocation of liabilities associated with the discontinued and/or divested operations and businesses of Historical EID is discussed below.

Discontinued and/or Divested Operations and Businesses ("DDOB") Liabilities of Historical EID

Under the DWDP Separation and Distribution Agreement and the Letter Agreement between Corteva and DuPont, DDOB liabilities of Historical EID primarily related to Historical EID’s agriculture business were allocated to or retained by Corteva and those primarily related to Historical EID’s specialty products business were allocated to or retained by the Company. Historical EID DDOB liabilities not primarily related to Historical EID’s agriculture business or specialty products business (“Stray Liabilities”), are allocated as follows:

•Generally, indemnifiable losses as defined in the DWDP Separation and Distribution Agreement, (“Indemnifiable Losses”) for Stray Liabilities, to the extent they do not arise out of actions related to or resulting from the development, testing, manufacture or sale of PFAS, defined below, (“Non-PFAS Stray Liabilities”) that are known as of April 1, 2019 are borne by Corteva up to a specified amount set forth in the schedules to the DWDP Separation and Distribution Agreement and/or Letter Agreement. Non-PFAS Stray Liabilities in excess of such specified amounts and any Non-PFAS Stray Liabilities not listed in the schedules to the DWDP Separation and Distribution Agreement or Letter Agreement are borne by Corteva and/or DuPont up to separate, aggregate thresholds of $200 million each to the extent Corteva or DuPont, as applicable, incurs an Indemnifiable Loss. Once Corteva’s or DuPont’s $200 million threshold is met, the other would generally bear all Non-PFAS Stray Liabilities until meeting its $200 million threshold. After the respective $200 million thresholds are met, DuPont will bear 71 percent of such losses and Corteva will bear 29 percent of such losses.

•Generally, Corteva and the Company will each bear 50 percent of the first $300 million (up to $150 million each) for Indemnifiable Losses arising out of actions to the extent related to or resulting from the development, testing, manufacture or sale of per- or polyfluoroalkyl substances, which include collectively perfluorooctanoic acids and its salts (“PFOA”), perfluorooctanesulfonic acid (“PFOS”) and perfluorinated chemicals and compounds (“PFCs”) (all such substances, “PFAS” and such Stray Liabilities referred to as “PFAS Stray Liabilities”). Indemnifiable Losses to the extent related to PFAS Stray Liabilities in excess of $300 million generally will be borne 71 percent by the Company and 29 percent by Corteva, unless either Corteva or DuPont has met its $200 million threshold. In that event, the other company would bear all PFAS Stray Liabilities until that company meets its $200 million threshold, at which point DuPont will bear 71 percent of such losses and Corteva will bear 29 percent of such losses.

•Indemnifiable Losses incurred by the companies in relation to PFAS Stray Liabilities up to $300 million (e.g., up to $150 million each) will be applied to each company’s respective $200 million threshold.

Indemnifiable Losses, as defined in the DWDP Separation and Distribution Agreement, include, among other things, attorneys’, accountants’, consultants’ and other professionals’ fees and expenses incurred in the investigation or defense of Stray Liabilities.

DuPont expects to continue to incur directly and as Indemnifiable Losses, costs and expenses related to litigation defense, such as attorneys’ fees and expenses and court costs, in connection with the Stray Liabilities described below. In accordance with its accounting policy for litigation matters, the Company will expense such litigation defense costs as incurred which could be significant to the Company’s financial condition and/or cash flows in the period.

Even when the Company believes the probability of loss or of an adverse unappealable final judgment is remote, the Company may consider settlement of these matters, and may enter into settlement agreements, if it believes settlement is in the best interest of the Company, including avoidance of future distraction and litigation defense cost, and its shareholders.

Stray Liabilities

Non-PFAS Stray Liabilities

While DuPont believes it is probable that it will incur a liability related to Non-PFAS Stray Liabilities, such liability is not reasonably estimable at September 30, 2020. Therefore, at September 30, 2020, DuPont has not recorded an accrual related to Non-PFAS Liabilities.

PFAS Stray Liabilities

Chemours Suit

On July 1, 2015, Historical EID completed the separation of Historical EID’s Performance Chemicals segment through the spin-off of all the issued and outstanding stock of The Chemours Company (“Chemours”) to holders of Historical EID common stock. In connection with the spin, Historical EID and Chemours entered into a Separation Agreement (as amended, the "Chemours Separation Agreement"). Pursuant to the Chemours Separation Agreement, Chemours is obligated to indemnify Historical EID, including its current or former affiliates, against certain litigation, environmental and other liabilities that arose prior to the Chemours Separation. The term of this indemnification is generally indefinite and includes defense costs and expenses, as well as monetary and non-monetary settlements and judgments.

In 2017, Historical EID and Chemours amended the Chemours Separation Agreement to provide for a limited sharing of potential future PFOA liabilities for a five-year period that began on July 6, 2017. The amended agreement provides that during that five-year period, Chemours will annually pay the first $25 million of future PFOA liabilities and, if that amount is exceeded, Historical EID will pay any excess amount up to the next $25 million, with Chemours annually bearing any excess liabilities above that amount. If Historical EID were required to pay PFOA liabilities pursuant to the amended agreement, fifty percent of such obligation would be borne by the Company in accordance with the Letter Agreement. In connection with the foregoing, the Company has not recorded or paid a PFOA liability. At the end of the five-year period, this limited sharing agreement will expire, and Chemours’ indemnification obligations under the Chemours Separation Agreement will continue unchanged.

On May 13, 2019, Chemours filed suit in the Delaware Court of Chancery against Historical EID, Corteva and the Company in an attempt to limit its responsibility for the litigation and environmental liabilities allocated to and assumed by Chemours under the Chemours Separation Agreement. Chemours is asking the court to rewrite the Chemours Separation Agreement by either limiting Chemours’ liabilities or, alternatively, ordering the return to Chemours of all or a portion of a $3.91 billion dividend that Chemours paid to Historical EID, Chemours’ then-sole-shareholder, just prior to the spin of Chemours. DuPont and Corteva, acting jointly, filed a motion to dismiss the lawsuit for lack of subject matter jurisdiction and initiated an arbitration of the dispute as required under the Chemours Separation Agreement. In December 2019, following argument, the Delaware Court of Chancery stayed arbitration pending resolution of the motion to dismiss. On March 30, 2020, the Court of Chancery granted the motion to dismiss and rejected Chemours’ arguments in their entirety. Chemours filed a notice of appeal on April 17, 2020 with the Delaware Supreme Court. The Delaware Supreme Court will hear oral argument on the appeal en banc on December 2, 2020. Meanwhile, the confidential arbitration process is proceeding.

Indemnifiable Losses related to the Chemours suit are PFAS Stray Liabilities subject to the sharing arrangement between DuPont and Corteva, described above. The Company believes the probability of a final unappealable judgment of liability with respect to the Chemours suit to be remote; the defendants continue to vigorously defend full indemnity rights as set forth in the Chemours Separation Agreement. 

PFAS Matters

Historical EID is a party to legal proceedings relating to the use of PFOA and PFCs by its former Performance Chemicals segment. Indemnifiable Losses related to PFAS liabilities allocated to and assumed by Chemours under the Chemours Separation Agreement generally are PFAS Stray Liabilities subject to the sharing arrangement between DuPont and Corteva, described above.

Generally, Chemours, with reservations, including as to alleged fraudulent conveyance and voidable transactions, is defending and indemnifying Historical EID in the PFAS Matters discussed below. Although Chemours has refused the tender of the Company’s defense in the actions in which the Company has been named, DuPont believes it is remote that it will ultimately incur a liability in connection with these PFAS Matters.

Ohio MDL Personal Injury Cases

DuPont, which was formed after the spin-off of Chemours, is not named in the personal injury and other PFAS actions discussed below.

In 2004, Historical EID settled a West Virginia state court class action, Leach v. DuPont, which alleged that PFOA from Historical EID’s former Washington Works facility had contaminated area drinking water supplies and affected the health of area residents. Historical EID has residual liabilities under the Leach settlement related to providing PFOA water treatment to six area water districts and private well users and to fund, through an escrow account, up to $235 million for a medical monitoring program for eligible class members.

Members of the Leach class have standing to pursue personal injury claims for just six health conditions that an expert panel appointed under the Leach settlement reported in 2012 had a “probable link” (as defined in the settlement) with PFOA: pregnancy-induced hypertension, including preeclampsia; kidney cancer; testicular cancer; thyroid disease; ulcerative colitis; and diagnosed high cholesterol. In 2017, Chemours and Historical EID each paid $335 million to settle the multi-district litigation in the U.S. District Court for the Southern District of Ohio (“Ohio MDL”), thereby resolving claims of about 3,550 plaintiffs alleging injury from exposure to PFOA in drinking water. The 2017 settlement did not resolve claims of Leach class members who did not have claims in the Ohio MDL or whose claims are based on diseases first diagnosed after February 11, 2017. About 80 claims alleging personal injury, including kidney and testicular cancer claims, have been filed since the 2017 settlement. These claims are currently pending in the Ohio MDL. The first two cases, one captioned “Abbott v E. I. du Pont de Nemours and Company” and the other “Swartz v. E. I. du Pont de Nemours and Company”, involving a testicular cancer and a kidney cancer claim, respectively, proceeded to trial in January 2020. In the Abbott case, the jury returned a verdict in March 2020 against Historical EID, awarding $50 million in compensatory damages to the plaintiff and his wife, who claimed that exposure to PFOA in drinking water caused him to develop testicular cancer. Historical EID will appeal the verdict. The plaintiffs also sought but were not awarded punitive damages. In the Swartz matter, the jury could not reach a verdict. Therefore, the court declared a mistrial and the matter will be retried at a later date. The trials in the cases originally scheduled for June 2020 have been further postponed from October 2020 to late November due to the COVID-19 pandemic.

Natural Resource Damage Claims and Other Claims for Environmental Damages

In addition to the actions described above, there several cases alleging damages to natural resources, the environment, water, and/or property as well as various other allegations. DuPont and Corteva are named or have been added as defendants in most of the actions discussed below. Such actions include additional claims based on allegations that the transfer by Historical EID of certain PFAS liabilities to Chemours prior to separating Chemours resulted in a fraudulent conveyance or voidable transaction.

Natural Resource Damage Matters

Since May 2017, a number of state attorneys general have filed lawsuits against DuPont, Corteva, Historical EID, Chemours, and others, claiming environmental contamination by certain PFAS compounds. Such actions are currently pending in Michigan, New Jersey, New Hampshire, New York, North Carolina, Ohio and Vermont. Generally, the states raise common law tort claims and seek economic impact damages for alleged harm to natural resources, punitive damages, present and future costs to cleanup contamination from certain PFAS compounds, and to abate the alleged nuisance. The North Carolina action includes fraudulent transfer claims related to the Chemours separation, the DowDuPont separations, and questions potential loss of assets caused by future divestitures.

Other PFAS Environmental Matters

Several lawsuits have been filed by residents, local water districts, and private water companies against Historical EID and Chemours in New York. Additionally, a water district in West Virginia, filed suit in state court against Historical EID, Chemours, Corteva, DuPont, and others alleging contamination as a result of PFOA and PFOS and seeking compensatory, consequential and punitive damages, and attorneys’ fees. The complaint includes a fraudulent transfer allegation associated with the Chemours separation. In September 2020, a complaint was filed in the Central District of California on behalf of Golden State Water Company against DuPont, Corteva, Historical EID, Chemours, and others, alleging contamination of water systems from PFOS and PFOA. The complaint includes fraudulent transfer claims related to the Chemours separation, the DowDuPont separations, and questions potential loss of assets caused by future divestitures.

North Carolina PFAS Actions

There are several actions pending in federal court against Historical EID and Chemours, relating to discharges of PFCs, including GenX, into the Cape Fear River. GenX is a polymerization processing aid and a replacement for PFOA introduced by Historical EID which Chemours continues to manufacture at its Fayetteville Works facility in Bladen County, North Carolina. One of these actions is a consolidated putative class action that asserts claims for damages and other relief on behalf of putative classes of property owners and residents in areas near or who draw drinking water from the Cape Fear River. Another action is

a consolidated action brought by various North Carolina water authorities, including the Cape Fear Public Utility Authority and Brunswick County, that seek actual and punitive damages as well as injunctive relief. In addition, an action is pending in North Carolina state court on behalf of about 100 plaintiffs who own wells and property near the Fayetteville Works facility. The plaintiffs seek damages for nuisance allegedly caused by releases of certain PFCs from the site.

In the third quarter 2020, 3 lawsuits were filed in North Carolina state court against Chemours, Historical EID, Corteva and DuPont. The lawsuits seek damages for alleged personal injuries to more than 100 individuals due to alleged exposure to PFOA and GenX originating from the Fayetteville Works plant. These lawsuits also include fraudulent transfer allegations related to the Chemours separation.

Aqueous Film Forming Foam

Beginning in April 2019, several dozen lawsuits involving water contamination arising from the use of PFAS-containing aqueous firefighting foams (“AFFF”) were filed against Historical EID, Chemours, 3M and other AFFF manufacturers and in different parts of the country. Most were consolidated in multi-district litigation docket in federal district court in South Carolina (the “SC MDL”). Many of those cases also name DuPont as a defendant. Those actions largely seek remediation of the alleged PFAS contamination in and around military bases and airports as well as medical monitoring of affected residents. In September 2020, a complaint was filed in Missouri state court on behalf of a deceased firefighter against 3M, DuPont, Corteva, Historical EID, Chemours and others. The suit seeks damages for injuries and wrongful death of the plaintiff allegedly from his exposure to PFAS contained in firefighting foam. This case has not been removed to the SC MDL.

As of the end of September 2020, approximately 750 personal injury cases have been filed directly in the SC MDL and assert claims on behalf of individual firefighters and others who allege that exposure to PFAS in firefighting foam caused them to develop cancer, including kidney and testicular cancer. DuPont has been named as a defendant in most of these personal injury AFFF cases. DuPont is seeking the dismissal of DowDuPont and DuPont from these actions. Historical EID and the Company have never made or sold aqueous film forming foam, PFOS or PFOS containing products.

Additionally, a case filed by a former firefighter is pending in the Southern District of Ohio seeking certification of a nationwide class of individuals who have detectable levels of PFAS in their blood serum. The suit was filed against 3M and several other defendants in addition to Chemours and Historical EID. The complaint specifically seeks, among other things, the creation of a “PFAS Science Panel” to study the effects of PFAS, but expressly states that the class does not seek compensatory damages for personal injuries. In February 2020, the court denied the defendants' motion to transfer this case to the SC MDL.

Other Litigation Matters

In addition to the specific matters described above, the Company is party to other claims and lawsuits arising out of the normal course of business with respect to product liability, patent infringement, governmental regulation, contract and commercial litigation, and other actions. Certain of these actions may purport to be class actions and seek damages in very large amounts. It is the opinion of the Company’s management that the possibility is remote that the aggregate of all such other claims and lawsuits will have a material adverse impact on the results of operations, financial condition and cash flows of the Company.

Environmental Matters

Accruals for environmental matters are recorded when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on current law and existing technologies. At September 30, 2020, the Company had accrued obligations of $79 million for probable environmental remediation and restoration costs, inclusive of $37 million retained and assumed following the DWDP Distributions and $42 million of indemnified liabilities. These obligations are included in "Accrued and other current liabilities" and "Other noncurrent obligations" in the interim Condensed Consolidated Balance Sheets. This is management’s best estimate of the costs for remediation and restoration with respect to environmental matters for which the Company has accrued liabilities, although it is reasonably possible that the ultimate cost with respect to these particular matters could range up to $172 million above the amount accrued at September 30, 2020. Consequently, it is reasonably possible that environmental remediation and restoration costs in excess of amounts accrued could have a material impact on the Company’s results of operations, financial condition and cash flows. Inherent uncertainties exist in these estimates primarily due to unknown conditions, changing governmental regulations and legal standards regarding liability, and emerging remediation technologies for handling site remediation and restoration. At December 31, 2019, the Company had accrued obligations of $77 million for probable environmental remediation and restoration costs.

Pursuant to the DWDP Separation and Distribution Agreement, the Company is required to indemnify certain clean-up responsibilities and associated remediation costs. The accrued environmental obligations of $79 million as of September 30, 2020 includes amount for which the Company indemnifies Dow and Corteva. At September 30, 2020, the Company has indemnified Dow and Corteva $8 million and $34 million, respectively.

Indemnifications

In connection with the ongoing divestitures and transactions, the Company has indemnified and has been indemnified by respective parties against certain liabilities that may arise in connection with these transactions and business activities prior to the completion of the respective transactions. The term of these indemnifications, which typically pertain to environmental, tax and product liabilities, is generally indefinite. At September 30, 2020, indemnified assets were $88 million within "Accounts and notes receivable, net" and $117 million within "Deferred charges and other assets" and indemnified liabilities were $60 million within "Accrued and other current liabilities" and $94 million within "Other noncurrent obligations."

Guarantees

Obligations for Equity Affiliates & Others

The Company has directly guaranteed various debt obligations under agreements with third parties related to equity affiliates and customers. At September 30, 2020 and December 31, 2019, the Company had directly guaranteed $177 million and $187 million, respectively, of such obligations. These amounts represent the maximum potential amount of future (undiscounted) payments that the Company could be required to make under the guarantees. The Company would be required to perform on these guarantees in the event of default by the guaranteed party.

The Company assesses the payment/performance risk by assigning default rates based on the duration of the guarantees. These default rates are assigned based on the external credit rating of the counterparty or through internal credit analysis and historical default history for counterparties that do not have published credit ratings. For counterparties without an external rating or available credit history, a cumulative average default rate is used.

In certain cases, the Company has recourse to assets held as collateral, as well as personal guarantees from customers. Assuming liquidation, these assets are estimated to cover less than 1 percent of the $17 million of guaranteed obligations of customers. The following table provides a summary of the final expiration year and maximum future payments for each type of guarantee:

Guarantees at September 30, 2020	Final Expiration Year	Maximum Future Payments
In millions
Obligations for customers 1:
Bank borrowings	2021	$	17
Obligations for non-consolidated affiliates 2:
Bank borrowings	2020	160
Total guarantees		$	177

1. Existing guarantees for select customers, as part of contractual agreements. The terms of the guarantees are equivalent to the terms of the customer loans that are primarily made to finance customer invoices. At September 30, 2020 all maximum future payments had terms less than a year.

2. Existing guarantees for non-consolidated affiliates' liquidity needs in normal operations.

XML

LEASES (Notes)

9 Months Ended

Sep. 30, 2020

Leases [Abstract]

Leases of Lessee Disclosure [Text Block]

OPERATING LEASES

The components of lease cost for operating leases were as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2020		2019		2020		2019
Operating lease costs	$	49	$	51	$	135	$	141

Operating cash flows from operating leases were $136 million and $150 million for the nine months ended September 30, 2020 and 2019, respectively.

Operating lease right-of-use assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. New operating lease assets and liabilities entered into during the nine months ended September 30, 2020 and 2019 were $168 million and $111 million, respectively. Supplemental balance sheet information related to leases was as follows:

In millions	September 30, 2020		December 31, 2019
Operating Leases
Operating lease right-of-use assets 1	$	621	$	556
Current operating lease liabilities 2	159		138
Noncurrent operating lease liabilities 3	465		416
Total operating lease liabilities	$	624	$	554

1.Included in "Deferred charges and other assets" in the interim Condensed Consolidated Balance Sheet.

2.Included in "Accrued and other current liabilities" in the interim Condensed Consolidated Balance Sheet.

3.Included in "Other noncurrent obligations" in the interim Condensed Consolidated Balance Sheet.

XML

STOCKHOLDERS' EQUITY

9 Months Ended

Sep. 30, 2020

Equity [Abstract]

STOCKHOLDERS' EQUITY AND ACCUMULATED OTHER COMPREHENSIVE LOSS

STOCKHOLDERS' EQUITY

Share Repurchase Program

On June 1, 2019, the Company's Board of Directors approved a $2 billion share buyback program, which expires on June 1, 2021. During the third quarter of 2020, the Company did not repurchase any shares. As of September 30, 2020, the Company had repurchased and retired 16.9 million shares under this program since inception at a total cost of $982 million.

Accumulated Other Comprehensive Loss

The following table summarizes the activity related to each component of accumulated other comprehensive loss ("AOCL") for the nine months ended September 30, 2020 and 2019:

Accumulated Other Comprehensive Loss	Unrealized Gains (Losses) on Investments		Cumulative Translation Adj		Pension and OPEB		Derivative Instruments		Total
In millions
2019
Balance at January 1, 2019	$	(51)	$	(3,785)	$	(8,476)	$	(82)	$	(12,394)
Other comprehensive income (loss) before reclassifications	68		(811)		47		(43)		(739)
Amounts reclassified from accumulated other comprehensive income (loss)	(1)		(18)		140		(15)		106
Net other comprehensive income (loss)	$	67	$	(829)	$	187	$	(58)	$	(633)
Spin-offs of Dow and Corteva	$	(16)	$	3,179	$	8,196	$	139	$	11,498
Balance at September 30, 2019	$	—	$	(1,435)	$	(93)	$	(1)	$	(1,529)
2020
Balance at January 1, 2020	$	—	$	(1,070)	$	(345)	$	(1)	$	(1,416)
Other comprehensive income (loss) before reclassifications	—		548		(9)		—		539
Amounts reclassified from accumulated other comprehensive income	—		—		18		—		18
Net other comprehensive income	$	—	$	548	$	9	$	—	$	557
Balance at September 30, 2020	$	—	$	(522)	$	(336)	$	(1)	$	(859)

The tax effects on the net activity related to each component of other comprehensive income (loss) for the three and nine months ended September 30, 2020 and 2019 were as follows:

Tax Benefit (Expense)	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2020		2019		2020		2019
Unrealized gains (losses) on investments	$	—	$	—	$	—	$	(18)
Cumulative translation adjustments	—		—		—		(1)
Pension and other post-employment benefit plans	1		(6)		3		(41)
Derivative instruments	—		—		—		16
Tax expense from income taxes related to other comprehensive income items	$	1	$	(6)	$	3	$	(44)

A summary of the reclassifications out of AOCL for the three and nine months ended September 30, 2020 and 2019 is provided as follows:

Reclassifications Out of Accumulated Other Comprehensive Loss	Three Months Ended September 30,				Nine Months Ended September 30,				Income Classification
In millions	2020		2019		2020		2019
Unrealized gains on investments	$	—	$	—	$	—	$	(1)	See (1) below
Tax expense (benefit)	—		—		—		—		See (2) below
After tax	$	—	$	—	$	—	$	(1)
Cumulative translation adjustments	$	—	$	—	$	—	$	(18)	See (3) below
Pension and other post-employment benefit plans	$	7	$	4	$	15	$	171	See (4) below
Tax expense (benefit)	2		(6)		3		(31)		See (2) below
After tax	$	9	$	(2)	$	18	$	140
Derivative Instruments	$	—	$	—	$	—	$	(18)	See (5) below
Tax expense	—		—		—		3		See (2) below
After tax	$	—	$	—	$	—	$	(15)
Total reclassifications for the period, after tax	$	9	$	(2)	$	18	$	106

1. "Net sales" and "Sundry income (expense) - net."

2. "Provision for income taxes on continuing operations."

3. "Sundry income (expense) - net."

4. These AOCL components are included in the computation of net periodic benefit cost of the Company's defined benefit pension and other post-employment benefit plans. See Note 17 for additional information.

5. "Cost of sales," "Sundry income (expense) - net" and "Interest expense."

XML

NONCONTROLLING INTERESTS

9 Months Ended

Sep. 30, 2020

Noncontrolling Interest [Abstract]

NONCONTROLLING INTERESTS

NONCONTROLLING INTERESTS

Ownership interests in the Company's subsidiaries held by parties other than the Company are presented separately from the Company's equity in the interim Condensed Consolidated Balance Sheets as "Noncontrolling interests." The amounts of consolidated net income attributable to the Company and the noncontrolling interests are both presented on the face of the interim Consolidated Statements of Operations.

The following table summarizes the activity for equity attributable to noncontrolling interests for the three and nine months ended September 30, 2020 and 2019:

Noncontrolling Interests	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2020		2019		2020		2019
Balance at beginning of period	$	572	$	570	$	569	$	1,608
Net income attributable to noncontrolling interests	7		5		20		90
Distributions to noncontrolling interests	(38)		(6)		(48)		(18)
Cumulative translation adjustments	4		(2)		(1)		14
Spin-off of Dow and Corteva	—		—		—		(1,124)
Other	14		1		19		(2)
Balance at end of period	$	559	$	568	$	559	$	568

XML

STOCK-BASED COMPENSATION

9 Months Ended

Sep. 30, 2020

Share-based Payment Arrangement [Abstract]

Share-based Payment Arrangement [Text Block]

STOCK-BASED COMPENSATION

A summary of the Historical Dow and Historical DuPont stock-based compensation plans can be found in Note 21 to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019. Historical Dow and Historical EID did not merge their equity incentive plans as a result of the DWDP Merger. The Historical Dow and Historical EID stock-based compensation plans were assumed by the Company and remained in place with the ability to grant and issue DowDuPont common stock until the DWDP Distributions.

Immediately following the Corteva Distribution, DuPont adopted the DuPont Omnibus Incentive Plan ("DuPont OIP") which provides for equity-based and cash incentive awards to certain employees, directors, independent contractors and consultants in the form of stock options, restricted stock units ("RSUs") and performance-based restricted stock units ("PSUs"). Upon adoption of the DuPont OIP, the Historical Dow and Historical EID plans were maintained and rolled into the DuPont OIP as separate subplans. The equity awards under these subplans have the same terms and conditions that were applicable to the awards under the Historical Dow and Historical EID plans immediately prior to the DWDP Distributions. Under the DuPont OIP, a maximum of 10 million shares of common stock are available for award as of September 30, 2020.

During the second quarter of 2020, the stockholders of DuPont approved the DuPont 2020 Equity and Incentive Plan (the "2020 Plan"). The 2020 Plan limits the number of shares that may be subject to awards payable in shares of DuPont common stock to 19 million. The 2020 Plan authorizes the Company to grant options, share appreciation rights, restricted shares, RSUs, share bonuses, other share-based awards, cash awards, each as defined in the 2020 Plan, or any combination of the foregoing. The approval of the 2020 Plan had no effect on the Company’s ability to make future grants under the DuPont OIP in accordance with its terms, and awards that are outstanding under the DuPont OIP remain outstanding in accordance with their terms. There has been no activity under the 2020 Plan to date.

DuPont recognized share-based compensation expense in continuing operations of $25 million and $30 million for the three months ended September 30, 2020 and 2019, respectively, and $94 million and $85 million during the nine months ended September 30, 2020 and 2019, respectively. The income tax benefits related to stock-based compensation arrangements were $5 million and $6 million for the three months ended September 30, 2020 and 2019, respectively, and $19 million and $18 million for the nine months ended September 30, 2020 and 2019, respectively.

In the first quarter of 2020, the Company granted 1.0 million RSUs, 0.8 million stock options and 0.3 million PSUs. The weighted-average fair values per share associated with the grants were $53.49 per RSU, $8.84 per stock option and $50.23 per PSU. The stock options had a weighted-average exercise price per share of $53.50. There was minimal activity in the second and third quarter of 2020.

XML

FINANCIAL INSTRUMENTS

9 Months Ended

Sep. 30, 2020

Investments, All Other Investments [Abstract]

FINANCIAL INSTRUMENTS

FINANCIAL INSTRUMENTS

The following table summarizes the fair value of financial instruments at September 30, 2020 and December 31, 2019:

Fair Value of Financial Instruments	September 30, 2020								December 31, 2019
In millions	Cost		Gain		Loss		Fair Value		Cost		Gain		Loss		Fair Value
Cash equivalents	$	2,534	$	—	$	—	$	2,534	$	417	$	—	$	—	$	417
Restricted cash equivalents 1	$	6,232	$	—	$	—	$	6,232	$	37	$	—	$	—	$	37
Total cash and restricted cash equivalents	$	8,766	$	—	$	—	$	8,766	$	454	$	—	$	—	$	454
Long-term debt including debt due within one year	$	(23,806)	$	2	$	(2,375)	$	(26,179)	$	(15,618)	$	—	$	(1,633)	$	(17,251)
Derivatives relating to:
Foreign currency 2	—		4		(6)		(2)		—		6		(7)		(1)
Total derivatives	$	—	$	4	$	(6)	$	(2)	$	—	$	6	$	(7)	$	(1)

1.Includes $26 million of restricted cash classified as "Other current assets" and $6.2 billion classified as "Restricted cash" in the interim Condensed Consolidated Balance Sheets. Refer to Note 6 for further information.

2.Presented net of cash collateral where master netting arrangements allow.

Derivative Instruments

Objectives and Strategies for Holding Derivative Instruments

In the ordinary course of business, the Company enters into contractual arrangements (derivatives) to reduce its exposure to foreign currency, interest rate and commodity price risks. The Company has established a variety of derivative programs to be utilized for financial risk management. These programs reflect varying levels of exposure coverage and time horizons based on an assessment of risk.

Derivative programs have procedures and controls and are approved by the Corporate Financial Risk Management Committee, consistent with the Company's financial risk management policies and guidelines. Derivative instruments used are forwards, options, futures and swaps. As of the third quarter of 2020, the Company has not designated any derivatives or non-derivatives as hedging instruments.

The Company's financial risk management procedures also address counterparty credit approval, limits and routine exposure monitoring and reporting. The counterparties to these contractual arrangements are major financial institutions and major commodity exchanges. The Company is exposed to credit loss in the event of nonperformance by these counterparties. The Company utilizes collateral support annex agreements with certain counterparties to limit its exposure to credit losses. The Company anticipates performance by counterparties to these contracts and therefore no material loss is expected. Market and counterparty credit risks associated with these instruments are regularly reported to management.

The notional amounts of the Company's derivative instruments were as follows:

Notional Amounts	September 30, 2020		December 31, 2019
In millions
Derivatives not designated as hedging instruments:
Foreign currency contracts 1	$	(299)	$	26
Commodity contracts	$	8	$	11

1.Presented net of contracts bought and sold.

Derivatives not Designated in Hedging Relationships

Foreign Currency Contracts

The Company routinely uses forward exchange contracts to reduce its net exposure, by currency, related to foreign currency-denominated monetary assets and liabilities of its operations so that exchange gains and losses resulting from exchange rate changes are minimized. The netting of such exposures precludes the use of hedge accounting; however, the required revaluation of the forward contracts and the associated foreign currency-denominated monetary assets and liabilities intends to achieve a minimal earnings impact, after taxes. The Company may use foreign currency exchange contracts to offset a portion of the Company's exposure to certain foreign currency-denominated revenues so that gains and losses on the contracts offset changes in the USD value of the related foreign currency-denominated revenues.

Commodity Contracts

The Company utilizes options, futures and swaps that are not designated as hedging instruments to reduce exposure to commodity price fluctuations on purchases of inventory such as soybeans, soybean oil and soybean meal.

Fair Value of Derivative Instruments

Asset and liability derivatives subject to an enforceable master netting arrangement with the same counterparty are presented on a net basis in the interim Condensed Consolidated Balance Sheets. The presentation of the Company's derivative assets and liabilities is as follows:

		September 30, 2020
In millions	Balance Sheet Classification	Gross		Counterparty and Cash Collateral Netting 1		Net Amounts Included in the Consolidated Balance Sheet
Asset derivatives:
Derivatives not designated as hedging instruments:
Foreign currency contracts	Other current assets	$	20	$	(16)	$	4
Total asset derivatives		$	20	$	(16)	$	4
Liability derivatives:
Derivatives not designated as hedging instruments:
Foreign currency contracts	Accrued and other current liabilities	$	22	$	(16)	$	6
Total liability derivatives		$	22	$	(16)	$	6

		December 31, 2019
In millions	Balance Sheet Classification	Gross		Counterparty and Cash Collateral Netting 1		Net Amounts Included in the Consolidated Balance Sheet
Asset derivatives:
Derivatives not designated as hedging instruments:
Foreign currency contracts	Other current assets	$	16	$	(10)	$	6
Total asset derivatives		$	16	$	(10)	$	6
Liability derivatives:
Derivatives not designated as hedging instruments:
Foreign currency contracts	Accrued and other current liabilities	$	17	$	(10)	$	7
Total liability derivatives		$	17	$	(10)	$	7

1.Counterparty and cash collateral amounts represent the estimated net settlement amount when applying netting and set-off rights included in master netting arrangements between the Company and its counterparties and the payable or receivable for cash collateral held or placed with the same counterparty.

Effect of Derivative Instruments

Foreign currency derivatives not designated as hedges are used to offset foreign exchange gains or losses resulting from the underlying exposures of foreign currency-denominated assets and liabilities. The amount charged on a pre-tax basis related to foreign currency derivatives not designated as a hedge, which was included in “Sundry income (expense) - net” in the interim Consolidated Statements of Operations, was a loss of $3 million for the three months ended September 30, 2020 and 2019, and a gain of $1 million for the nine months ended September 30, 2020 ($63 million loss for the nine months ended September 30, 2019). The income statement effects of other derivatives were immaterial.

Reclassification from AOCL

The Company does not expect to reclassify gains or losses related to foreign currency contracts from AOCL to income within the next 12 months and there are currently no such amounts included within AOCL.

XML

FAIR VALUE MEASUREMENTS

9 Months Ended

Sep. 30, 2020

Fair Value Disclosures [Abstract]

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS

Fair Value Measurements on a Recurring Basis

The following tables summarize the basis used to measure certain assets and liabilities at fair value on a recurring basis:

Basis of Fair Value Measurements on a Recurring Basis at September 30, 2020	Significant Other Observable Inputs (Level 2)
In millions
Assets at fair value:
Cash equivalents and restricted cash equivalents 1	$	8,766
Derivatives relating to: 2
Foreign currency contracts	20
Total assets at fair value	$	8,786
Liabilities at fair value:
Long-term debt including debt due within one year 3	$	26,179
Derivatives relating to: 2
Foreign currency contracts	22
Total liabilities at fair value	$	26,201

1.Treasury bills, time deposits, and money market funds included in "Cash and cash equivalents" and money market funds included in "Other current assets" and "Restricted cash" in the interim Condensed Consolidated Balance Sheets and held at amortized cost, which approximates fair value.

2. See Note 19 for the classification of derivatives in the interim Condensed Consolidated Balance Sheets.

3. Fair value is based on quoted market prices for the same or similar issues, or on current rates offered to the company for debt of the same remaining maturities and terms.

Basis of Fair Value Measurements on a Recurring Basis at December 31, 2019	Significant Other Observable Inputs (Level 2)
In millions
Assets at fair value:
Cash equivalents and restricted cash equivalents 1	$	454
Derivatives relating to: 2
Foreign currency contracts	16
Total assets at fair value	$	470
Liabilities at fair value:
Long-term debt including debt due within one year 3	$	17,251
Derivatives relating to: 2
Foreign currency contracts	17
Total liabilities at fair value	$	17,268

1. Treasury bills, time deposits, and money market funds included in "Cash and cash equivalents" and money market funds included in "Other current assets" in the interim Condensed Consolidated Balance Sheets and held at amortized cost, which approximates fair value.

2. See Note 19 for the classification of derivatives in the interim Condensed Consolidated Balance Sheets.

3. Fair value is based on quoted market prices for the same or similar issues, or on current rates offered to the company for debt of the same remaining maturities and terms.

Fair Value Measurements on a Nonrecurring Basis

During the third quarter of 2020, the Company recorded impairment charges related to goodwill, indefinite-lived intangible assets, and long-lived assets within the Non-Core segment. These impairment analyses were performed using Level 3 inputs within the fair value hierarchy. See Notes 3, 5, and 11 for further discussion.

During the second quarter of 2020, the Company recorded impairment charges related to goodwill and indefinite-lived intangible assets within the Transportation & Industrial segment. See Notes 5 and 11 for further discussion of these fair value measurements.

During the first quarter of 2020, the Company recorded impairment charges related to goodwill and long-lived assets within the Non-Core segment. See Notes 5 and 11 for further discussion of these fair value measurements.

During the second quarter of 2019, the Company recorded goodwill impairment charges related to the Nutrition & Biosciences and Non-Core segments. The Company also recorded an other-than-temporary impairment, classified as Level 3 measurements, on an equity method investment. See Notes 5 and 11 for further discussion of these fair value measurements.

XML

SEGMENTS AND GEOGRAPHIC REGIONS

9 Months Ended

Sep. 30, 2020

Segment Reporting [Abstract]

SEGMENTS AND GEOGRAPHIC REGIONS

SEGMENTS AND GEOGRAPHIC REGIONS

In the first quarter of 2020, in preparation for the Intended N&B Transaction, DuPont changed its management and reporting structure to realign costs associated with its polysaccharides pre-commercial activities from the Non-Core segment to the N&B segment. The reporting changes have been retrospectively reflected in the segment results for all periods presented.

Prior to April 1, 2019, the Company's measure of profit / loss for segment reporting purposes is pro forma Operating EBITDA as this is the manner in which the Company's chief operating decision maker ("CODM") assessed performance and allocates resources. The Company defines pro forma Operating EBITDA as pro forma earnings (i.e. pro forma "Income (loss) from continuing operations before income taxes") before interest, depreciation, amortization, non-operating pension / other post-employment benefits (“OPEB”) / charges, and foreign exchange gains/losses, excluding the impact of costs historically allocated to the materials science and agriculture businesses that did not meet the criteria to be recorded as discontinued operations and adjusted for significant items. Effective April 1, 2019, the Company's measure of profit/loss for segment reporting purposes is Operating EBITDA as this is the manner in which the Company's chief operating decision maker ("CODM") assesses performance and allocates resources. The Company defines Operating EBITDA as earnings (i.e., “Income from continuing operations before income taxes") before interest, depreciation, amortization, non-operating pension / OPEB benefits / charges, and foreign exchange gains / losses, adjusted for significant items. Reconciliations of these measures are provided on the following pages.

Pro forma adjustments were determined in accordance with Article 11 of Regulation S-X. Pro forma financial information is based on the Consolidated Financial Statements of DuPont, adjusted to give effect to the impact of certain items directly attributable to the DWDP Distributions, and the Term Loan Facilities, the 2018 Senior Notes and the Funding CP Issuance (together, the "Financings"), including the use of proceeds from such Financings (collectively the "Transactions"). The historical consolidated financial information has been adjusted to give effect to pro forma events that are (1) directly attributable to the Transactions, (2) factually supportable and (3) with respect to the statements of operations, expected to have a continuing impact on the results. Events that are not expected to have a continuing impact on the combined results are excluded from the pro forma adjustments. Those pro forma adjustments include the impact of various supply agreements entered into in connection with the Dow Distribution ("supply agreements") and are adjustments to "Cost of sales." Pro forma Operating EBITDA for the nine months ended September 30, 2019 has been adjusted to reflect the supply agreements if they had been effective January 1, 2018 as they are included in the measure of profit/loss reviewed by the CODM in order to show meaningful comparability among periods while assessing performance and making resource allocation decisions. There were no pro forma adjustments for the three or nine months ended September 30, 2020 and the three months ended September 30, 2019.

Segment Information	Elect. & Imaging		Nutrition & Biosciences		Transp. & Industrial		Safety & Const.		Non-Core		Corp.		Total
In millions
Three months ended September 30, 2020
Net sales	$	1,004	$	1,467	$	1,045	$	1,249	$	331	$	—	$	5,096
Operating EBITDA 1	$	357	$	379	$	242	$	324	$	14	$	(16)	$	1,300
Equity in earnings of nonconsolidated affiliates	$	8	$	1	$	1	$	7	$	13	$	—	$	30
Three months ended September 30, 2019
Net sales	$	934	$	1,525	$	1,209	$	1,327	$	431	$	—	$	5,426
Operating EBITDA 1	$	320	$	354	$	306	$	352	$	94	$	(25)	$	1,401
Equity in earnings of nonconsolidated affiliates 2	$	10	$	—	$	1	$	7	$	26	$	—	$	44
Nine months ended September 30, 2020
Net sales	$	2,793	$	4,557	$	3,021	$	3,769	$	1,005	$	—	$	15,145
Operating EBITDA 1	$	887	$	1,182	$	599	$	1,041	$	149	$	(102)	$	3,756
Equity in earnings of nonconsolidated affiliates	$	27	$	2	$	3	$	19	$	121	$	—	$	172
Nine months ended September 30, 2019
Net sales	$	2,617	$	4,618	$	3,795	$	3,951	$	1,327	$	—	$	16,308
Pro forma operating EBITDA 1	$	854	$	1,089	$	1,036	$	1,108	$	296	$	(130)	$	4,253
Equity in earnings of nonconsolidated affiliates 2	$	18	$	—	$	3	$	22	$	92	$	—	$	135

1.A reconciliation of "Income (loss) from continuing operations, net of tax" to Operating EBITDA and pro forma Operating EBITDA, as applicable, is provided below.

2.Represents equity in earnings (losses) of nonconsolidated affiliates included in pro forma Operating EBITDA, the Company's measure of profit/loss for segment reporting purposes, which excludes significant items. Accordingly, the Non-Core segment presented above excludes restructuring charges of $1 million and $3 million for the three and nine months ended September 30, 2019, respectively, which is presented in "Equity in earnings of nonconsolidated affiliates" in the Company's interim Consolidated Statements of Operations.

Reconciliation of "Income (loss) from continuing operations, net of tax" to Operating EBITDA for the Three Months Ended September 30, 2020 and 2019	Three Months Ended September 30,
In millions	2020		2019
Loss (income) from continuing operations, net of tax	$	(72)	$	372
+ Provision for income taxes on continuing operations	92		78
Income from continuing operations before income taxes	$	20	$	450
+ Depreciation and amortization	780		499
- Interest income 1	3		1
+ Interest expense 2	165		177
- Non-operating pension/OPEB benefit 1	5		21
- Foreign exchange losses, net 1	(10)		(23)
- Significant items 3	(333)		(274)
Operating EBITDA	$	1,300	$	1,401

1. Included in "Sundry income (expense) - net."

2. The three months ended September 30, 2020 excludes N&B financing activity. Refer to details of significant items below.

3. The significant items for the three months ended September 30, 2020 and 2019 are presented on an as reported basis.

Reconciliation of "Income (loss) from continuing operations, net of tax" to Operating EBITDA for the Nine Months Ended September 30, 2020 and 2019	Nine Months Ended September 30,
In millions	2020		2019
Loss from continuing operations, net of tax	$	(3,153)	$	(805)
+ Provision for income taxes on continuing operations	100		142
Loss from continuing operations before income taxes	$	(3,053)	$	(663)
+ Pro forma adjustments 1	—		122
+ Depreciation and amortization	2,326		1,533
- Interest income 2	7		50
+ Interest expense 3	519		522
- Non-operating pension/OPEB benefit 2	24		60
- Foreign exchange losses, net 2	(41)		(101)
+ Costs historically allocated to the materials science and agriculture businesses 4	—		256
- Significant items 5	(3,954)		(2,492)
Operating EBITDA 1	$	3,756	$	4,253

1. For the nine months ended September 30, 2019, operating EBITDA is on a pro forma basis. The pro forma adjustment reflects the net pro forma impact of items directly attributable to the Transactions, as applicable.

2. Included in "Sundry income (expense) - net."

3. The nine months ended September 30, 2020 excludes N&B financing activity. Refer to details of significant items below.

4. Costs previously allocated to the materials science and agriculture businesses that did not meet the definition of expenses related to discontinued operations in accordance with ASC 205.

5. The significant items for the nine months ended September 30, 2020 are presented on an as reported basis. The significant items for the nine months ended September 30, 2019 are presented on a pro forma basis.

The significant items for the three months ended September 30, 2020 and 2019 and the nine months ended September 30, 2020 are presented on an as reported basis. The significant items for the nine months ended September 30, 2019 are presented on a pro forma basis. The following tables summarize the pre-tax impact of significant items by segment that are excluded from Operating EBITDA and pro forma Operating EBITDA above:

Significant Items by Segment for the Three Months Ended September 30, 2020	Elect. & Imaging		Nutrition & Biosciences		Transp. & Industrial		Safety & Construction		Non-Core		Corporate		Total
In millions
Integration and separation costs 1	$	—	$	—	$	—	$	—	$	—	$	(127)	$	(127)
Restructuring and asset related credits (charges) - net 2	(1)		(5)		—		(2)		(1)		(5)		(14)
Goodwill impairment charges 3	—		—		—		—		(183)		—		(183)
Asset impairment charges 3, 4	—		—		—		—		(370)		—		(370)
Gain on divestitures 5	—		—		—		—		393		—		393
N&B financing activity - net 6	—		—		—		—		—		(32)		(32)
Total	$	(1)	$	(5)	$	—	$	(2)	$	(161)	$	(164)	$	(333)

1. Integration and separation costs related to the post-DWDP Merger integration and the intended separation of the N&B Business.

2. Includes Board approved restructuring plans and asset related charges. See Note 5 for additional information.

3. Refer to Note 11 for additional information.

4. Refer to Note 5 for additional information.

5. Refer to Note 3 for additional information.

6. Represents interest expense, net related to the N&B Notes as well as the financing fee amortization related to the intended separation of the N&B Business.

Significant Items by Segment for the Three Months Ended September 30, 2019	Elect. & Imaging		Nutrition & Biosciences		Transp. & Industrial		Safety & Construction		Non-Core		Corporate		Total
In millions
Integration and separation costs 1	$	—	$	—	$	—	$	—	$	—	$	(191)	$	(191)
Restructuring and asset related charges - net 2	(35)		(7)		(6)		(5)		(2)		(28)		(83)
Total	$	(35)	$	(7)	$	(6)	$	(5)	$	(2)	$	(219)	$	(274)

1.Integration and separation costs related to post-DWDP Merger integration and business separation activities.

2. Includes Board approved restructuring plans and asset related charges. See Note 5 for additional information.

Significant Items by Segment for the Nine Months Ended September 30, 2020	Elect. & Imaging		Nutrition & Biosciences		Transp. & Industrial		Safety & Construction		Non-Core		Corporate		Total
In millions
Integration and separation costs 1	$	—	$	—	$	—	$	—	$	—	$	(469)	$	(469)
Restructuring and asset related charges - net 2	(2)		(9)		(15)		(15)		(1)		(104)		(146)
Goodwill impairment charges 3	—		—		(2,498)		—		(716)		—		(3,214)
Asset impairment charges 3, 4	—		—		(21)		—		(640)		—		(661)
Gain on divestitures 5	197		—		—		—		393		—		590
N&B financing activity - net 6	—		—		—		—		—		(54)		(54)
Total	$	195	$	(9)	$	(2,534)	$	(15)	$	(964)	$	(627)	$	(3,954)

1. Integration and separation costs related to the post-DWDP Merger integration and the intended separation of the N&B Business.

2. Includes Board approved restructuring plans and asset related charges. See Note 5 for additional information.

3. Refer to Note 11 for additional information.

4. Refer to Note 5 for additional information.

5. Refer to Note 3 for additional information.

6. Represents interest expense, net related to the N&B Notes as well as the financing fee amortization related to the intended separation of the N&B Business.

Significant Items by Segment for the Nine Months Ended September 30, 2019 (Pro Forma)	Elect. & Imaging		Nutrition & Biosciences		Transp. & Industrial		Safety & Construction		Non-Core		Corporate		Total
In millions
Integration and separation costs 1	$	—	$	—	$	—	$	—	$	—	$	(976)	$	(976)
Restructuring and asset related charges - net 2	(42)		(56)		(18)		(27)		(2)		(85)		(230)
Goodwill impairment charges 3	—		(933)		—		—		(242)		—		(1,175)
Asset impairment charges 4	—		(63)		—		—		—		—		(63)
Income tax relates item 5	—		—		—		(48)		—		—		(48)
Total	$	(42)	$	(1,052)	$	(18)	$	(75)	$	(244)	$	(1,061)	$	(2,492)

1.Integration and separation costs related to the DWDP Merger, post-DWDP Merger integration and business separation activities.

2. Includes Board approved restructuring plans and asset related charges. See Note 5 for additional information.

3. Refer to Note 11 for additional information.

4. Refer to Note 5 for additional information.

5. Charge included in "Sundry income (expense) - net" which reflects a reduction in gross proceeds from lower withholding taxes related to a prior year legal settlement.

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

Basis of Presentation

Interim Financial Statements

The accompanying unaudited interim Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP") for interim financial information and the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. In the opinion of management, the interim statements reflect all adjustments (including normal recurring accruals) which are considered necessary for the fair statement of the results for the periods presented. Results from interim periods should not be considered indicative of results for the full year. These interim Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, collectively referred to as the “2019 Annual Report.” The interim Consolidated Financial Statements include the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained.

Basis of Presentation and Significant Accounting Policies [Text Block]

Impact of the Novel Coronavirus (“COVID-19”) Pandemic

The COVID-19 pandemic has resulted in significant economic disruption and continues to adversely impact the broader global economy. The extent of the impact on the Company's operational and financial performance will depend on future developments, including, but not limited to, the duration and spread of the outbreak and its impact on the Company's customers and suppliers. As of the date of issuance of these interim Consolidated Financial Statements, the full extent to which the COVID-19 pandemic may materially impact the Company's financial condition, liquidity, or results of operations remains uncertain.

Basis of Presentation

Effective August 31, 2017, pursuant to the merger of equals transaction contemplated by the Agreement and Plan of Merger, dated as of December 11, 2015, as amended on March 31, 2017 ("DWDP Merger Agreement"), The Dow Chemical Company ("Historical Dow") and E. I. du Pont de Nemours and Company ("Historical EID") each merged with subsidiaries of DowDuPont Inc. ("DowDuPont") and, as a result, Historical Dow and Historical EID became subsidiaries of DowDuPont (the "DWDP Merger"). Prior to the DWDP Merger, DowDuPont did not conduct any business activities other than those required for its formation and matters contemplated by the DWDP Merger Agreement. Historical Dow was determined to be the accounting acquirer in the DWDP Merger.

Except as otherwise indicated by the context, the term "Historical Dow" includes Historical Dow and its consolidated subsidiaries, "Historical EID" includes Historical EID and its consolidated subsidiaries, and "Dow Silicones" means Dow Silicones Corporation, a wholly owned subsidiary of Historical Dow.

Discontinued Operations, Policy [Policy Text Block]

Effective as of 5:00 p.m. on April 1, 2019, the Company completed the separation of its materials science business into a separate and independent public company by way of a distribution of Dow Inc. (“Dow”) through a pro rata dividend in-kind of all of the then-issued and outstanding shares of Dow’s common stock (the “Dow Common Stock”), to holders of the Company’s common stock (the “DowDuPont common stock”), as of the close of business on March 21, 2019 (the “Dow Distribution”).

Effective as of 12:01 a.m. on June 1, 2019, the Company completed the separation of its agriculture business into a separate and independent public company by way of a distribution of Corteva, Inc. (“Corteva”) through a pro rata dividend in-kind of all of the then-issued and outstanding shares of Corteva’s common stock (the “Corteva Common Stock”), to holders of the Company’s common stock as of the close of business on May 24, 2019 (the “Corteva Distribution” and, together with the Dow Distribution, the “DWDP Distributions”).

Following the Corteva Distribution, DuPont holds the specialty products business. On June 1, 2019, DowDuPont changed its registered name from "DowDuPont Inc." to "DuPont de Nemours, Inc." doing business as "DuPont." Beginning on June 3, 2019, the Company's common stock is traded on the NYSE under the ticker symbol "DD."

The results of operations of DuPont for the 2019 interim periods presented reflect the historical financial results of Dow and Corteva as discontinued operations, as applicable. The cash flows and comprehensive income related to Dow and Corteva have not been segregated and are included in the interim Consolidated Statements of Cash Flows and interim Consolidated Statements of Comprehensive Income, respectively, for the applicable period. Unless otherwise indicated, the information in the notes to the interim Consolidated Financial Statements refer only to DuPont's continuing operations and do not include discussion of balances or activity of Dow or Corteva.

On December 15, 2019, the Company entered into definitive agreements to separate and combine the Nutrition & Biosciences business segment (the "N&B Business") with International Flavors & Fragrances Inc. ("IFF") in a tax-efficient Reverse Morris Trust transaction, (the "Intended N&B Transaction"). The transaction is expected to close in the first quarter of 2021, subject to approval by IFF shareholders and other customary closing conditions, including regulatory approvals and receipt by DuPont of an opinion of tax counsel. The financial results of the N&B Business are included in continuing operations for the periods presented.

XML

RECENT ACCOUNTING GUIDANCE (Policies)

9 Months Ended

Sep. 30, 2020

Recent Accounting Guidance [Abstract]

New Accounting Pronouncements, Policy [Policy Text Block]

Recently Adopted Accounting Guidance

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, and associated ASUs related to Topic 326. The new guidance introduces the current expected credit loss (“CECL”) model, which requires organizations to record an allowance for credit losses for certain financial instruments and financial assets, including trade receivables, based on expected losses rather than incurred losses. Under this update, on initial recognition and at each reporting period, an entity will be required to recognize an allowance that reflects the entity’s current estimate of credit losses expected to be incurred over the life of the financial instrument. This update became effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019.

The Company adopted the new standard in the first quarter of 2020, which required a modified retrospective transition approach, applying the new standard's cumulative-effect adjustment at the date of initial adoption. This cumulative-effect has been reflected as of January 1, 2020 and prior periods have not been restated. The impact of initial adoption was not material to the Company’s interim Condensed Consolidated Balance Sheet, interim Consolidated Statements of Operations, and interim Consolidated Statement of Cash Flows.

XML

DIVESTITURES (Tables)

9 Months Ended

Sep. 30, 2020

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Integration and Separation Costs [Table Text Block]

	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2020		2019		2020		2019
Integration and separation costs	$	127	$	191	$	469	$	1,149

Materials Science Division [Member]

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Disposal Groups, Including Discontinued Operations [Table Text Block]

The results of operations of the Materials Science Division are presented as discontinued operations as summarized below:

	Nine Months Ended September 30, 2019
In millions
Net sales	$	10,867
Cost of sales	8,917
Research and development expenses	163
Selling, general and administrative expenses	329
Amortization of intangibles	116
Restructuring and asset related charges - net	157
Integration and separation costs	44
Equity in earnings of nonconsolidated affiliates	(13)
Sundry income (expense) - net 1	17
Interest expense	240
Income from discontinued operations before income taxes	905
Provision for income taxes on discontinued operations 1	176
Income from discontinued operations, net of tax	729
Income from discontinued operations attributable to noncontrolling interests, net of tax	37
Income from discontinued operations attributable to DuPont stockholders, net of tax	$	692

1.The three and nine months ended September 30, 2019 includes $82 million of expense in "Sundry income (expense) - net" and a benefit of $85 million in "Provision for income taxes on discontinued operations" related to certain unrecognized tax benefits for positions taken on items from prior years.

The following table presents depreciation, amortization, and capital expenditures of the discontinued operations related to the Materials Science Division:

	Nine Months Ended September 30, 2019
In millions
Depreciation and amortization	$	744
Capital expenditures	$	597

Agriculture Division [Member]

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Disposal Groups, Including Discontinued Operations [Table Text Block]

The results of operations of the Agriculture Division are presented as discontinued operations as summarized below:

	Nine Months Ended September 30, 2019
In millions
Net sales	$	7,144
Cost of sales	4,218
Research and development expenses	470
Selling, general and administrative expenses	1,294
Amortization of intangibles	176
Restructuring and asset related charges - net	117
Integration and separation costs	430
Equity in earnings of nonconsolidated affiliates	(4)
Sundry income (expense) - net 1	52
Interest expense	91
Income from discontinued operations before income taxes	396
Provision for income taxes on discontinued operations 1	74
Income from discontinued operations, net of tax	322
Income from discontinued operations attributable to noncontrolling interests, net of tax	35
Income from discontinued operations attributable to DuPont stockholders, net of tax	$	287

1.The three and nine months ended September 30, 2019 includes $6 million of expense in "Sundry income (expense) - net" and a benefit of $8 million in "Provision for income taxes on discontinued operations" related to certain unrecognized tax benefits for positions taken on items from prior years.

The following table presents depreciation, amortization, and capital expenditures of the discontinued operations related to the Agriculture Division:

	Nine Months Ended September 30, 2019
In millions
Depreciation and amortization	$	385
Capital expenditures	$	383

Non-Core Held for Sale Disposal Groups

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Disposal Groups, Including Discontinued Operations [Table Text Block]

The following table summarizes the carrying value of the major assets and liabilities of the biomaterials business unit, as well as these certain other assets and liabilities within Non-Core classified as held for sale as of September 30, 2020 (collectively, the “Non-Core Held for Sale Disposal Groups”):

In millions	September 30, 2020
Assets
Accounts and notes receivable - net	$	61
Inventories	96
Other current assets	40
Investments in nonconsolidated affiliates	166
Property, plant and equipment - net	32
Goodwill	267
Other intangible assets	169
Deferred charges and other assets	4
Assets held for sale	$	835
Liabilities
Accounts payable	$	29
Income taxes payable	1
Accrued and other current liabilities	48
Deferred income tax liabilities	30
Pension and other post-employment benefits - noncurrent	1
Other noncurrent obligations	18
Liabilities related to assets held for sale	$	127

XML

REVENUE (Tables)

9 Months Ended

Sep. 30, 2020

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue [Table Text Block]

Net Trade Revenue by Segment and Business or Major Product Line	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2020		2019		2020		2019
Image Solutions	$	172	$	167	$	491	$	507
Interconnect Solutions	370		339		910		859
Semiconductor Technologies	462		428		1,392		1,251
Electronics & Imaging	$	1,004	$	934	$	2,793	$	2,617
Food & Beverage	$	686	$	736	$	2,163	$	2,237
Health & Biosciences	570		582		1,754		1,756
Pharma Solutions	211		207		640		625
Nutrition & Biosciences	$	1,467	$	1,525	$	4,557	$	4,618
Healthcare & Specialty	$	352	$	376	$	1,002	$	1,148
Industrial & Consumer	233		274		680		875
Mobility Solutions	460		559		1,339		1,772
Transportation & Industrial	$	1,045	$	1,209	$	3,021	$	3,795
Safety Solutions	$	534	$	630	$	1,746	$	1,952
Shelter Solutions	387		411		1,051		1,166
Water Solutions	328		286		972		833
Safety & Construction	$	1,249	$	1,327	$	3,769	$	3,951
Biomaterials	$	37	$	54	$	98	$	166
Clean Technologies	48		78		175		219
DuPont Teijin Films	47		48		124		127
Photovoltaic & Advanced Materials 1	199		223		608		707
Sustainable Solutions 2	—		28		—		108
Non-Core	$	331	$	431	$	1,005	$	1,327
Total	$	5,096	$	5,426	$	15,145	$	16,308

1. The TCS Business within Photovoltaic & Advanced Materials was divested in the third quarter of 2020.

2. The Sustainable Solutions business was divested in the third quarter of 2019.

Net Trade Revenue by Geographic Region	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2020		2019		2020		2019
U.S. & Canada	$	1,620	$	1,822	$	4,875	$	5,424
EMEA 1	1,069		1,227		3,405		3,898
Asia Pacific	2,120		2,057		6,045		6,036
Latin America	287		320		820		950
Total	$	5,096	$	5,426	$	15,145	$	16,308

1.Europe, Middle East and Africa.

Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]

Contract Balances	September 30, 2020		December 31, 2019
In millions
Accounts and notes receivable - trade 1	$	2,938	$	3,007
Contract assets - current 2	$	—	$	35
Deferred revenue - current 3	$	18	$	20
Deferred revenue - noncurrent 4	$	25	$	24

1.Included in "Accounts and notes receivable - net" in the interim Condensed Consolidated Balance Sheets.

2.Included in "Other current assets" in the interim Condensed Consolidated Balance Sheets.

3.Included in "Accrued and other current liabilities" in the interim Condensed Consolidated Balance Sheets.

4.Included in "Other noncurrent obligations" in the interim Condensed Consolidated Balance Sheets.

XML

RESTRUCTURING AND ASSET RELATED CHARGES - NET (Tables)

9 Months Ended

Sep. 30, 2020

2020 Restructuring Program [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring Charges

	Three Months Ended September 30, 2020		Nine Months Ended September 30, 2020
In millions
Severance and related benefit costs	$	10	$	112
Asset related charges	4		28
Total restructuring and asset related charges - net	$	14	$	140

2020 Restructuring Program Charges by Segment	Three Months Ended September 30, 2020		Nine Months Ended September 30, 2020
In millions
Electronics & Imaging	$	1	$	5
Nutrition & Biosciences	5		12
Transportation & Industrial	—		21
Safety & Construction	2		24
Non-Core	1		1
Corporate	5		77
Total	$	14	$	140

Schedule of Restructuring Reserve by Type of Cost [Table Text Block]

The following table summarizes the activities related to the 2020 Restructuring Program:

2020 Restructuring Program	Severance and Related Benefit Costs		Asset Related Charges		Total
In millions
Year-to-date restructuring charges	$	112	$	28	$	140
Charges against the reserve	—		(28)		(28)
Cash payments	(42)		—		(42)
Reserve balance at September 30, 2020	$	70	$	—	$	70

2019 Restructuring Program [Domain]

Restructuring Cost and Reserve [Line Items]

Restructuring Charges

The following table summarizes the charges incurred for the three months ended September 30, 2019 and the nine months ended September 30, 2020 and September 30, 2019:

	Three Months Ended September 30,		Nine Months Ended September 30,
In millions	2019		2020		2019
Severance and related benefit costs	$	48	$	2	$	98
Asset related charges	21		—		24
Total restructuring and asset related charges - net	$	69	$	2	$	122

2019 Restructuring Program Charges (Credits) by Segment	Three Months Ended September 30,		Nine Months Ended September 30,
In millions	2019		2020		2019
Electronics & Imaging	$	35	$	(3)	$	42
Nutrition & Biosciences	4		(3)		18
Transportation & Industrial	6		(7)		18
Safety & Construction	3		(14)		20
Non-Core	3		—		3
Corporate	18		29		21
Total	$	69	$	2	$	122

Schedule of Restructuring Reserve by Type of Cost [Table Text Block]

The following table summarizes the activities related to the 2019 Restructuring Program:

2019 Restructuring Program	Severance and Related Benefit Costs
In millions
Reserve balance at December 31, 2019	$	86
Year-to-date restructuring charges	2
Non-cash compensation	(6)
Cash payments	(55)
Reserve balance at September 30, 2020	$	27

DowDuPont Cost Synergy Program [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring Charges

	Three Months Ended September 30,		Nine Months Ended September 30,
In millions	2019		2020		2019
Severance and related benefit costs (credits)	$	—	$	(2)	$	49
Contract termination and other charges	—		6		16
Asset related charges	14		—		43
Total restructuring and asset related charges - net 1	$	14	$	4	$	108

1. The charge for the three and nine months ended September 30, 2019 includes $13 million and $105 million which was recognized in "Restructuring and asset related charges - net" and $1 million and $3 million which was recognized in "Equity in earnings of nonconsolidated affiliates" in the interim Consolidated Statements of Operations.

DowDuPont Cost Synergy Program Charges (Credits) by Segment	Three Months Ended September 30,		Nine Months Ended September 30,
In millions	2019		2020		2019
Electronics & Imaging	$	—	$	—	$	—
Nutrition & Biosciences	3		—		38
Transportation & Industrial	—		1		—
Safety & Construction	2		5		7
Non-Core	(1)		—		(1)
Corporate	10		(2)		64
Total	$	14	$	4	$	108

Schedule of Restructuring Reserve by Type of Cost [Table Text Block]

The following table summarizes the activities related to the DowDuPont Cost Synergy Program:

DowDuPont Cost Synergy Program	Severance and Related Benefit Costs		Contract Termination Charges		Total
In millions
Reserve balance at December 31, 2019	$	74	$	2	$	76
Year-to-date restructuring (credits) charges	(2)		6		4
Charges against the reserve	—		(1)		(1)
Cash payments	(47)		(2)		(49)
Reserve balance at September 30, 2020	$	25	$	5	$	30

XML

SUPPLEMENTARY INFORMATION (Tables)

9 Months Ended

Sep. 30, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of sundry income (expense), net

Sundry Income (Expense) - Net	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2020		2019		2020		2019
Non-operating pension and other post-employment benefit (OPEB) credits	$	5	$	21	$	24	$	60
Interest income	3		1		7		50
Net gain on divestiture and sales of other assets and investments 1,2,3	419		64		612		127
Foreign exchange losses, net	(10)		(23)		(41)		(101)
Miscellaneous income (expenses) - net 4	13		16		25		8
Sundry income (expense) - net	$	430	$	79	$	627	$	144

1.The three and nine months ended September 30, 2020 includes a net benefit of $393 million related to the TCS/HSC Disposal, including the settlement of a supply agreement dispute, within the Non-Core segment. Refer to Note 3 for further information.

2. The nine months ended September 30, 2020 includes income of $197 million related to the gain on sale of the Compound Semiconductor Solutions business unit within the Electronics & Imaging segment.

3. The three and nine months ended September 30, 2020 includes income of $30 million related to a prior year sale of assets within the Electronics & Imaging segment. The three and nine months ended September 30, 2019 includes income of $34 million and $85 million, respectively, related to a sale of assets within the Electronics & Imaging segment, as well as a gain of $28 million related to the sale of the Sustainable Solutions business unit within the Non-Core segment.

4. Miscellaneous income (expenses) - net for the nine months ended September 30, 2019 includes a $48 million charge reflecting a reduction in gross proceeds from lower withholding taxes related to a prior year settlement. The nine months ended September 30, 2019 also includes $26 million related to licensing income within the Safety & Construction segment.

XML

EARNINGS PER SHARE CALCULATIONS (Tables)

9 Months Ended

Sep. 30, 2020

Earnings Per Share [Abstract]

Schedule of Earnings Per Share

The following tables provide earnings per share calculations for the three and nine months ended September 30, 2020 and 2019:

Net Income for Earnings Per Share Calculations - Basic & Diluted	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2020		2019		2020		2019
(Loss) income from continuing operations, net of tax	$	(72)	$	372	$	(3,153)	$	(805)
Net income from continuing operations attributable to noncontrolling interests	7		5		20		18
Net income from continuing operations attributable to participating securities 1	—		—		—		1
(Loss) income from continuing operations attributable to common stockholders	$	(79)	$	367	$	(3,173)	$	(824)
Income from discontinued operations, net of tax	—		5		—		1,217
Net income from discontinued operations attributable to noncontrolling interests	—		—		—		72
Income from discontinued operations attributable to common stockholders	—		5		—		1,145
Net (loss) income attributable to common stockholders	$	(79)	$	372	$	(3,173)	$	321

Earnings Per Share Calculations - Basic	Three Months Ended September 30,				Nine Months Ended September 30,
Dollars per share	2020		2019		2020		2019
(Loss) earnings from continuing operations attributable to common stockholders	$	(0.11)	$	0.49	$	(4.31)	$	(1.10)
Income from discontinued operations, net of tax	—		0.01		—		1.53
Net (loss) earnings attributable to common stockholders	$	(0.11)	$	0.50	$	(4.31)	$	0.43

Earnings Per Share Calculations - Diluted	Three Months Ended September 30,				Nine Months Ended September 30,
Dollars per share	2020		2019		2020		2019
(Loss) earnings from continuing operations attributable to common stockholders	$	(0.11)	$	0.49	$	(4.31)	$	(1.10)
Income from discontinued operations, net of tax	—		0.01		—		1.53
Net (loss) earnings attributable to common stockholders	$	(0.11)	$	0.50	$	(4.31)	$	0.43

Share Count Information	Three Months Ended September 30,		Nine Months Ended September 30,
Shares in millions	2020	2019	2020	2019
Weighted-average common shares - basic	734.4	745.5	735.8	748.2
Plus dilutive effect of equity compensation plans	—	2.2	—	—
Weighted-average common shares - diluted	734.4	747.7	735.8	748.2
Stock options and restricted stock units excluded from EPS calculations 2	5.5	3.8	6.3	2.8

1.Historical Dow restricted stock units are considered participating securities due to Historical Dow's practice of paying dividend equivalents on unvested shares.

2. These outstanding options to purchase shares of common stock and restricted stock units were excluded from the calculation of diluted earnings per share because the effect of including them would have been antidilutive.

XML

INVENTORIES Inventories (Tables)

9 Months Ended

Sep. 30, 2020

Inventory [Abstract]

Schedule of Inventory, Current [Table Text Block]

Inventories	September 30, 2020		December 31, 2019
In millions
Finished goods	$	2,407	$	2,621
Work in process	803		855
Raw materials	465		599
Supplies	227		244
Total inventories	$	3,902	$	4,319

XML

NONCONSOLIDATED AFFILIATES (Tables)

9 Months Ended

Sep. 30, 2020

Equity Method Investments and Joint Ventures [Abstract]

Nonconsolidated Affiliates - Investments [Table Text Block]

The Company's investments in companies accounted for using the equity method ("nonconsolidated affiliates"), by classification in the interim Condensed Consolidated Balance Sheets, are shown in the following table:

Investments in Nonconsolidated Affiliates	September 30, 2020		December 31, 2019
In millions
Investments in nonconsolidated affiliates	$	951	$	1,204
Accrued and other current liabilities	(74)		(85)
Other noncurrent obligations	—		(358)
Net investment in nonconsolidated affiliates	$	877	$	761

Equity Method Investments [Table Text Block]

The following table reflects the carrying value of the HSC Group investments at December 31, 2019:

Investment in the HSC Group		Investment
In millions	Balance Sheet Classification	Dec 31, 2019
Hemlock Semiconductor L.L.C.	Other noncurrent obligations	$	(358)
DC HSC Holdings LLC	Investments in nonconsolidated affiliates	$	87

XML

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)

9 Months Ended

Sep. 30, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of goodwill

The changes in the carrying amounts of goodwill during the nine months ended September 30, 2020 were as follows:

	Elect. & Imaging		Nutrition & Biosciences		Transp. & Industrial		Safety & Const.		Non-Core		Total
In millions
Balance at December 31, 2019	$	7,092	$	11,012	$	6,931	$	6,711	$	1,405	$	33,151
Acquisitions	—		—		—		53		—		53
Divestitures 1	(199)		—		—		—		(514)		(713)
Impairments	—		—		(2,498)		—		(716)		(3,214)
Currency Translation Adjustment	41		206		67		84		—		398
Measurement Period Adjustments	—		—		—		15		—		15
Balance at September 30, 2020	$	6,934	$	11,218	$	4,500	$	6,863	$	175	$	29,690

1. Includes $267 million of goodwill related to the Non-Core segment reclassified as held for sale in connection with the Non-Core Held for Sale Disposal Groups. Refer to Note 3 for further information.

Schedule of other finite intangible assets

The gross carrying amounts and accumulated amortization of other intangible assets by major class are as follows:

	September 30, 2020						December 31, 2019
In millions	Gross Carrying Amount		Accum Amort		Net		Gross Carrying Amount		Accum Amort		Net
Intangible assets with finite lives:
Developed technology	$	4,229	$	(1,705)	$	2,524	$	4,343	$	(1,361)	$	2,982
Trademarks/tradenames	2,395		(1,378)		1,017		2,433		(455)		1,978
Customer-related	8,942		(2,644)		6,298		8,986		(2,229)		6,757
Other	175		(85)		90		303		(98)		205
Total other intangible assets with finite lives	$	15,741	$	(5,812)	$	9,929	$	16,065	$	(4,143)	$	11,922
Intangible assets with indefinite lives:
Trademarks/tradenames	1,599		—		1,599		1,671		—		1,671
Total other intangible assets	1,599		—		1,599		1,671		—		1,671
Total	$	17,340	$	(5,812)	$	11,528	$	17,736	$	(4,143)	$	13,593

Schedule of other indefinite intangible assets

The gross carrying amounts and accumulated amortization of other intangible assets by major class are as follows:

	September 30, 2020						December 31, 2019
In millions	Gross Carrying Amount		Accum Amort		Net		Gross Carrying Amount		Accum Amort		Net
Intangible assets with finite lives:
Developed technology	$	4,229	$	(1,705)	$	2,524	$	4,343	$	(1,361)	$	2,982
Trademarks/tradenames	2,395		(1,378)		1,017		2,433		(455)		1,978
Customer-related	8,942		(2,644)		6,298		8,986		(2,229)		6,757
Other	175		(85)		90		303		(98)		205
Total other intangible assets with finite lives	$	15,741	$	(5,812)	$	9,929	$	16,065	$	(4,143)	$	11,922
Intangible assets with indefinite lives:
Trademarks/tradenames	1,599		—		1,599		1,671		—		1,671
Total other intangible assets	1,599		—		1,599		1,671		—		1,671
Total	$	17,340	$	(5,812)	$	11,528	$	17,736	$	(4,143)	$	13,593

Intangible Assets Disclosure

The following table provides the net carrying value of other intangible assets by segment:

Net Intangibles by Segment	September 30, 2020		December 31, 2019
In millions
Electronics & Imaging	$	1,686	$	1,833
Nutrition & Biosciences	3,360		4,377
Transportation & Industrial	3,429		3,590
Safety & Construction	2,956		3,082
Non-Core	97		711
Total	$	11,528	$	13,593

XML

COMMITMENTS AND CONTINGENT LIABILITIES (Tables)

9 Months Ended

Sep. 30, 2020

Commitments and Contingencies Disclosure [Abstract]

Schedule of Guarantor Obligations

The following table provides a summary of the final expiration year and maximum future payments for each type of guarantee:

Guarantees at September 30, 2020	Final Expiration Year	Maximum Future Payments
In millions
Obligations for customers 1:
Bank borrowings	2021	$	17
Obligations for non-consolidated affiliates 2:
Bank borrowings	2020	160
Total guarantees		$	177

1. Existing guarantees for select customers, as part of contractual agreements. The terms of the guarantees are equivalent to the terms of the customer loans that are primarily made to finance customer invoices. At September 30, 2020 all maximum future payments had terms less than a year.

2. Existing guarantees for non-consolidated affiliates' liquidity needs in normal operations.

XML

LEASES Schedule of Leases (Tables)

9 Months Ended

Sep. 30, 2020

Leases [Abstract]

Lease, Cost [Table Text Block]

The components of lease cost for operating leases were as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2020		2019		2020		2019
Operating lease costs	$	49	$	51	$	135	$	141

Schedule of Lease Assets and Liabilities [Table Text Block]

Supplemental balance sheet information related to leases was as follows:

In millions	September 30, 2020		December 31, 2019
Operating Leases
Operating lease right-of-use assets 1	$	621	$	556
Current operating lease liabilities 2	159		138
Noncurrent operating lease liabilities 3	465		416
Total operating lease liabilities	$	624	$	554

1.Included in "Deferred charges and other assets" in the interim Condensed Consolidated Balance Sheet.

2.Included in "Accrued and other current liabilities" in the interim Condensed Consolidated Balance Sheet.

3.Included in "Other noncurrent obligations" in the interim Condensed Consolidated Balance Sheet.

XML

STOCKHOLDERS' EQUITY (Tables)

9 Months Ended

Sep. 30, 2020

Equity [Abstract]

Schedule of Components of Other Comprehensive Income (Loss)

The following table summarizes the activity related to each component of accumulated other comprehensive loss ("AOCL") for the nine months ended September 30, 2020 and 2019:

Accumulated Other Comprehensive Loss	Unrealized Gains (Losses) on Investments		Cumulative Translation Adj		Pension and OPEB		Derivative Instruments		Total
In millions
2019
Balance at January 1, 2019	$	(51)	$	(3,785)	$	(8,476)	$	(82)	$	(12,394)
Other comprehensive income (loss) before reclassifications	68		(811)		47		(43)		(739)
Amounts reclassified from accumulated other comprehensive income (loss)	(1)		(18)		140		(15)		106
Net other comprehensive income (loss)	$	67	$	(829)	$	187	$	(58)	$	(633)
Spin-offs of Dow and Corteva	$	(16)	$	3,179	$	8,196	$	139	$	11,498
Balance at September 30, 2019	$	—	$	(1,435)	$	(93)	$	(1)	$	(1,529)
2020
Balance at January 1, 2020	$	—	$	(1,070)	$	(345)	$	(1)	$	(1,416)
Other comprehensive income (loss) before reclassifications	—		548		(9)		—		539
Amounts reclassified from accumulated other comprehensive income	—		—		18		—		18
Net other comprehensive income	$	—	$	548	$	9	$	—	$	557
Balance at September 30, 2020	$	—	$	(522)	$	(336)	$	(1)	$	(859)

The tax effects on the net activity related to each component of other comprehensive income (loss) for the three and nine months ended September 30, 2020 and 2019 were as follows:

Tax Benefit (Expense)	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2020		2019		2020		2019
Unrealized gains (losses) on investments	$	—	$	—	$	—	$	(18)
Cumulative translation adjustments	—		—		—		(1)
Pension and other post-employment benefit plans	1		(6)		3		(41)
Derivative instruments	—		—		—		16
Tax expense from income taxes related to other comprehensive income items	$	1	$	(6)	$	3	$	(44)

Schedule of Reclassifications Out of Accumulated Other Comprehensive Income

Reclassifications Out of Accumulated Other Comprehensive Loss	Three Months Ended September 30,				Nine Months Ended September 30,				Income Classification
In millions	2020		2019		2020		2019
Unrealized gains on investments	$	—	$	—	$	—	$	(1)	See (1) below
Tax expense (benefit)	—		—		—		—		See (2) below
After tax	$	—	$	—	$	—	$	(1)
Cumulative translation adjustments	$	—	$	—	$	—	$	(18)	See (3) below
Pension and other post-employment benefit plans	$	7	$	4	$	15	$	171	See (4) below
Tax expense (benefit)	2		(6)		3		(31)		See (2) below
After tax	$	9	$	(2)	$	18	$	140
Derivative Instruments	$	—	$	—	$	—	$	(18)	See (5) below
Tax expense	—		—		—		3		See (2) below
After tax	$	—	$	—	$	—	$	(15)
Total reclassifications for the period, after tax	$	9	$	(2)	$	18	$	106

1. "Net sales" and "Sundry income (expense) - net."

2. "Provision for income taxes on continuing operations."

3. "Sundry income (expense) - net."

4. These AOCL components are included in the computation of net periodic benefit cost of the Company's defined benefit pension and other post-employment benefit plans. See Note 17 for additional information.

5. "Cost of sales," "Sundry income (expense) - net" and "Interest expense."

XML

NONCONTROLLING INTERESTS (Tables)

9 Months Ended

Sep. 30, 2020

Noncontrolling Interest [Abstract]

Schedule Of Noncontrolling Interest

The following table summarizes the activity for equity attributable to noncontrolling interests for the three and nine months ended September 30, 2020 and 2019:

Noncontrolling Interests	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2020		2019		2020		2019
Balance at beginning of period	$	572	$	570	$	569	$	1,608
Net income attributable to noncontrolling interests	7		5		20		90
Distributions to noncontrolling interests	(38)		(6)		(48)		(18)
Cumulative translation adjustments	4		(2)		(1)		14
Spin-off of Dow and Corteva	—		—		—		(1,124)
Other	14		1		19		(2)
Balance at end of period	$	559	$	568	$	559	$	568

XML

FINANCIAL INSTRUMENTS (Tables)

9 Months Ended

Sep. 30, 2020

Investments, All Other Investments [Abstract]

Schedule of the fair value of financial instruments

The following table summarizes the fair value of financial instruments at September 30, 2020 and December 31, 2019:

Fair Value of Financial Instruments	September 30, 2020								December 31, 2019
In millions	Cost		Gain		Loss		Fair Value		Cost		Gain		Loss		Fair Value
Cash equivalents	$	2,534	$	—	$	—	$	2,534	$	417	$	—	$	—	$	417
Restricted cash equivalents 1	$	6,232	$	—	$	—	$	6,232	$	37	$	—	$	—	$	37
Total cash and restricted cash equivalents	$	8,766	$	—	$	—	$	8,766	$	454	$	—	$	—	$	454
Long-term debt including debt due within one year	$	(23,806)	$	2	$	(2,375)	$	(26,179)	$	(15,618)	$	—	$	(1,633)	$	(17,251)
Derivatives relating to:
Foreign currency 2	—		4		(6)		(2)		—		6		(7)		(1)
Total derivatives	$	—	$	4	$	(6)	$	(2)	$	—	$	6	$	(7)	$	(1)

1.Includes $26 million of restricted cash classified as "Other current assets" and $6.2 billion classified as "Restricted cash" in the interim Condensed Consolidated Balance Sheets. Refer to Note 6 for further information.

2.Presented net of cash collateral where master netting arrangements allow.

Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]

Notional Amounts	September 30, 2020		December 31, 2019
In millions
Derivatives not designated as hedging instruments:
Foreign currency contracts 1	$	(299)	$	26
Commodity contracts	$	8	$	11

1.Presented net of contracts bought and sold.

Schedule of fair value of derivative instruments using Level 2 inputs

		September 30, 2020
In millions	Balance Sheet Classification	Gross		Counterparty and Cash Collateral Netting 1		Net Amounts Included in the Consolidated Balance Sheet
Asset derivatives:
Derivatives not designated as hedging instruments:
Foreign currency contracts	Other current assets	$	20	$	(16)	$	4
Total asset derivatives		$	20	$	(16)	$	4
Liability derivatives:
Derivatives not designated as hedging instruments:
Foreign currency contracts	Accrued and other current liabilities	$	22	$	(16)	$	6
Total liability derivatives		$	22	$	(16)	$	6

		December 31, 2019
In millions	Balance Sheet Classification	Gross		Counterparty and Cash Collateral Netting 1		Net Amounts Included in the Consolidated Balance Sheet
Asset derivatives:
Derivatives not designated as hedging instruments:
Foreign currency contracts	Other current assets	$	16	$	(10)	$	6
Total asset derivatives		$	16	$	(10)	$	6
Liability derivatives:
Derivatives not designated as hedging instruments:
Foreign currency contracts	Accrued and other current liabilities	$	17	$	(10)	$	7
Total liability derivatives		$	17	$	(10)	$	7

1.Counterparty and cash collateral amounts represent the estimated net settlement amount when applying netting and set-off rights included in master netting arrangements between the Company and its counterparties and the payable or receivable for cash collateral held or placed with the same counterparty.

XML

FAIR VALUE MEASUREMENTS (Tables)

9 Months Ended

Sep. 30, 2020

Fair Value Disclosures [Abstract]

Schedule of the fair value of assets and liabilities measured on a recurring basis

The following tables summarize the basis used to measure certain assets and liabilities at fair value on a recurring basis:

Basis of Fair Value Measurements on a Recurring Basis at September 30, 2020	Significant Other Observable Inputs (Level 2)
In millions
Assets at fair value:
Cash equivalents and restricted cash equivalents 1	$	8,766
Derivatives relating to: 2
Foreign currency contracts	20
Total assets at fair value	$	8,786
Liabilities at fair value:
Long-term debt including debt due within one year 3	$	26,179
Derivatives relating to: 2
Foreign currency contracts	22
Total liabilities at fair value	$	26,201

1.Treasury bills, time deposits, and money market funds included in "Cash and cash equivalents" and money market funds included in "Other current assets" and "Restricted cash" in the interim Condensed Consolidated Balance Sheets and held at amortized cost, which approximates fair value.

2. See Note 19 for the classification of derivatives in the interim Condensed Consolidated Balance Sheets.

3. Fair value is based on quoted market prices for the same or similar issues, or on current rates offered to the company for debt of the same remaining maturities and terms.

Basis of Fair Value Measurements on a Recurring Basis at December 31, 2019	Significant Other Observable Inputs (Level 2)
In millions
Assets at fair value:
Cash equivalents and restricted cash equivalents 1	$	454
Derivatives relating to: 2
Foreign currency contracts	16
Total assets at fair value	$	470
Liabilities at fair value:
Long-term debt including debt due within one year 3	$	17,251
Derivatives relating to: 2
Foreign currency contracts	17
Total liabilities at fair value	$	17,268

1. Treasury bills, time deposits, and money market funds included in "Cash and cash equivalents" and money market funds included in "Other current assets" in the interim Condensed Consolidated Balance Sheets and held at amortized cost, which approximates fair value.

2. See Note 19 for the classification of derivatives in the interim Condensed Consolidated Balance Sheets.

3. Fair value is based on quoted market prices for the same or similar issues, or on current rates offered to the company for debt of the same remaining maturities and terms.

XML

SEGMENTS AND GEOGRAPHIC REGIONS (Tables)

9 Months Ended

Sep. 30, 2020

Segment Reporting Information [Line Items]

Schedule of Operating Segment Information

Segment Information	Elect. & Imaging		Nutrition & Biosciences		Transp. & Industrial		Safety & Const.		Non-Core		Corp.		Total
In millions
Three months ended September 30, 2020
Net sales	$	1,004	$	1,467	$	1,045	$	1,249	$	331	$	—	$	5,096
Operating EBITDA 1	$	357	$	379	$	242	$	324	$	14	$	(16)	$	1,300
Equity in earnings of nonconsolidated affiliates	$	8	$	1	$	1	$	7	$	13	$	—	$	30
Three months ended September 30, 2019
Net sales	$	934	$	1,525	$	1,209	$	1,327	$	431	$	—	$	5,426
Operating EBITDA 1	$	320	$	354	$	306	$	352	$	94	$	(25)	$	1,401
Equity in earnings of nonconsolidated affiliates 2	$	10	$	—	$	1	$	7	$	26	$	—	$	44
Nine months ended September 30, 2020
Net sales	$	2,793	$	4,557	$	3,021	$	3,769	$	1,005	$	—	$	15,145
Operating EBITDA 1	$	887	$	1,182	$	599	$	1,041	$	149	$	(102)	$	3,756
Equity in earnings of nonconsolidated affiliates	$	27	$	2	$	3	$	19	$	121	$	—	$	172
Nine months ended September 30, 2019
Net sales	$	2,617	$	4,618	$	3,795	$	3,951	$	1,327	$	—	$	16,308
Pro forma operating EBITDA 1	$	854	$	1,089	$	1,036	$	1,108	$	296	$	(130)	$	4,253
Equity in earnings of nonconsolidated affiliates 2	$	18	$	—	$	3	$	22	$	92	$	—	$	135

Reconciliation of Income from Continuing Operations, net of tax to Operating EBITDA

Reconciliation of "Income (loss) from continuing operations, net of tax" to Operating EBITDA for the Three Months Ended September 30, 2020 and 2019	Three Months Ended September 30,
In millions	2020		2019
Loss (income) from continuing operations, net of tax	$	(72)	$	372
+ Provision for income taxes on continuing operations	92		78
Income from continuing operations before income taxes	$	20	$	450
+ Depreciation and amortization	780		499
- Interest income 1	3		1
+ Interest expense 2	165		177
- Non-operating pension/OPEB benefit 1	5		21
- Foreign exchange losses, net 1	(10)		(23)
- Significant items 3	(333)		(274)
Operating EBITDA	$	1,300	$	1,401

1. Included in "Sundry income (expense) - net."

2. The three months ended September 30, 2020 excludes N&B financing activity. Refer to details of significant items below.

3. The significant items for the three months ended September 30, 2020 and 2019 are presented on an as reported basis.

Reconciliation of "Income (loss) from continuing operations, net of tax" to Operating EBITDA for the Nine Months Ended September 30, 2020 and 2019	Nine Months Ended September 30,
In millions	2020		2019
Loss from continuing operations, net of tax	$	(3,153)	$	(805)
+ Provision for income taxes on continuing operations	100		142
Loss from continuing operations before income taxes	$	(3,053)	$	(663)
+ Pro forma adjustments 1	—		122
+ Depreciation and amortization	2,326		1,533
- Interest income 2	7		50
+ Interest expense 3	519		522
- Non-operating pension/OPEB benefit 2	24		60
- Foreign exchange losses, net 2	(41)		(101)
+ Costs historically allocated to the materials science and agriculture businesses 4	—		256
- Significant items 5	(3,954)		(2,492)
Operating EBITDA 1	$	3,756	$	4,253

1. For the nine months ended September 30, 2019, operating EBITDA is on a pro forma basis. The pro forma adjustment reflects the net pro forma impact of items directly attributable to the Transactions, as applicable.

2. Included in "Sundry income (expense) - net."

3. The nine months ended September 30, 2020 excludes N&B financing activity. Refer to details of significant items below.

4. Costs previously allocated to the materials science and agriculture businesses that did not meet the definition of expenses related to discontinued operations in accordance with ASC 205.

5. The significant items for the nine months ended September 30, 2020 are presented on an as reported basis. The significant items for the nine months ended September 30, 2019 are presented on a pro forma basis.

Schedule of Certain Items by Segment

The following tables summarize the pre-tax impact of significant items by segment that are excluded from Operating EBITDA and pro forma Operating EBITDA above:

Significant Items by Segment for the Three Months Ended September 30, 2020	Elect. & Imaging		Nutrition & Biosciences		Transp. & Industrial		Safety & Construction		Non-Core		Corporate		Total
In millions
Integration and separation costs 1	$	—	$	—	$	—	$	—	$	—	$	(127)	$	(127)
Restructuring and asset related credits (charges) - net 2	(1)		(5)		—		(2)		(1)		(5)		(14)
Goodwill impairment charges 3	—		—		—		—		(183)		—		(183)
Asset impairment charges 3, 4	—		—		—		—		(370)		—		(370)
Gain on divestitures 5	—		—		—		—		393		—		393
N&B financing activity - net 6	—		—		—		—		—		(32)		(32)
Total	$	(1)	$	(5)	$	—	$	(2)	$	(161)	$	(164)	$	(333)

1. Integration and separation costs related to the post-DWDP Merger integration and the intended separation of the N&B Business.

2. Includes Board approved restructuring plans and asset related charges. See Note 5 for additional information.

3. Refer to Note 11 for additional information.

4. Refer to Note 5 for additional information.

5. Refer to Note 3 for additional information.

6. Represents interest expense, net related to the N&B Notes as well as the financing fee amortization related to the intended separation of the N&B Business.

Significant Items by Segment for the Three Months Ended September 30, 2019	Elect. & Imaging		Nutrition & Biosciences		Transp. & Industrial		Safety & Construction		Non-Core		Corporate		Total
In millions
Integration and separation costs 1	$	—	$	—	$	—	$	—	$	—	$	(191)	$	(191)
Restructuring and asset related charges - net 2	(35)		(7)		(6)		(5)		(2)		(28)		(83)
Total	$	(35)	$	(7)	$	(6)	$	(5)	$	(2)	$	(219)	$	(274)

1.Integration and separation costs related to post-DWDP Merger integration and business separation activities.

2. Includes Board approved restructuring plans and asset related charges. See Note 5 for additional information.

Significant Items by Segment for the Nine Months Ended September 30, 2020	Elect. & Imaging		Nutrition & Biosciences		Transp. & Industrial		Safety & Construction		Non-Core		Corporate		Total
In millions
Integration and separation costs 1	$	—	$	—	$	—	$	—	$	—	$	(469)	$	(469)
Restructuring and asset related charges - net 2	(2)		(9)		(15)		(15)		(1)		(104)		(146)
Goodwill impairment charges 3	—		—		(2,498)		—		(716)		—		(3,214)
Asset impairment charges 3, 4	—		—		(21)		—		(640)		—		(661)
Gain on divestitures 5	197		—		—		—		393		—		590
N&B financing activity - net 6	—		—		—		—		—		(54)		(54)
Total	$	195	$	(9)	$	(2,534)	$	(15)	$	(964)	$	(627)	$	(3,954)

1. Integration and separation costs related to the post-DWDP Merger integration and the intended separation of the N&B Business.

2. Includes Board approved restructuring plans and asset related charges. See Note 5 for additional information.

3. Refer to Note 11 for additional information.

4. Refer to Note 5 for additional information.

5. Refer to Note 3 for additional information.

6. Represents interest expense, net related to the N&B Notes as well as the financing fee amortization related to the intended separation of the N&B Business.

Significant Items by Segment for the Nine Months Ended September 30, 2019 (Pro Forma)	Elect. & Imaging		Nutrition & Biosciences		Transp. & Industrial		Safety & Construction		Non-Core		Corporate		Total
In millions
Integration and separation costs 1	$	—	$	—	$	—	$	—	$	—	$	(976)	$	(976)
Restructuring and asset related charges - net 2	(42)		(56)		(18)		(27)		(2)		(85)		(230)
Goodwill impairment charges 3	—		(933)		—		—		(242)		—		(1,175)
Asset impairment charges 4	—		(63)		—		—		—		—		(63)
Income tax relates item 5	—		—		—		(48)		—		—		(48)
Total	$	(42)	$	(1,052)	$	(18)	$	(75)	$	(244)	$	(1,061)	$	(2,492)

1.Integration and separation costs related to the DWDP Merger, post-DWDP Merger integration and business separation activities.

2. Includes Board approved restructuring plans and asset related charges. See Note 5 for additional information.

3. Refer to Note 11 for additional information.

4. Refer to Note 5 for additional information.

5. Charge included in "Sundry income (expense) - net" which reflects a reduction in gross proceeds from lower withholding taxes related to a prior year legal settlement.

XML

DIVESTITURES Material Sciences Components of Income (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income from discontinued operations, net of tax		$ 0	$ 5	$ 0	$ 1,217
Income (Loss) from Discontinued Operations, Attributable to Noncontrolling Interests, Net of Tax		$ 0	0	$ 0	72
Materials Science Division [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net Sales, Discontinued Operation					10,867
Cost of Sales, Discontinued Operations					8,917
Research and Development Expense, Discontinued Operations					163
Selling, General and Administrative Expense, Discontinued Operations					329
Amortization of Intangibles, Discontinued Operations					116
Restructuring and Asset Related Charges - Net, Discontinued Operations					157
Integration and Separation Costs, Discontinued Operations					44
Equity in Earnings on Nonconsolidated Affiliates, Discontinued Operations					(13)
Sundry Income (expense), Discontinued Operations	[1]				17
Interest Expense, Discontinued Operations					240
Income (Loss) from Discontinued Operation, before Income Tax					905
Provision for Income Taxes on Discontinued Operations	[1]				176
Income from discontinued operations, net of tax					729
Income (Loss) from Discontinued Operations, Attributable to Noncontrolling Interests, Net of Tax					37
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent					692
Materials Science Division [Member] | Sundry income (expense) - net
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income Tax Credits and Adjustments			82		82
Materials Science Division [Member] | Provision for income taxes on discontinued operations [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income Tax Credits and Adjustments			$ 85		$ 85

[1] The three and nine months ended September 30, 2019 includes $82 million of expense in "Sundry income (expense) - net" and a benefit of $85 million in "Provision for income taxes on discontinued operations" related to certain unrecognized tax benefits for positions taken on items from prior years.

XML

DIVESTITURES Materials Science Components of Cash Flows & Other (Details) - USD ($) $ in Millions		9 Months Ended
	Apr. 01, 2019	Sep. 30, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Contributions to Dow	$ 2,024
Materials Science Division [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Depreciation and Amortization		$ 744
Capital Expenditure, Discontinued Operations		$ 597

XML

DIVESTITURES Agriculture Division Components of Income (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income from discontinued operations, net of tax		$ 0	$ 5	$ 0	$ 1,217
Income (Loss) from Discontinued Operations, Attributable to Noncontrolling Interests, Net of Tax		$ 0	0	$ 0	72
Agriculture Division [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net Sales, Discontinued Operation					7,144
Cost of Sales, Discontinued Operations					4,218
Research and Development Expense, Discontinued Operations					470
Selling, General and Administrative Expense, Discontinued Operations					1,294
Amortization of Intangibles, Discontinued Operations					176
Restructuring and Asset Related Charges - Net, Discontinued Operations					117
Integration and Separation Costs, Discontinued Operations					430
Equity in Earnings on Nonconsolidated Affiliates, Discontinued Operations					(4)
Sundry Income (expense), Discontinued Operations	[1]				52
Interest Expense, Discontinued Operations					91
Income (Loss) from Discontinued Operation, before Income Tax					396
Provision for Income Taxes on Discontinued Operations	[1]				74
Income from discontinued operations, net of tax					322
Income (Loss) from Discontinued Operations, Attributable to Noncontrolling Interests, Net of Tax					35
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent					287
Agriculture Division [Member] | Sundry income (expense) - net
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income Tax Credits and Adjustments			6		6
Agriculture Division [Member] | Provision for income taxes on discontinued operations [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income Tax Credits and Adjustments			$ 8		$ 8

[1] The three and nine months ended September 30, 2019 includes $6 million of expense in "Sundry income (expense) - net" and a benefit of $8 million in "Provision for income taxes on discontinued operations" related to certain unrecognized tax benefits for positions taken on items from prior years.

XML

DIVESTITURES Agriculture Division Components of Cash Flows & Other (Details) - USD ($) $ in Millions		9 Months Ended
	Jun. 01, 2019	Sep. 30, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Contribution to Corteva	$ 7,139
Agriculture Division [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Depreciation and Amortization		$ 385
Capital Expenditure, Discontinued Operations		$ 383

XML

DIVESTITURES Non-Core HFS Balance Sheet (Details) - USD ($) $ in Millions	Sep. 30, 2020	Dec. 31, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Assets held for sale	$ 835	$ 0
Liabilities related to assets held for sale	127	$ 0
Non-Core Held for Sale Disposal Groups
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Accounts and Notes Receivable, Net	61
Inventories	96
Other Assets	40
Investments in nonconsolidated affiliates	166
Property, Plant and Equipment - net	32
Goodwill	267
Other intangible assets	169
Deferred charges and other assets	4
Assets held for sale	835
Accounts Payable	29
Income Taxes Payable	1
Accrued and other current liabilities	48
Deferred Income Tax Liabilities	30
Pensions and other post-employment benefits	1
Other noncurrent obligations	18
Liabilities related to assets held for sale	$ 127

XML

DIVESTITURES Non-Core HFS (Details) - USD ($) $ in Millions	3 Months Ended			9 Months Ended
	Sep. 30, 2020		Sep. 30, 2019	Sep. 30, 2020		Sep. 30, 2019	Oct. 08, 2020
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Goodwill impairment charges	$ 183	[1]	$ 0	$ 3,214	[2]	$ 1,175
Non-Core Held for Sale Disposal Groups | Non Core Segment [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Goodwill impairment charges	$ 25			$ 25
Non-Core Held for Sale Disposal Groups | Subsequent Event [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Consideration							$ 240

[1] Refer to Note 11 for additional information.

[2] Refer to Note 11 for additional information.

XML

DIVESTITURES Other Divestitures (Details) - USD ($) $ in Millions	3 Months Ended			9 Months Ended
	Sep. 30, 2020		Sep. 30, 2019	Sep. 30, 2020		Sep. 30, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Integration and separation costs	$ 127		$ 191	$ 469		$ 1,149
Gain (Loss) on Disposition of Business	393	[1]		590	[2]
Income from discontinued operations, net of tax	0		5	0		1,217
Electronics & Imaging
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from Divestiture of Businesses				420
Gain (Loss) on Disposition of Business				197
Gain (Loss) on Disposition of Business, Net of Tax				102
Non Core Segment [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain (Loss) on Disposition of Business			28			28
Gain (Loss) on Disposition of Business, Net of Tax			$ 22			22
Non-core
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from Divestiture of Businesses				550
Gain (Loss) on Disposition of Business	393			393
Gain (Loss) on Disposition of Business, Net of Tax	$ 232			232
Proceeds from supply agreement settlement				$ 175
Historical EID
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income from discontinued operations, net of tax						86
Historical EID Crop Protection and R&D [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income from discontinued operations, net of tax						$ 80

[1] Refer to Note 3 for additional information.

[2] Refer to Note 3 for additional information.

XML

REVENUE (Details) - USD ($) $ in Millions		3 Months Ended			9 Months Ended
		Sep. 30, 2020		Sep. 30, 2019	Sep. 30, 2020		Sep. 30, 2019	Dec. 31, 2019
Net sales		$ 5,096		$ 5,426	$ 15,145		$ 16,308
Revenue recognized which was deferred at the beginning of the period					25		28
Accounts and notes receivable - Trade	[1]	2,938			2,938			$ 3,007
Contract assets - current	[2]	0			0			35
Deferred revenue - current	[3]	18			18			20
Deferred revenue - noncurrent	[4]	25			25			$ 24
Image Solutions
Net sales		172		167	491		507
Interconnect Solutions
Net sales		370		339	910		859
Semiconductor Technologies
Net sales		462		428	1,392		1,251
Food & Beverage
Net sales		686		736	2,163		2,237
Health & Biosciences
Net sales		570		582	1,754		1,756
Pharma Solutions
Net sales		211		207	640		625
Healthcare & Specialty
Net sales		352		376	1,002		1,148
Industrial & Consumer
Net sales		233		274	680		875
Mobility Solutions
Net sales		460		559	1,339		1,772
Safety Solutions
Net sales		534		630	1,746		1,952
Shelter Solutions
Net sales		387		411	1,051		1,166
Water Solutions
Net sales		328		286	972		833
Biomaterials
Net sales		37		54	98		166
Clean Technologies
Net sales		48		78	175		219
DuPont Teijin Films
Net sales		47		48	124		127
Photovoltaic & Advanced Materials
Net sales		199		223	608		707
Sustainable Solutions
Net sales		0	[5]	28	0	[5]	108
Electronics & Imaging
Net sales		1,004		934	2,793		2,617
Nutrition & Biosciences
Net sales		1,467		1,525	4,557		4,618
Transportation & Industrial
Net sales		1,045		1,209	3,021		3,795
Safety & Construction
Net sales		1,249		1,327	3,769		3,951
Non-core
Net sales		331		431	1,005		1,327
U.S. & Canada
Net sales		1,620		1,822	4,875		5,424
EMEA
Net sales	[6]	1,069		1,227	3,405		3,898
Asia Pacific
Net sales		2,120		2,057	6,045		6,036
Latin America
Net sales		$ 287		$ 320	$ 820		$ 950

[1] Included in "Accounts and notes receivable - net" in the interim Condensed Consolidated Balance Sheets.

[2] Included in "Other current assets" in the interim Condensed Consolidated Balance Sheets.

[3] Included in "Accrued and other current liabilities" in the interim Condensed Consolidated Balance Sheets.

[4] Included in "Other noncurrent obligations" in the interim Condensed Consolidated Balance Sheets.

[5] The Sustainable Solutions business was divested in the third quarter of 2019

[6] Europe, Middle East and Africa.

XML

RESTRUCTURING AND ASSET RELATED CHARGES - NET (Details) - USD ($) $ in Millions	3 Months Ended			9 Months Ended
	Sep. 30, 2020		Sep. 30, 2019	Sep. 30, 2020		Sep. 30, 2019	Dec. 31, 2019
Restructuring Cost and Reserve [Line Items]
Restructuring and asset related charges	$ 384		$ 82	$ 807		$ 290
Restructuring Reserve	127			127			$ 162
Asset Impairment Charges	370	[1],[2]		661	[3],[4]
Transportation & Industrial
Restructuring Cost and Reserve [Line Items]
Asset Impairment Charges				21
Asset impairment charges, net of tax				16
Non-core
Restructuring Cost and Reserve [Line Items]
Asset Impairment Charges	370			640
Equity Method Investments [Member] | Nutrition & Biosciences
Restructuring Cost and Reserve [Line Items]
Asset Impairment Charges						63
Asset impairment charges, net of tax						$ 47
Indefinite-lived Intangible Assets [Member] | Non-core
Restructuring Cost and Reserve [Line Items]
Asset Impairment Charges	52			52
Asset impairment charges, net of tax	39			39
Finite-Lived Intangible Assets and Property, Plant, and Equipment [Member] | Non-core
Restructuring Cost and Reserve [Line Items]
Asset Impairment Charges	318			318
Asset impairment charges, net of tax	$ 242			242
Finite-Lived Intangible Assets and Property, Plant, and Equipment [Member] | Non-core | Biomaterials
Restructuring Cost and Reserve [Line Items]
Asset Impairment Charges				270
Asset impairment charges, net of tax				$ 206

[1] Refer to Note 11 for additional information.

[2] Refer to Note 5 for additional information.

[3] Refer to Note 11 for additional information.

[4] Refer to Note 5 for additional information.

XML

RESTRUCTURING AND ASSET RELATED CHARGES - NET 2020 Restructuring Program (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2020	Dec. 31, 2019
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	$ 127	$ 127	$ 162
2020 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	14	140
Charges against reserve		(28)
Cash Payments for Restructuring		(42)
Restructuring Reserve	70	70
Employee Severance [Member] | 2020 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	10	112
Cash Payments for Restructuring		(42)
Restructuring Reserve	70	70
Asset Related Charges And Other [Member] | 2020 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	4	28
Charges against reserve		(28)
Electronics & Imaging | 2020 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	1	5
Nutrition & Biosciences | 2020 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	5	12
Transportation & Industrial | 2020 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges		21
Safety & Construction | 2020 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	2	24
Non-core | 2020 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	1	1
Corporate | 2020 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	5	77
Accrued and other current liabilities | 2020 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	$ 70	$ 70

XML

RESTRUCTURING AND ASSET RELATED CHARGES - NET 2019 Restructuring Program (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		18 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Dec. 31, 2019
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	$ 127		$ 127		$ 127	$ 162
2019 Restructuring Program [Domain]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	0	$ 69	2	$ 122	140
2019 Restructuring Program [Domain] | Accrued and other current liabilities
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	27		27		27	86
2019 Restructuring Program [Domain] | Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges		48	2	98	106
Non-cash compensation			(6)
Cash Payments for Restructuring			(55)
Restructuring Reserve	$ 27		27		27	$ 86
2019 Restructuring Program [Domain] | Asset Related Charges And Other [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges		21		24	$ 34
2019 Restructuring Program [Domain] | Electronics & Imaging
Restructuring Cost and Reserve [Line Items]
Restructuring Charges		35	(3)	42
2019 Restructuring Program [Domain] | Nutrition & Biosciences
Restructuring Cost and Reserve [Line Items]
Restructuring Charges		4	(3)	18
2019 Restructuring Program [Domain] | Transportation & Industrial
Restructuring Cost and Reserve [Line Items]
Restructuring Charges		6	(7)	18
2019 Restructuring Program [Domain] | Safety & Construction
Restructuring Cost and Reserve [Line Items]
Restructuring Charges		3	(14)	20
2019 Restructuring Program [Domain] | Corporate
Restructuring Cost and Reserve [Line Items]
Restructuring Charges		18	$ 29	21
2019 Restructuring Program [Domain] | Non-core
Restructuring Cost and Reserve [Line Items]
Restructuring Charges		$ 3		$ 3

XML

RESTRUCTURING AND ASSET RELATED CHARGES - NET DowDuPont Cost Synergy Program (Details) - USD ($) $ in Millions	3 Months Ended			9 Months Ended			37 Months Ended
	Sep. 30, 2020	Sep. 30, 2019		Sep. 30, 2020	Sep. 30, 2019		Sep. 30, 2020	Dec. 31, 2019
Restructuring Cost and Reserve [Line Items]
Restructuring and asset related charges	$ 384	$ 82		$ 807	$ 290
Restructuring Reserve	127			127			$ 127	$ 162
Non-core | Income (Loss) From Equity Method Investments [Domain]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges		1			3
DowDuPont Cost Synergy Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and asset related charges							489
Restructuring Reserve	30			30			30	76
Restructuring Charges	0	14	[1]	4	108	[1]
Charges against reserve				(1)
Cash Payments for Restructuring				(49)
DowDuPont Cost Synergy Program [Member] | Restructuring Settlement And Impairment Provisions [Domain]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges		13			105
DowDuPont Cost Synergy Program [Member] | Income (Loss) From Equity Method Investments [Domain]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges		1			3
DowDuPont Cost Synergy Program [Member] | Accrued and other current liabilities
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve								76
DowDuPont Cost Synergy Program [Member] | Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and asset related charges							213
Restructuring Reserve	25			25			25	74
Restructuring Charges				(2)	49
Cash Payments for Restructuring				(47)
DowDuPont Cost Synergy Program [Member] | Contract Termination [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and asset related charges							67
Restructuring Reserve	$ 5			5			5	$ 2
Restructuring Charges				6	16
Charges against reserve				(1)
Cash Payments for Restructuring				(2)
DowDuPont Cost Synergy Program [Member] | Asset Related Charges And Other [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and asset related charges							$ 209
Restructuring Charges		14			43
DowDuPont Cost Synergy Program [Member] | Nutrition & Biosciences
Restructuring Cost and Reserve [Line Items]
Restructuring Charges		3			38
DowDuPont Cost Synergy Program [Member] | Transportation & Industrial
Restructuring Cost and Reserve [Line Items]
Restructuring Charges				1
DowDuPont Cost Synergy Program [Member] | Safety & Construction
Restructuring Cost and Reserve [Line Items]
Restructuring Charges		2		5	7
DowDuPont Cost Synergy Program [Member] | Non-core
Restructuring Cost and Reserve [Line Items]
Restructuring Charges		(1)			(1)
DowDuPont Cost Synergy Program [Member] | Corporate
Restructuring Cost and Reserve [Line Items]
Restructuring Charges		$ 10		$ (2)	$ 64

[1] The charge for the three and nine months ended September 30, 2019 includes $13 million and $105 million which was recognized in "Restructuring and asset related charges - net" and $1 million and $3 million which was recognized in "Equity in earnings of nonconsolidated affiliates" in the interim Consolidated Statements of Operations.

XML

SUPPLEMENTARY INFORMATION - Summary of Sundry Income (Expense) - Net (Details) - USD ($) $ in Millions		3 Months Ended				9 Months Ended
		Sep. 30, 2020		Sep. 30, 2019		Sep. 30, 2020		Sep. 30, 2019
Schedule Of Sundry Income (Expense) [Line Items]
Non-operating pension and other post employment benefit (OPEB) credits		$ 5	[1]	$ 21		$ 24	[2]	$ 60
Interest income		3	[1]	1		7	[2]	50
Net (loss) gain on divestiture and sales of other assets and investments	[4]	419	[3]	64		612	[3]	127	[5]
Foreign exchange gains (losses), net		(10)	[1]	(23)		(41)	[2]	(101)
Miscellaneous Income (Expense), Net		13		16	[6]	25		8
Sundry income (expense) - net		430		79		627		144
Income Tax Related Items								48
Gain (Loss) on Disposition of Business		393	[7]			590	[8]
Electronics & Imaging
Schedule Of Sundry Income (Expense) [Line Items]
Net (loss) gain on divestiture and sales of other assets and investments		30		$ 34		30		85
Gain (Loss) on Disposition of Business						197
Non-core
Schedule Of Sundry Income (Expense) [Line Items]
Net (loss) gain on divestiture and sales of other assets and investments						393		28
Gain (Loss) on Disposition of Business		$ 393				$ 393
Safety & Construction
Schedule Of Sundry Income (Expense) [Line Items]
Proceeds from License Fees Received								$ 26

[1] Included in "Sundry income (expense) - net."

[2] Included in "Sundry income (expense) - net."

[3] The three and nine months ended September 30, 2020 includes a net benefit of $393 million related to the TCS/HSC Disposal, including the settlement of a supply agreement dispute, within the Non-Core segment. Refer to Note 3 for further information.

[4] The three and nine months ended September 30, 2020 includes income of $30 million related to a prior year sale of assets within the Electronics & Imaging segment. The three and nine months ended September 30, 2019 includes income of $34 million and $85 million, respectively, related to a sale of assets within the Electronics & Imaging segment, as well as a gain of $28 million related to the sale of the Sustainable Solutions business unit within the Non-Core segment.

[5] The nine months ended September 30, 2020 includes income of $197 million related to the gain on sale of the Compound Semiconductor Solutions business unit within the Electronics & Imaging segment.

[6] Miscellaneous income (expenses) - net for the nine months ended September 30, 2019 includes a $48 million charge reflecting a reduction in gross proceeds from lower withholding taxes related to a prior year settlement. The nine months ended September 30, 2019 also includes $26 million related to licensing income within the Safety & Construction segment

[7] Refer to Note 3 for additional information.

[8] Refer to Note 3 for additional information.

XML

SUPPLEMENTARY INFORMATION - Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2020	Sep. 16, 2020	Jan. 17, 2020	Dec. 31, 2019
Supplementary Information
Restricted cash and cash equivalents	$ 26			$ 37
Accrued and other current liabilities	1,364			1,342
Employee-related Liabilities	$ 431			479
Debt Instrument, Redemption Price, Percentage	101.00%
Restricted cash	$ 6,206			0
Special Cash Payment	7,300
N&B Bridge Loan [Member]
Supplementary Information
N&B Notes Offering	$ 6,250	$ 0	$ 6,250	$ 7,500

XML

INCOME TAXES Effective Income Tax Rate (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Tax Contingency [Line Items]
Effective Income Tax Rate Reconciliation, Percent	460.00%	17.30%	(3.30%)	(21.40%)

XML

EARNINGS PER SHARE CALCULATIONS - Summary of Net Income for EPS Calculations, Basic (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Earnings Per Share [Abstract]
(Loss) income from continuing operations, net of tax		$ (72)	$ 372	$ (3,153)	$ (805)
Net income from continuing operations attributable to noncontrolling interests		7	5	20	18
Net income from continuing operations attributable to participating securities	[1]	0	0	0	(1)
(Loss) income from continuing operations attributable to common stockholders		(79)	367	(3,173)	(824)
Income from discontinued operations, net of tax		0	5	0	1,217
Net income from discontinued operations attributable to noncontrolling interests		0	0	0	(72)
Income from discontinued operations attributable to common stockholders		0	5	0	1,145
Net (loss) income attributable to common stockholders		$ (79)	$ 372	$ (3,173)	$ 321

[1] Historical Dow restricted stock units are considered participating securities due to Historical Dow's practice of paying dividend equivalents on unvested shares.

XML

EARNINGS PER SHARE CALCULATIONS - Summary of EPS Calculations, Basic (Details) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Earnings Per Share [Abstract]
(Loss) earnings from continuing operations attributable to common stockholders	$ (0.11)	$ 0.49	$ (4.31)	$ (1.10)
Income from discontinued operations, net of tax	0	0.01	0	1.53
Net (loss) earnings attributable to common stockholders	$ (0.11)	$ 0.50	$ (4.31)	$ 0.43

XML

EARNINGS PER SHARE CALCULATIONS - Summary of EPS Calculations, Diluted (Details) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Earnings Per Share [Abstract]
(Loss) earnings from continuing operations attributable to common stockholders	$ (0.11)	$ 0.49	$ (4.31)	$ (1.10)
Income from discontinued operations, net of tax	0	0.01	0	1.53
Net (loss) earnings attributable to common stockholders	$ (0.11)	$ 0.50	$ (4.31)	$ 0.43

XML

EARNINGS PER SHARE CALCULATIONS - Summary of Count Information (Details) - $ / shares shares in Millions		3 Months Ended		9 Months Ended
		Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Oct. 28, 2020	Dec. 31, 2019
Earnings Per Share [Abstract]
Par Value		$ 0.01		$ 0.01		$ 0.01	$ 0.01
Weighted-average common shares - basic		734.4	745.5	735.8	748.2
Plus dilutive effect of equity compensation plans		0.0	2.2	0.0	0.0
Weighted-average common shares - diluted		734.4	747.7	735.8	748.2
Stock options and restricted stock units excluded from EPS calculations	[1]	5.5	3.8	6.3	2.8

[1] These outstanding options to purchase shares of common stock and restricted stock units were excluded from the calculation of diluted earnings per share because the effect of including them would have been antidilutive.

XML

INVENTORIES (Summary of Inventory) (Details) - USD ($) $ in Millions	Sep. 30, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Finished goods	$ 2,407	$ 2,621
Work in process	803	855
Raw materials	465	599
Supplies	227	244
Total inventories	$ 3,902	$ 4,319

XML

NONCONSOLIDATED AFFILIATES - (Details) $ in Millions	Sep. 30, 2020 USD ($) entity	Dec. 31, 2019 USD ($)
Investments in and Advances to Affiliates [Line Items]
Investments in nonconsolidated affiliates	$ 951	$ 1,204
Accrued and other current liabilities	(74)	(85)
Other noncurrent obligations		(358)
Net of investment in nonconsolidated affiliates	$ 877	761
Equity Method Investment Ownership Interest Number Of Affiliates | entity	18
Schedule of Equity Method Investments [Line Items]
Other noncurrent obligations		(358)
Investments in nonconsolidated affiliates	$ 951	1,204
Hemlock Semiconductor L.L.C. [Member]
Investments in and Advances to Affiliates [Line Items]
Other noncurrent obligations		(358)
Schedule of Equity Method Investments [Line Items]
Other noncurrent obligations		(358)
DC HSC Holdings LLC [Member]
Investments in and Advances to Affiliates [Line Items]
Investments in nonconsolidated affiliates		87
Schedule of Equity Method Investments [Line Items]
Investments in nonconsolidated affiliates		$ 87

XML

NONCONSOLIDATED AFFILIATES - Sales to and Purchases from Nonconsolidated Affiliates (Details) - Equity Method Investee [Member]	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenue Benchmark [Member] | Customer Concentration Risk [Member]
Investments in and Advances to Affiliates [Line Items]
Concentration Risk, Percentage	2.00%	3.00%	2.00%	3.00%
Cost of Goods and Service Benchmark [Member] | Supplier Concentration Risk [Member]
Investments in and Advances to Affiliates [Line Items]
Concentration Risk, Percentage	2.00%	2.00%	2.00%	2.00%

XML

GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details) - USD ($) $ in Millions	3 Months Ended			9 Months Ended
	Sep. 30, 2020		Sep. 30, 2019	Sep. 30, 2020		Sep. 30, 2019	Dec. 31, 2019
Goodwill [Line Items]
Goodwill impairment charges	$ 183	[1]	$ 0	$ 3,214	[2]	$ 1,175
Indefinite-lived Intangible Assets [Line Items]
Asset Impairment Charges	370	[1],[3]		661	[2],[4]
Indefinite-lived Intangible Assets (Excluding Goodwill)	1,599			1,599			$ 1,671
Transportation & Industrial
Goodwill [Line Items]
Goodwill impairment charges				2,498
Indefinite-lived Intangible Assets [Line Items]
Asset Impairment Charges				21
Asset impairment charges, net of tax				16
Non-core
Goodwill [Line Items]
Goodwill impairment charges	183			716
Indefinite-lived Intangible Assets [Line Items]
Asset Impairment Charges	370			640
Non-core | Photovoltaic and Advanced Materials (“PVAM”) [Member]
Goodwill [Line Items]
Goodwill impairment charges				533
Non-core | Indefinite-lived Intangible Assets [Member]
Indefinite-lived Intangible Assets [Line Items]
Asset Impairment Charges	52			52
Asset impairment charges, net of tax	39			39
Trademarks and Trade Names [Member]
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived Intangible Assets (Excluding Goodwill)	1,599			1,599			$ 1,671
Trademarks and Trade Names [Member] | Transportation & Industrial
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived Intangible Assets (Excluding Goodwill)	$ 289			$ 289

[1] Refer to Note 11 for additional information.

[2] Refer to Note 11 for additional information.

[3] Refer to Note 5 for additional information.

[4] Refer to Note 5 for additional information.

XML

GOODWILL AND OTHER INTANGIBLE ASSETS - Summary of Goodwill (Details) - USD ($) $ in Millions		3 Months Ended			9 Months Ended
		Sep. 30, 2020		Sep. 30, 2019	Sep. 30, 2020		Sep. 30, 2019
Goodwill [Roll Forward]
Net goodwill, beginning of period					$ 33,151
Goodwill, Acquisitions					53
Goodwill, Written off Related to Sale of Business Unit					(713)
Goodwill impairment charges		$ (183)	[1]	$ 0	(3,214)	[2]	$ (1,175)
Currency Translation Adjustment					398
Goodwill, Measurement Period Adjustments					15
Net goodwill, end of period		29,690			29,690
Non-Core Held for Sale Disposal Groups
Goodwill [Roll Forward]
Non-Core Held for Sales Disposal Group, Goodwill		267			267
Electronics & Imaging
Goodwill [Roll Forward]
Net goodwill, beginning of period					7,092
Goodwill, Acquisitions					0
Goodwill, Written off Related to Sale of Business Unit					(199)
Goodwill impairment charges					0
Currency Translation Adjustment					41
Goodwill, Measurement Period Adjustments					0
Net goodwill, end of period		6,934			6,934
Nutrition & Biosciences
Goodwill [Roll Forward]
Net goodwill, beginning of period					11,012
Goodwill, Acquisitions					0
Goodwill, Written off Related to Sale of Business Unit					0
Goodwill impairment charges					0
Currency Translation Adjustment					206
Goodwill, Measurement Period Adjustments					0
Net goodwill, end of period		11,218			11,218
Transportation & Industrial
Goodwill [Roll Forward]
Net goodwill, beginning of period					6,931
Goodwill, Acquisitions					0
Goodwill, Written off Related to Sale of Business Unit					0
Goodwill impairment charges					(2,498)
Currency Translation Adjustment					67
Goodwill, Measurement Period Adjustments					0
Net goodwill, end of period		4,500			4,500
Safety & Construction
Goodwill [Roll Forward]
Net goodwill, beginning of period					6,711
Goodwill, Acquisitions					53
Goodwill, Written off Related to Sale of Business Unit					0
Goodwill impairment charges					0
Currency Translation Adjustment					84
Goodwill, Measurement Period Adjustments					15
Net goodwill, end of period		6,863			6,863
Non-core
Goodwill [Roll Forward]
Net goodwill, beginning of period					1,405
Goodwill, Acquisitions					0
Goodwill, Written off Related to Sale of Business Unit	[3]				(514)
Goodwill impairment charges		(183)			(716)
Currency Translation Adjustment					0
Goodwill, Measurement Period Adjustments					0
Net goodwill, end of period		$ 175			$ 175

[1] Refer to Note 11 for additional information.

[2] Refer to Note 11 for additional information.

[3] Includes $267 million of goodwill related to the Non-Core segment reclassified as held for sale in connection with the Non-Core Held for Sale Disposal Groups. Refer to Note 3 for further information.

XML

GOODWILL AND OTHER INTANGIBLE ASSETS - Summary of Other Intangible Assets (Details) - USD ($) $ in Millions	Sep. 30, 2020	Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Finite other intangible assets, gross carrying amount	$ 15,741	$ 16,065
Finite other intangible assets, accumulated amortization	(5,812)	(4,143)
Finite other intangible assets, net	9,929	11,922
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived Intangible Assets (Excluding Goodwill)	1,599	1,671
Intangible Assets, Gross (Excluding Goodwill)	17,340	17,736
Other intangible assets, net	11,528	13,593
Trademarks / tradenames
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived Intangible Assets (Excluding Goodwill)	1,599	1,671
Developed technology
Finite-Lived Intangible Assets [Line Items]
Finite other intangible assets, gross carrying amount	4,229	4,343
Finite other intangible assets, accumulated amortization	(1,705)	(1,361)
Finite other intangible assets, net	2,524	2,982
Trademarks / tradenames
Finite-Lived Intangible Assets [Line Items]
Finite other intangible assets, gross carrying amount	2,395	2,433
Finite other intangible assets, accumulated amortization	(1,378)	(455)
Finite other intangible assets, net	1,017	1,978
Customer-related
Finite-Lived Intangible Assets [Line Items]
Finite other intangible assets, gross carrying amount	8,942	8,986
Finite other intangible assets, accumulated amortization	(2,644)	(2,229)
Finite other intangible assets, net	6,298	6,757
Other Intangible Assets
Finite-Lived Intangible Assets [Line Items]
Finite other intangible assets, gross carrying amount	175	303
Finite other intangible assets, accumulated amortization	(85)	(98)
Finite other intangible assets, net	$ 90	$ 205

XML

GOODWILL AND OTHER INTANGIBLE ASSETS - Summary of Intangibles by Segment (Details) - USD ($) $ in Millions	Sep. 30, 2020	Dec. 31, 2019
Schedule of Intangible Assets [Line Items]
Other intangible assets	$ 11,528	$ 13,593
Electronics & Imaging
Schedule of Intangible Assets [Line Items]
Other intangible assets	1,686	1,833
Nutrition & Biosciences
Schedule of Intangible Assets [Line Items]
Other intangible assets	3,360	4,377
Transportation & Industrial
Schedule of Intangible Assets [Line Items]
Other intangible assets	3,429	3,590
Safety & Construction
Schedule of Intangible Assets [Line Items]
Other intangible assets	2,956	3,082
Non-core
Schedule of Intangible Assets [Line Items]
Other intangible assets	$ 97	$ 711

XML

SHORT TERM BORROWINGS, LONG-TERM DEBT AND AVAILABLE CREDIT FACILITIES Narrative (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2020	May 01, 2020	Sep. 30, 2019
Debt Instrument [Line Items]
Debt Instrument, Redemption Price, Percentage	101.00%
Senior unsecured notes due 2023 [Member]
Debt Instrument [Line Items]
Debt Instrument, Redemption Price, Percentage	100.00%
Senior floating rate note due 2020 [Member]
Debt Instrument [Line Items]
Senior Notes, Current	$ 500
Senior Fixed Rate Notes due 2020 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	3.77%
Senior Notes, Current	$ 1,500
Old 364-day Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity			$ 750
1B Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$ 1,000
Senior Notes [Member] | Senior unsecured notes due 2023 [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount		$ 2,000
Debt Instrument, Interest Rate, Stated Percentage		2.169%

XML

SHORT TERM BORROWINGS, LONG-TERM DEBT AND AVAILABLE CREDIT FACILITIES Nutrition & Biosciences Financing (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2020	Sep. 16, 2020	Jan. 17, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Restricted cash	$ 6,206			$ 0
Debt Instrument, Redemption Price, Percentage	101.00%
N&B Bridge Loan [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$ 6,250	$ 0	$ 6,250	$ 7,500
N&B senior unsecured term loan facility [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$ 1,250
N&B Senior Unsecured Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Redemption Price, Percentage	101.00%
N&B Senior Unsecured Notes [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount		$ 6,250
N&B Senior Unsecured Notes due 2022 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		0.697%
N&B Senior Unsecured Notes due 2022 [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount		$ 300
N&B Senior Unsecured Notes due 2025 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		1.23%
N&B Senior Unsecured Notes due 2025 [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount		$ 1,000
N&B Senior Unsecured Notes due 2027 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		1.832%
N&B Senior Unsecured Notes due 2027 [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount		$ 1,200
N&B Senior Unsecured Notes due 2030 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		2.30%
N&B Senior Unsecured Notes due 2030 [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount		$ 1,500
N&B Senior Unsecured Notes due 2040 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		3.268%
N&B Senior Unsecured Notes due 2040 [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount		$ 750
N&B Senior Unsecured Notes due 2050 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		3.468%
N&B Senior Unsecured Notes due 2050 [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount		$ 1,500

XML

COMMITMENTS AND CONTINGENT LIABILITIES - Narrative (Details) - USD ($) $ in Millions	Sep. 30, 2020	Dec. 31, 2019
Loss Contingencies [Line Items]
Estimated Litigation Liability	$ 23
Accrual for Environmental Loss Contingencies	79	$ 77
Accrual For Environmental Loss Contingencies, Potential Exposure In Excess Of Accrual	172
Non-PFAS Stray Liabilities Threshold	200
Indemnifiable Losses Threshold related to PFAS Stray Liabilities - Total	300
Indemnifiable Losses Threshold related to PFAS Stray Liabilities - Per Party	150
Retained and Assumed at Divestiture [Domain]
Loss Contingencies [Line Items]
Estimated Litigation Liability	2
Accrual for Environmental Loss Contingencies	37
Accrual For Environmental Loss Contingencies, Potential Exposure In Excess Of Accrual	108
Indemnification Agreement [Member] | Litigation and Environmental [Domain]
Loss Contingencies [Line Items]
Indemnification Liabilities	$ 58
DuPont and Corteva
Loss Contingencies [Line Items]
Percentage Split of PFAS Liabilities under the Separation Agreement	50.00%
DuPont
Loss Contingencies [Line Items]
Non-PFAS Stray Liabilities percent split after Threshold	71.00%
DuPont | Indemnification Agreement [Member]
Loss Contingencies [Line Items]
Accrual for Environmental Loss Contingencies	$ 42
DuPont | Corteva | Indemnification Agreement [Member]
Loss Contingencies [Line Items]
Accrual for Environmental Loss Contingencies	34
DuPont | Dow | Indemnification Agreement [Member]
Loss Contingencies [Line Items]
Accrual for Environmental Loss Contingencies	$ 8
Corteva
Loss Contingencies [Line Items]
Non-PFAS Stray Liabilities percent split after Threshold	29.00%

XML

COMMITMENTS AND CONTINGENT LIABILITIES - PFOA & Natural Resources (Details) $ in Millions	3 Months Ended	9 Months Ended
	Mar. 31, 2017 USD ($)	Sep. 30, 2020 USD ($)	Dec. 31, 2004 USD ($)
Firefighter Foam Cases [Domain] | Historical EID And Chemours
Loss Contingencies [Line Items]
Number of lawsuits		750
Chemours Suit [Member] | DuPont and Corteva
Loss Contingencies [Line Items]
Claim related to pending litigation		$ 3,910
PFOA Multi-District Litigation (MDL)
Loss Contingencies [Line Items]
Number of lawsuits		80
Abbott Case [Member]
Loss Contingencies [Line Items]
Litigation Settlement, Amount Awarded to Other Party		$ 50
PFOA Multi-District Litigation (MDL) | Chemours
Loss Contingencies [Line Items]
Additional annual PFOA liabilities paid by Chemours		25
PFOA Multi-District Litigation (MDL) | Historical EID
Loss Contingencies [Line Items]
Additional annual PFOA liabilities paid by Historical EID		$ 25
PFOA Matters | PFOA Multi-District Litigation (MDL) | Historical EID
Loss Contingencies [Line Items]
Number of Plaintiffs	3,550
PFOA Matters | PFOA Multi-District Litigation (MDL) | Historical EID And Chemours
Loss Contingencies [Line Items]
Litigation Settlement, Amount Awarded to Other Party	$ 335
PFOA Matters | Leach v. DuPont [Member] | Historical EID
Loss Contingencies [Line Items]
Litigation Settlement, Medical Monitoring Program, Escrow Account, Disbursements			$ 235
NORTH CAROLINA | PFOA Matters | Historical EID And Chemours
Loss Contingencies [Line Items]
Number of Plaintiffs		100

XML

COMMITMENTS AND CONTINGENT LIABILITIES - Environmental Matters (Details) - USD ($) $ in Millions	Sep. 30, 2020	Dec. 31, 2019
Site Contingency [Line Items]
Accrual for Environmental Loss Contingencies	$ 79	$ 77
Accrual For Environmental Loss Contingencies, Potential Exposure In Excess Of Accrual	172
Retained and Assumed at Divestiture [Domain]
Site Contingency [Line Items]
Accrual for Environmental Loss Contingencies	37
Accrual For Environmental Loss Contingencies, Potential Exposure In Excess Of Accrual	108
Indemnification Agreement [Member] | DuPont
Site Contingency [Line Items]
Accrual for Environmental Loss Contingencies	42
Indemnification Agreement [Member] | Dow | DuPont
Site Contingency [Line Items]
Accrual for Environmental Loss Contingencies	8
Indemnification Agreement [Member] | Corteva | DuPont
Site Contingency [Line Items]
Accrual for Environmental Loss Contingencies	$ 34

XML

COMMITMENTS AND CONTINGENT LIABILITIES - Summary of Guarantees (Details) - USD ($) $ in Millions		9 Months Ended
		Sep. 30, 2020	Dec. 31, 2019
Guarantor Obligations [Line Items]
Guarantor Obligations, Maximum Exposure, Undiscounted		$ 177	$ 187
Customer and Supplier Guarantee Bank Borrowings [Member]
Guarantor Obligations [Line Items]
Guarantor Obligations, Maximum Exposure, Undiscounted	[1]	$ 17
Guarantor Obligations, Liquidation Proceeds, Percentage		1.00%
Equity Affiliates Guarantee Bank Borrowings [Member]
Guarantor Obligations [Line Items]
Guarantor Obligations, Maximum Exposure, Undiscounted	[2]	$ 160

[1] Existing guarantees for select customers, as part of contractual agreements. The terms of the guarantees are equivalent to the terms of the customer loans that are primarily made to finance customer invoices. At September 30, 2020 all maximum future payments had terms less than a year.

[2] Existing guarantees for non-consolidated affiliates' liquidity needs in normal operations.

XML

COMMITMENTS AND CONTINGENT LIABILITIES (Details) Indemnifications $ in Millions	Sep. 30, 2020 USD ($)
Accounts And Notes Receivable, Other
Loss Contingencies [Line Items]
Indemnification Asset	$ 88
Deferred Charges And Other Assets [Member]
Loss Contingencies [Line Items]
Indemnification Asset	117
Accrued and other current liabilities
Loss Contingencies [Line Items]
Indemnification Liabilities	60
Other noncurrent obligations
Loss Contingencies [Line Items]
Indemnification Liabilities	$ 94

XML

LEASES (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Leases [Abstract]
Operating Lease, Cost		$ 49	$ 51	$ 135	$ 141
Operating Lease, Payments				136	150
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability				168	$ 111
Operating Lease, Right-of-Use Asset	[1]	621		621		$ 556
Operating Lease, Liability, Current	[2]	159		159		138
Operating Lease, Liability, Noncurrent	[3]	465		465		416
Operating Lease, Liability		$ 624		$ 624		$ 554

[1] Included in "Deferred charges and other assets" in the interim Condensed Consolidated Balance Sheet.

[2] Included in "Accrued and other current liabilities" in the interim Condensed Consolidated Balance Sheet.

[3] Included in "Other noncurrent obligations" in the interim Condensed Consolidated Balance Sheet.

XML

STOCKHOLDERS' EQUITY - Summary of Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Jun. 30, 2020	Jan. 01, 2020	Dec. 31, 2019	Jun. 30, 2019	Jan. 01, 2019	Dec. 31, 2018
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income (Loss), Net of Tax					$ (859)			$ (1,416)
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	$ 38,118	$ 41,912	$ 38,118	$ 41,912	38,118	$ 37,577		41,556	$ 42,576		$ 95,900
Other comprehensive income (loss) before reclassifications			539	(739)
Amounts reclassified from accumulated other comprehensive income			18	106
Net other comprehensive income (loss)			557	(633)
Total other comprehensive income (loss)	610	(699)	556	(621)
Spin-off of Dow and Corteva				(50,487)
Ending balance	38,118	41,912	38,118	41,912
Tax expense from income taxes related to other comprehensive income items	1	(6)	3	(44)
Spin-off of Dow and Corteva				11,498
Unrealized Gains (Losses) on Investments
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	0	0	0	0	0		$ 0			$ (51)
Other comprehensive income (loss) before reclassifications			0	68
Amounts reclassified from accumulated other comprehensive income			0	(1)
Net other comprehensive income (loss)			0	67
Ending balance	0	0	0	0
Tax expense from income taxes related to other comprehensive income items	0	0	0	(18)
Spin-off of Dow and Corteva				(16)
Cumulative translation adjustments
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	(522)	(1,435)	(522)	(1,435)	(522)		(1,070)			(3,785)
Other comprehensive income (loss) before reclassifications			548	(811)
Amounts reclassified from accumulated other comprehensive income			0	(18)
Net other comprehensive income (loss)			548	(829)
Ending balance	(522)	(1,435)	(522)	(1,435)
Tax expense from income taxes related to other comprehensive income items	0	0	0	(1)
Spin-off of Dow and Corteva				3,179
Pension and other post-employment benefit plans
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	(336)	(93)	(336)	(93)	(336)		(345)			(8,476)
Other comprehensive income (loss) before reclassifications			(9)	47
Amounts reclassified from accumulated other comprehensive income			18	140
Net other comprehensive income (loss)			9	187
Ending balance	(336)	(93)	(336)	(93)
Tax expense from income taxes related to other comprehensive income items	1	(6)	3	(41)
Spin-off of Dow and Corteva				8,196
Derivative Instruments
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	(1)	(1)	(1)	(1)	(1)		(1)			(82)
Other comprehensive income (loss) before reclassifications			0	(43)
Amounts reclassified from accumulated other comprehensive income			0	(15)
Net other comprehensive income (loss)			0	(58)
Ending balance	(1)	(1)	(1)	(1)
Tax expense from income taxes related to other comprehensive income items	0	0	0	16
Spin-off of Dow and Corteva				139
Total
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	(859)	(1,529)	(859)	(1,529)	$ (859)	$ (1,465)	$ (1,416)	$ (1,416)	$ (831)	$ (12,394)	$ (12,394)
Total other comprehensive income (loss)	606	(698)	557	(633)
Spin-off of Dow and Corteva				11,498
Ending balance	$ (859)	$ (1,529)	$ (859)	$ (1,529)

XML

STOCKHOLDERS' EQUITY - Summary of Reclassifications Out of Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Millions		3 Months Ended			9 Months Ended
		Sep. 30, 2020		Sep. 30, 2019	Sep. 30, 2020		Sep. 30, 2019
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Total reclassifications for the period (net of tax)					$ 18		$ 106
Cumulative Translation Adjustment		$ 430		$ 79	627		144
Unrealized gains on investments
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Total reclassifications for the period (net of tax)					0		(1)
Cumulative translation adjustments
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Total reclassifications for the period (net of tax)					0		(18)
Pension and other post-employment benefit plans
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Total reclassifications for the period (net of tax)					18		140
Derivative Instruments
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Total reclassifications for the period (net of tax)					0		(15)
Reclassification out of Accumulated Other Comprehensive Loss
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Total reclassifications for the period (net of tax)		9		(2)	18		106
Reclassification out of Accumulated Other Comprehensive Loss | Unrealized gains on investments
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Total before tax	[1]	0		0	0		(1)
Tax expense (benefit)	[2]	0		0	0		0
Total reclassifications for the period (net of tax)		0		0	0		(1)
Reclassification out of Accumulated Other Comprehensive Loss | Cumulative translation adjustments
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Cumulative Translation Adjustment		0	[3]	0	0	[3]	(18)	[3]
Reclassification out of Accumulated Other Comprehensive Loss | Pension and other post-employment benefit plans
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Total before tax	[4]	7		4	15		171
Tax expense (benefit)	[2]	2		(6)	3		(31)
Total reclassifications for the period (net of tax)		9		(2)	18		140
Reclassification out of Accumulated Other Comprehensive Loss | Derivative Instruments
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Total before tax	[5]	0		0	0		(18)
Tax expense (benefit)	[2]	0		0	0		3
Total reclassifications for the period (net of tax)		$ 0		$ 0	$ 0		$ (15)

[1] "Net sales" and "Sundry income (expense) - net."

[2] "Provision for income taxes on continuing operations."

[3] "Sundry income (expense) - net."

[4] These AOCL components are included in the computation of net periodic benefit cost of the Company's defined benefit pension and other post-employment benefit plans. See Note 17 for additional information.

[5] "Cost of sales," "Sundry income (expense) - net" and "Interest expense."

XML

STOCKHOLDERS' EQUITY Stockholders' Equity Narrative (Details) - USD ($) shares in Millions, $ in Millions	13 Months Ended
	Jun. 30, 2020	Jun. 01, 2019
Equity, Class of Treasury Stock [Line Items]
Stock Repurchase Program, Authorized Amount		$ 2,000
Stock Repurchased and Retired During Period, Shares	16.9
Payments for Repurchase of Common Stock	$ 982

XML

NONCONTROLLING INTERESTS - Summary of Noncontrolling Interests (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Balance at beginning of period	$ 572	$ 570	$ 569	$ 1,608
Net income attributable to noncontrolling interests	7	5	20	90
Distributions to noncontrolling interests	(38)	(6)	(48)	(18)
Cumulative translation adjustments	4	(2)	(1)	14
Spin-off of Dow and Corteva	0	0	0	(1,124)
Other	14	1	19	(2)
Balance at end of period	$ 559	$ 568	$ 559	$ 568

XML

PENSION PLANS AND OTHER POSTRETIREMENT BENEFITS (Summary of Net Periodic Benefit Costs) (Details) - USD ($) $ in Millions	3 Months Ended				9 Months Ended
	Sep. 30, 2020		Sep. 30, 2019		Sep. 30, 2020		Sep. 30, 2019
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Expected Future Employer Contributions, Remainder of Fiscal Year	$ 30				$ 30
Net periodic benefit cost (credit) - total	5	[1]	$ 21		24	[2]	$ 60
Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	20		17	[3]	55		166	[3]
Interest cost	14		19	[4]	42		610	[4]
Expected return on plan assets	(28)		(35)	[5]	(82)		(954)	[5]
Amortization of prior service credit	(1)		(1)	[6]	(4)		(8)	[6]
Amortization of net (gain) loss	3		(6)	[7]	11		129	[7]
Curtailment/settlement	6		1	[8]	8		(1)	[8]
Net periodic benefit cost (credit) - total	14		(5)		30		(58)
Other Postretirement Benefits Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	0		0	[3]	0		5	[3]
Interest cost	1		0	[4]	1		52	[4]
Amortization of net (gain) loss	0		0	[7]	0		(6)	[7]
Net periodic benefit cost (credit) - total	1		0		1		51
Discontinued Operations, Disposed of by Means Other than Sale, Spinoff [Member] | Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Net periodic benefit cost (credit) - total	0		0		0		(45)
Discontinued Operations, Disposed of by Means Other than Sale, Spinoff [Member] | Other Postretirement Benefits Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Net periodic benefit cost (credit) - total	0		0		0		50
Continuing Operations [Member] | Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost			17				47
Interest cost			19				60
Expected return on plan assets			(35)				(114)
Amortization of prior service credit			(1)				(2)
Amortization of net (gain) loss			(6)				(3)
Curtailment/settlement			1				(1)
Net periodic benefit cost (credit) - total	14		(5)		30		(13)
Continuing Operations [Member] | Other Postretirement Benefits Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Net periodic benefit cost (credit) - total	$ 1		$ 0		$ 1		$ 1

[1] Included in "Sundry income (expense) - net."

[2] Included in "Sundry income (expense) - net."

[3] The service cost from continuing operations was $17 million and $47 million for the three and nine months ended September 30, 2019, respectively. The activity from OPEBs was immaterial.

[4] The interest cost from continuing operations was $19 million and $60 million for the three and nine months ended September 30, 2019, respectively. The activity from OPEBs was immaterial.

[5] The expected return on plan assets from continuing operations was $35 million and $114 million for the three and nine months ended September 30, 2019, respectively. The activity from OPEBs was immaterial.

[6] The amortization of prior service credit from continuing operations was $1 million and $2 million for the three and nine months ended September 30, 2019, respectively. The activity from OPEBs was immaterial.

[7] The amortization of unrecognized net gain from continuing operations was $6 million and $3 million for the three and nine months ended September 30, 2019, respectively. The activity from OPEBs was immaterial.

[8] Curtailments and settlements from continuing operations resulted in a loss of $1 million for the three months ended September 30, 2019 and a gain of $1 million for the nine months ended September 30, 2019. The activity from OPEBs was immaterial.

XML

STOCK-BASED COMPENSATION (DuPont) (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended			9 Months Ended
	Sep. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Share-based Payment Arrangement, Expense	$ 25		$ 30	$ 94	$ 85
Share-based Payment Arrangement, Expense, Tax Benefit	$ 5		$ 6	$ 19	$ 18
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		0.8
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value		$ 8.84
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price		$ 53.50
Restricted Stock Units (RSUs) [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period		1.0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value		$ 53.49
Performance Shares [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period		0.3
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value		$ 50.23
DuPont Omnibus Incentive Plan [Domain]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance	10.0			10.0
2020 Equity and Incentive Plan [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance	19.0			19.0

XML

FINANCIAL INSTRUMENTS (Summary of Fair Value of Financial Instruments) (Details) - USD ($) $ in Millions		Sep. 30, 2020		Dec. 31, 2019
Debt Securities, Available-for-sale [Line Items]
Cash Equivalents, Cost		$ 2,534		$ 417
Cash Equivalents, Fair Value		2,534		417
Restricted Cash, Cost		6,232	[1]	37
Restricted Cash, Fair Value		6,232	[1]	37
Cash and Restricted Cash Equivalents, Marketable Securities and Other Investments, Cost		8,766		454
Cash and Restricted Cash Equivalents, Marketable Securities and Other Investments, Fair Value		8,766		454
Long-term debt including debt due within one year, Cost		(23,806)		(15,618)
Long Term Debt including debt due within one year, Gain		2
Long Term Debt including debt due within one year, Loss		(2,375)		(1,633)
Long Term Debt, Including Debt Due within one year, Fair Value		(26,179)		(17,251)
Derivative Assets (Liabilities), Gain		4		6
Derivative Assets (Liabilities), Loss		(6)		(7)
Derivative Assets (Liabilities), Fair Value		(2)		(1)
Foreign Exchange Contract
Debt Securities, Available-for-sale [Line Items]
Derivative Assets (Liabilities), Gain	[2]	4		6
Derivative Assets (Liabilities), Loss	[2]	(6)		(7)
Derivative Assets (Liabilities), Fair Value	[2]	$ (2)		$ (1)

[1] Includes $26 million of restricted cash classified as "Other current assets" and $6.2 billion classified as "Restricted cash" in the interim Condensed Consolidated Balance Sheets. Refer to Note 6 for further information.

[2] Presented net of cash collateral where master netting arrangements allow.

XML

FINANCIAL INSTRUMENTS (Derivatives) (Details) - Not Designated as Hedging Instrument [Member] - USD ($) $ in Millions		Sep. 30, 2020	Dec. 31, 2019
Derivatives, Fair Value [Line Items]
Derivative Asset, Gross		$ 20	$ 16
Counterparty and Cash Collateral Netting, Assets		(16)	(10)
Net Assets included in Consolidated Balance Sheet		4	6
Derivative Liability, Gross		22	17
Counterparty and Cash Collateral Netting, Liabilities		(16)	(10)
Net Liability included in Consolidated Balance Sheet		6	7
Other Current Assets [Member] | Foreign Exchange Contract
Derivatives, Fair Value [Line Items]
Derivative Asset, Gross		20	16
Counterparty and Cash Collateral Netting, Assets	[1]	(16)	(10)
Net Assets included in Consolidated Balance Sheet		4	6
Accrued and other current liabilities | Foreign Exchange Contract
Derivatives, Fair Value [Line Items]
Derivative Liability, Gross		22	17
Counterparty and Cash Collateral Netting, Liabilities	[1]	(16)	(10)
Net Liability included in Consolidated Balance Sheet		$ 6	$ 7

[1] Counterparty and cash collateral amounts represent the estimated net settlement amount when applying netting and set-off rights included in master netting arrangements between the Company and its counterparties and the payable or receivable for cash collateral held or placed with the same counterparty.

XML

FINANCIAL INSTRUMENTS Effect of Derivative Instrument (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Other Nonoperating Income (Expense) [Member] | Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract
Derivative [Line Items]
Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net	$ (3)	$ (3)	$ (1)	$ (63)

XML

FINANCIAL INSTRUMENTS Notional Amounts (Details) - Not Designated as Hedging Instrument [Member] - USD ($) $ in Millions		Sep. 30, 2020	Dec. 31, 2019
Foreign Exchange Contract
Derivative [Line Items]
Derivative, Notional Amount	[1]	$ (299)	$ 26
Commodity Contract [Member]
Derivative [Line Items]
Derivative, Notional Amount		$ 8	$ 11

[1] Presented net of contracts bought and sold.

XML

FAIR VALUE MEASUREMENTS - Summary of Recurring Measured Fair Values (Details) - USD ($) $ in Millions		Sep. 30, 2020		Dec. 31, 2019
Liabilities, Fair Value Disclosure [Abstract]
Long Term Debt, Including Debt Due within one year, Fair Value		$ (26,179)		$ (17,251)
Recurring | Level 2
Assets, Fair Value Disclosure [Abstract]
Cash equivalents and restricted cash equivalents		8,766	[1]	454	[2]
Total assets at fair value		8,786		470
Liabilities, Fair Value Disclosure [Abstract]
Long Term Debt, Including Debt Due within one year, Fair Value	[3]	26,179		17,251
Total liabilities at fair value		26,201		17,268
Recurring | Level 2 | Foreign currency
Assets, Fair Value Disclosure [Abstract]
Foreign Currency Contracts	[4]	20		16
Liabilities, Fair Value Disclosure [Abstract]
Foreign Currency Contracts	[4]	$ 22		$ 17

[1] Treasury bills, time deposits, and money market funds included in "Cash and cash equivalents" and money market funds included in "Other current assets" and "Restricted cash" in the interim Condensed Consolidated Balance Sheets and held at amortized cost, which approximates fair value.

[2] Treasury bills, time deposits, and money market funds included in "Cash and cash equivalents" and money market funds included in "Other current assets" in the interim Condensed Consolidated Balance Sheets and held at amortized cost, which approximates fair value.

[3] Fair value is based on quoted market prices for the same or similar issues, or on current rates offered to the company for debt of the same remaining maturities and terms.

[4] See Note 19 for the classification of derivatives in the interim Condensed Consolidated Balance Sheets.

XML

SEGMENTS AND GEOGRAPHIC REGIONS - Summary of Operating Segment Information (Details) - USD ($) $ in Millions		3 Months Ended			9 Months Ended
		Sep. 30, 2020	Sep. 30, 2019		Sep. 30, 2020		Sep. 30, 2019
Segment Reporting Information [Line Items]
Net sales		$ 5,096	$ 5,426		$ 15,145		$ 16,308
Operating EBITDA	[1]	1,300	1,401		3,756	[2]
Equity in earnings of nonconsolidated affiliates		30	43		172		132
Pro Forma
Segment Reporting Information [Line Items]
Pro forma Operating EBITDA	[1]						4,253
Adjusted for Significant Item [Member]
Segment Reporting Information [Line Items]
Equity in earnings of nonconsolidated affiliates			44	[3]			135
Electronics & Imaging
Segment Reporting Information [Line Items]
Net sales		1,004	934		2,793		2,617
Operating EBITDA	[1]	357	320		887
Equity in earnings of nonconsolidated affiliates		8	10	[3]	27		18
Electronics & Imaging | Pro Forma
Segment Reporting Information [Line Items]
Pro forma Operating EBITDA	[1]						854
Nutrition & Biosciences
Segment Reporting Information [Line Items]
Net sales		1,467	1,525		4,557		4,618
Operating EBITDA	[1]	379	354		1,182
Equity in earnings of nonconsolidated affiliates		1	0	[3]	2		0
Nutrition & Biosciences | Pro Forma
Segment Reporting Information [Line Items]
Pro forma Operating EBITDA	[1]						1,089
Transportation & Industrial
Segment Reporting Information [Line Items]
Net sales		1,045	1,209		3,021		3,795
Operating EBITDA	[1]	242	306		599
Equity in earnings of nonconsolidated affiliates		1	1	[3]	3		3
Transportation & Industrial | Pro Forma
Segment Reporting Information [Line Items]
Pro forma Operating EBITDA	[1]						1,036
Safety & Construction
Segment Reporting Information [Line Items]
Net sales		1,249	1,327		3,769		3,951
Operating EBITDA	[1]	324	352		1,041
Equity in earnings of nonconsolidated affiliates		7	7	[3]	19		22
Safety & Construction | Pro Forma
Segment Reporting Information [Line Items]
Pro forma Operating EBITDA	[1]						1,108
Non-core
Segment Reporting Information [Line Items]
Net sales		331	431		1,005		1,327
Operating EBITDA	[1]	14	94		149
Equity in earnings of nonconsolidated affiliates		13			121
Non-core | Income (Loss) From Equity Method Investments [Domain]
Segment Reporting Information [Line Items]
Restructuring Charges			1				3
Non-core | Pro Forma
Segment Reporting Information [Line Items]
Pro forma Operating EBITDA	[1]						296
Non-core | Adjusted for Significant Item [Member]
Segment Reporting Information [Line Items]
Equity in earnings of nonconsolidated affiliates	[3]		26				92
Corporate
Segment Reporting Information [Line Items]
Net sales		0	0		0		0
Operating EBITDA	[1]	(16)	(25)		(102)
Equity in earnings of nonconsolidated affiliates		$ 0	$ 0	[3]	$ 0		0
Corporate | Pro Forma
Segment Reporting Information [Line Items]
Pro forma Operating EBITDA	[1]						$ (130)

[1] A reconciliation of "Income (loss) from continuing operations, net of tax" to Operating EBITDA and pro forma Operating EBITDA, as applicable, is provided below

[2] For the nine months ended September 30, 2019, operating EBITDA is on a pro forma basis. The pro forma adjustment reflects the net pro forma impact of items directly attributable to the Transactions, as applicable.

[3] Represents equity in earnings (losses) of nonconsolidated affiliates included in pro forma Operating EBITDA, the Company's measure of profit/loss for segment reporting purposes, which excludes significant items. Accordingly, the Non-Core segment presented above excludes restructuring charges of $1 million and $3 million for the three and nine months ended September 30, 2019, respectively, which is presented in "Equity in earnings of nonconsolidated affiliates" in the Company's interim Consolidated Statements of Operations

XML

SEGMENTS AND GEOGRAPHIC REGIONS - Summary of Reconciliation of Operating EBITDA (Details) - USD ($) $ in Millions		3 Months Ended				9 Months Ended
		Sep. 30, 2020		Sep. 30, 2019		Sep. 30, 2020		Sep. 30, 2019
Segment Reporting Information [Line Items]
Loss from continuing operations, net of tax		$ (72)		$ 372		$ (3,153)		$ (805)
Provision for income taxes on continuing operations		92		78		100		142
Loss from continuing operations before income taxes		20		450		(3,053)		(663)
Depreciation and amortization		780		499		2,326
Interest income		3	[1]	1		7	[2]	50
Interest expense		197		177		573		493
Non-operating pension and other post employment benefit (OPEB) credits		5	[1]	21		24	[2]	60
Foreign exchange gains (losses), net		(10)	[1]	(23)		(41)	[2]	(101)
Costs Historically Allocated to the Materials Science Business and Agriculture Business						0
Significant items		(333)	[3]	(274)	[3]	(3,954)	[4]
Operating Income (Loss) Before Interest, Taxes, Depreciation,Amortization, Foreign Exchange Gains (Losses), And Significant Items	[5]	1,300		$ 1,401		3,756	[6]
Adjusted for Significant Item [Member]
Segment Reporting Information [Line Items]
Interest expense		$ 165	[7]			$ 519	[8]
Pro Forma
Segment Reporting Information [Line Items]
Pro Forma Adjustments	[6]							122
Depreciation and amortization								1,533
Interest income	[2]							50
Non-operating pension and other post employment benefit (OPEB) credits	[2]							60
Foreign exchange gains (losses), net	[2]							(101)
Costs Historically Allocated to the Materials Science Business and Agriculture Business	[9]							256
Significant items	[4]							(2,492)
Pro forma Operating EBITDA	[6]							4,253
Pro Forma | Adjusted for Significant Item [Member]
Segment Reporting Information [Line Items]
Interest expense								$ 522

[1] Included in "Sundry income (expense) - net."

[2] Included in "Sundry income (expense) - net."

[3] The significant items for the three months ended September 30, 2020 and 2019 are presented on an as reported basis.

[4] The significant items for the nine months ended September 30, 2020 are presented on an as reported basis. The significant items for the nine months ended September 30, 2019 are presented on a pro forma basis.

[5] A reconciliation of "Income (loss) from continuing operations, net of tax" to Operating EBITDA and pro forma Operating EBITDA, as applicable, is provided below

[6] For the nine months ended September 30, 2019, operating EBITDA is on a pro forma basis. The pro forma adjustment reflects the net pro forma impact of items directly attributable to the Transactions, as applicable.

[7] The three months ended September 30, 2020 excludes N&B financing activity. Refer to details of significant items below.

[8] The nine months ended September 30, 2020 excludes N&B financing activity. Refer to details of significant items below.

[9] Costs previously allocated to the materials science and agriculture businesses that did not meet the definition of expenses related to discontinued operations in accordance with ASC 205.

XML

SEGMENTS AND GEOGRAPHIC REGIONS - Summary of Certain Items by Segment (Details) - USD ($) $ in Millions		3 Months Ended				9 Months Ended
		Sep. 30, 2020		Sep. 30, 2019		Sep. 30, 2020		Sep. 30, 2019
Significant Items
Integration and separation costs		$ 127	[1]	$ 191	[2]	$ 469	[3]
Restructuring and asset related charges - net		14	[4]	83	[5]	146	[6]
Goodwill impairment charges		183	[7]	0		3,214	[8]	$ 1,175
Asset Impairment Charges		370	[7],[9]			661	[8],[10]
Gain (Loss) on Disposition of Business		393	[11]			590	[12]
Income Tax Related Items								(48)
Significant items		(333)	[13]	(274)	[13]	(3,954)	[14]
N&B financing [Member]
Significant Items
Financing fee amortization		(32)	[15]			(54)	[16]
Pro Forma
Significant Items
Integration and separation costs	[17]							976
Restructuring and asset related charges - net	[18]							230
Goodwill impairment charges	[19]							1,175
Asset Impairment Charges	[20]							63
Income Tax Related Items	[21]							(48)
Significant items								(2,492)
Electronics & Imaging
Significant Items
Restructuring and asset related charges - net		1		35		2
Goodwill impairment charges						0
Gain (Loss) on Disposition of Business						197
Significant items		(1)		(35)		195
Electronics & Imaging | Pro Forma
Significant Items
Restructuring and asset related charges - net								42
Significant items								(42)
Nutrition & Biosciences
Significant Items
Restructuring and asset related charges - net		5		7		9
Goodwill impairment charges						0
Significant items		(5)		(7)		(9)
Nutrition & Biosciences | Pro Forma
Significant Items
Restructuring and asset related charges - net								56
Goodwill impairment charges								933
Asset Impairment Charges								63
Significant items								(1,052)
Transportation & Industrial
Significant Items
Restructuring and asset related charges - net		0		6		15
Goodwill impairment charges						2,498
Asset Impairment Charges						21
Significant items		0		(6)		(2,534)
Transportation & Industrial | Pro Forma
Significant Items
Restructuring and asset related charges - net								18
Significant items								(18)
Safety & Construction
Significant Items
Restructuring and asset related charges - net		2		5		15
Goodwill impairment charges						0
Significant items		(2)		(5)		(15)
Safety & Construction | Pro Forma
Significant Items
Restructuring and asset related charges - net								27
Income Tax Related Items								(48)
Significant items								(75)
Non-core
Significant Items
Restructuring and asset related charges - net		1		2		1
Goodwill impairment charges		183				716
Asset Impairment Charges		370				640
Gain (Loss) on Disposition of Business		393				393
Significant items		(161)		(2)		(964)
Non-core | Pro Forma
Significant Items
Restructuring and asset related charges - net								2
Goodwill impairment charges								242
Significant items								(244)
Corporate
Significant Items
Integration and separation costs		127		191		469
Restructuring and asset related charges - net		5		28		104
Significant items		(164)		$ (219)		(627)
Corporate | N&B financing [Member]
Significant Items
Financing fee amortization		$ (32)	[15]			$ (54)	[16]
Corporate | Pro Forma
Significant Items
Integration and separation costs								976
Restructuring and asset related charges - net								85
Significant items								$ (1,061)

[1] Integration and separation costs related to the post-DWDP Merger integration and the intended separation of the N&B Business.

[2] Integration and separation costs related to post-DWDP Merger integration and business separation activities

[3] Integration and separation costs related to the post-DWDP Merger integration and the intended separation of the N&B Business.

[4] Includes Board approved restructuring plans and asset related charges. See Note 5 for additional information.

[5] Includes Board approved restructuring plans and asset related charges. See Note 5 for additional information.

[6] Includes Board approved restructuring plans and asset related charges. See Note 5 for additional information.

[7] Refer to Note 11 for additional information.

[8] Refer to Note 11 for additional information.

[9] Refer to Note 5 for additional information.

[10] Refer to Note 5 for additional information.

[11] Refer to Note 3 for additional information.

[12] Refer to Note 3 for additional information.

[13] The significant items for the three months ended September 30, 2020 and 2019 are presented on an as reported basis.

[14] The significant items for the nine months ended September 30, 2020 are presented on an as reported basis. The significant items for the nine months ended September 30, 2019 are presented on a pro forma basis.

[15] Represents interest expense, net related to the N&B Notes as well as the financing fee amortization related to the intended separation of the N&B Business.

[16] Represents interest expense, net related to the N&B Notes as well as the financing fee amortization related to the intended separation of the N&B Business.

[17] Integration and separation costs related to the DWDP Merger, post-DWDP Merger integration and business separation activities.

[18] Includes Board approved restructuring plans and asset related charges. See Note 5 for additional information.

[19] Refer to Note 11 for additional information.

[20] Refer to Note 5 for additional information.

[21] Charge included in "Sundry income (expense) - net" which reflects a reduction in gross proceeds from lower withholding taxes related to a prior year legal settlement.